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Nurses legally deliver medication through independent nurse prescribing (INP) or patient group 




Multiple mixed methods design was used in this study involving: staff interviews and 
questionnaires, clinical diary, clinical notes review, consultation observations, patient 
questionnaires and a costs review in five UK sexual health services, between September 2015 
and August 2016.  
 
RESULTS:  
Staff interviews reported governance and service delivery preferences for INP over PGDs, but 
they valued both methods.  
Staff questionnaire response rate: 64% (61/95; INP=26/28, 93%; PGD=35/67, 52%). INP were 
mainly Band 7 (n=13/26, 50%), educated to Masters (n=16/26, 62%); PGD users were mostly 
Band 6 (n=24/35, 68.6%), educated to Diploma (n=13/35, 37%). Both groups reported that 
medication access made their roles easier (n=60/61, 98%).  
Clinical diary: There was no difference in medication delivery frequency between both groups 
(INP=460/737 care episodes, 62%; PGD=348/593, 59%; p=0.168); however, PGD users required 
more professional support for medication delivery compared to INPs (INP=419/460 care 
episodes, 91%; PGD=245/348, 70%; p<0.001).  
Notes review: INPs delivered medication more frequently (INP=385/711 care episodes, 54%; 
PGD=548/1,140, 48%; p=0.011) and worked more autonomously than PGD users (INP=310/399 
medication delivery care episodes, 78%; PGD=308/480, 64%, p<0.001). Overall, 91% 
(n=798/879) of medication delivery episodes were assessed against guidelines as ‘safe and 
appropriate’ (INP=372/399, 93%; PGD=426/480, 89%). The main reason for not being ‘safe and 
appropriate’ was lack of documentation (n=56/104, 54%). PGDs were used outside their 
restrictions in 8% (n=39/480) of consultations.  
Patient questionnaires: 92% response rate (n=360/393). Patients reported a high degree of 
satisfaction with information about medication (Satisfaction with Information about Medicines 
Scores: 13.4/16: the higher the score the greater the satisfaction). 
Observational study: nurses medication delivery consultations scored very highly against the 
prescribing framework (INP=44.7/46; PGD=45.4/46, p=0.407).  
Costs: INP training and governance required more initial investment, compared to PGDs, but 
facilitated INPs to autonomously manage more clinically complex patient presentations.  
 
DISCUSSION: 
INPs and PGDs support safe autonomous practice. INP offered a highly flexible method of 
medication delivery that facilitated management of complex patient presentations but requires 
extensive resources from the NHS, and individual nurses, which were not always readily 
available. PGDs offer a suitable alternative, but were sometimes used outside of their restrictions. 
Improved clinical documentation is recommended throughout. 
 
CONCLUSION: 
Independent access to medication using INP and PGDs has facilitated a paradigm shift for nurses, 
progressing them from doctors’ handmaidens to autonomous advanced clinical practitioners. 




Table of Contents 
ABSTRACT .................................................................................................................................... 2 
TABLE OF CONTENTS ................................................................................................................. 3 
TABLE OF FIGURES ................................................................................................................... 12 
TABLE OF TABLES ..................................................................................................................... 13 
ACKNOWLEDGEMENTS ............................................................................................................ 17 
ABBREVIATIONS ........................................................................................................................ 18 
PREFACE: OVERVIEW ............................................................................................................... 20 
RESEARCH CONTEXT ........................................................................................................................................ 20 
RESEARCH AIM AND OBJECTIVES ......................................................................................................................... 21 
OVERVIEW OF RESEARCH DESIGN ........................................................................................................................ 22 
THESIS STRUCTURE .......................................................................................................................................... 22 
 BACKGROUND .................................................................................................. 24 
1.1 INTRODUCTION ...................................................................................................................................... 24 
1.2 NURSE MEDICATION DELIVERY LEGISLATION BACKGROUND .............................................................................. 24 
1.2.1 Patient group directions ......................................................................................................... 27 
1.2.2 Independent nurse prescribing .............................................................................................. 28 
1.3 INP VERSUS PGDS.................................................................................................................................. 28 
1.4 NURSE DELIVERY OF MEDICATIONS INTERNATIONALLY .................................................................................... 29 
1.5 OVERVIEW OF MEDICATION DELIVERY BY NURSES IN THE UNITED KINGDOM ....................................................... 30 
1.6 BACKGROUND SUMMARY ......................................................................................................................... 32 
 SEXUAL HEALTH AND NURSING .................................................................... 34 
2.0 INTRODUCTION ...................................................................................................................................... 34 
2.1 SEXUAL HEALTH AS A CLINICAL SPECIALTY ..................................................................................................... 34 
2.2 SEXUAL HEALTH LEGISLATION AND GOVERNANCE ......................................................................................... 35 
2.3 DEMOGRAPHICS OF SEXUALLY TRANSMITTED INFECTIONS ................................................................................ 36 
2.4 MODERNISATION OF NURSING ROLES IN SEXUAL HEALTH ................................................................................. 37 
4 
 
 LITERATURE REVIEW OF EMPIRICAL EVIDENCE ........................................ 39 
3.0 INTRODUCTION ...................................................................................................................................... 39 
3.1 SCOPE OF REVIEW ................................................................................................................................... 39 
3.2 SEARCH STRATEGY................................................................................................................................... 40 
3.3 INCLUSION OF PAPERS AND ASSESSMENT OF QUALITY ..................................................................................... 43 
3.4 SAFETY AND APPROPRIATENESS OF NURSE PRESCRIBING .................................................................................. 54 
3.4.1 Overview of prescribing errors incidence and nature ............................................................ 54 
3.4.2 Prescribing practice: doctors versus nurses ........................................................................... 55 
3.4.3 Safety of nurse prescribing ..................................................................................................... 57 
3.4.4 Appropriateness of nurse prescribing consultations .............................................................. 58 
3.4.5 Safety of patient group directions .......................................................................................... 60 
3.4.6 Nurse prescribing versus PGDs ............................................................................................... 61 
3.4.7 Organisational nurse prescribing governance ........................................................................ 61 
3.4.8 Conclusions ............................................................................................................................. 62 
3.5 PATIENT EXPERIENCE AND NURSE PRESCRIBING ............................................................................................. 69 
3.5.1 Patients’ expectations of nurse prescribing ........................................................................... 69 
3.5.2 Patients’ experience of nurse prescribing .............................................................................. 70 
3.5.3 Conclusions on patient experience ........................................................................................ 72 
3.6 COSTS .................................................................................................................................................. 75 
3.6.1 Resource and cost assessments ............................................................................................. 75 
3.6.2 Conclusions ............................................................................................................................. 77 
3.7 CHAPTER SUMMARY ................................................................................................................................ 77 
3.8 PAPERS PUBLISHED AFTER INITIAL LITERATURE REVIEW.................................................................................... 79 
 METHODS .......................................................................................................... 81 
4.0 INTRODUCTION ...................................................................................................................................... 81 
4.1 RESEARCH DESIGN OUTLINE ...................................................................................................................... 83 
4.2 AIM AND OBJECTIVES ............................................................................................................................... 83 
4.3 MIXED METHODS PARADIGM’S INFLUENCE ON RESEARCH DESIGN ..................................................................... 84 
4.4 OVERVIEW OF METHODS .......................................................................................................................... 86 
5 
 
4.5 DATA COLLECTION TOOLS AND STUDY DOCUMENTS........................................................................................ 90 
4.6 PATIENT AND PUBLIC INVOLVEMENT........................................................................................................... 91 
4.7 INCLUSION AND EXCLUSION CRITERIA .......................................................................................................... 92 
4.8 STUDY SITES AND SETTINGS ....................................................................................................................... 93 
4.9 DATA ANALYSIS OVERVIEW ....................................................................................................................... 94 
4.10 STUDY-WIDE ETHICAL CONSIDERATIONS ...................................................................................................... 95 
4.10.1 Research Governance and approvals process ........................................................................ 95 
4.10.2 Data protection and storage .................................................................................................. 96 
4.10.3 Participation of staff and patients .......................................................................................... 97 
4.10.4 Potential for observing or discovering poor practice ............................................................. 97 
4.10.5 Accessing and assessing data where the researcher is not employed ................................... 98 
4.10.6 Research Governance ............................................................................................................. 98 
4.11 DEFINING MEDICATION ERRORS IN PRACTICE ................................................................................................ 98 
4.11.1 Prescribing error definition and severity ................................................................................ 99 
4.12 CHAPTER SUMMARY .............................................................................................................................. 102 
CHAPTER 5: DETAILED METHODS AND RESULTS FOR EACH TASK ............................. 103 
5.1 INTRODUCTION .................................................................................................................................... 103 
5.2 STAFF INTERVIEWS: TASK-SPECIFIC METHODS ............................................................................................. 103 
5.2.1 Purpose ................................................................................................................................. 103 
5.2.2 Method design ..................................................................................................................... 103 
5.2.3 Recruitment .......................................................................................................................... 104 
5.2.4 Data collection ...................................................................................................................... 104 
5.2.5 Analysis ................................................................................................................................. 105 
5.3 STAFF INTERVIEWS: FINDINGS ................................................................................................................. 107 
5.3.1 Coding ................................................................................................................................... 107 
5.3.2 Overview of themes ............................................................................................................. 107 
5.3.3 Theme 1: Clinical governance ............................................................................................... 108 
5.3.4 Theme 2: Service Delivery .................................................................................................... 116 
5.3.5 Theme 3: Training and resources ......................................................................................... 118 
6 
 
5.3.6 Staff interviews summary ..................................................................................................... 122 
5.4 STAFF QUESTIONNAIRES: TASK-SPECIFIC METHODS ...................................................................................... 124 
5.4.1 Purpose ................................................................................................................................. 124 
5.4.2 Method design ..................................................................................................................... 124 
5.4.3 Recruitment .......................................................................................................................... 125 
5.4.4 Data collection ...................................................................................................................... 126 
5.4.5 Analysis ................................................................................................................................. 127 
5.5 STAFF QUESTIONNAIRES: FINDINGS .......................................................................................................... 128 
5.5.1 Response rate ....................................................................................................................... 128 
5.5.2 Demographic data ................................................................................................................ 128 
5.5.3 Nurses’ attitudes to independent delivery of medication ................................................... 131 
5.5.4 Motivation for independently delivering medications ......................................................... 132 
5.5.5 PGDs likelihood to undertake INP training ........................................................................... 132 
5.6 CLINICAL DIARY: TASK-SPECIFIC METHODS.................................................................................................. 134 
5.6.1 Purpose ................................................................................................................................. 134 
5.6.2 Method design ..................................................................................................................... 134 
5.6.3 Recruitment .......................................................................................................................... 135 
5.6.4 Data collection ...................................................................................................................... 135 
5.6.5 Analysis ................................................................................................................................. 136 
5.7 CLINICAL DIARY: FINDINGS ...................................................................................................................... 138 
5.7.1 Response rate ....................................................................................................................... 138 
5.7.2 Nurses’ clinical diary activity ................................................................................................ 138 
5.7.3 Consultation length .............................................................................................................. 140 
5.7.4 Support from professional colleagues .................................................................................. 142 
5.8 CLINICAL NOTES REVIEW: TASK-SPECIFIC METHODS ...................................................................................... 143 
5.8.1 Purpose ................................................................................................................................. 143 
5.8.2 Method design ..................................................................................................................... 143 
5.8.3 Recruitment .......................................................................................................................... 148 
5.8.4 Data collection ...................................................................................................................... 149 
5.8.5 Analysis ................................................................................................................................. 150 
7 
 
5.9 CLINICAL NOTES REVIEW: FINDINGS .......................................................................................................... 154 
5.9.1 Clinical notes inclusion/ exclusion ........................................................................................ 154 
5.9.2 Frequency of medication delivery ........................................................................................ 154 
5.9.3 Distribution of notes across research groups ....................................................................... 156 
5.9.4 Patient management and diagnoses in sexual health .......................................................... 157 
5.9.5 Autonomous practice ........................................................................................................... 159 
5.9.6 Medications delivered .......................................................................................................... 161 
5.9.7 Completeness of prescription documentation and provision of medication delivery ......... 162 
5.9.8 Professionals who wrote prescriptions ................................................................................ 164 
5.9.9 Safety of medication provision ............................................................................................. 166 
5.9.10 Medication appropriateness index ....................................................................................... 167 
5.9.11 Appropriateness of PGD medication delivery in clinical practice ......................................... 171 
5.9.12 Where no medication was delivered, was this appropriate? ............................................... 173 
5.9.13 Unplanned repeat consultations for index condition or non-attendance to follow-up ....... 175 
5.9.14 Medication error categories and rates ................................................................................. 177 
5.9.15 Assessment of safety and appropriateness of care for patient presentations .................... 180 
5.9.16 Interrater reliability and validity assessments...................................................................... 182 
5.10 CLINICAL OBSERVATIONS: TASK-SPECIFIC METHODS ..................................................................................... 184 
5.10.1 Purpose ................................................................................................................................. 184 
5.10.2 Method design ..................................................................................................................... 184 
5.10.3 Recruitment .......................................................................................................................... 185 
5.10.4 Data collection ...................................................................................................................... 187 
5.10.5 Analysis ................................................................................................................................. 188 
5.11 CLINICAL OBSERVATIONS: FINDINGS ......................................................................................................... 190 
5.11.1 Characteristics of nurse-patient consultations ..................................................................... 190 
5.11.2 Patient demographics........................................................................................................... 191 
5.11.3 Assessment of consultations against the prescribing framework ........................................ 192 
5.11.4 Autonomous practice ........................................................................................................... 197 
5.11.5 Completeness of prescription documentation and method of medication delivery ........... 197 
5.11.6 Safety in medication provision ............................................................................................. 199 
8 
 
5.11.7 Medication appropriateness index ....................................................................................... 199 
5.11.8 Patient experience feedback ................................................................................................ 203 
5.12 PATIENT EXPERIENCE QUESTIONNAIRE: TASK-SPECIFIC METHODS .................................................................... 206 
5.12.1 Purpose ................................................................................................................................. 206 
5.12.2 Method design ..................................................................................................................... 206 
5.12.3 Recruitment .......................................................................................................................... 207 
5.12.4 Data collection ...................................................................................................................... 208 
5.12.5 Analysis ................................................................................................................................. 209 
5.13 PATIENT EXPERIENCE QUESTIONNAIRE: FINDINGS ........................................................................................ 210 
5.13.1 Response rate ....................................................................................................................... 210 
5.13.2 Patient’s experience of the consultation .............................................................................. 211 
5.13.3 Satisfaction with Information about Medicine Scale ........................................................... 212 
5.13.4 Content analysis of patients’ handwritten comments ......................................................... 214 
5.14 ECONOMIC ANALYSIS: TASK-SPECIFIC METHODS .......................................................................................... 215 
5.14.1 Introduction .......................................................................................................................... 215 
5.14.2 Methods and costing ............................................................................................................ 218 
5.15 ECONOMIC ANALYSIS: FINDINGS .............................................................................................................. 225 
5.15.1 NHS cost implications ........................................................................................................... 225 
5.15.2 NHS patient outcomes .......................................................................................................... 240 
5.15.3 Nurses’ private costs ............................................................................................................ 240 
5.15.4 Nurses’ private benefits ....................................................................................................... 243 
5.15.5 Synthesis ............................................................................................................................... 245 
 DISCUSSION.................................................................................................... 249 
6.1 INTRODUCTION .................................................................................................................................... 249 
6.2 CONTRIBUTION TO KNOWLEDGE .............................................................................................................. 250 
6.3 OBJECTIVE 1 ........................................................................................................................................ 252 
6.3.1 Professional experience of those delivering medications .................................................... 252 
6.3.2 INPs and PGD users’ scope of practice ................................................................................. 254 
6.3.3 Objective 1 summary ............................................................................................................ 255 
9 
 
6.4 OBJECTIVE 2 ........................................................................................................................................ 256 
6.4.1 Frequency of medication delivery ........................................................................................ 256 
6.4.2 Range of medication ............................................................................................................. 257 
6.4.3 Appropriateness of medication delivery .............................................................................. 258 
6.4.4 Safety of medication delivery ............................................................................................... 260 
6.4.5 Outcomes of medicines delivery .......................................................................................... 262 
6.4.6 Objective 2 summary ............................................................................................................ 264 
6.5 OBJECTIVE 3 ........................................................................................................................................ 265 
6.5.1 Benefits to patients .............................................................................................................. 265 
6.5.2 Benefits to health professionals ........................................................................................... 266 
6.5.3 Benefits to the NHS .............................................................................................................. 268 
6.5.4 Quality of patient care .......................................................................................................... 269 
6.5.5 Appropriate management of genitourinary and reproductive healthcare .......................... 269 
6.5.6 Value for money ................................................................................................................... 271 
6.5.7 Objective 3 Summary ........................................................................................................... 273 
6.6 STUDY LIMITATIONS AND IMPLICATIONS .................................................................................................... 274 
6.6.1 Representativeness of study ................................................................................................ 274 
6.6.2 Study methods and design ................................................................................................... 275 
6.6.3 Implications for practice ....................................................................................................... 279 
6.6.4 Future research .................................................................................................................... 281 
6.7 CONCLUSION ....................................................................................................................................... 283 
6.8 POST-SCRIPT: ABOUT THE RESEARCHER AND HIS PHD JOURNEY ...................................................................... 285 
REFERENCES ........................................................................................................................... 287 
APPENDIX A. STAFF INTERVIEWS: INTERVIEW SCHEDULE......................................... 303 
APPENDIX B. STAFF INTERVIEWS: PARTICIPANT INFORMATION SHEET .................. 304 
APPENDIX C. STAFF INTERVIEWS: CONSENT FORM .................................................... 306 
APPENDIX D. STAFF QUESTIONNAIRE: PARTICIPANT INFORMATION SHEET ........... 307 
APPENDIX E. STAFF QUESTIONNAIRE: INDEPENDENT NURSE PRESCRIBERS ....... 309 
10 
 
APPENDIX F. STAFF QUESTIONNAIRE: PATIENT GROUP DIRECTION USERS .......... 316 
APPENDIX G. CLINICAL DIARY: DATA COLLECTION TOOL ........................................... 323 
APPENDIX H. CLINICAL DIARY: EXPLANATORY NOTES ................................................ 324 
APPENDIX I. CLINICAL DIARY: PARTICIPANT INFORMATION SHEET ............................ 325 
APPENDIX J. CLINICAL DIARY: CONSENT FORM ........................................................... 327 
APPENDIX K. CLINICAL NOTES REVIEW: DATA COLLECTION FIELD LIST .................. 328 
APPENDIX L. PATIENT EXPERIENCE QUESTIONNAIRE ................................................ 330 
APPENDIX M. PATIENT EXPERIENCE QUESTIONNAIRE: PARTICIPANT INFORMATION 
SHEET (ENGLISH VERSION) ................................................................................................... 332 
APPENDIX N. PATIENT EXPERIENCE QUESTIONNAIRE: PARTICIPANT INFORMATION 
SHEET (WELSH VERSION) ...................................................................................................... 334 
APPENDIX O. OBSERVATIONAL STUDY: OBSERVATIONAL SCHEDULE ..................... 336 
APPENDIX P. OBSERVATIONAL STUDY: STAFF PARTICIPANT INFORMATION 
SHEET 340 
APPENDIX Q. OBSERVATIONAL STUDY: STAFF CONSENT FORM ............................... 342 
APPENDIX R. OBSERVATIONAL STUDY: PATIENT PARTICIPANT INFORMATION 
SHEET (ENGLISH VERSION) ................................................................................................... 343 
APPENDIX S. OBSERVATIONAL STUDY: PATIENT PARTICIPANT INFORMATION 
SHEET (WELSH VERSION) ...................................................................................................... 345 
APPENDIX T. OBSERVATIONAL STUDY: PATIENT CONSENT FORM (ENGLISH 
VERSION) 347 
APPENDIX U. OBSERVATIONAL STUDY: PATIENT CONSENT FORM (WELSH 
VERSION) 348 
APPENDIX V. OBSERVATIONAL STUDY: ADVERTISING POSTER ................................ 349 
APPENDIX W. RESEARCH ETHICS COMMITTEE APPROVAL (28/05/2015) ................... 350 
APPENDIX X. RESEARCH ETHICS COMMITTEE NON-SUBSTANTIAL AMENDMENT 
APPROVAL (21/09/2015) .......................................................................................................... 351 
11 
 
APPENDIX Y. RESEARCH ETHICS COMMITTEE SUBSTANTIAL AMENDMENT 
APPROVAL (21/03/2016) .......................................................................................................... 352 
APPENDIX Z. STAFF INTERVIEWS: EXAMPLE OF TRANSCRIPT CODING ................... 353 
APPENDIX AA. NURSE QUESTIONNAIRE: PARTICIPANTS’ ATTITUDES TO IMPACT 
INDEPENDENT ACCESS TO MEDICATION HAS ON THEIR CLINICAL PRACTICE ............ 354 
APPENDIX BB. CLINICAL DIARY: DETAILED DIARY ACTIVITY BY SITE .......................... 356 
APPENDIX CC. CLINICAL NOTES REVIEW: BREAKDOWN OF NURSES’ PROCEDURAL 
AND DIAGNOSTIC ACTIVITY ................................................................................................... 358 
APPENDIX DD. CLINICAL NOTES REVIEW: SPECIFIC MEDICATIONS DELIVERED BY 
INPS AND PGD USERS ............................................................................................................ 360 
APPENDIX EE. CLINICAL NOTES REVIEW: SPECIFIC MEDICATIONS PRESCRIBED BY 
DOCTORS FOR INPS AND PGD USERS ................................................................................ 362 
APPENDIX FF. CLINICAL NOTES REVIEW: MEDICATION SAFETY ASSESSMENTS 
BASED ON RISK ASSESSMENTS ........................................................................................... 364 
APPENDIX GG. SPECIFIC MEDICATION AVAILABLE THROUGH PGDS BY SITE ........... 365 
APPENDIX HH. CLINICAL NOTES REVIEW: DETAILED RATIONALES FOR NOT BEING 
SAFE AND/ OR APPROPRIATE PRACTICE ............................................................................ 367 
APPENDIX II. CLINICAL NOTES REVIEW: EXAMPLE OF RESEARCHER AND 
PHARMACIST REVIEW OF POTENTIAL MEDICATION INTERACTIONS ............................. 369 
APPENDIX JJ. OBSERVATIONAL STUDY: CONSULTATION CONTENT .......................... 370 
APPENDIX KK. OBSERVATIONAL STUDY: DETAILED PRESCRIBING FRAMEWORK 
SCORING OF OBSERVATIONS ............................................................................................... 372 
APPENDIX LL. PATIENT QUESTIONNAIRE: SATISFACTION WITH INFORMATION ABOUT 





Table of Figures 
FIGURE 1-1 THE EVOLUTION OF INDEPENDENT NURSE ACCESS TO MEDICATION ............................................................ 26 
FIGURE 3-1 PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEWS AND META-ANALYSES (PRISMA) DIAGRAM FOR 
SEARCH PROCESS ..................................................................................................................................... 42 
FIGURE 3-2 STRUCTURE OF PRESENTED PAPERS ..................................................................................................... 44 
FIGURE 4-1 OVERVIEW OF METHODS .................................................................................................................. 82 
FIGURE 5-1 STRUCTURE AND SAMPLE SIZE OF CLINICAL NOTES REVIEW FINDINGS ....................................................... 153 
FIGURE 5-2 PROCEDURAL MANAGEMENT OF PATIENTS ......................................................................................... 158 
FIGURE 5-3 PATIENTS' DIAGNOSTIC CATEGORIES ................................................................................................. 158 
FIGURE 5-4 NHS COSTS AND CONSEQUENCES ANALYSIS LOGIC DIAGRAM ................................................................. 218 
FIGURE 5-5 PGD APPROVAL PROCESS ............................................................................................................... 221 





Table of Tables 
TABLE 1-1 GOVERNMENT HEALTHCARE DEPARTMENTS ACROSS THE UNITED KINGDOM................................................. 24 
TABLE 1-2 SUMMARY OF INP AND PGD GOVERNANCE REQUIREMENTS ..................................................................... 29 
TABLE 3-1 SEARCH TERMS ................................................................................................................................ 40 
TABLE 3-2 DESCRIPTIVE SAFETY AND APPROPRIATENESS PAPERS ............................................................................... 45 
TABLE 3-3 EVALUATIVE SAFETY AND APPROPRIATENESS PAPERS ............................................................................... 48 
TABLE 3-4 SEVERITY CATEGORISATION OF PRESCRIBING ERRORS AND CLINICAL ROLES ................................................... 56 
TABLE 3-5 DESCRIPTIVE PATIENT EXPERIENCE PAPERS ............................................................................................. 63 
TABLE 3-6 EVALUATIVE PATIENT EXPERIENCE PAPERS ............................................................................................. 68 
TABLE 3-7 HEALTH ECONOMICS LITERATURE ........................................................................................................ 74 
TABLE 4.1 HOW METHODS ALIGN WITH THE DISCUSSION IN CHAPTER 6 ..................................................................... 85 
TABLE 4-2 RESEARCH METHODS: STRENGTHS AND WEAKNESSES .............................................................................. 89 
TABLE 4-3 DATA COLLECTION TOOLS AND VERSIONS OVERVIEW................................................................................ 90 
TABLE 4-4 INCLUSION AND EXCLUSION CRITERIA .................................................................................................... 92 
TABLE 4-5 NUMBER OF INPS AND PGD USERS PER SITE ......................................................................................... 94 
TABLE 4-6 GOVERNANCE REFERENCE NUMBERS AND DATES .................................................................................... 96 
TABLE 5-1 STAGES OF THEMATIC ANALYSIS UNDERTAKEN ...................................................................................... 105 
TABLE 5-2 LENGTH AND CODE DETAILS OF STAFF INTERVIEWS ................................................................................ 107 
TABLE 5-3 OVERVIEW OF THEMES FOR STAKEHOLDER INTERVIEWS .......................................................................... 107 
TABLE 5-4 PGD COMPETENCY ASSESSMENTS AS REPORTED DURING INTERVIEWS ....................................................... 121 
TABLE 5-5 DEMOGRAPHICS OF NURSE QUESTIONNAIRE RESPONDENTS..................................................................... 128 
TABLE 5-6 CLINICAL EXPERIENCE OF SEXUAL HEALTH NURSES BY GROUP ................................................................... 129 
TABLE 5-7 METHODS OF MEDICATION DELIVERY USED BY SEXUAL HEALTH NURSES BY SITE ........................................... 130 
TABLE 5-8 CLINICAL COMPETENCY OF INPS AND PGD USERS ................................................................................ 130 
TABLE 5-9 MOTIVATION IN TRAINING TO BECOME INP OR PGD USERS ................................................................... 132 
TABLE 5-10 LIKELIHOOD OF PGD USERS UNDERTAKING INP TRAINING .................................................................... 132 
TABLE 5-11 SUMMARY OF DIARY RESULTS ......................................................................................................... 139 
TABLE 5-12 PATIENTS’ AGE DEMOGRAPHICS ...................................................................................................... 139 
TABLE 5-13 OVERALL TIME SPENT MANAGING PATIENT CARE EPISODES.................................................................... 140 
14 
 
TABLE 5-14 FACE-TO-FACE TIME (MINUTES) ...................................................................................................... 141 
TABLE 5-15 COLLEAGUES' TIME FOR ADVICE OR PRESCRIPTIONS (MINUTES) .............................................................. 142 
TABLE 5-16 MEDICATION APPROPRIATENESS INDEX WEIGHTED QUESTIONS SCORING ................................................. 148 
TABLE 5-17 STRATIFIED SAMPLE SIZE QUOTAS PER SITE ......................................................................................... 149 
TABLE 5-18 RATIONALE FOR EXCLUDING PATIENTS’ NOTES FROM THE CLINICAL NOTES REVIEW ..................................... 155 
TABLE 5-19 NOTES INCLUDED IN EACH GROUP .................................................................................................... 156 
TABLE 5-20 DEMOGRAPHICS OF PATIENTS INCLUDED IN THE CLINICAL NOTES REVIEW ................................................. 157 
TABLE 5-21 LIKELIHOOD OF AUTONOMOUS PRACTICE, ALL PATIENT PRESENTATIONS (MEDICATION DELIVERED AND NOT 
DELIVERED) .......................................................................................................................................... 159 
TABLE 5-22 AUTONOMOUS PRACTICE LIMITED TO PATIENT PRESENTATIONS WHERE MEDICATION WAS DELIVERED ........... 159 
TABLE 5-23 AUTONOMOUS PRACTICE FREQUENCY AND REASONS FOR NURSES SEEKING ADDITIONAL PROFESSIONAL SUPPORT
 .......................................................................................................................................................... 160 
TABLE 5-24 MEDICATION DELIVERED DRUG CATEGORIES ...................................................................................... 161 
TABLE 5-25 COMPLETENESS OF DOCUMENTED 'PRESCRIPTION' IN PATIENTS’ CLINICAL NOTES ....................................... 163 
TABLE 5-26 METHOD OF DELIVERING MEDICATION .............................................................................................. 163 
TABLE 5-27  PROFESSIONAL GROUP WRITING ‘PRESCRIPTIONS’ .............................................................................. 164 
TABLE 5-28 DRUG CATEGORIES PRESCRIBED BY DOCTORS ..................................................................................... 165 
TABLE 5-29 DOCUMENTATION OF PAST MEDICAL HISTORY, CONCURRENT MEDICATIONS, ALLERGIES AND PREGNANCY RISK 166 
TABLE 5-30 NUMBER OF PATIENT WITH EXISTING MEDICAL ISSUES AND/ OR CONCURRENT MEDICATION ........................ 168 
TABLE 5-31 MEDICATION APPROPRIATENESS INDEX SUMMARY ............................................................................. 169 
TABLE 5-32 RATIONALE FOR MEDICATION APPROPRIATENESS INDEX SCORES NOT BEING CLASSIFIED AS ‘APPROPRIATE’ ...... 170 
TABLE 5-33 MEDICATION APPROPRIATENESS INDEX WEIGHTED SCORING RESULTS ..................................................... 171 
TABLE 5-34 APPROPRIATE DELIVERY OF MEDICATIONS USING PGDS ....................................................................... 172 
TABLE 5-35 APPROPRIATENESS OF PGDS TO MANAGE ALL PATIENT EPISODES ........................................................... 172 
TABLE 5-36 APPROPRIATE NON-PROVISION OF MEDICATION ................................................................................. 174 
TABLE 5-37 MEDICATION INAPPROPRIATELY NOT PROVIDED/ OFFERED/ DOCUMENTED BY NURSES ............................... 174 
TABLE 5-38 MEDICATION INDICATED OR ACKNOWLEDGED BUT APPROPRIATELY NOT GIVEN ......................................... 174 
TABLE 5-39 UNEXPECTED RE-ATTENDANCE RATES ............................................................................................... 175 
TABLE 5-40 RATIONALES FOR RE-ATTENDING ..................................................................................................... 176 
TABLE 5-41 MEDICATION ERROR CATEGORIES AND RATES ..................................................................................... 178 
15 
 
TABLE 5-42 CATEGORISATION OF ERROR SEVERITY .............................................................................................. 179 
TABLE 5-43 OVERALL CATEGORISATION OF SAFE AND APPROPRIATE MEDICATION DELIVERY ......................................... 181 
TABLE 5-44 INTER-RATER ASSESSMENT BETWEEN RESEARCHER AND LOCAL REPRESENTATIVE........................................ 183 
TABLE 5-45 LOCAL CLARIFICATION OF CLINICAL QUERIES, SAFETY AND APPROPRIATENESS ............................................ 183 
TABLE 5-46 COMPETENCY FRAMEWORK FOR PRESCRIBERS’ DIMENSIONS ................................................................. 185 
TABLE 5-47 CONSULTATION LENGTHS ............................................................................................................... 190 
TABLE 5-48 PATIENT DEMOGRAPHICS ............................................................................................................... 191 
TABLE 5-49 SUMMARY OF PRESCRIBING FRAMEWORK SCORES .............................................................................. 193 
TABLE 5-50  RESEARCHER’S RATIONALE FOR SCORING ‘NOT OBSERVED’ IN PRESCRIBING FRAMEWORK COMPETENCIES ...... 195 
TABLE 5-51 COMPETENCIES BASED ON PATIENT AND PUBLIC INVOLVEMENT CONCERNS .............................................. 196 
TABLE 5-52 AUTONOMOUS PRACTICE ............................................................................................................... 197 
TABLE 5-53 QUALITY OF COMPLETED 'PRESCRIPTION' DOCUMENTATION .................................................................. 198 
TABLE 5-54 METHOD OF DELIVERING MEDICATION .............................................................................................. 198 
TABLE 5-55 DOCUMENTATION OF PAST MEDICAL HISTORY, CONCURRENT MEDICATION, ALLERGY AND PREGNANCY RISK .... 199 
TABLE 5-56 NUMBER OF PATIENTS WITH EXISTING MEDICAL ISSUES AND/ OR CONCURRENT MEDICATION ....................... 199 
TABLE 5-57 MEDICATION APPROPRIATENESS INDEX ASSESSMENT (DOCUMENTATION & OBSERVATIONS) ....................... 201 
TABLE 5-58 MEDICATION APPROPRIATENESS INDEX WEIGHTED SCORING RESULTS OF DOCUMENTATION, THEN TRIANGULATED 
WITH OBSERVATIONAL DATA .................................................................................................................... 202 
TABLE 5-59 PATIENTS’ SATISFACTION WITH THEIR CONSULTATION WITH NURSES ....................................................... 203 
TABLE 5-60 SUMMARY OF SATISFACTION WITH INFORMATION ON MEDICINES SCALE CATEGORIES ................................. 204 
TABLE 5-61 SUMMARY OF SATISFACTION WITH INFORMATION ON MEDICINES SCALE SCORES ....................................... 205 
TABLE 5-62 CONTENT ANALYSIS OF PATIENTS’ COMMENTS.................................................................................... 205 
TABLE 5-63 DISTRIBUTION OF PATIENT QUESTIONNAIRES DURING CLINICAL DIARY...................................................... 210 
TABLE 5-64 PATIENT'S SATISFACTION WITH THEIR CONSULTATIONS WITH NURSES ...................................................... 211 
TABLE 5-65 SUMMARY OF SATISFACTION WITH INFORMATION ON MEDICINES SCALE CATEGORIES ................................. 212 
TABLE 5-66 SATISFACTION WITH INFORMATION ON MEDICINES SCALE SCORES .......................................................... 213 
TABLE 5-67 CONTENT ANALYSIS OF PATIENTS' COMMENTS .................................................................................... 214 
TABLE 5-68 COMPONENTS AND DATA SOURCES FOR COST-CONSEQUENCE ANALYSES.................................................. 217 
TABLE 5-69 HIGHER EDUCATION INSTITUTION INP COURSE FEES ............................................................................ 225 
TABLE 5-70 CLINICAL SUPERVISION REPORTED BY INP RESPONDENTS DURING TRAINING ............................................. 227 
16 
 
TABLE 5-71 INP’S PROFESSIONAL STUDY TIME NATIONAL HEALTH SERVICE INVESTMENT ............................................ 229 
TABLE 5-72 TIME TO WRITE PGDS BASED ON STAFF RESOURCE LOG ....................................................................... 230 
TABLE 5-73 COMMITTEE TIME TO APPROVE PGDS .............................................................................................. 231 
TABLE 5-74 FORMAL PGD TRAINING RESOURCES ................................................................................................ 233 
TABLE 5-75 PGDS' PROFESSIONAL STUDY TIME (HOURS) ...................................................................................... 234 
TABLE 5-76 MEDICATION REGIME COSTS ........................................................................................................... 235 
TABLE 5-77 COSTS OF WRONG/ UNDER/ OVER PRESCRIBING ................................................................................. 236 
TABLE 5-78 SUMMARY OF INAPPROPRIATE ACTIVITY ............................................................................................ 237 
TABLE 5-79 IMPACT ON WORKLOAD FOR OTHER PROFESSIONALS’ SUPPORT .............................................................. 239 
TABLE 5-80 STAFFING RESOURCES FOR UNEXPECTED RETURN FOR THE INDEX CONDITION ............................................ 240 
TABLE 5-81 NURSES' PERSONAL STUDY TIME & LOSS OF LEISURE ............................................................................ 241 
TABLE 5-82 OUT-OF-POCKET EXPENSES ............................................................................................................ 242 
TABLE 5-83 MEAN SALARY DIFFERENCES BETWEEN INPS AND PGD USERS ............................................................... 243 
TABLE 5-84 COSTING SUBJECTIVE BENEFITS, JOB SATISFACTION TO INP AND PGDS ................................................... 244 
TABLE 5-85 COST CONSEQUENCE ANALYSIS BALANCE SHEET .................................................................................. 247 
TABLE 5-86 APPLICATION OF COSTS AND CONSEQUENCES ANALYSIS BALANCE SHEET TO COMPARE TRAINING AND 
GOVERNANCE ....................................................................................................................................... 248 
TABLE 0-1 PROCEDURAL MANAGEMENT OF PATIENTS .......................................................................................... 358 






Dedicated to my mother Beatrice Elizabeth Black (1st April 1951 to 24th November 2014) and my 
‘wonderful father’ Duncan James Black who survives her. 
My mother wanted nothing more than to see me graduate, but sadly lost her long and difficult 
battle with cancer in my first year. I dedicate my thesis to you and my father for providing me with 
a solid start in life, a safe and loving home and my commitment to keep going. Mum, I miss you 
more with every passing day. My family, friends and colleagues have provided unyielding support 
from conception of my PhD journey through to its completion. Your love, patience and support 
has made this journey possible, thank you.  
I would like to express my extreme gratitude to my supervisor team, who have provided me with 
invaluable support, advice, encouragement, patience and direction. Professor Molly Courtenay, 
Professor Heather Gage, Professor Christine Norton, Trevor Murrells and Professor Bryony Dean 
Franklin, I could not have completed this without you.  
I would also like to give a special thank you to all the participants, and for everyone who made 
me feel very welcome at the research sites. I was overwhelmed at the generosity and kindness 
shown by my professional colleagues and patients accessing our services.   
A final expression of gratitude goes to the teams at the National Institute for Health Research and 
Health Education England, who generously funded this project through a Clinical Doctoral 
Research Fellowship award and provided governance support throughout. I am forever grateful. 
Disclaimer: the views expressed are those of the author and not necessarily those of the NHS, 





AEI Approved Education Institution 
AU Action & Usage (part of SIMS) 
BASHH British Association of Sexual Health & HIV 
BME Black & Minority Ethnic  
BNF British National Formulary  
BV Bacterial Vaginosis 
CASP Critical Appraisal Skills Programme 
CCA Costs & Consequences Analysis 
CCG Clinical Commissioning Groups 
COCP Combined Oral Contraception Pill 
CRN Clinical Research Network 
CSP Co-ordinated System for gaining NHS Permission 
df degrees of freedom 
DFSRH Diploma for Faculty of Sexual & Reproductive Health 
DH Department of Health 
DHSSPSNI 
Department of Health, Social Services and Public Safety 
Northern Ireland 
DMP Designated Medical Practitioner 
DOB Date Of Birth 
EC European Community 
EEC European Economic Community 
EU European Union 
FPA Family Planning Association 
FSRH Faculty of Sexual & Reproductive Health 
GCP Good Clinical Practice 
GDPR General Data Protection Regulation 
GP General Practitioner 
GSL General Sales List medication 
GUM Genitourinary medicine 
HEE Health Education England 
HEI Higher Education Institute 
HIV Human Immunodeficiency Virus 
HRA Health Research Authority 
HSCIC Health & Social Care Information Centre 
INP Independent Nurse Prescribing/ Prescriber(s) 
INP med Medication episodes primarily managed by INP  
INP no med Medication NOT provided in episodes managed by INP  
IT Information Technology 
IUD/ IUS Intra-Uterine Device/ Intra Uterine System 
KCL King's College London 
LA Local Authorities 
MAI Medication Appropriateness Index 
MedFASH Medical Foundation for HIV & Sexual Health 
MHRA Medicines and Healthcare products Regulatory Agency 
MSM Men who have Sex with Men 
NAAT Nucleic Acid Amplification Test 
NHS National Health Service 
NICE National Institute for Health and Care Excellence 




NMC Nursing & Midwifery Council 
NPC National Prescribing Centre  
NPSA National Patient Safety Agency 
NSU Non-Specific Urethritis 
P  Pharmacy sales medication 
P. Participant 
PCF Prescribing Competency Framework 
PCT  Primary Care Trust 
PEP/SE Post Exposure Prophylaxis (/Sexual Exposure) 
PGD Patient Group Direction 
PGD med Medication episodes primarily managed by PGD  
PGD no med Medication NOT provided in episodes managed by PGD 
PHE Public Health England 
PID Pelvic Inflammatory Disease 
PIS  Participant Information Sheet 
PMH Past Medical History 
POM Prescription Only Medication 
PPI Patient Public Involvement  
PPM  Potential Problems of Medication (part of SIMS) 
PSD Patient Specific Direction 
R&D Research & Development 
REC Research Ethics Committee 
RPS Royal Pharmaceutical Society 
SI Statutory Instrument 
SIMS Satisfaction with Information about Medications Scale 
SPSS Statistical Package for Social Sciences 
SRH Sexual & Reproductive Health 
STI Sexually Transmitted Infection(s) 
STIF Sexually Transmitted Infection Foundation 
TOP Termination Of Pregnancy 
TTO To Take Out 
TV Trichomonas vaginalis 
UK United Kingdom 
UKMEC UK Medical Eligibility Criteria (for contraception provision) 
WHO World Health Organisation 
2 Chi-squared test 
t Independent Samples t Test 






 Research Context 
Appropriately trained nurses in the United Kingdom (UK) are able to independently deliver 
medication through patient group directions (PGDs) and independent nurse prescribing (INP). 
PGDs allow groups of locally competent nurses to supply/ administer specific medications from a 
range of pre-determined clinical presentations. Conversely, INP affords individual nurses 
prescribing powers comparable to doctors following successful completion of a Nursing & 
Midwifery Council (NMC) approved training course. Over the last 13 years there has been an 
853% (n=35,407) increase in NMC registered ‘Nurse Independent / Supplementary Prescribers’; 
rising from 4,151 in 2005 to 39,558 in 2018 (NMC, 2005; NMC Freedom of Information, 2018). 
Due to the episodic nature of sexual health patient presentations, both INP and PGDs have been 
found to be clinically effective in this speciality (Miles et al., 2001; Black, 2012). Of note, PGD use 
is not ‘prescribing’, rather they facilitate nurses’ independent supply and/ or administration of 
medication. Consequently, throughout this thesis the term ‘medication delivery’ is used to denote 
both PGD users and INPs’ independent provision of medications.  
Any form of medication delivery is a complex process that involves multiple considerations to 
achieve desired pharmacological effects in a safe, cost effective and patient focussed way. 
Prescriptions were the second highest cost to the National Health Service (NHS) (after staffing: 
Health & Social Care Information Centre (HSCIC), 2014) costing £17.4 billion in England in 2016-
17 (NHS Digital, 2017). As well as being one of the most expensive outlays, medicine provision 
is also one of the most hazardous (Leufer and Cleary-Holdforth, 2013). Medication errors were 
the third highest patient safety incidents reported, after accidents and implementation of care/ 
monitoring issues (NHS Improvement, 2017). The most common medication incidents included 
wrong dose, omitted or delayed drugs and wrong medication supplied (National Patient Safety 
Agency (NPSA), 2012).  
Despite the exponential growth of nurses delivering medication, there is limited evidence available 
that has specifically explored safety and cost effectiveness of medicines delivery by nurses. This 
health services research study explored nurse delivery of medication within the context of sexual 
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health, an area in which nurses’ roles have become increasingly autonomous as a result of 
increased service demand (NHS, 2013). 
 
 Research aim and objectives 
 
The study’s aim was to explore how sexual health nurses’ use of independent nurse prescribing 
compared with the use of patient group directions in terms of clinical application, patients’ 
experience and cost. 
The study’s objectives were to: 
1. Determine the extent to which sexual health nurses’ professional experience and scope 
of practice affect prescribing practice or PGD use.  
 
2. Explore INP practice and the use of PGDs by nurses working in sexual health services; 
investigating frequency, range, appropriateness, safety and outcomes of medicines 
delivery. 
 
3. Assess whether and how local application of INP and/ or PGDs has benefited patients, 
health professionals and the NHS, with reference to quality of care, appropriate 





 Overview of research design 
 
A multiple mixed methods approach was adopted with data collected concurrently and 
simultaneously across three inter-related work streams. These work-streams explored INP vs. 
PGDs in sexual health within the context of: 
 Clinical application: 
o Impact on professional practice and service delivery 
o Safety and appropriateness of medication delivery 
 Patients’ experience and satisfaction with information about medicines 
 Costs comparison of INP vs. PGDs using a costs & consequences analysis 
 
The methods involved NHS senior staff interviews, INP and PGD staff questionnaires, quantitative 
clinical diaries, clinical notes review, an observational study, patient experience questionnaires 
and an economic evaluation. These methods were based on a Department of Health (DH) 
commissioned study, carried out by Latter et al. (2005), which subsequently supported the 
expansion of INPs’ prescribing powers (DH, 2006). Five city-based UK sexual health services 




This thesis comprises of six chapters. The first chapter presents INP and PGD legislation and a 
general overview of the literature relating to nurses’ medication delivery. Chapter two discusses 
sexual health as a clinical speciality, healthcare governance within the field, sexually transmitted 
infection (STI) demographics and modernisation of the sexual health nursing role. Chapter three 
presents empirical research specifically related to safety and appropriateness of INP/PGDs, 
patients’ experience of nurses’ medication delivery, and a cost comparison between INP vs. 
PGDs.  
The multiple mixed methods study design added a layer of complexity on how best to present the 
methods and findings. For ease of reference, chapter four provides a general overview of the 
study’s overarching methods, detailing justification for the chosen approach, data collection and 
research governance considerations. Chapter five then presents each task’s specific methods 
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alongside their findings, starting with ‘staff interviews: task specific methods’, followed by ‘staff 
interviews: findings’. The staff questionnaires, clinical diary, clinical notes review, clinical 
observations, patient experience questionnaire and costs then follow a similar structure. The sixth 
chapter initially presents this project’s contribution to knowledge, before discussing how INP vs. 
PGDs compared through triangulation of the various methods’ findings around the study’s 
objectives. The thesis concludes by highlighting the study’s limitations, impact for clinical practice, 








1.1 Introduction  
 
This project explored nurses’ delivery of medication from a clinical application, patient experience 
and cost perspective in sexual health. Sexual health was specifically chosen due to the 
researcher’s extensive clinical experience in this field. Moreover, the researcher’s clinical, 
professional and academic interest lay in ensuring nurses provided safe, patient focussed, cost 
effective care. This chapter presents the legislation relevant to nurses’ delivery of medication, 
specifically focussing upon comparing INP vs. PGDs, as these two methods are frequently used 
in sexual health (Black, 2012). A general overview of literature relating to nurses’ medication 
delivery internationally and UK-based is then presented.  
 
1.2 Nurse medication delivery legislation background 
The UK’s medication legislation is governed from a variety of sources (Woodley, 2009), which is 
likely to be amended following the UK’s vote to leave the European Union (UK Government, 
2018a). However, during this study the European Community (EC) had certain Regulations and 
Directives that took precedence over UK law. UK based legislature could then govern the entire 
UK or be unique to the devolved parliaments of England, Scotland, Wales and Northern Ireland 
(Woodley, 2009) through country specific government health departments, as detailed in Table 
1-1.  
Table 1-1 Government healthcare departments across the United Kingdom 
Country Healthcare Department 
England Department of Health & Social Care (DH: Previously Department of Health) 
Scotland Scottish Government Health and Social Care Directorate 
Wales Welsh Government Department for Health & Social Services 
Northern Ireland Department of Health (Northern Ireland) (previously Department of Health, Social 
Services and Public Safety (DHSSPSNI)) 





The ‘Medicines Act 1968’ constituted the UK’s introduction of medicines regulation. Medicines 
were categorised as ‘Prescription Only Medication’ (POM) which could only be prescribed by a 
doctor, dentist or vet; ‘Pharmacy’ medicines (P) which could be provided by pharmacists; or a 
‘General Sales List’ (GSL) which could be generally supplied (Medicines Act, 1968, c.67). Nurses’ 
independent access to medication was first introduced following ‘The Cumberledge Report’ 
(1986). This allowed community-based nurses to access commonly used dressings and 
medications, avoiding the need to obtain general practitioner’s (GP) prescription. Subsequent 
legislation expansions are summarised in Figure 1-1. Most significant for nurses was the 
introduction of PGDs in 2000 (Department of Health (DH), 2000), and in 2006 the substantial 
legislation amendment giving INPs the authority to prescribe any licensed medication (and some 
controlled drugs) within their competence (DH, 2006; NMC, 2006). Scotland and Wales have both 
incorporated non-medical prescribing legislation based on England’s DH authorisations and 
updates (Home Office, 2012). Northern Ireland incorporated non-medical prescribing using their 
own legislative process, sanctioning it seven months after the rest of the UK, in December 2006 
(DHSSPSNI, 2006). Nurse and pharmacy independent prescribers were afforded similar 
prescribing powers as doctors. Patient safety, improvements in service delivery and better use of 
professional’s skills were the key drivers (DH, 2006). These acts have since been superseded 
with ‘The Human Medicines Regulations 2012’ (SI 2012/1916). This study focused on PGDs and 






Figure 1-1 The evolution of independent nurse access to medication
1968
• Medicines Act, 1968, chapter.67
• UK legislation regulates manufacture and supply of medicines; categories into prescription-only medication (POM), pharmacy sales (P) and general sales list (GSL)
• Prescription dominance given to doctors, dentists & vets
1986
• Cumberledge  Report proposes giving community nurses independent access to some dressings and medicinal items from limited formulary to reduce need to obtain a general practitioner 
prescription
1992
• Medicinal Products: Prescription by Nurses etc. Act 1992
• District nurses and health visitors able to provide medication independently from the limited ‘Nurse Prescriber’s Formulary’ (NPF)
• Intergrated into practice in 1994 when 'Order' obtained; only applicable to community nurses after additional training
1999
• Review of Prescribing, Supply and Administration of Medicines Report
• Lifted restriction to community nurses only
• 2 specific prescribers: independent prescriber (responsible for assessing ‘undiagnosed conditions’) and a dependent prescriber (responsible for continuing care) 
2000
• Patient Group Directions (Department of Health, 2000)
• Pre-determined medication protocols that permit the supply and/ or administration of medication in specific clinical presentations
• Inflexible method of medication access; useful in areas where clinical situations can be predicted, e.g. management sexually transmitted infections or contraception provision 
2001
• Health and Social Care Bill 2001 introduces Supplementary Prescribing (legal April 2003) (Great Britain. Health & Social Care Act 2001)
• Clinical management plan between doctor, prescriber & patient sets out incidences when medication can be delivered. Particularly usesful in chronic conditions 
2006
• The Medicines and Human Use (Prescribing) (Miscellaneous Amendments) Order
• Significant change in legislation, independent nurse prescribers able to prescribe all licensed medication within their compentence (excluding controlled drugs)
• Amendment in 2009 to allow provision of non-licensed and mixing of medication, if agreed by employer (Medicines and Healthcare products Regulatory Agency (MHRA), 2009)
2012
• The Human Medicines Regulations 2012 (Statutory Instrument (SI) 2012/1916): No 973 ‘The Misuse of Drugs (England, Wales, and Scotland) Regulations 2012’ 
• Allows nurses and pharmacists to prescribe Schedule 2-5 controlled drugs independently and by PGD. 
• The use of diamorphine, cocaine and dipipanone for the treatment of addiction is excluded from this legislation. 
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1.2.1 Patient group directions 
PGDs are pre-determined medication protocols, which were introduced in 2000 to improve access to 
medications (DH, 2000). PGDs must be signed by a doctor and agreed by a pharmacist and the lead 
professional of the team(s) using them. PGDs authorise groups of registered healthcare practitioners 
to independently supply and/ or administer specific medications in pre-defined circumstances (using 
their own assessment of patient need), without referring to a doctor for a prescription. Supply or 
administering medication using a PGD is not prescribing. Unlike prescribing patients do not need to 
be individually identified prior to PGD use, however their presentation must meet the pre-set criteria 
for legal supply and/ or administration of the medication. PGDs offer no flexibility; if the PGD does not 
cover the patient’s presentation, a prescription from a qualified prescriber is required. PGDs are 
extremely useful in clinical areas where treatment patterns and patient presentations are predictable; 
e.g. management of sexual infections or contraception. PGDs have the benefit of facilitating entire 
teams of registered practitioners to independently deliver medication without the need for additional 
Higher Education Institute (HEI) qualifications (The National Institute for Health and Care Excellence 
(NICE), 2013). PGDs’ legal content is presented in Box 1.1. Legally, PGDs must be reviewed every 
3 years and can include all licensed POM and some controlled drugs. They cannot, however, contain 
unlicensed medications. The person supplying or administering the medication using a PGD cannot 
‘delegate’ another professional to supply, dispense or administer the medication (NICE, 2013). 
 
Box 1.1 PGD legal content 
 Dates they are valid (from – to) 
 Name of medicine and the eligible condition(s) that can be treated using this medication 
 Exclusion criteria, limitations of use and when the patient should be referred/ discussed 
with another healthcare professional 
 Pharmaceutical form(s), strength, dose, route, frequency of administration of medicines 
and the minimum/ maximum times the medicine can be supplied/ administered 
 Relevant warnings, follow-up instructions and arrangements for medical advice 
 How the provision of medication via a PGD will be recorded (The Human Medicines 






1.2.2 Independent nurse prescribing 
The NMC, who regulate all UK registered nurses and their prescribing powers, specify nurses must 
always be aware of their professional, clinical, legal, accountable and ethical positions as nurses and 
prescribers (NMC, 2006; NMC, 2015). To become an INP, candidates must be a registered first level 
nurse, with a minimum of 3 years post-registration experience; the preceding year in the clinical area 
in which prescribing is likely to occur. Candidates should be able to undertake clinical assessments, 
make diagnoses, consider treatment options and create care management plans. Upon successful 
completion of the INP course, registration with the NMC and authorisation from the prescribers’ 
employer must be obtained before nurses can commence prescribing (DH, 2006; NMC, 2006). Only 
an NMC Approved Education Institution (AEI) can provide prescribing training. The programme is a 
combination of 12 clinical training days and 26 theoretical days (minimum) delivered at degree level 
or higher. Designated Medical Practitioners (DMPs) are required to supervise and mentor students 
through the 12 clinical training days (DH, 2006). Evidence suggests one third of prescribing students 
spend the full allocated time with their DMP, while others rely upon other professional colleagues; 
including pharmacists, nurses and other doctors (Latter et al., 2007c). While most students are 
satisfied with their DMP, some also report their DMPs have a lack of time for the role or inadequate 
teaching skills (Latter et al 2007c; Ahuja, 2009; Smith et al., 2014).  
 
1.3 INP versus PGDs 
INP and PGDs both have advantages and disadvantages, summarised in Table 1-2. The key 
differences are that PGDs can be used by large groups of clinical staff through internal competency 
training, however they are extremely restrictive in application and require extensive stakeholder effort 
to create, govern and maintain them (NICE, 2013). By contrast, INP is extremely flexible but can only 
be used by individual nurses who have undertaken appropriate AEI training (NMC, 2015). Both INP 
and PGDs have resource implications which require additional investigation, particularly on costs 
versus returns for the NHS. Two papers (Brookes & Smith, 2007; Wat et al., 2014) argue PGD 
benefits outweighed INPs, particularly as PGDs do not require individual nurses to undertake 
expensive and time-consuming prescribing courses. However, these studies do not consider the 
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complex PGD governance processes, or that PGDs are not always used appropriately in practice 
(Deave et al., 2003; Black, 2012). That being said, should an INP leave employment the investment 
in that nurse is also lost; therefore, PGDs offer suitable resilience should staff leave. Nevertheless, 
university-based training mean that INPs benefit from rigorous, regulated, standardised training which 
provide university credits towards Degree or Masters pathways (NMC, 2006). Similar standards of 
training or academic pathways are not available for PGD training (Bradley and Nolan, 2007). Both 
INP and PGDs are widely reported to benefit clinical practice in various clinical areas (Miles et al., 
2001; Brooks et al., 2003; Deave et al., 2003; Balieff, 2007; Latter et al., 2007a; Stenner and 
Courtenay, 2008; Courtenay et al., 2009a, Courtenay et al., 2009b; Courtenay et al., 2010; Jones et 
al., 2010; Courtenay et al., 2011; Price et al., 2012; Black and Dawood, 2013; Wilkinson et al., 2013; 
Carey et al., 2014; Creedon et al., 2015; Ross, 2015).  
 
Table 1-2 Summary of INP and PGD governance requirements 
Requirements of use INP PGD 
Local Trust permission   
Professional registration & accountability   
Additional registration   
University education   
Flexibility Within competence None 
Range of use Individual nurses 
Individuals/ groups deemed 
locally competent 
INP= independent nurse prescribing, PGD= patient group directions 
 
1.4 Nurse delivery of medications internationally 
Nurses are able to independently prescribe in a variety of countries including Australia, Canada, 
Ireland, Spain, New Zealand, Norway, South Africa, Sweden, the Netherlands, UK, United States of 
America (Kroezen et al., 2011; Gielen et al., 2014), Israel and Poland, and other countries are 
considering doing so (e.g. China (Ling et al., 2018)).  Australia, Canada and the UK also use PGDs/ 
medical directives. The number of countries adopting nurse prescribing has grown considerably within 
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the last two decades (Kroezen et al., 2014c). However, the actual freedom to prescribe varies 
considerably between countries; consequently the term ‘independent nurse prescriber’ does not have 
the same definition globally. Internationally this can refer to a limited formulary of specific medications 
or a wider freedom to prescribe (Gielen et al., 2014). The legal, educational and stakeholder 
conditions heavily influences how nurse prescribing can be integrated into service delivery (Kroezen 
et al., 2011). Research that has reviewed the success of nurse prescribing is limited nationally and 
internationally (Gielen et al., 2014). This study, therefore, focussed predominantly on UK literature to 
support relevant comparisons with UK legislation and clinical practice. 
 
1.5 Overview of medication delivery by nurses in the United Kingdom 
Existing UK literature identified INPs are predominantly based in primary care services (Courtenay, 
Carey & Burke, 2007a; Latter et al., 2007c; Courtenay & Carey, 2008; Courtenay & Gordon, 2009; 
Bhanbhro et al., 2011; Carey et al., 2013; Drennan et al., 2014) but the benefits of independent 
medication delivery are increasingly becoming recognised in a range of secondary care settings 
(Jones, 2009; Cole & Gillet, 2015). It is evident that the job titles of nurse prescribers vary and include: 
nurse practitioners, practice nurses, team leaders and nurse specialists, and the majority of INPs 
significantly exceed the NMC’s three year minimum qualified experience, and nurses have academic 
achievements of degree level or higher (Courtenay, et al., 2007a; Latter et al., 2007c; Courtenay and 
Carey, 2008; Courtenay et al., 2012; Boreham et al., 2013; Smith et al., 2014). Sexual health and 
emergency contraception prescribing are frequently undertaken in primary care (Courtenay & 
Gordon, 2008; Drennan et al., 2014), and medications are delivered for approximately every second 
patient episode in sexual health and emergency departments (Black, 2012).  
A range of organisational, clinical, professional, and patient benefits of nurses’ delivering medications 
have been identified. These benefits primarily focus on improved medication access and patient 
experience (Courtenay et al., 2009a; Courtenay et al., 2009b, Courtenay et al., 2011; Drennan et al., 
2011; Stenner et al., 2011; Bergman et al., 2013; Tinelli et AL., 2013). Studies reported that being 
responsive to patients’ clinical and medication needs facilitated better disease control and symptom 
management (Latter and Courtenay, 2004; Bradley and Nolan, 2007; Stenner and Courtenay, 2008; 
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Wilkinson et al. 2013; Carey et al, 2014). Improved safety associated with medicines management 
have also been found as nurses take responsibility and accountability for their own medication 
decisions (Bradley et al., 2005; Bradley et al., 2007; Bradley and Nolan, 2007; Pontin and Jones, 
2007; Stenner and Courtenay, 2008; Courtenay et al., 2009b; Price et al. 2012; Schirle & McCabe, 
2016), although some studies have identified medication delivery errors by nurses (Carey et al., 2008; 
Dornan et al., 2009; Bates et al., 2010; Avery et al., 2012; Seden et al., 2013). Therefore, safety of 
medicines management needs to remain at the forefront of practitioners’ practice. Improvements in 
communication and therapeutic relationships have also been frequently reported (Latter and 
Courtenay, 2004; Bradley et al., 2005; Pontin and Jones, 2007; McCann et al., 2008; Hobson et al., 
2010; Norman et al., 2010; Dhalivall, 2011; Drennan et al., 2011; Stenner et al., 2011; Wilkinson et 
al., 2013; Ross et al., 2013; Ross 2015), as has closer working relationships between doctors and 
nurses (Avery et al., 2007; Bradley and Nolan, 2007; Earle et al., 2011; Bowskill et al., 2013; Ross, 
2015). Nurses’ independent delivery of medication has been identified as having the potential to 
improve medication adherence, patient involvement, and quality of consultations (Latter et al., 2007d; 
Drennan et al., 2011; Banicek, 2012). From an organisational perspective, implementing nurses’ 
medication delivery has made better use of the workforces’ skills through autonomous practice, which 
has facilitated a more comprehensive and efficient service delivery (Bradley et al., 2005; Bradley and 
Nolan, 2007; Pontin and Jones, 2007; Stenner and Courtenay, 2008; Courtenay et al., 2009b; Black, 
2012; Naughton et al., 2012; Wilkinson et al., 2013; Carey et al., 2014; Creedon et al. 2015). Nurses 
also report that the ability to deliver medicines has improved job satisfaction, self-esteem and 
confidence (Courtenay et al, 2007a; Pontin and Jones, 2007; Stenner and Courtenay, 2008; Jones 
et al, 2010; Gumber and Gajebasia, 2012; Carey et al., 2014; Creedon et al., 2015). Moreover, 
medical staff report that the ability of nurses to deliver medicines enables them to focus on more 
complicated clinical presentations (Earle et al., 2007; McCann et al., 2008; Berry et al., 2008; 
Courtenay et al., 2010; Banicek, 2012, Mac Lure et al., 2013). Medicines delivery by nurses has also 
been reported to facilitate flexible working, saving time for patients as a result of involving fewer 
healthcare professionals across their consultation appointments (Jones et al., 2010; Courtenay et al., 
2011; Drennan et al., 2011; Earle et al., 2011; Ross, 2015). Furthermore, the time spent with patients 
has been reported by nurses as more beneficial, as they are able to focus upon answering patient 
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questions and information provision concerning medication regimens, as opposed to obtaining 
prescriptions from doctors (Bradley and Nolan, 2007; Drennan et al., 2011, Stenner et al., 2011), and 
patients positively valued these interactions with nurses (Latter et al., 2007d; Drennan et al., 2011).  
Barriers related to nurses’ medication delivery have been reported, these barriers primarily associated 
with logistics and medication governance (e.g. difficulties in accessing prescribing stationary, budgets 
or electronic systems). In some areas, doctors and pharmacists have been reported to be reluctant 
to allow nurses to deliver medicines (Bradely and Nolan, 2007; Courtenay et al., 2007a), while 
conversely, other nurses have reported being sent on the prescribing course rather than volunteering 
(Bradley et al., 2005). This has created concern over additional burdens to already heavy workloads, 
and a shift from foundational nursing care to advanced practice roles (Bradley and Nolan, 2007). 
However, many trusts now include nurse prescribing within job descriptions and contracts, suggesting 
medication delivery had become an expectation for nurse practitioner roles (Smith et al., 2014). 
Moreover, a small minority of nurses have reported that they do not feel fully prepared for delivering 
medications following training (Latter et al., 2007c; Smith et al., 2014). Indeed Bradley and Nolan 
(2007) identified that completion of training was seen as the start of the process, rather than equipping 
nurses with lifelong medication knowledge and skills. Confidence was seen to grow with experience 
(Bradley and Nolan, 2007; Cashin et al., 2014). A lack of continuing professional development (CPD) 
opportunities, peer support, and confidence in prescribing skills has also been reported (Courtenay 
et al., 2007b; Latter et al., 2007c; Green et al., 2008; Courtenay and Gordon, 2009; Creedon, 2010; 
Gumber and Gajebasia, 2012; Creedon et al., 2015). However, the main barrier to INP is the 
prescribing programme, and the need to undertake much of this in nurses’ personal time, frequently 
without recompense (Earle et al., 2011; Boreham et al., 2013). 
 
1.6 Background summary 
The expansion of UK legislation has facilitated nurses to deliver medications independently through 
INP and PGDs. Benefits and barriers for both methods have been demonstrated throughout this 
chapter. INP is a flexible method of medication delivery, however, is limited to individual nurses who 
have successfully completed an expensive labour-intensive university course. By contrast, PGDs can 
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be used by entire teams of practitioners following local training, yet are extremely restrictive in clinical 
practice, and require a large amount of local governance. Nevertheless, the integration of INP and 
PGDs has supported organisational, clinical, professional and patient benefits across a wide range 
of clinical specialities. However, the potential for medication errors and barriers to delivering 
medication have been reported. The nature of sexual health means that INP and PGDs are both 
appropriate mechanisms by which sexual health nurses are able to deliver medications 
independently. The next chapter presents an overview of sexual health and the nurses’ role within 
this speciality.   
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This chapter presents sexual health as a clinical speciality, how it is governed/ influenced, STI 
demographics, and the modernisation of the sexual health nurses’ role. 
 
2.1 Sexual health as a clinical specialty 
Sexual health is defined as “a state of physical, emotional, mental and social well-being in relation to 
sexuality; it is not merely the absence of disease, dysfunction or infirmity. Sexual health requires a 
positive and respectful approach to sexuality and sexual relationships, as well as the possibility of 
having pleasurable and safe sexual experiences, free of coercion, discrimination and violence. For 
sexual health to be attained and maintained, the sexual rights of all persons must be respected, 
protected and fulfilled” (WHO, 2006). The concept of being sexually healthy therefore goes beyond 
being free from sexual infections, but incorporates a holistic approach of contentment, freedom and 
wellbeing. Individuals, communities and cultures all have different perceptions and experiences of 
what constitutes good sexual health.  Consequently healthcare strategies must be sympathetic to the 
requirements and influences affecting sexual expression and choice in the populations they serve. 
This permeates to all healthcare fields as sexual health can be affected by other medical and 
psychological conditions or treatments (Evans, 2013). 
 
Sexual health specific services in the UK aim to support and promote healthy sexual lives. Delivery 
of these services has historically been through distinct specialities: Sexual & Reproductive Health 
(SRH); Genitourinary Medicine (GUM) and Psychosexual. These services are now moving to an 
integrated approach providing contraception; STI screening, management and prevention; 
termination of pregnancy services; and health and relationship promotion (DH, 2013). The benefits of 




2.2 Sexual Health Legislation and Governance 
There are a number of factors that govern and support the complex array of sexual health services. 
Services in the UK are mostly open-access, delivered free to the user and include the provision of 
medication with no prescription charges, regardless of the patients’ country of origin (DH, 2013). 
Users’ identity and confidentiality (with regards to STI screening, diagnosis and treatment) is 
protected through the ‘NHS (Venereal Diseases) Regulations 1974’, and the ‘Health and Social Care 
(Safety and Quality) Act 2015’. This legislation restricts an individual’s information being shared 
unless it is for treating or preventing the spread of an STI. Delivering free, open access and 
confidential services to individuals aims to improve sexual health on a public health level. 
Confidentiality under existing legislation does, however, have limitations, particularly where abuse is 
evident or suspected, or other vulnerabilities are exposed (e.g. sexual exploitation, child abuse, 
domestic violence, sexual assault, safeguarding issues, female genital mutilation). This is particularly 
relevant when managing children, young people or vulnerable adults (Family Law Reform Act 1969, 
c.46; Sexual Offences Act 2003, c.42; British Association for Sexual Health & HIV (BASHH), 2010; 
BASHH 2011, Care Quality Commission (CQC), 2014).  
Policies and frameworks from a range of sources heavily influence standards and delivery of services. 
Three distinct ‘Levels’ of service provision were set out based on the complexity of care: Level 1: 
asymptomatic care, Level 2: uncomplicated symptomatic (excluding men who have sex with men, 
male discharge and ulceration) and Level 3: specialist services (DH, 2001). Strategies for 
improvements in contraception provision and reducing health inequalities in young people, and other 
vulnerable groups, have since been implemented through the DH’s (2013) ‘A Framework for Sexual 
Health Improvement in England’. Services need to continually provide innovative ways of working to 
increase capacity and keep control of costs (DH, 2013). One such example involves services 
managing asymptomatic patients through online/ postal sexual health services to free-up specialist 
services for more complex patients (London Councils, 2017; SH:24, 2017). There are two extremely 
influential organisations in sexual health that provide an array of evidence-based guidelines for 
services to follow, these are BASHH (which provides guidelines on genital, STI and HIV screening/ 
management) and the Faculty of Sexual and Reproductive Health (FSRH: which provides guidelines 
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on reproductive health/ contraception). These organisations’ clinical guidelines provided the 
benchmark for clinical assessments made throughout this study. 
 
2.3 Demographics of sexually transmitted infections 
 
Despite a 4% (n=19,344) decrease in STI rates between 2015 and 2016, England continues to have 
high rates of STIs sustaining a major public health concern. In 2016, there were 417,584 new 
diagnoses of STIs in England; the most common being chlamydia (n=202,546, 49%), genital warts 
(n=62,721, 15%) gonorrhoea (n=36,244, 9%) and non-specific genital infections (n=36,774, 9%). 
Under 25 year olds, men who have sex with men (MSM) and black & minority ethnic (BME) groups 
accounted for having the highest levels of infection (PHE, 2017). A range of issues that influence 
sexual behaviour and risk include: confidence, religious and culture beliefs, peer pressure, coercion, 
abuse and interpretation of social norms (DH, 2013). Access to sexual partners, and potential abuse, 
is easily facilitated through social media, smart phones and the internet (BASHH, 2010). The use of 
drugs and alcohol is also related to having a higher number of sexual partners and inconsistent 
condom use (BASHH, 2010). Young people aged 15- 25 are at particular risk of acquiring STIs and 
unwanted pregnancy because of inexperience, lack of knowledge, inability to negotiate safer sex, 
vulnerability or abuse (BASHH, 2010; DH, 2013). Young people account for 62% (n=66,701) of 
heterosexual chlamydia diagnoses, 50% (n-8,896) of gonorrhoea and 49% (n=28,540) of genital 
warts. Higher rates of infection are found in urban regions, particularly in areas of deprivation where 
cultural, economic and behavioural influences affect higher risk taking and lower health-seeking 
behaviours. Urban areas also contain higher concentration of BME groups, putting them at higher 
risk of STI and unwanted pregnancy (PHE, 2017). MSM are at higher risk due to multiple sexual 
partners and risker sexual behaviour (e.g. anal sex without condoms). The highest rates of syphilis 
(n=4,788, 81%) are disproportionately found in MSM (PHE, 2017). There has, however, been a 
decrease in teenage pregnancy rates, which are now at their lowest levels since records began in 
1969. This has been attributed, in part, to the use of long-acting reversible contraception (DH, 2013; 




2.4 Modernisation of nursing roles in sexual health 
Historically the sexual health nursing role was one of chaperoning and procedural duties (Miles et al., 
2002), but since 1996 (Davis, 2008), the role has progressively expanded to include autonomous 
management of full episodes of care. This involved extending nurses’ roles to facilitate an increase 
in patient capacity by distributing the workload to the most appropriately skilled practitioners 
(Robinson & Rogstad, 2003; DH, 2013). The specialist sexual health nurse practitioner role involves 
taking a sexual history, performing a physical examination, making a diagnosis and delivering 
medications. Nurses are fully responsible and accountable for patients they independently manage 
(Miles et al., 2002; Roberts, 2005; Keefe, 2008). Nurse practitioners and nurse consultants are now 
commonplace in sexual health services (MedFASH, 2008; DH, 2013) following the integration of 
competency-based training, assessment and clinical supervision (Miles et al., 2002; Robinson & 
Rogstad, 2003). A questionnaire survey of English GUM clinics, which obtained a 91% (n=190) 
response rate, identified that 78.9% (n=150) of clinics had some form of nurse-led clinic (Miles et al., 
2002). Despite such expansion in the sexual health nurses’ role since 1996, there was very limited 
recent evidence found with regards to current advanced practice roles in sexual health. 
 
Nevertheless, nurse practitioners (NP) working within sexual health are expected to practice at a high 
level of competency to maintain safe, appropriate and cost-effective care (DH, 2013; MedFASH, 
2014). Additional competency-based training and HEI qualifications, preferably Masters, are 
advocated (RCN, 2012). A previous lack of university-based preparedness for sexual health nurses 
has been noted (Estcourt et al., 2011); however, the education arm of BASHH introduced ‘Sexually 
Transmitted Infection Foundation’ (STIF) training, which acts as an introduction to STI management. 
STIF Competencies then provide nationally recognised levels of clinical competence from novice to 
expert, i.e. ‘Fundamental’, ‘Sexual health advising’, ‘Intermediate’ and ‘Advanced’ (BASHH, 2018). 
Moreover, the ‘Diplomate Assessment of the Faculty of Sexual & Reproductive Healthcare’ (DFSRH: 
FSRH, 2014) and the ‘Diploma of the Institute of Psychosexual Medicine’ (Institute of Psychosexual 
Medicine, 2018) have recently been made available to nurses, after previously being applicable to 
medical staff only. Although there is a move to introduce BASHH STIF competencies and the DFSRH 
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as standard across all sexual health services, NP training and assessment is currently governed 
locally by individual services.  
One component that has been consistent throughout the literature is the need for sexual health NPs 
to have access to medication for STI management and contraception provision (Handy, 2002; 
Dinsdale & Duffin, 2004; Roberts 2005; Robinson, 2009; DH, 2013; Wilson 2014). Where nurses were 
working in advanced practice roles in 2002, a range of medication pathways were evident, including: 
transferring patients to medical teams; doctors prescribed and nurses supplied; medication protocols; 
and, of concern, a small number of nurses provided medications using retrospectively obtained 
prescriptions (Miles et al., 2002). One study concluded that sexual health nurses frequently delivered 
medication, and that nurses who had independent access to medication were more likely to complete 
episodes of care autonomously, as compared to nurses who did not have independent access (Black, 
2013). Therefore, in order to deliver sexual health services effectively and legally, independent access 
to medication by nurses has always been considered an essential component of their role (Miles et 
al., 2002; Walsh, 2004; Keefe, 2008; Black, 2013).  
The next chapter provides a general overview of the empirical evidence related to the delivery of 
medicines by nurses, and provides support for this research.  
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 LITERATURE REVIEW OF EMPIRICAL EVIDENCE 
 
3.0 Introduction 
The significant changes to medication legislation and expansion of nurses’ clinical roles in sexual 
health explored in Chapters 1 & 2 demonstrated a considerable increase in sexual health nurses’ 
clinical responsibility. Nurses’ ability to assess, diagnose and manage patients’ care episodes is 
facilitated by independent access to medication. While medication access supports autonomous 
practice, it is essential that patients receive safe, high quality and cost effective care. This chapter 
presents a review of the current empirical evidence related to safety and appropriateness of nurse 
prescribing/ patient group directions (PGDs); patients’ experience of nurses’ independently delivering 
medication and the associated cost implications. The literature will demonstrate gaps in the current 
evidence base to justify undertaking this study; sexual health being an area where nurses regularly 
deliver medication independently (Courtenay & Gordon, 2009; Black, 2013). This chapter presents 
the scope of the literature review, detailing the search process, and then presenting the empirical 
research evidence.  
 
3.1 Scope of review 
Nurse prescribing and PGD literature from 2006 onwards was searched as these were more likely to 
represent nurse medication delivery practice following the significant change in legislation permitting 
specially trained nurses to prescribe any licensed medicines (and some controlled drugs: DH, 2006). 
In line with the overall aims of the research, available evidence was identified and analysed under 
three key questions: (i) to determine if nurses use their access to medications responsibly, rationally 
and in accordance with clinical standards, (ii) to explore the patient experience of nurses delivering 
medication, and patient satisfaction as service users, (iii) to investigate the resource and cost 
implications of nurses delivering medication independently and issues of cost-effectiveness. Due to 
the limited volume of PGD evidence from 2006, the search dates were subsequently extended to 
include literature from 2000 onwards, which yielded four more papers. The relevant literature was 
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searched and scrutinised with the intention of exploring independent nurse delivery of medication 
within sexual health.  
 
3.2 Search strategy 
A comprehensive search strategy was used to search professional and academic journals for 
literature related specifically to nurse prescribing and PGDs. The terms used to search the British 
Nursing Index (ProQuest); the Cumulative Index to Nursing and Allied Health Literature (CINAHL); 
Medline/Ovid/Embase/PschInfo are presented in Table 3-1. Given the focus of the research enquiry, 
the search strategy focussed specifically on three aspects: ‘safety & appropriateness’; ‘patient 
experience’ and ‘health economics/ cost’. The term ‘supplementary’ was not included as this type of 
prescribing is rarely appropriate for sexual health as patients attend infrequently, therefore the 
creation of clinical management plans (required in supplementary prescribing) are generally 
impractical. The terms ‘prescription*’; ‘treatment’; ‘formulary’ were removed during the search using 
MedLine/Ovid/Embase/PschInfo databases as results rarely referred to nurses delivering medication. 
The search areas were connected by: [‘Nurse’] AND [‘Prescribing’ OR ‘PGD’]. 
 
Table 3-1 Search terms 
Search area Words used in search strategy 
Nurse (independent) [Nurs* OR independent OR non-medical] 
Prescribing [Prescrib* OR access OR prescription* OR treatment OR formulary] 
PGD [“Patient group direction*” OR “medication protocols” OR guidelines OR PGD] 
 
 
Papers’ titles were used to initially identify potential articles for inclusion in May 2015.  Abstracts were 
read to determine suitability and relevance to the search criteria. Papers read in full were entered 
onto a spreadsheet to chart relevant data and summarise papers for potential use in the review. Due 
to the limited PGD papers, a secondary search was undertaken in July 2015. Figure 3-1 summaries 
the process taken using a Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) diagram.  
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The following inclusion/ exclusion criteria were used to determine if an article was suitable for 
inclusion within the literature review: 
Inclusion: 
 Published studies in peer reviewed journals incorporating empirical evidence only (inclusive 
of research, detailed audits and/or service reviews). 
 PGD use after 2000 and independent nurse prescribing after 2006 
 Papers published in English 
Exclusion: 
 Articles not based on primary research, audit or service review 
 Studies exploring issues not related to the three key search themes (e.g. nurse/ stakeholders’ 
perceptions, continuing professional development (CPD), training or education) 
 Studies assessing supplementary prescribing (search focussed on medication delivery 
methods likely to be used in sexual health). Exception: Norman et al. (2010), which was 
reviewed as it was the only paper that reported an economic assessment involving 
independent nurse prescribing or PGD use.   









3.3 Inclusion of papers and assessment of quality 
 
Thirty-eight papers are included for review in this chapter; three papers had content relating to both 
safety and patient experience (Courtenay et al., 2009a; Courtenay et al., 2009b; Wilkinson et al., 
2014); and nine of the papers made reference to costs/ resources, but did not undertake specific 
economic assessments. Figure 3.2 outlines the structure of the analysis in this chapter.  Papers were 
categorised as either ‘descriptive’ or ‘evaluative’. For the purposes of this thesis ‘descriptive’ papers 
predominantly described existing practice (i.e. based on audit, retrospective notes review) or 
situations (i.e. qualitative methods or opinions/ attitudes surveys). Papers are presented as 
‘evaluative’ if they used validated research tools to measure outcomes from the collected data. 
Relevant information from each study is presented in: Table 3-2 Descriptive safety and 
appropriateness papers studies (10 papers); Table 3-3 Evaluative safety and appropriateness papers 
studies (13 papers); Table 3-5 Descriptive patient experience papers (15 papers); Table 3-6 
Evaluative patient experience papers (two papers); and Table 3-7 Health economics literature (one 
evaluative paper). 
 
The assignment of ‘Strong’; ‘Moderate’; and ‘Weak’ to determine papers’ quality is a subjective 
process (Aveyard, 2014). In order to provide a level of objectivity in assessing the papers’ quality, the 
Critical Appraisal Skills Programme (CASP, 2013) tools were used to support critical analysis. The 
CASP tools prompt the assessor to consider 12 questions across three sections, involving: validity of 
the study; consideration of the results; and will the results help locally (CASP, 2013). Papers receiving 
0-4 positive responses to the 12 questions were considered weak, 5-8 were moderate and 9-12 were 
strong. The methodology, sample size, participants involved, detail of the data presented and analysis 
method were considered in conjunction with relevance to this thesis to assign strength. Overall 18 
papers were classified as strong; 21 as moderate; and two as weak. The quality of the paper is 






Figure 3-2 Structure of presented papers 
  
Structure of literature review areas and themes  
 Safety and appropriateness of nurse prescribing (23 papers) 
o Overview of prescribing errors incidence and nature 
 Three papers: Dornan et al., 2009; Avery et al., 2012; Seden et al., 2013 
o Prescribing practice: doctors versus nurses 
 Four papers: Dornan et al., 2009; Avery et al., 2012; Carberry et al., 2012; 
Seden et al., 2013 
o Safety of nurse prescribing 
 Seven papers: Latter et al., 2007a; Carey et al., 2008; Carey et al., 2009; 
Courtenay et al., 2009b; Avery et al., 2012; Black, 2013; Wilkinson et al., 
2013 
o Appropriateness of nurse prescribing consultations 
 Eight papers: Latter et al., 2007a; Latter et al 2007b; Courtenay et al., 
2009a; Courtenay et al, 2009b; Sibley et al., 2011; Latter et al., 2012; 
Naughton et al., 2012; Riley et al., 2013  
o Safety of patient group directions 
 Six papers: Miles et al., 2001; Brooks et al., 2003; Deave et al., 2003; 
Baileff, 2007; Williams & Know, 2011, Black & Dawood, 2014 
o Nurse prescribing versus PGDs 
 One paper: Black & Dawood, 2014 
o Organisational nurse prescribing governance 
 Two papers: Dornan et al., 2009; Smith et al., 2014 
 
 Patient experience and nurse prescribing (17 papers) 
o Patients’ expectations of nurse prescribing  
 Five papers: Berry et al., 2008; McCann & Clark, 2008; Banicek, 2012; 
MacLure et al., 2013; Natan et al., 2013 
o Patients’ experience of nurse prescribing 
 12 papers: Courtenay et al., 2009a; Courtenay et al., 2009b; Hobson et 
al 2009; Courtenay et al., 2010; Jones et al., 2010; Courtenay et al., 2011; 
Dhalivaal, 2011; Drennan et al., 2011; Earle et al., 2011; Ross et al., 
2013; Wilkinson et al., 2013; Tinelli et al., 2013 
 
 Costs (10 papers) 
o Resource and cost assessments 
 9 of the papers refer to cost or resources (but no formal assessment): 
Latter et al. (2007b); Carey et al. (2008); Courtenay et al. (2009b); 
Courtenay et al. (2010); Courtenay et al. (2011); Earle et al. (2011); Latter 
et al. (2012); Naughton et al. (2012); Wilkinson et al. (2013). 
 1 paper cost consequence analysis: Norman et al., 2010 
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Table 3-2 Descriptive safety and appropriateness papers 
Author Setting & participants 
Research aim/ 
question 
Design Sample size Key findings Quality of study 
Baileff 
(2007) 
Two walk-in centres, 
England, UK 
To audit the 
standard of 
practice on supply 
and administration 












10 different drugs used. No evidence of unsafe 
practice. PMH, allergies (191, 96%) & current 
medication (188, 94%) consistently recorded; 
inclusion (191, 96%) and exclusion (190, 95%) 
criteria largely met; Poorer documentation of 
contraindications (97, 49%) and side effects (94, 
47%). Drugs named 99% (199) but dose poorly 
documented 76% (151) 
Moderate 
+ Strong audit design; Defined 
measurement standards; 
Good sample size. 
- Single person (consultant 




One A&E & one sexual 
health department, 
England, UK 


















(382 in both 






569 drugs, 409 patients, 675 diagnoses; frequent 
prescribing (A&E: 197, 51.6%; sexual 212, 
55.5%); 99.8% (568) safe prescribing; poor 
documentation (sexual: 2) and inappropriate 
medication for allergy (A&E: 1). Prescribing 
statistically facilitated independent practice in 
sexual health (chi-squared, p<0.001) 
Moderate 
+ Large sample size; Random 
sample used 
- Single organisation; Single 
researcher interpretation, open 
to bias; Validated research 




One A&E & one sexual 
health department, 
England, UK 
To explore nurse 
prescribing versus 















PGD users: 117 individual drugs, 25 different 
medications; patients provided medication: 32.3% 
(76). Nurse prescribers: 274 drugs, 29 different 
medications, 403 diagnoses; patients provided 
medications: 51.6% (197) patients. Frequency of 
medication delivery statistically significant (chi-
squared, p<0.001). Nurse prescribers 99.7% (381) 
safe medication decisions; 0.3% (1) provision of 
penicillin to allergic patient. Restrictive PGDs: 
11.8% (9) of drugs not covered by the PGD. No 
difference in independent practice between 
methods (chi-squared, p=0.710) 
Moderate 
+ Large sample size, although 
difference in numbers in each 
group; Random sample used 
- Single site; Data analysis 
open to bias; Validated 
research tools not used. 
Brooks et 
al. (2003) 
One walk-in centre, 
England, UK 
To assess nurses’ 
record-keeping 
and knowledge for 
antibiotic PGDs  
Audit of clinical 
records October 




99.3% (841) medications supplied in accordance 
with PGD. 0.7% (6) of medication given outside 
PGD restrictions. Poor documentation noted, 63% 
(534) notes documented allergy or 
contraindication information. Improvements 
needed in documentation concluded. 
Moderate 
+ Random second check of 
results; Large sample size; Set 
standards used for assessment 
- Audit design in single site 
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Author Setting & participants 
Research aim/ 
question 




Three intensive care 









Audit of ICU 
prescriptions over 





1,418 drug entries, 23.8% (338) from nurses. 
Error rates: overall 2.8% (40); nurses 0.6% 
(2/388); trainee medical staff errors (33/984, 
3.4%); consultant errors (5/73, 6.8%). Error rates 
statistically different between groups (p<0.01; chi 
squared test), nurses (2/338, 0.6%) being least 
likely to make errors, consultants (5/73, 6.8%) 
most likely. Nurses errors: illegible prescription 
(1); incorrect dose, time or rate (1) 
Moderate 
+ Audit design in multiple sites; 
Involved all prescriptions on 
separate days; Adequate 
patient size, large number 
individual prescriptions 
- Validated tool not used, 




Four general practices, 
England, UK  
To explore 
prescriptions 
issued to patients 
with diabetes by 
nurse prescribers 
in general practice 




criteria. Oct 2007 








Prescription compliance: generic prescribing; 
products; dose & preparation; terminology; written 
in ink and used appropriate forms (19, 100%); 
writing dosage number/words (18, 94.7%). 
Number of days (2, 10.5%); clear accurate 
frequency/ timing instructions (7, 36.8%); supply 
quantity (11, 57.9%). Overall nurses wrote 
appropriate prescriptions; however, extra vigilance 
required for accurate documentation.   
Moderate 
+ Multiple sites, large data 
collection timescale; Used 
national standards for 
prescription writing 




20 walk-in centres, 
England, UK 









PGDs against 21 
legal standards, 
Feb 2001 & 












7/20 documents contained all legal aspects; all 
documents included drug description; clinical 
condition; clinical situation; dosage; frequency; 
strength; pharmaceutical form (20, 100%). Less 
consistency: valid from date; staff qualified to use 
PGD; signed PGD; administration route (each 12, 
60%); record-keeping (11, 55%) and expiry date 
(10, 50%). Clinical notes review identified 65% 
(5,074/7,823) of required documentation recorded. 
Drug description, clinical condition & situation 
consistently recorded (all 98%); relevant warnings 
(15%), extra contraception warnings (13% of 122 
cases) and pharmaceutical form (6%).  
Moderate 
+ Multiple sites with strong audit 
design; Large sample of clinical 
notes reviewed 
- Data collection at introduction 
of PGD legislation, likely out-of-





Single site sexual 
health clinic, England, 
UK  
To audit the 
supply of 
medications using 

















Three separate PGDs: 31.4% (128) nurses 
consultation required medication; 14.7% (60) 
doctor prescription; 14.5% (59) by PGD; 2.2% (9) 
by PGD and prescription. Review of 36 case 
notes: 37 supply of medication by PGDs (1 patient 
need medication from 2 different PGDs); 78.4% 
(29) were compliant, remaining 21.6% (9) clinically 
appropriate, but outside PGD limitations.  
Moderate 
+ Large sample size for PGD 
use, adequate sample size for 
documentation review 
- Only two PGDs used not 
covering sexual infections 
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Author Setting & participants 
Research aim/ 
question 























Leaders included PCT (26), acute/ foundation (37) 
and mental health (23) respondents. Responses 
identified: non-medical prescribing committee 
(PCT (P) = 63%; acute (A)= 74%; mental (M)= 
50%); Non-medical prescribing policy up-to-date 
(P= 96%; A= 97%; M= 95%); Up-to-date 
controlled drugs policy (P= 83%; A=94%; M= 
80%); Clear lines of responsibility & accountability 
(P= 96%; A= 97%; M= 95%); Definition of scope 
of practice (P= 75%; A= 85%; M= 95%); Systems 
for managing poor performance (P= 67%; A= 
86%; M= 90%). 
Strong 
+ National survey; Good 
representation of NHS 
providers (despite response 
rate); 
Coverage of different types of 
service providers; 
- Reliance on accurate 





Single Emergency Care 
Centre, England, UK. 
To identify use 
frequency of PGD 
use, PGDs are 
used appropriately 
and determine if 
additional PGDs 
were required.  
Audit of clinical 
records where a 
PGD was used, 
over two 









in first audit, 
121 in second 
= 234 notes in 
total 
16/47 PGDs used on both occasions; most 
commonly used for analgesia (169, 72%), eye 
care (45, 19%) and vaccinations (12, 5%). 
Compliance with clinical condition: first audit (1st) 
87%; second re-audit (2nd) 96% compliant. 
Inclusion criteria compliance: 1st 99%; 2nd 96% 
complaint. Exclusion compliance: 1st 97%; 2nd 
98%. Appropriate dose: 1st 89%; 2nd 94%. 
Quantity of medication: 1st 92%; 2nd 96%. 
Documentation in clinical records: improved 
between 1st and 2nd, however no specific data 
presented. PGD users signed the PGD register: 
1st 61%; 2nd 65%.  
Moderate 
+ Re-audit results included 
- Single site; Large number of 
PGDs not reviewed; Limited 
raw data presented (over 

























































































































Error rate 12.2% (737/6048: 95% CI 10.5%-13.6%): 
247 prescribing errors; 55 monitoring errors; 427 
suboptimal prescribing, 8 legal problems. Most 
common drug types involved in errors: 
cardiovascular (41, 16.6%); skin (39, 15.8%); central 
nervous system (33, 13.4%). 17.8 % (1,200) patients 
received at least 1 medication. Error risk factors: 
patients aged 75 years and older (129, 38%); 
patients receiving 5 or more drugs (471, 30.1%); 
patients receiving 10 or more drugs (172, 47%). Most 
common prescribing errors: incomplete information 
on prescription (74, 30.0%); dose/strength errors (44, 
17.8%); incorrect timing (26, 10.5%). Error severity: 
42.4% (128) minor; 54.0% (163) moderate; 3.6% (11) 
severe. Majority of prescribing errors from GP 
partners (4859, 80.3%); nurses’ error rate: 1.0% (60). 
Prescribing/ monitoring errors not associated with 
type of prescriber. Modelled prescribing error risk 
factors: additional prescribed items increases error 
risk by 16% (odds ratio (OR) 1.16, 95% CI 1.12-1.19, 
p<0.001); male patients (OR 0.66, 95% CI 0.48-0.92, 
p=0.013); aged less than 15 (OR 1.87 95% CI 1.19-
2.94, p=0.006); aged 65-74 (OR 1.68 95% CI 1.04-
2.73, p=0.035); aged 75 and over (OR 1.95 95% CI 
1.19-3.19, p=0.008). Risk of nurses making error 
compared with doctors: OR 1.55 (95% CI 0.47-5.13, 
p=0.469);  Interviews & root cause analysis: range of 
influences on medication errors, relating to the 
prescriber, patient, the team, the working 
environment, the task, the computer system and the 
primary/ secondary care interface. Education and 






















































on Rx errors 










= 27 before 














ion chart  
Reduction in medication errors from 520 to 146 after 
DSN intervention; a mean reduction of 21 errors 
(p=0.016) and 3 days reduction in mean in-patient 
stay (17.5 days (IQR 10.25-46.75) to 14.5 days (IQR 
9.75-32.25: independent sample t-test, p=0.15). Most 
common errors: medicines not signed as given (340) 
and incorrect/unclear prescribing (189). Maximum 
errors in individual patients reduced from 130 to 33 
with DSN. Nurse prescribing improves patient 





























































Good consultation communication (33, 100%); 
sensitive issues managed well (32, 100%); clear 
instructions regarding medicines (28, 96.6%); 
associated risks and benefits (230, 92%); allergies 
not asked (4, 20%); side effects advice (15, 75%). 



































































Nurses consistent at planning review (yes= 97.1%); 
identifying chief compliant (94.3%); exploring 
management (91.4%). Less consistent with 
considering non-pharmacological options (no= 
11.4%); exploring symptoms (11.4%), allergies (5, 
14.3%) and OTC/ herbal medications (77%); 













































































































Error rate 8.9% (11,077/ 124,260): FY1 8.4% error 
rate (4190/50,016); FY2 10.3% (3,568/ 34,781); 
consultants 5.9% (188/3,177); nurses 6.1% (60/977). 
Nurse versus consultants prescribing errors: OR 1.00 
95% CI 0.71-1.39. Admission most likely for an error 
to occur (13.4%, 5,973/ 11,079); patients 70% more 
at risk than discharge (OR 1.70 95% CI 1.61-1.80). 
Most common errors: medication omission (3,272, 
29.8%); under-dose (1,221, 11.1%); overdose (936, 
8.5%) and strength/ dose missing (815, 7.4%). 
Doctors rely heavily on pharmacists and nurses to 
identify errors, FY1 inadequately supported in 
prescribing. Errors influenced by complex network of 
contextual factors, most commonly busy stressful 















































































































Prescribing frequency 2.82 consultations (range 
1.58-6.45). Prescriptions well written: strength (86, 
99%); dose (110, 95%); frequency (116, 95%); 
patients’ age/DOB (127, 96%). Nurses demonstrated 
range of assessment and diagnostic skills. All 
prescriptions appropriate for Nurse Prescribers’ 
Extended Formulary (NPEF). Nurses identified chief 
complaint (111, 94%); presenting symptoms (110, 
93%). Less consistent: allergy (42, 36%); OTC 
medication (40, 34%); and exploring family history 
(15, 13%). Good compliance with written 
prescriptions. Contemporaneous notes made in all 
cases, but specific details not recorded: diagnosis 
(21, 21%); management plan (40, 34%); assessment 




































































































Nurses overall prescribe appropriately on all aspects 
of the MAI: indication for medication 84% (70), not 
indicated 8% (7); effective 83% (69), ineffective 2% 
(2); insignificant medication interaction 63% (53), 
significant interaction 10% (8); insignificant 
medication disease interactions 64% (54), significant 
8% (7); correct directions 76% (64), incorrect 
directions 18% (15). Overall appropriateness 
concluded, however, areas to improve practice and 























































































Nurses make appropriate and safe prescribing 
decisions: indication for drug 93%, no indication 7%; 
effective for condition (96%), not effective 4%; 
dosage correct 91%, incorrect 9%; directions correct 
88%, incorrect 12%; directions practical 96%, not 
practical 4%; drug-drug interactions appropriate 97%. 
Highest area of nurses’ inappropriateness: correct 
directions given (12%) and cost of prescribed drug 
(16%). Nurses (and pharmacists) safe and 
appropriate prescribers, although improvements in 
history taking, assessments and diagnostic skills 
identified. STATA software: high level of appropriate 








































Differences of opinion between reviewers, low inter-
rater reliability (Cohen’s kappa statistic score 0.19; 


























































Appropriate medication 95% (197); effective for 
condition 96% (199). Most disagreement: treatment 
duration; reviewer 1: 99% (205) appropriate: reviewer 
2: 77% (161). Removal of duration increases 
reliability to 0.41 (moderate reliability), giving 
moderate inter-rater score. Overall nurses safe and 


















































































Consultation length: GPs (10.1 minutes; SD=4.6 m); 
nurses (11.2 minutes; SD=6.5m); Pharmacists 
statistically spend longer with patients (18.2 minutes; 
SD= 9.7m; p<0.0001). Pharmacists (81%, 299) & 
nurses (72%, 517) statistically more likely to identify 
concerns and act on cues than GPs (53%, 398). 
Most common reason for not acting: not 
acknowledging an issue raised by the patient (GP 
26%, nurse 14%, pharmacist 10%), redirection (GP 
15%, nurse 11%, pharmacist 9%) or interrupting the 



























































Error rate: 10.9%, but 43.8% (1857) of prescriptions 
have errors; range 20% to 60% across sites; 3,011 
errors identified; 41.9% (1,264) minor; 54.1% (1,629) 
significant; 3.6% (109) serious and 0.3% (9) 
potentially life threatening. Non-medical prescribing: 
0.8% (35) of all prescriptions, with 25.7% (9) error 
rate. Multivariable analyses: overall risk of error 
increased 14% for each additional item. More errors 
at admission than discharge (OR 1.16, 95% CI 0.70 
































linked to grade of prescriber: error rates junior 
(49.1%; 729/1,484), mid-grade (48.1%; 176/366); & 
newly qualified (39.8%; 718/1,805) doctors. Nurse 
prescribers (25.7%; 9/35) had a lower prescribing 
error rate than consultant doctors (32.4%; 46/142). 
Multivariate logistic regression modelling: risk of 
nurses making an error compared with doctors: OR 































































Mean 4.4 medications discussed per consultation. 
Predominantly cardiovascular (28.8%) and endocrine 
(27.5%) drugs discussed. 260 instances of medicine 
discussion identified. The most frequently raised 
themes were ‘medication named’ (231, 88.8%), 
usage of medication (170, 65.4%) and instructions 
(126, 48.5%). Less frequently discussed: ‘reasons for 
medication’ (22, 8.5%) and ‘concerns about 
medication’ (7, 2.7%). Preponderance of initiative 
score 0.51 (-1 more patient to +1 more nurses), 

















































































1,274 patients, 3,402 prescribing events. Patient 
notes audit (117): no adverse DSN prescribing 
events; 3.9% (9/227) prescription administration 
errors: missed signature; registration number; date & 
amount to dispense. DSN independent practice: 
94.2% (3,206/3,402); dual consultations: 2.6% (89); 
retrospective prescribing: 3.1% (107). Rubric rating 
for quality, safety and clinical appropriateness of 
DSN prescribing: excellent. Rubric for DSN 




















3.4 Safety and appropriateness of nurse prescribing 
Twenty-three papers explored safety and/ or appropriateness of independent nurse delivery of 
medication; 10 descriptive (Table 3-2) and 13 evaluative (Table 3-3). The papers were categorised 
into seven main themes: 1) overview of incidence and nature of prescribing errors; 2) prescribing 
practice: doctors versus nurses; 3) safety of nurse prescribing; 4) appropriateness of nurse 
prescribing consultations; 5) patient group directions safety; 6) nurse prescribing versus PGDs; and 
7) organisational nurse prescribing governance. Each of these themes are presented below. 
3.4.1 Overview of prescribing errors incidence and nature 
Three papers used quantitative methods to explore the incidence and nature of prescribing errors in 
general practice (Avery et al., 2012) and hospitals (Dornan et al., 2009; Seden et al., 2013) in 
England. While predominantly focussing on doctors, nurses’ prescribing data was also captured; 
however, nurses prescribed considerably less frequently compared to doctors. A prospective review 
of medication charts (Dornan et al., 2009; Seden et al., 2013) and retrospective review of clinical 
records (Avery et al., 2012) determined a range of prescribing error rates ranging from 8.9% (Dornan 
et al., 2009); 10.9% (Seden et al., 2013); and 12.2% (Avery et al., 2012). Seden et al. (2013) identified 
a prescribing error rate of 10.9% per prescribed item; however, 43.8% of prescribing charts reviewed 
contained at least one prescribing error, which has wide-ranging implications for patients’ safety. 
Within GP services, logistic regression identified one in eight patients were at risk of a prescribing 
error, or, one in 20 items were provided inaccurately (Avery et al., 2012). For each additional drug 
prescribed, the chance of an error occurring was found to increase by 16% in primary care (Avery et 
al., 2012) and 14% in secondary care (Seden et al., 2013). Certain categories of patients were found 
to be at higher risk of prescribing errors, including: the young, the elderly, those on multiple 
medications and certain disease specific drugs; most commonly cardiovascular, skin and central 
nervous system. Common prescribing errors in primary care included incomplete information on the 
prescription including dose/ strength errors and incorrect timing of doses (Avery et al., 2012). Within 
secondary care omission of medication at hospital admission was the most common error, followed 




Exploring the causes of prescribing errors using interviews, focus groups (Dornan et al., 2009; Avery 
et al., 2012) and root cause analyses (Avery et al., 2012), multiple organisational and individual 
factors have been identified as frequently interacting to cause the error. Organisational influences 
include workload, staffing levels, clinical complexity of the environment/ ward and shift patterns. 
Individual issues include: a lack of knowledge (drug, therapeutic or of the patient) or lack of continuing 
professional development; poor labelling, poor handwriting or documentation; inaccurate histories; 
poor communication or mathematical skills; transcription errors; and distractions (Dornan et al., 2009; 
Avery et al., 2012).  The comprehensive nature of enquiry and large sample sizes associated with 
these studies provides a solid basis from which the how, when and why prescribing errors occurs 
within both primary and secondary care services can be understood.  
 
 
3.4.2 Prescribing practice: doctors versus nurses 
Dornan et al. (2009), Avery et al. (2012) and Seden et al. (2013) each utilised a panel of experts to 
assign severity categories to prescribing errors based on the potential consequences to patients’ 
safety. Scrutinising data specifically from the nursing perspective, Dornan et al. (2009) found that 
although nurses’ error rates were marginally higher than medical consultants, nurses were not unsafe 
prescribers. Conversely, Seden et al. (2013) found nurses actually had a lower prescribing error rate 
than consultants. However, nurses had a higher percentage of prescribing errors classified as 
‘serious’ [potential to cause permanent harm] or ‘potentially lethal’ compared to junior doctors, but 
were comparable or safer than medical consultants (Dornan et al., 2009; Seden et al., 2013: see 
Table 3-4). Seden et al. (2013) and Avery et al. (2012) both found nurses were just as safe at 
prescribing as doctors overall. However, a true comparison cannot be concluded from these studies 
due to the significant difference in number and types of medicines prescribed by nurses as compared 
to doctors. Moreover, given the small sample of nurses in each of these studies, a small number of 
errors made by nurses has the potential to significantly increase nurses overall error percentage rates 




Table 3-4 Severity categorisation of prescribing errors and clinical roles 
Severity Grade 
Avery et al. (2012) 
PRACtICe study 
Dornan et al. (2009) 
EQUIP* study 




1,638 (39.1%) 519 (48.8%) 
FY2 1,400 (39.2%) 496 (39.2%) 
Midgrade 571 (41.1%) 93 (33.6%) 
Consultant 87 (46.3%) 36 (42.4%) 




2,253 (53.8%) 507 (47.7%) 
FY2 1,925 (54.0%) 725 (57.4%) 
Midgrade 703 (50.4%) 166 (59.9%) 
Consultant 82 (43.6%) 43 (50.6%) 




220 (5.3%) 35 (3.3%) 
FY2 187 (5.24%) 41 (3.2%) 
Midgrade 89 (6.4%) 15 (5.4%) 
Consultant 17 (9.0%) 6 (7.1%) 
Nurse** 4 (6.8%) 1 (7.1%) 
Potentially 
lethal 
FY1  79 (1.9%) 3 (0.3%) 
FY2 56 (1.57%) 2 (0.2%) 
Midgrade 28 (2.0%) 3 (1.1%) 
Consultant 2 (1.1%) 0 (0%) 
Nurse** 5 (5.0%) 0 (0%) 
*the full data have not been presented. Percentages relate to the percentage of prescriptions made by 
each prescriber that had an error in them ** nurses were prescribers, but not presented as bands.  
FY1/FY2 = Foundation Year [1/2] doctors 
 
A fourth paper, involving an audit of patient medication charts in a critical care unit, also compared 
prescribing errors between doctors and nurses (Carberry et al., 2012). Nurses were found to prescribe 
more frequently and had a lower prescribing error rate than doctors (Carberry et al., 2012). 
Interestingly, the overall error rate was considerably lower than that reported in the other studies: 
2.8% compared with 8.9% (Dornan et al., 2009); 10.9% (Seden et al., 2013); and 12.2% (Avery et al., 
2012). However, definitions of what constitutes an error differed between studies, therefore, an 
accurate comparison cannot be made between these studies. Moreover, across these four studies 
the patients’ clinical complexity was not explored; consequently, accurate clinical comparisons 
between doctors and nurses cannot be concluded. The lower prescribing error rate in Carberry et 
al.’s (2012) critical care speciality, compared with the other three papers, supports Sedan et al. (2013) 
findings that prescribers working in specialist areas (in this case paediatrics, women’s health and 
mental health) are less likely to make prescribing errors, compared with prescribers in generalist 
clinical areas. It was considered that a comprehensive knowledge of specialist drugs improves safety 
(Seden et al., 2013); yet, commonly used drugs were also associated with the majority of errors 
(Dornan et al., 2009; Avery et al., 2012; Seden et al., 2013). A comprehensive knowledge of drugs, 
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therefore, may not always be a defence against prescribing errors. Additional research by specialist 
services is required before any generalisable inferences can be made. 
 
3.4.3 Safety of nurse prescribing 
Qualitative comments from three papers (Courtenay et al., 2009b; Avery et al., 2012; Wilkinson et al., 
2014) have discussed nurses’ “quasi-autonomous role” (Avery et al., 2012), where nurses assess 
patients but request a doctor to write a prescription, and how this negatively impacts on prescribing 
safety. Findings identified that interruption of a prescriber is a risk to patient safety (Courtenay et al., 
2009b; Avery et al., 2012; Wilkinson et al., 2014). The benefit of nurse prescribing was identified by 
some GPs as a way of improving safety where nurses have autonomous patient management roles 
(Avery et al., 2012). 
 
Three quantitative papers have specifically explored the safety of nurse prescribing (Carey et al., 
2008; Black, 2013; Wilkinson et al., 2013). Carey et al. (2008) explored the impact of a diabetic 
specialist nurse (DSN) prescriber on medication errors for inpatient diabetic patients, and found 
diabetic inpatients were less likely to receive medication errors from this nurse due to their addition 
prescribing training than patients being managed under standard care. Wilkinson et al. (2013) also 
explored the safety of prescribing by DSNs through a process and outcome clinical evaluation of 
patient records. All prescriptions were deemed clinically appropriate, despite five minor instances of 
unclear documentation. Overall the Rubric rating (measure of standard or performance) for safety, 
quality and clinical appropriateness for DSN was ‘excellent’ (Wilkinson et al., 2013). A further study 
using clinical records also found, despite minor documentation issues, nurse prescribers in sexual 
health and Accident & Emergency (A&E) provided safe and appropriate prescribing decisions (Black, 
2013). While these studies consistently found nurses to be safe and appropriate prescribers, there 
were methodological weaknesses which may affect the reliability of their findings; these include: 
conclusions based on a single nurse’s intervention (Carey et al., 2008); relying on a single 
researcher’s interpretation of medication appropriateness who did not use a validated research tool 
(Black, 2013); and results from a healthcare system outside the UK (Wilkinson et al., 2013). 
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Three papers evaluated the accuracy of the written prescriptions (Latter et al., 2007a; Carey et al., 
2009; Wilkinson et al., 2013). Nurses were found to produce comprehensive, detailed and accurate 
prescriptions (Latter et al., 2007a; Wilkinson et al., 2013). Carey et al. (2009) found that although 19 
diabetic prescriptions consistently recorded appropriate generic products, dose & preparation and 
terminology; DSNs were less consistent at recording medication quantity, number of days, timing and 
frequency. Moreover, while Latter et al. (2007a) found prescriptions were accurate, the subsequent 
clinical records lacked details of specific aspects of the consultation; specifically, there were 
documentation omissions for diagnosis, management plans, follow-up requirements and specific 
prescription details. The need for improved documentation is consistent with Black (2013) and 
Wilkinson et al.’s (2013) findings. 
 
3.4.4 Appropriateness of nurse prescribing consultations 
One paper (Riley et al., 2013) explored the appropriateness of how GPs, nurses and pharmacists 
react to patients’ cues for information during medication consultations in primary care. Pharmacists 
and nurse prescribers were more likely to identify a cue or concern from patients and act on it 
compared to GPs. Three further high-quality studies (Latter et al., 2007a; Courtenay et al., 2009a; 
Courtenay et al., 2009b) utilised the 2001 version of the National Prescribing Centre’s (NPC) 
prescribing framework, which supports communication during prescribing consultations. The NPC 
framework was used to assess videotaped nurse-patient consultations in dermatology (Courtenay et 
al., 2009a) and diabetes (Courtenay et al., 2009b), and to create structured schedules in non-
participant observations of primary and secondary care consultations (Latter et al., 2007a). Nurses 
were found to communicate well with patients, identifying the chief complaint, exploring clinical 
management and providing clear instructions regarding medicines and their associated risks and 
benefits (Courtenay et al., 2009a; Courtenay et al., 2009b); however, they performed less consistently 
on enquiring about allergies and over-the-counter (OTC) medicines (Latter et al., 2007a; Courtenay 
et al., 2009a; Courtenay et al., 2009b). Although nurses believed they provided patients with 
information on medication side effects, this was not consistently identified during videotaped 
consultations (Courtenay et al., 2009a). Latter et al. (2007a) highlights that prescribing may have 
been for minor conditions, and so full and extensive histories may not have been deemed to be 
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warranted; however, this author also identifies that not taking and recording full medical histories each 
presentation does not conform to safety guidelines. Courtenay et al. (2009b) point out that the 
management of chronic conditions means that similar discussions may have taken place in previous 
consultations. Research by Sibley et al. (2011) designed to measure medicine communication in the 
consultations of DSN prescribers’, identified that DSNs commonly discussed the name and usage of 
the medicine, and instructions for use; however, in-line with Courtenay et al. (2009a), side effects 
were less commonly discussed. Furthermore, it was also evident that the majority of the conversation 
related to asking a question and obtaining an answer, as opposed to exploring patient choice (Sibley 
et al., 2011). 
Three studies (Latter et al., 2007b; Latter et al., 2012; Naughton et al., 2012) explored 
appropriateness of nurse prescribing using the Medication Appropriateness Index (MAI), a validated 
research tool for assessing medication appropriateness across 10 areas (see Chapter 4; Latter et al, 
2007b). Two of these studies (Latter et al., 2007b; Latter et al., 2012) assessed transcripts from 
primary and secondary care nurse prescribers’ consultations, and one (Naughton et al., 2012) used 
secondary care clinical records. All three studies concluded that generally medication was indicated 
and effective for the condition being managed. The MAI’s weighted scoring system demonstrated a 
high level of appropriate prescribing by nurses (Latter et al., 2012). However, concerns were identified 
in relation to informing patients how to take medication (Latter et al., 2007b; Latter et al., 2012), the 
duration of regimens (Latter et al., 2012; Naughton et al., 2012), medicine/disease interactions 
(Naughton et al., 2012) and ensuring cost-effective prescribing (Latter et al., 2012). Qualitative data 
identified that assessors were overall confident in nurses’ history taking, assessment and diagnosis 
skills; however, in some cases these were areas that could also be improved (Latter et al., 2012). 
While the findings are encouraging, there are some methodological weaknesses including the 
prescribing knowledge of assessors and poor interrater reliability between assessors on 
appropriateness of prescribing (Naughton et al., 2012); quality of audio recording; and consultations 
where only a single drug was provided (Latter et al., 2007b). 
As these studies used multiple assessors, and validated research tools based on actual consultations, 
the evidence of nurses’ competence and safety in prescribing is strengthened. That being said, the 
use of transcripts and clinical documentation independently may not provide a true reflection of the 
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consultation, as not all aspects of the consultation can be verbalised or documented (e.g. checking 
notes, non-verbal communication), and therefore may not be easily visible to the observer, audiotape 
or camera (Courtenay et al., 2009a; Courtenay et al., 2009b; Latter et al., 2007a). Consequently, 
nurses may have performed better than recorded in these studies; nevertheless, nurses need to 
continually undertake comprehensive patient histories to ensure continued safety and 
appropriateness of medication delivery.  
 
3.4.5 Safety of patient group directions 
Six papers evaluated the safety and appropriateness of medication supply and/ or administration 
through PGDs: one in sexual health (Miles et al., 2001); three in walk-in centres (Brooks et al., 2003; 
Deave et al., 2003; Baileff, 2007); and two in emergency care centres (Williams & Know, 2011; Black 
& Dawood, 2014). Miles et al. (2001) undertook an audit of case notes. The restrictive nature of PGDs 
and the potential risk of nurses using them outside their limitations was evident (Miles et al., 2001). 
Conversely, Brooks et al. (2003) and Baileff (2007) both investigated the supply of antibiotics in walk-
in centres, and found that PGDs were predominantly used safely, appropriately and within their 
limitations. Baileff (2007) found nurses were not consistent at recording drug contra-indications and 
discussing medicines’ side effects. Furthermore, although the drug’s name was always documented, 
the dose was not. Overall the use of antibiotics was considered safe and appropriate for the 
presenting complaints and PGD (Brooks et al., 2003; Baileff, 2007). Williams & Know (2011) also 
identified good overall compliance with PGDs through an audit of 47 separate PGDs, of which only 
17 were utilised in the audit timeframes. PGDs were shown to be appropriately used across the nine 
audited standards, despite incidents in which they were used outside their limitations. Moreover, the 
audit highlighted the extensive administration required for PGDs, detailing multiple documents each 
of which required regular updating and auditing to ensure safety governance. Black & Dawood (2014) 
similarly found that PGDs were used outside their limitations, despite them being clinically appropriate 
for the condition managed. As PGDs are locally determined these findings may not be generalisable; 
however, these studies consistently report PGD limitations and their use to supply medicines outside 
of their restrictions.  
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Work by Deave et al. (2003) evaluated the legislative compliance of PGDs in walk-in centres. These 
authors identified that most PGDs failed to adhere to PGD legislation. Deave et al. (2003) explored 
the quality of nurses’ record-keeping in clinical notes, and found only 65% of the expected PGD 
documentation. Relevant warnings, contraception advice and pharmaceutical form were inadequately 
recorded. These researchers also identified that nurses failed to provide the specific medication 
information they provided to patients in the clinical notes. This is consistent with the findings of other 
researchers who have reported the need for improved documentation (Brooks et al., 2003; Baileff, 
2007; Williams & Know, 2011). 
 
3.4.6 Nurse prescribing versus PGDs 
One paper (Black & Dawood, 2014) compared nurse prescribing with PGDs. PGD users were less 
consistent in documentation than nurse prescribers and provided medication more often when 
aspects of past medical history, concurrent drugs and allergies were not recorded. Patients being 
managed by nurse prescribers were 2.23 times more likely to have medication delivered than PGD 
users, despite both groups managing similar patient presentations. While all PGD users’ medication 
delivery choices were clinically appropriate, 11.8% (n=9) were not within the PGD’s limitations. There 
was one episode where a nurse prescriber provided an unsafe medication for a patient with an allergy 
but no similar episodes with PGDs. Nurse prescribing was found to be more flexible than PGDs, but 
potentially facilitated increased frequency of medication delivery and potential to make errors. 
Improvements in documentation for both groups were advised, but more so for PGD users.  
 
3.4.7 Organisational nurse prescribing governance 
One paper (Smith et al., 2014) used a questionnaire survey to explore non-medical prescribing 
governance safety across organisations in Primary, Secondary and Mental Health services. Despite 
the limited response rate, the authors identify that the response coverage provides an accurate 
representation throughout England. All respondents reported their organisation held a register of non-
medical prescribers, and most had an up-to-date non-medical prescribing policy in place. Secondary 
care was most likely to operate specific non-medical prescribing governance committees and have 
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up-to-date controlled drug policies. There were clear lines of responsibility and accountability detailed 
for non-medical prescribers; however, mental health was more likely to define nurses’ scope of 
practice and have systems for managing poor performance. Despite the majority of services having 
up to date policies, the process for ensuring supervision and support for newly qualified prescribers 
was less consistent; on average only 84% of Trusts provided official support for newly qualified 
prescribers, and only 59% required prescribers to participate in clinical audit (Smith et al., 2014). 
Given the evidence presented on medication errors it is important that organisational support or 
monitoring of clinical and prescribing practice is formally undertaken to avoid patients’ safety being 
put at risk.  
 
3.4.8 Conclusions 
The incidence of prescribing errors among prescribers varies across healthcare providers involving 
primary, secondary and specialist services. Error rates across studies range from 2.8% to 12.2% with 
varying degrees of severity (low: no harm to severe: permanent harm or death) across different 
healthcare professional groups. While some studies have shown nurses to be safer prescribers than 
consultant doctors, others have demonstrated that there is no difference in the risk of prescribing 
error across each health professional group. Consequently, it is not possible to make generalised 
conclusions in all clinical specialities on how nurses compare against their medical colleagues. 
Despite reports that areas of nursing practice require improvement (i.e. more comprehensive 
documentation and history taking, particularly around concurrent medication and allergies), research 
specifically examining nurses’ delivery of medication has demonstrated that nurses are safe and 
practice is appropriate. PGDs have also been shown to support clinically appropriate medication 
delivery; however, PGD limitations and restrictions have also consistently led to their inappropriate 
use, affecting safe and legal practice. Research exploring nurse prescribing and PGDs in specialist 
services is lacking, and therefore further research investigation is recommended.
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Table 3-5 Descriptive patient experience papers 
Author Setting & participants 
Research aim/ 
question 




inpatients in a single site 














response rate)  
Level of concern about taking medication from a nurse: none 36.8% 
(21); slight 22.8% (13); moderate 26.3% (15); very much 7.0% (4); 
extreme 5.3% (3). Confidence between doctor and nurse 
prescribing: no difference 60% (34); doctor preferred 40% (23). 
Likelihood of taking medication: no difference 74% (42), more likely if 
doctor prescribed 26% (15). Concern about taking medication: less 
concerned if doctor prescribed 18% (10), no difference 82% (47). 
Weak 
+ High response 
rate; Previously 
used 
questionnaire;   
Adequate sample 
size  




Berry et al. 
(2008) 

















54 patients (95% 
response rate) 
40% concerned about side effects of medication; 20% concerned 
about qualifications and experience of nurse to prescribe. Six point 
Likert scales mean scores: medication function 5.74; possible side 
effects 5.69; drug interactions 5.65; effectiveness of medication 5.65; 
medication type 5.50; awareness of medication working 5.41; risks of 
not taking medication 5.41; answering detailed questions about 
medication 5.20; action if medication taken incorrectly 5.19; 
medication alternatives 4.83. 55% stated they have more confidence 
in doctors than nurse prescribers. 
Moderate 
+ High response 
rate; Adequate 
sample size 




Ten case study sites: primary & 
secondary dermatology 
services (specialist and non-
specialist), England, UK  


















Communication highly rated (no negative ratings from patients): 
good/ excellent scores: nurses thoroughness of asking about 
symptoms 84.2%; nurses listening 92.1%; involvement in treatment 
decisions 87.7%; explained problems of treatment 93.2%; 
medication information 83.4%; info dealing with condition 87%; time 
spent 85.9%; nurses patience 86.1%; nurses caring 91.5%. Access 
to nurse: poor/very poor 1.9% (3); fair/ good 30.4% (48); very good/ 
excellent 67.7% (107). Continuity of care: poor/very poor 0.7% (1); 
fair/good 21.2% (29); very good/ excellent 78.1% (107).  
Strong 
+ Multiple sites; 
Patients attending 
different levels of  
service provider; 
Good sample size; 
Good response 
rate 




Author Setting & participants 
Research aim/ 
question 




Nine case study sites: primary, 
community and secondary care 
(specialist and non-specialist), 
England, UK 















Communication highly rated (no negative ratings from patients): 
good/ excellent scores: nurses thoroughness of asking about 
symptoms 81%; nurses listening 88.1%; putting at ease 86.9%; 
involvement in treatment decisions 83.6%; explained problems of 
treatment 86.4%; medication information 80.5%; info dealing with 
condition 80.6%; time spent 83.3%; nurses patience 85.7%; nurses 
caring 87.3%. Continuity of care: fair 3.3% (4); good/ very good 
63.1% (77); excellent 33.6% (41). Access to nurse: poor/very poor 
4.8% (5); fair/ good 42.1% (48); very good/ excellent 53.5% (61). 
Strong 
+ Multiple sites; 
Patients attending 
different levels of 
service provider; 








Seven primary care diabetic 
services, England, UK 
Explore the views 
of patients with 
diabetes on the 
advantages and 
disadvantages of 
nurse prescribing  
Patient audiotaped 





Patients identified less need for medical input, reduced need to see 
multiple professionals on each visit and reduced wait for 
prescriptions. Nurses’ appointments were more flexible and easier to 
access by telephone. Patients had confidence in nurses’ prescribing 
knowledge and communication. Patients expect nurses to speak to 
doctors if they were unsure. Some patients felt nurses had limited 
medical knowledge, training and abilities to prescribe and would 
prefer a doctor to manage new medical conditions or treatment 
regimens. 
Strong 
+ Multiple sites; 









Patients of seven dermatology 
nurses across four strategic 
health authorities in primary 
and secondary care, England, 
UK 
To explore views 
of dermatology 










Patients were supportive of nurse prescribing finding it improved 
access, efficiency of the clinical services. Telephone contact and 
information and involvement in treatment decisions were all valued 
by the patients. This meant treatment plans were realistic and 
supported adherence. Patients had confidence in nurses as 
prescribers. 
Strong 
+ Multiple sites; 








Four inner city GP practices, 
England, UK  
Explore patients’ 
attitudes to and 
experiences of 






All participants identified nurse prescribing had a positive impact on 
their care; 73% (11) finding it was easier and quicker to obtain an 
appointment; nurses were skilled and competent to manage their 
care; 86% (13) patients felt nurses provided better medicines 
information than GPs and felt they had a good relationship with the 
nurse prescriber 
Weak 








Author Setting & participants 
Research aim/ 
question 
Design Sample size Key findings Quality of study 
Earle et al. 
(2011) 
Single mental health case 
study site, England, UK   
To explore the 









6 service users All service users felt nurse prescribers were easily accessible and 
had developed trusting relationships with their nurse. Service users 
had confidence in their nurses’ abilities and happy to accept 
prescriptions; often preferring this to standard care. Four did not 
realise nurse prescribing was ‘novel’. Information on the medicine 
and side effects was beneficial; however, two identified they’d like 
more medicines information relating to choice, and one on what to 
do if they forgot to take medicine. Two service users realised some 
others may prefer to see a doctor.   
Moderate 




- Single site; Small 
sample size  
Hobson et 
al. (2010) 
Four primary and secondary 
NHS Trusts, England, UK. 
















Patients held nurses in high regard compared to doctors in relation 
to having more time and better relationships. Training, convenience 
and location of prescribers were seen as more favourable to patients 
than the profession. Although some respondents question the depth 
of nurses’ prescribing knowledge. 
Moderate 







General public, nationwide, 
Scotland, UK 
Explore the views 
of the Scottish 





analysis, Nov 2006 
1,855 (response 
rate from 5,000: 
37.1%); 27.2% 
(505) with written 
comments 
Pharmacist prescribing comments (312); generic non-medical 
prescribing comments (172); other healthcare professionals (79). 
Nine themes were identified: perception of knowledge and training 
(253); support for a limited range of non-medical prescribing (159); 
access to medical records (104); motivation and convenience (86); 
confidence, faith and trust; privacy and confidentiality (85); risks, 
controls and continuity of care (51); supervision and conflict of 













Author Setting & participants 
Research aim/ 
question 




Community patients with 
schizophrenia, Melbourne & 















81 patients Patient attitudes for nurses prescribing antipsychotic drugs: strongly 
agree/agree: 53, indifferent: 16, disagree/strongly disagree: 31. 
Nurses changing dose: strongly agree/agree 47, indifferent: 16, 
disagree/strongly disagree: 37. Nurses discontinuing: strongly agree/ 
agree: 48, indifferent: 14, disagree/ strongly disagree: 38. Patients’ 
responses on likelihood to take medications if prescribed by a nurse: 
no difference 72.2% (57); less likely to take 17.7% (14): more likely 
to take 10.1% (8). Patients’ satisfaction with nurses’ knowledge of 
antipsychotic medication: satisfied with how concerns were managed 
yes 94.2% (49); satisfied with knowledge of medications 90.4% (47).  
Moderate 
+ Questionnaire 
based on existing 
theoretical 
framework 








Natan et al. 
(2013) 
Patients with chronic 
conditions, on at least one drug 
and hospitalised within 













60% (138) respondents in favour of expanding nurse authority to 
manage chronic condition; 10% (23) strongly object but only 31% 
(73) agree with nurses prescribing, 43.9% (101) strongly disagree 
with nurse prescribing. Respondents have low level of knowledge on 
nurses’ authority to prescribe (M=1.66) 
Strong 
+ Good sample 





- Non UK study 
Ross et al. 
(2014) 
One mental health NHS 
Foundation Trust, England, 
UK. Stakeholders and patients 
in adult mental health, older 
adults and substance misuse 
To explore the 
impact of nurse 




focus group.  
7 client 
interviews, 9 





Some clients report their relationship with the nurse hasn’t been 
affected by the ability to prescribe, while others have noticed a closer 
relationship. Some clients report being more open with nurses than 
psychiatrists. Nurse prescribers were  seen as more accessible and 
preferred to rotational junior doctors due to established relationships 
Moderate 






- Single site 
67 
 
Author Setting & participants 
Research aim/ 
question 
Design Sample size Key findings Quality of study 
Tinelli et al. 
(2013) 
Six general practices in 
different regions, England, UK 
To obtain patient 
feedback on the 




















rate from 975: 
149 nurses 
patients & 145 
pharmacist) 
Patient feedback on nurses only. Satisfied with nurse prescriber 
94.3% (133); advised appropriately on medication 87.9% (124); 
consultation could be improved 12.8% (18); nurse prescriber 
understood my point of view 87.2% (123); more time required 24.1% 
(34); patient asked opinion on medication 48.9% (69). Patient 
reported they received better care from a nurse 12.7% (17), doctor 
13.4% (18), no difference 73.9% (99). Patients felt they received 
safer care from a nurse 8.2% (11), doctor 20.9% (28), no difference 
70.9% (95). 43.3% (61) patients are happier they received 
medication from a nurse, 18.4% (26) stated they were more likely to 
take their medication from a nurse. If patients have a concern about 
a medication they find it easier to raise with nurse 24.4% (33), doctor 
30.4% (41), no difference 45.2% (61). Patients feel their condition is 
better monitored by prescriber 28.0% (37), doctor 22.0% (29), no 
difference 50.0% (66). Patients feel they are better informed about 
medication by the nurse 25.6% (34), doctor 25.6% (34), no 
difference 48.9% (65). Patients feel they are more likely to be asked 
how medications fit around their routine by a nurse 24.4% (33), 
doctor 11.1% (15), no difference 64.4% (87).Patients feel side 
effects are most likely to be discussed by nurse 16.3% (22), doctor 
29.6% (40), no difference 54.1% (73). Patients feel their condition is 
better controlled by nurse 43.3% (61). Patients feel they can get 
prescriptions quicker from a nurse 21.6% (29), doctor 14.2% (19), no 
difference 64.2% (86) and easier from a nurse 20.1% (27), doctor 
15.7% (21), no difference 64.2% (86).  
Moderate 
















Four localities providing 











evaluation using  
patient interviews. 
Apr-Sep 2011  





Patients report: 96.6% (86) content with DSN prescribing; 2.2% (2) 
prefer doctor prescribing; 1.1% (1) prefers DSN to check with doctor. 
DSN extremely knowledgeable about diabetic medications (99%, 87) 
and patients extremely or very confident in DSN prescribing (7.8%, 
84). Patients reported DSN prescribing was more proactive way to 
manage their condition. Patients found DSN more accessible, 
convenient and cost-effective than GP. Rubric rating for patient 
experience: excellent. Patients report good availability of DSN and 
comprehensive consultations. 
Moderate 


























































































Education & advice (percentage agreement): time 
given to clarify medication questions 99.1%; 
information given on times to take medicines 97.5%; 
frequency of medicine 95.9%; purpose of medicine 
97.6%; how to take medicine 94.9%; name of 
medicine 98.3%; side effects discussed 90.0%. 
Patients reporting they would like more information on 
medicines 68.3%. Patients reported satisfaction with 
the consultation (mean scores closer to 100 mean 
higher satisfaction) in terms of professional care 
(90.28); overall satisfaction (85.74); however, 
perceived time was rated lower (75.68). Overall intent 
to comply was high (83.47). Largest predictor for 
intent to comply was patients’ satisfaction with time 
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prescribing 
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Patient questionnaires: 50 were seen by a nurse, 14 
by a doctor. All patients had confidence and trust in 
their prescriber. Patients had strong beliefs in the 
value of taking medicines to maintain or improve their 
health, no difference between doctor or nurse 
prescribers. Satisfaction scores ranged from 2-17; 
higher the score, higher satisfaction: Scores 1-10: 
nurses 12% (6), doctors 29% (4); 11-16: nurses 22% 
(11), doctors 64% (9); 17: nurses 66% (33), doctors 
7% (1). Patients are more satisfied with nurse 















3.5 Patient experience and nurse prescribing 
Studies investigated patients’ experience of medication delivery from two perspectives: (i) five studies 
explored the expectations of patients who had not experienced nurse prescribing, and (ii) 12 papers 
that sought the experiences of those who had. The 17 papers are presented under these two 
perspectives; 15 descriptive studies are presented in Table 3-5 and two evaluative studies in Table 
3-6. 
 
3.5.1 Patients’ expectations of nurse prescribing  
Five papers explored patients’ expectations of nurse prescribing (Berry et al., 2008; McCann & Clark, 
2008; Banicek, 2012; Mac Lure et al., 2013; Natan et al., 2013). Mac Lure et al. (2013) received mixed 
responses from surveyed members of the public on their views of non-medical prescribing. 
Respondents identified concerns relating to training and competence in the role. While some 
respondents felt appropriate public awareness on levels of training and supervision would alleviate 
these concerns, others were strongly opposed to anyone other than doctors making a diagnosis and 
prescribing. A potential benefit of non-medical prescribing was access to medicines as some 
respondents reported difficulties obtaining GP appointments; however, access to clinical records and 
confidentiality was a concern raised by respondents. Mac Lure et al. (2013) concluded that the 
general public did not fully understand the concept of non-medical prescribing and that further 
clarification of the roles was required. The survey, however, did take place only six months after the 
significant change in nurse prescribing legislation in 2006 across Scotland, and had a poor response 
rate. 
Two papers (Berry et al., 2008; McCann & Clark, 2008) used questionnaires to explore theoretical 
confidence in nurse prescribing; one in rheumatology and another in schizophrenia. While overall 
support for nurse prescribing was found, both papers identified that only a small majority were in 
favour of it in their clinical areas. McCann & Clark (2008) found patients were not confident in allowing 
nurses to modify doses or discontinue medications, despite nearly all respondents reporting they 
were satisfied with nurses’ management of medication concerns, and nurses’ knowledge. 
Conversely, Natan et al.’s (2013) questionnaire survey of patients living with chronic conditions in 
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Israel found only a third of respondents were supportive of nurses being able to prescribe. Nearly a 
third (n=69) were supportive of nurses expanding their prescribing authority, however, 44% (n=101) 
strongly oppose it. Main concerns were relating to nurses not having the necessary knowledge to 
initiate or change medication without speaking to a doctor. Over half the respondents reported having 
no knowledge about the remit of nurses prescribing authority. While Israel’s healthcare system is not 
directly comparable to the UKs, the study draws attention to patients’ apprehensions when 
considering significant changes to healthcare delivery, which may have also influenced the publics’ 
opinion found by MacLure et al. (2013). A further paper (Banicek, 2012) explored patients’ 
expectations of nurse prescribing. While the majority of respondents were supportive, a significant 
number had ‘moderate’ to ‘extreme’ concerns about nurses prescribing. Banicek (2012) concluded 
that although 60% of patients had no preference on whether a doctor or nurse manages the condition, 
40% would prefer a doctor to prescribe the medicines. So while there is general support for nurse 
prescribing, some apprehension is evident. This study did, however, survey post-operative surgical 
patients about a theoretical medical condition, and therefore may influence the responses obtained. 
Nevertheless, from 41 qualitative responses, Banicek (2012) identified that half of patients had 
concerns regarding side effects and medication effectiveness; similar concerns were also raised in 
Berry et al.’s (2008) work. This in in-line with studies that have explored safety, which have identified 
information relating to these areas can be lacking (Baileff, 2007; Latter et al., 2007a; Courtenay et al., 
2009a; Sibley et al., 2011). 
 
3.5.2 Patients’ experience of nurse prescribing 
Twelve papers explored patients’ actual experience of nurse prescribing using a variety of data 
collection methods. Two studies used questionnaires in renal/ hypertension clinics and across primary 
and secondary care (Jones et al., 2010; Tinelli et al., 2013); six undertook patient interviews in: 
primary and secondary care, diabetes, dermatology, GP practices and (two) mental health services 
(Hobson et al., 2009; Courtenay et al., 2010; Courtenay et al., 2011; Dhalivaal 2011; Earle et al., 
2011; Ross et al., 2013); one observed consultations in secondary care (Drennan et al., 2011); one 
used questionnaires and interviews in diabetes (Wilkinson et al., 2013); and two adopted a 
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combination of questionnaires and consultation observations in dermatology and diabetes (Courtenay 
et al., 2009a; Courtenay et al., 2009b), respectively. 
High levels of satisfaction and confidence in nurse prescribing is a consistent theme. Nurses’ level of 
knowledge and experience is held in high regard and patients report that nurses are more accessible 
than doctors with regards to consultation appointments and accessing medication (Hobson et al., 
2009; Courtenay et al., 2009a; Courtenay et al., 2010; Courtenay et al., 2011; Dhalivaal 2011; Earle 
et al 2011; Wilkinson et al., 2013). Patients consider nurses to be flexible, efficient and able to provide 
comprehensive information about their condition/ medication (Courtenay et al., 2009b; Courtenay et 
al., 2010; Courtenay et al., 2011; Dhalivaal, 2011). Good communication in the nurse-patient 
relationship also facilitates confidence in the nurses’ ability to manage conditions, and supports a 
trusting relationship, continuity of care (Courtenay et al., 2009a; Courtenay et al., 2009b; Hobson et 
al., 2009; Courtenay et al., 2010; Courtenay et al., 2011; Dhalivaal, 2011; Earle et al., 2011; Ross et 
al., 2013) and patient involvement in the decision making process (Courtenay et al., 2009a; Earle et 
al., 2011). Some patients also feel confident that nurses know their limitations, and will seek advice 
if they are unsure (Courtenay et al., 2010; Courtenay et al., 2011). The experience of patients 
managed by DSNs has been reported to be ‘excellent’ (Wilkinson et al., 2013).  
While the majority of patients report confidence and satisfaction in nurse prescribing, a very small 
number express a perceived limitation in nurses' medication knowledge, training and ability to 
prescribe (Hobson et al., 2009; Courtenay et al., 2010; Courtenay et al., 2011). Additionally, small 
numbers also report they would prefer to see a doctor if they experienced new medical problems, 
although they are confident in nurses maintaining or amending established regimens (Courtenay et 
al., 2010; Courtenay et al., 2011; Earle et al., 2011; Tinelli et al., 2013; Wilkinson et al., 2013). Tinelli 
et al. (2013) also identified a small number of patients reported some mild dissatisfaction with their 
nurse prescriber consultations. Although the majority of patients reported no preference in being 
managed by a doctor or a non-medical prescriber, some patients reported they received better quality 
and safer care from a doctor than a nurse. Nevertheless, the majority of patients in this study had no 
preference or preferred the nurse prescriber in terms of quality and access. Nurses scored higher 
than doctors on access to medications; ease of getting medications; monitoring health; fitting 
medications around lifestyle; ability to ask questions about medicines; and availability of non-drug 
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options. Doctors, however, were seen as more knowledgeable with regards to new medications and 
better informed about side effects (Tinelli et al., 2013). Conversely, Jones et al. (2010) found while 
hypertensive and renal respondents have confidence and trust in their clinician, patients are more 
satisfied with nurses over doctors. 
Dermatology patients report that their relationship with the nurse and the provision of medicines 
information supports medicines concordance (Courtenay et al., 2011). Drennan et al. (2011) explored 
patient satisfaction and intent to comply with medication using a ‘Consultation Satisfaction 
Questionnaire’ and the ‘Compliance Intent’ section of the Medical Intervention Satisfaction Scale 
(MISS: Meakin and Weinman, 2002). Nurse prescribers scored highly on time for clarification of 
questions, timing of medication, frequency, purpose, how to take, name of treatment and side effects. 
However, only 68.3% of respondents felt nurses and midwives provided comprehensive advice and 
education about medications (Drennan et al., 2011). What additional information would be beneficial 
was not clear given the high scores in the other areas. Given the diverse range of long and short term 
conditions managed (e.g. diabetes, cancer, infection) each patients’ medication information 
requirements will differ (Drennan et al., 2011). Overall, patients reported being satisfied with nurse 
prescribers, finding them accessible practitioners who provide relaxed consultations and appropriate 
information to facilitate continuity of care and beneficial outcomes (Drennan et al., 2011). Patients 
overall reported a high intention to comply with medication regimens; however, actual compliance 
was not measured. 
  
3.5.3 Conclusions on patient experience  
Generally, patients’ feedback on nurse prescribing is very positive, and more so in UK based studies 
where nurses’ prescribing authority is more established. While the findings conclude patients are 
generally supportive of nurse prescribing, there is some low lying trepidation in relation to nurses 
initiating new medication, which is more evident in studies that have explored patient perceptions, 
rather than actual experience. Nevertheless, patients feel confident in nurses in terms of access to 
appointments/ medication, nurses’ specialist knowledge and communication during consultations. An 
issue raised in a commentary by Latter (2011), however, highlights that patient experience studies 
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self-select patients for inclusion which may bias the overall picture. Indeed in this review, 11 studies 
involved the selection of patients by nurses to include in interviews, observations and questionnaire 
studies (Courtenay et al., 2009a; Courtenay et al., 2009b; Hobson et al 2009; Courtenay et al., 2010; 
Jones et al., 2010; Courtenay et al., 2011; Dhalivaal, 2011; Drennan et al., 2011; Earle et al., 2011; 
Ross et al., 2013; Wilkinson et al., 2013). Tinelli et al. (2013) was the only patient experience study 
that posted questionnaires out to all participants. Consequently, their work appears to have a wider 
spread of patient preferences and attitudes towards prescribing compared to the other 11 experience 
studies reviewed. This could confirm Latter’s (2011) comments relating to biased participant 
populations when exploring patient experience. Researchers should, therefore, facilitate data 
collection methods that target all patients to reduce selection bias.  
While there is a growing evidence base supporting nurse prescribing, there is no evidence available 
that has explored patients’ experience of PGDs. Moreover, no studies were found relating to patients’ 
experience of nurses independent practice in sexual health. Consequently, based on this literature 
review the thesis will compare and contrast patients’ satisfaction and confidence in sexual health 
nurses using nurse prescribing and PGDs.  
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Table 3-7 Health economics literature 
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Medical prescribers’ patients (BDI: 20.69) more 
depressed than nurses’ patients (BDI: 17.95). 
Psychiatrists’ patients had greater number of 
contacts with other therapists (35.0) than 
nurses (10.1); and psychiatric day care (nurse 
14.5, medical 56.0). Inpatient user costs higher 
for nurses (£2,049) compared with medics 
(£863). Fewer medical patients (9%, 4) 
required in-patient care compared with nurses’ 
patients (20%, 9). Nurses annual costs £803 
(95% CI -£1,341-£3,020) more expensive 
without informal care and £1,713 (95% CI -
£3,950-£6,699) with informal care included; 
however, difference is not statistically 
significant. Bootstrapping found nurses always 
more expensive than psychiatrists, but not 
statistically significant. Supplementary 
prescriber training is additional £497 to each 
































There is no evidence available that has explored the economic implications of nurse independent 
medicines delivery.  Even though strictly outside the search criteria, only one study, a cost-
consequences analysis, (Norman et al., 2010) was found. This work is discussed alongside the 
resource implications raised by other studies. Refer to Table 3-7. 
 
3.6.1 Resource and cost assessments 
Overall, the literature search highlighted an absence of consideration of economic implications 
associated with INPs and PGDs. While the majority of the articles, presented in the safety and 
patient experience sections, mention enhancing care and providing more efficient service 
delivery, most do not provide quantifiable evidence on cost or resource outcomes. Three studies 
in diabetes (Courtenay et al., 2009b; Courtenay et al., 2010; Wilkinson et al., 2013) and one in 
dermatology (Courtenay et al., 2011) state that nurse prescribing has facilitated an efficient, 
smooth and flexible service from both staff and patients’ perspectives. These papers 
demonstrated reduced time spent by doctors supporting nurse management of patients, and 
reduced waiting times for healthcare practitioners to get prescriptions signed. Patients described 
a more efficient service with improved access to medication (Courtenay et al., 2010), and being 
managed by fewer healthcare professionals (Courtenay et al., 2011). Wilkinson et al. (2013) also 
found that increased access to nurse prescribers in New Zealand saved diabetic patients money 
as they could liaise with the nurse prescriber for free, thus avoiding paying for GP consultations; 
an issue not relevant in the British NHS as all care is free at the point of delivery. These findings, 
based on perceptions rather than evidence of actual savings or increased capacity, indicate the 
need for robust cost assessments to investigate the impact of nurse prescribing on resources 
required to manage patients. Many factors need to be considered, including nurse training. Earle 
et al. (2011) determined that an individual mental health nurse becoming an INP was required to 
undertake approximately 29 clinical supervision training days, keep a reflective diary, pass 
examinations and undertake 70-80 hours of study via a flexible course. A consultant grade doctor 
was also required for clinical supervision and training. Furthermore, after the nurse qualifies, they 
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are required to attend prescribing fora every two months, and undertake personal continuing 
professional development (Earle et al., 2011); as per NMC requirements (NMC, 2006). So while 
nurse prescribing is perceived to improve service delivery, the training required to introduce and 
maintain the skill has cost and resource implications. These need to be fully investigated in 
comparative studies that cover staff costs, consultation length, prescribing and referral patterns 
and patient outcomes.  
Three further studies discussed costs in relation to assessments using the Medication 
Appropriateness Index (MAI: Latter et al., 2007b; Latter et al., 2012; Naughton et al., 2012). Latter 
et al. (2007b) and Naughton et al. (2012) detail that nurses had restrictive choice for medications, 
therefore a review of costs was not undertaken. Latter et al. (2012), however, found 84% (n=44) 
of nurse prescribing decisions chose the cheapest appropriate medication. The remaining 16% 
(n=8), where cheaper alternatives could be used, were related to the management of long term 
conditions; indicating, according to the interpretation of the authors, that nurses may be reluctant 
to alter existing treatment regimens, despite the product being more expensive.  
A further study explored the impact of introducing an in-patient diabetic specialist nurse (DSN: 
Carey et al., 2008). The findings indicated that the intervention reduced the median length of 
hospital stay by three days. While this difference was not statistically significant (p=0.15, t-test), 
it equated to an expected saving of £168,000 per year in the management of diabetic in-patients 
in a single hospital trust. The authors suggested that this saving would be enough to employ 
another DSN. The prediction is based on an assessment of one DSN in a single hospital, and 
may not therefore be generalisable. However, this study does indicate the potential for significant 
cost savings that deserve to be investigated further.  
While the search yielded no independent nurse prescribing or PGD empirical papers specifically 
relating to health economic assessments, one paper (Norman et al., 2010) was identified (during 
the screening of abstracts) that undertook a health economics assessment related to 
supplementary prescribing. As no other papers were found providing health economic 
assessments in nurse prescribing and/ or PGDs, this paper was reviewed (Table 3-7). It compared 
the overall costs associated with the clinical management of mental health patients between 
consultant psychiatrists and nurse supplementary prescribers. Despite psychiatrists’ patients 
having higher Beck Depression Inventory (BDI) scores and utilising additional therapists more 
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frequently, supplementary nurse prescribers were found to be £1,713 (including informal care 
costs) more expensive in the management of the study population than consultant psychiatrists. 
A large confidence interval does, however, exist and these cost differences were not statistically 
significant. The higher nursing costs were largely attributable to the fact that twice as many of the 
nurses’ patients received inpatient care compared with doctors. Therefore, five patients who 
required in-patient care more than doubled the nurses’ costs creating a large impact on the health 
economics assessment. The outcome could be down to chance, given the small numbers 
involved, but further investigation is indicated to determine the costs effectiveness, and the 
competence of nurses’ independent management of patients. A lateral search of Norman et al.’s 
(2010) reference list did not identify any further empirical health economic assessment papers. 
 
3.6.2 Conclusions 
There is a noticeable scarcity of research that provides a robust health economic assessments 
on the costs versus the returns of nurse prescribing and/ or PGD use. The only comprehensive 
costs assessment paper available, has evaluated supplementary prescribing in mental health 
services managing depression, anxiety and/or schizophrenia. This study concluded that there 
was no statistical difference in service utilisation costs for managing patients between consultant 
psychiatrists and nurses; however, nurses’ management did appear to be more expensive. It 
should also be borne in mind that doctors’ medication training is integral with their pre-registration 
education, however, nurses need to obtain further resources in order to obtain independent 
medication delivery authorisation. There is a need for further investigations to explore the costs 
of nurse prescribing interventions and to evaluate benefits to the NHS and to patients.  
 
3.7 Chapter summary 
This literature review has demonstrated that providing patients with medication is a complex 
process involving consideration of appropriateness, clinical safety, patient involvement and cost. 
Medication errors frequently occur within practice, both in primary and secondary care (Avery et 
al., 2012; Seden et al., 2013). Despite nurses being less experienced at prescribing than doctors, 
both professions are comparable in terms of clinical safety (Avery et al., 2012). Nurses, however, 
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often provide better quality patient experience, although some patients may prefer doctors to 
initiate new medication regimens (Tinelli et al., 2013). Despite this, studies that have specifically 
explored nurse prescribing have frequently and consistently shown nurses to provide safe and 
appropriate practice, valued by patients who experience it. Nurse prescribing studies have 
adopted validated tools (MAI and NPC Prescribing Competencies) to undertake robust 
investigations. Nurses were overall found to be safe and appropriate prescribers; however, a 
small number of issues with regards to clinical history taking, patient assessment, documentation, 
advice and low levels of inappropriate medication choices were also highlighted (Latter et al., 
2007a; Latter et al., 2007b; Courtenay et al., 2009a; Naughton et al., 2012). Studies that have 
specifically explored PGDs have also demonstrated clinically appropriate medication delivery; 
however, PGD limitations and use outside of their restrictions have been consistently 
demonstrated. Further studies exploring how PGDs are applied in clinical settings are therefore 
essential to inform practice and ensure safe and legal PGD use (Deave et al., 2003; Black & 
Dawood et al., 2014). There is limited literature to be found that has explored the cost 
effectiveness or resource implications for nurses independently delivering medication. The 
literature did, however, highlight presumed cost benefits; however, only one study undertook a 
health economics assessment (Norman et al., 2010), and found supplementary mental health 
nurse prescribers were more expensive at clinically managing patients than consultant 
psychiatrists (excluding additional professional training resources required by nurses post-
qualification).  In order to ensure value for money and justification of resources, more health 
economics evidence evaluating the costs versus the returns is required. 
The literature review identified that medication errors may be less frequent in clinical specialties 
than in more general clinical areas (Carberry et al., 2012; Seden et al., 2012); however, more 
evidence is required before this can be substantiated. Sexual health services have modernised 
and expanded the nurses’ role to enable them to independently manage episodes of care (see 
Chapter 2). As sexual health services commonly use both PGDs and nurse prescribing, this 
specialty provides an excellent platform to explore nurses’ medication delivery, and the 
associated patients’ experience and cost implications. Given the considerable gaps in the current 
evidence base, this study sets out to explore and quantify the impact nurse prescribing and PGD 
use has on sexual health nurses, service delivery and patient experience.  
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3.8 Papers published after initial literature review 
From 15th May 2015 until the 31st March 2018 automated weekly search results were emailed to 
the researcher using the original search criteria. This process highlighted 82 results which 
represented 46 papers (after duplicates were removed). Removal of non-relevant papers by titles 
or non-empirical research resulted in 24 abstracts being reviewed. After reading 12 papers in full, 
four papers met the original search criteria: one related to clinical care, patient experience and 
cost-effectiveness (Courtenay et al., 2015); one related to nurse prescribing safety (Hyde et al., 
2016); one explored patients’ experience (Courtenay et al., 2017b); and one related to cost-
effectiveness of non-medical prescribing (Noblets et al., 2018). Courtenay et al. (2015) compared 
general practice diabetic patients being managed by INPs with non-INPs using a matched case 
study design. This involved 12 GP practices participating in staff interviews, clinical notes review, 
observations and clinical diaries and patient interviews. There was no difference found with 
regards to patients’ clinical outcomes (except a reduction in the BMI of INP’s patients) between 
prescribers and non-prescribers. However, prescribers’ consultations were longer and they were 
on higher salaries compared to non-prescribers. Non-prescribers needed support and 
prescriptions from the GP more frequently. Nevertheless, non-prescribers were found to be less 
expensive compared with prescribers despite non-prescribers needing additional GP resources. 
However, patients reported being overall more satisfied with prescribers.  
Hyde et al. (2016) undertook a survey of 300 nurses, radiologists and medics across Ireland to 
determine perceptions of risk and safety of INPs prescribing ionisation radiation. Obtaining 167 
responses (55.7% response rate), they identified professional barriers which were still evident 
with regards to perceptions of the safety of nurses prescribing; predominantly from radiologists 
who could not prescribe (when this study was undertaken: Hyde et al., 2016). This was despite 
existing evidence demonstrating nurses’ safe and responsible prescribing practice elsewhere (as 
previously reported). With regards to patient experience, Courtenay et al. (2017b) identified, 
through 120 patient questionnaires and 22 interviews, that although some patients with 
respiratory conditions expected antibiotics (43%), patients more frequently sought information 
(58%) and reassurance (52%) regarding their condition, or a physical examination (44%). 
Moreover, nurse prescribers avoided antibiotic prescribing through ‘patient-centred management’ 
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which provided education and reassurance rather than antibiotics. Overall, 96% of patients were 
satisfied with nurse prescribers’ consultations, however, those expecting antibiotics, and didn’t 
receive them, were less satisfied with treatment decisions (Courtenay et al., 2017b). With regards 
to health economics, Noblets et al. (2018) undertook a systematic review to determine the clinical 
and cost effectiveness of non-medical prescribing, and in line with the literature search 
undertaken by the researcher, found very limited evidence on this topic. One study exploring 
pharmacist prescribers vs. secondary care prescribing for pain was discussed. When adjusted for 
baseline clinical costs, pharmacists were more expensive than treatment as usual. This 
strengthened the need for more cost-effectiveness research with regards to the impact of non-
medical prescribing on service delivery.  
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  METHODS 
 
4.0 Introduction 
Based on the evidence gaps presented in the preceding chapters, this study compared and 
contrasted sexual health nurses’ use of INP vs. PGDs. A health services research approach 
(Bowling, 2009) was adopted to determine the provision, effectiveness and practicalities across 
three core themes: the clinical impact of nurses’ medication delivery; patients’ experiences of 
nurses delivering medications; and estimated costs associated with each approach.  
In practice, “medicines management is not a tag-on at the end of a consultation but is dependent 
upon and part of the whole consultation” (Cushing and Metcalf, 2007, p.1055). Due to the multiple 
considerations and perspectives required to comprehensively explore this topic, and to obtain the 
most clinically valuable outcomes, a mixed methods design (Creswell, 2014) was deemed by the 
researcher as the most appropriate. The ‘Mixed Methods’ approach employed seven separate 
data-collection ‘tasks’, involving: [clinical] NHS staff stakeholder interviews; staff questionnaires; 
clinical diaries; clinical notes review; observations of nurse-patient consultations; [patient] patient 
experience questionnaires; and [cost] a health economics/ cost assessment. The interactions 
between these tasks are summarised in Figure 4-1.  
Due to the complexity of the study, this chapter presents an overview of methods. Methods 
specific to each ‘task’ are subsequently presented alongside their findings in the next chapter. 
The methods overview presents:  an outline of the project’s design; the study’s aims, objectives 
and research question; justification for employing a mixed methods design; an overview of the 
specific methods used; patient public involvement; inclusion/ exclusion criteria; site selection; an 
overview of data analysis; study-wide ethical considerations; research project governance; 
defining errors in prescribing; and determining how safety and appropriateness were measured.  
 
   82 
 
Figure 4-1 Overview of methods  
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4.1 Research design outline 
A convergent mixed methods design (Creswell, 2014) collected qualitative and quantitative data 
in parallel, analysed each component separately, and then merged data (see Figure 4-1) to 
generate descriptions, inferences and conclusions. Quantitative data were collected in clinical 
diaries, a clinical notes review and through questionnaires. These data supported descriptive 
overviews of nursing demographics; generalisable inferences relating to clinical practice; and 
patients’ satisfaction with nurses independently delivering medications. Qualitative data were 
collected in parallel through stakeholder interviews and consultation observations. A high-level 
costs assessment was undertaken based on all of the data collected. Collecting both quantitative 
and qualitative data in this manner created a deep, yet generalisable, research design which was 
sympathetic to the complex interaction of how sexual health nurses’ independent delivery of 
medications affected individual nurses, patients and the wider NHS. 
 
4.2 Aim and objectives 
Aim:  
To explore how sexual health nurses’ use of independent nurse prescribing (INP) compared with 
the use of patient group directions (PGDs) in terms of clinical application, patients’ experience 
and cost. 
Objectives: 
1. Determine the extent to which sexual health nurses’ professional experience and scope 
of practice affected prescribing practice or PGD use.  
 
2. Explore INP practice and the use of PGDs by nurses working in sexual health services; 
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3. To assess whether and how local application of INP and/ or PGDs has benefited 
patients, health professionals and the NHS, with reference to quality of care, 
appropriate management of sexual health care episodes, and value for money. 
 
How data collected through the multiple methods aligned with the objectives is presented in Table 
4.1. This table is structured to align with later discussion sections (see Chapter 6).  
Research question:  
How does sexual health nurses’ use of INP compare with the use of PGDs in terms of clinical 
application, patients’ experience and cost? 
 
4.3 Mixed methods paradigm’s influence on research design 
‘Mixed methods’ combines influences from positivist (absolute scientific truth) and interpretivist 
(subjective interpretation of experiences) paradigms to create a pragmatic approach (Creswell, 
2014; Gerrish & Lacey, 2010). The pragmatic approach in this study, made the investigation of 
nurse delivery of medication the main driver for determining the research methods; as opposed 
to the study’s aims and objectives being restricted by a specific method. The benefits of 
pragmatism, according to Creswell (2014), is that the researcher is not committed to one 
philosophy or reality, allowing greater choice of methods. However, mixed method designs are 
criticised for adopting opposing theoretical contexts, reducing the validity of their results (Bowling, 
2009). Yet as nurse delivery of medication is a complex process, a singular research approach 
would not have provided the comprehensive exploration required to achieve the study’s aim. 
Moreover, the use of multiple mixed methods in this study strengthened the overall design, and 
validity, by addressing inherent weakness in individual methods and triangulating the findings to 
achieve more reliable, valid and comprehensive conclusions (Creswell, 2014; Gerrish & Lacey, 
2010). Consequently, these methods will generate new nursing epistemological knowledge 
through expert nursing experiences and robust empirical data collection (Chultz and Meleis, 
1988) and new ontological knowledge through exploring the process of how nurses care (Reed, 
1997).     
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Table 4.1 How methods align with the discussion in Chapter 6  
Objective sub-section 
Method 






Professional experience of those 
delivering medication       
INPs & PGD users’ scope of practice       
Frequency of medication delivery       
Range of medication       
Appropriateness of medication delivery       
Safety of medication delivery       
Consultation characteristics       
Autonomous practice       
Consultation duration       
Benefits to patients       
Benefits to health professionals       
Benefits to NHS       
Quality of patient care       
Appropriate management of 
genitourinary & reproductive care       
Value for money       
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4.4 Overview of methods 
The study involved five separate sexual health sites located in cities throughout the UK mainland. 
The process and rationale for selecting specific sites are presented in ‘4.8 Study sites and 
settings’ (page 93). The seven data collection methods used in this study are summarised below: 
Staff interviews 
The staff interviews (schedule Appendix A) formed a qualitative basis to the project. They 
explored the governance benefits and barriers of nurses independently delivering medications. 
Purposively sampled senior NHS staff members participated in semi-structured interviews. 
Interviews were audio taped, transcribed verbatim and thematically analysed.  
Staff questionnaires  
The staff questionnaires explored nurses’ demographics, opinions on medication delivery and 
costs associated with training. All nurses using INP or PGDs at the five sites were invited to 
participate. Specific questionnaires for INPs (Appendix E) and PGD users (Appendix F) were 
distributed to all eligible staff. The last section of the questionnaire invited nurses to declare an 
expression of interest for participating in the clinical diary.  
Clinical diary 
The clinical diary (Appendix G) involved participating nurses keeping a record over a 2 week 
period of patients they managed; detailing patients’ clinic numbers and coded responses for: 
attendance type; whether medication was delivered and if it was done so independently; whether 
the nurse needed clinical and/ or medication support; who nurses sought support from; and 
approximate time spent managing patients. Explanatory notes for the codes were detailed on the 
diary’s front page (Appendix H). Participants were requested to distribute patient questionnaires 
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Patient experience questionnaire 
A patient experience questionnaire (Appendix L) involved patients completing a two-page 
questionnaire that explored patients’ confidence in nurses’ management of their care episode, 
and satisfaction with information about medicines. The questionnaire was based on validated 
research tools: STI clinic patient satisfaction survey (Weston et al., 2010) and Satisfaction with 
Information about Medicines Scale (SIMS: Horne et al., 2001). Patients were requested to return 
the completed questionnaires in boxes situated in reception areas prior to leaving the department. 
There was an optional prize draw, to win one of ten £20 high street vouchers to encourage 
responses. The questionnaire was also distributed to patients in the observational study. 
Clinical notes review 
The researcher’s review of patients’ clinical notes randomised a sample of INP and PGD users 
documentation of patients’ presentations over a six-month timeframe (01/07/2015 to 31/12/2015), 
sourced from clinic attendance lists. Assessments of safety and appropriateness were based on 
local and national sexual health guidelines/ legislation (BASHH, 2016; FSRH, 2016; NICE, 2014; 
The Human Medicines Regulations 2012; NMC, 2006; DH, 2006) and the validated Medication 
Appropriateness Index (MAI: Hanlon et al., 1992), which measures appropriateness of medication 
provision based on 10 specific areas (see section 5.8.2.1 on 146). Clinical records from nurse-
patient consultations were included for review under four distinct categories (presented in Box 
4.1) to determine if medication was (i) given appropriately, or (ii) appropriately not given. 
Anonymised data were recorded on a specifically designed Microsoft Access® database 
(Appendix K).  
Box 4.1: Research categories 
1. Medication episodes primarily managed by INP 
2. Medication episodes primarily managed by PGD 
3. Medication NOT provided in episodes managed by INP 
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Observations 
Nurse-patient medication consultations were observed by a single observer, audio recorded and 
transcribed. Nurses who participated in the clinical diary were invited to participate. To keep data 
collection and analysis manageable, six nurses (three INP and three PGD users) from across all 
five sites were sought to participate. Five consultations were observed for each nurse (n=30 in 
total). The Royal Pharmaceutical Society’s (RPS) ‘Prescribing Competency Framework’ (2016), 
which described the competencies central to prescribing, formed the analysis basis of prescribing 
consultations. The observation schedule was based on an earlier version by NICE (2012: 
Appendix O). Transcripts were compared against local and national policies for the management 
of sexual health presentation (STI management and contraception provision). To support deeper 
analysis and triangulation, the observations were also assessed against the data collection tools 
used in the clinical diary, clinical notes review and patient experience questionnaire. 
Cost assessment 
The costs assessment utilised data collected from the preceding methods to compare the costs 
versus returns between INP and PGDs from the perspective of the individual nurse, the patient 
and the NHS. The resource and cost implications for setting up and maintaining nurses’ 
independently delivering medication in sexual health were synthesised in a ‘Cost & 
Consequences Analysis’ and presented as a balance sheet. Table 4-2 highlights the strengths 
and weaknesses of each of these individual research methods. 
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Deeper, in-depth understanding of governance issues which allowed 
probing and clarifications; supported a level of standardisation 
between interviews while allowing freedom to explore concepts 
Not able to generalise. Focussed on individuals’ perception when the 
governance processes affected multiple staff. Researcher had ability to lead or 
direct the conversation. Perception bias when coding transcripts. Time 






Collected demographic data, opinions, and estimated costs for 
quantitative analysis; potential to generalise; standardised for all 
participants. Participants completed away from researcher.  
Pre-determined by researcher enquiry, limited amount of free information 
participants can provide. Relied on participants returning questionnaire. High 




Allowed real-time information to be recorded by the nurse for 
research purposes. Allowed data collection that was not readily 
available by other methods. Distributed patient questionnaires.  
Participants needed to remember to complete. Accuracy affected if not 
completed properly. Relies on volunteers. Participants could have become 




Allowed generalisable conclusions on the provision, safety and 
appropriateness of medication delivery. Used validated research 
tools for assessment. Reduced researcher’s bias. 
Data were not recorded for research purposes; may not have included all 
aspects of the consultation. Relied on accuracy, quality and completeness of 




Provided data on interactions, communication and performance not 
achievable by the other methods. Used validated research tools 
which supported standardisation between all observations. 
Validated findings from other sections through triangulation.  
Hawthorne effect (i.e. altered behaviour of participants being observed). Difficult 
for researcher to be truly non-participant. May have effected patients’ ability to 
fully discuss their health concerns. Subtleties and non-verbal communication 
may have been over-looked. Observer and participant fatigue may have 




Allowed high volume of responses. Based on two validated research 
tools. Provided patients’ opinions on their satisfaction with nurses 
managing their care. Researcher did not need to be present to 
distribute questionnaires.  
Relied on suitable return rate; biased patient choice as nurses may have 
selectively distributed. Nurses needed to remember to distribute when 
medication was delivered. Took additional patients’ time at the end of 






Supported an economic evaluation of benefits to service delivery, 
patients and staff. Costs and consequences allowed different 
professionals to assess costs relating to their own specific interest. 
Majority of costs based on estimations, affecting accuracy. The costs for drugs 
for the five sites may be different to those in the BNF due to local procurement 
contracts.  
(Parahoo, 2006; Bowling, 2009; Moule & Goodman, 2009; Gerrish & Lacey, 2010; Creswell, 2014).   
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4.5 Data collection tools and study documents 
The data collection tools were selected or designed/ refined by the researcher and experts in 
nurse prescribing, health economics, nursing research and medication safety, and through critical 
appraisal of existing literature. Validated tools were used where relevant to the study’s objectives; 
these included the Medication Appropriateness Index (MAI: Hanlon et al., 1992, see section 
5.8.2.1 on page 146), the Satisfaction with Information about Medications Scale (SIMS: Horne et 
al., 2001, see section 5.12.5 on page 209) and aspects of a patient experience questionnaire from 
Birmingham’s sexual health department (Weston et al., 2010, see section 5.12.5 on page 209). 
Following refinement by the study team, tools were piloted or sent to potential users for feedback. 
Further details on individual tool development, refinement, validity and reliability is presented 
alongside their methods, where applicable. Participant information sheets and consent forms 
were designed specifically for the research project; refined by the researcher, supervisor team, 
and the Health Research Authority approvals process. Table 4-3 details the appendices for 
research tools, participant information sheets and consent forms. 
 
Table 4-3 Data collection tools and versions overview 
Section Item Appendix 
NHS stakeholders’ 
interviews 
Interview outline Appendix A 
Staff interviews participant information sheet Appendix B 
Staff interviews consent form Appendix C 
Staff questionnaire 
Participant information sheet Appendix D 
Staff questionnaire: independent nurse prescribers Appendix E 
Staff questionnaire: patient group directions  Appendix F 
Clinical diary 
Clinical diary data collection tool Appendix G 
Diary explanatory notes Appendix H 
Diary participant information sheet Appendix I 
Diary & notes review consent form Appendix J 
Clinical notes review Data collection field list (based on Microsoft Access®) Appendix K 
Patient experience 
questionnaire 
Patient questionnaire Appendix L 
Patient questionnaire participant information sheet: English 
version 
Appendix M 
Patient questionnaire participant information sheet: Welsh version Appendix N 
Observation study 
Observational schedule  Appendix O 
Staff observational participant information sheet Appendix P 
Staff observational consent form Appendix Q 
Patient observational participant information sheet: English 
version 
Appendix R 
Patient observational participant information sheet: Welsh version Appendix S 
Patient observational consent form: English version Appendix T 
Patient observational consent form: Welsh version Appendix U 
Observational study advertising poster Appendix V 
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4.6 Patient and Public Involvement  
During the research design stage, eight patients, who had used a variety of healthcare services, 
gave their opinions with regards to the information they sought when receiving medicines. All had 
queries relating to medication effects and potential side effects. This is in-line with evidence 
presented in the empirical literature chapter, which highlighted that although nurses perceive they 
addressed these issues, patients often felt this was not the case. Therefore, the decision was 
made to observe nurse-patient interactions during medication consultations to determine the 
extent to which patients’ concerns were addressed. These issues could not be accurately 
assessed through documents. Moreover, this stage also identified the need to assess patients’ 
satisfaction with medication advice, thus supporting use of the patient experience questionnaire.  
Six further sexual health patients were informally approached to obtain feedback on the draft 
patients’ experience questionnaire. Minor modifications were made with formatting to make 
certain aspects clearer. Feedback also identified that the participant information sheet needed to 
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4.7 Inclusion and exclusion criteria 
The study’s inclusion and exclusion criteria are presented in Table 4-4. Criteria are set out for all 
aspects of the study relevant to service providers, nurses and/ or patients.  
Table 4-4 Inclusion and exclusion criteria 




 Nurses used INP and/ or PGDs 
 NHS services that provided complex 
specialist management of sexual 
health presentations and conditions 
 Site provided appropriate 
authorisation 
 Easily commutable by train for the 
researcher from their London base. 
 Support for project not achieved by 
local manager or Trust R&D office 
 Nurses did not work independently in 
patients’ case management 
 No provision of a suitably trained 
clinician for discussion of local 
procedures and prescribing decisions 
Nurses  
 Worked in sexual health services 
that routinely used INP or PGDs 
 Voluntarily agreed to participate 
(except clinical notes review) 
 Declined to participate in the study 
(except clinical notes review) 
 Did not use INP or PGDs 
 
Patients  
 Managed by nurses using INP or 
PGDs 
 Aged over 16 years’ old 
 Good understanding of English 
 Voluntarily participated in the 
observational study and/ or 
questionnaire 
 Patients attending for non-sexual health 
related complaint/ issue 
 Primarily managed by non-nursing staff 
(e.g. a doctor) 
 Patients deemed vulnerable (e.g. 
sexual assault, vulnerable adult/ child) 
or obviously uncomfortable during the 
consultation (observations & patient 
questionnaire) 
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4.8 Study sites and settings 
Study sites were purposively chosen, primarily if they employed nurses using INP and/ or PGD 
users in sexual health, with scope to independently manage patients’ episodes. For sites to be 
easily commutable from the researcher’s London base, cities were preferred. Cities were also 
regarded as having a larger pool of staff, thus facilitating the achievement of the sample quotas. 
Furthermore, specialist sexual health services, with the resources to manage complex 
presentations and conditions, tended to be city based, although many provided satellite clinics. 
Five sites were regarded as the maximum achievable within the project’s time and resource 
constraints. The sites that participated in the study were situated in: 
Site 1: Central London 
Site 2: South Coast England 
Site 3: Northern England 
Site 4: Scotland 
Site 5: Wales 
 
The participating sites provided a range of highly specialist services from sexual health screening, 
sexual and reproductive health provision, HIV care, psychosexual services, specialist services 
(e.g. young people, sex workers, men who have sex with men, research, sexual dysfunction, 
sexual assault, ‘chemsex’, PEP/ PrEP) using blended walk-in and appointment services (based 
on clinics’ websites, and orientation to departments, 2015/16). In line with expected service 
redevelopment to fully integrate genitourinary medicine and sexual and reproductive health 
services (DH, 2013), all sites were in advanced stages, or were already fully integrated. Across 
these services there were 95 nurses (INP=28; PGD=67) who could deliver medication 
independently, as presented in Table 4-5.  
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Table 4-5 Number of INPs and PGD users per site 
Number of 
INP/PGD 
Site 1 Site 2 Site 3 Site 4 Site 5 
n % n % n % n % n % 
INP (n=28) 11 39.3 1 3.6 0 0.0 13 46.4 3 10.7 
PGD (n=67) 18 26.9 8 11.9 10 14.9 16 23.9 15 22.4 
Total (n=95) 29 30.5 9 9.5 10 10.5 29 30.5 18 18.9 
INP= independent nurse prescribers; PGD= patient group directions. ‘%’ relates to distribution of each group 
across the five sites.  
 
4.9 Data analysis overview  
Data were analysed using descriptive and inferential statistics using the Statistical Package for 
Social Sciences (SPSS) version 24.0 statistical software, Microsoft Access®, Microsoft Excel® 
and Nvivo version 10. Descriptive statistics present the characteristics of the sites, nurses, 
patients and consultations with reference to age, ethnic origin, diagnosis, medicines provided, 
appropriateness and safety in medication delivery and clinical practice. Data are presented, 
where appropriate, using the mean, standard deviation, range and frequency distribution. NHS 
stakeholders, nurses and patients’ opinions were also presented throughout. Data analysis is 
presented as text, tables and charts to support the conclusions made.  
The majority of quantitative data collected throughout this study involved categorical data; 
however, where possible inferential statistics were used to compare differences between INPs 
and PGD users. Statistical tests applied relied on data meeting the relevant tests’ assumptions 
for use. The Chi Squared (2) test was used to compare relationships between INPs and PGD 
users if each cell in the contingency tables was greater than 5, or Fisher’s Exact Test if any field 
had less than 5 (Field, 2009). Where ‘means’ or ‘collated mean scores’ were collected, the 
Independent Samples t Test (t) was favoured when the sample size was over n=30, as per 
sampling theory (assumed equal variances used unless otherwise stated). The Mann-Whitney U 
test was used for smaller samples that were not normally distributed. To avoid a Type I error (false 
positive) the level of significance was calculated at 5% (0.05), where if the p-value is more than 
(p > 0.05) the results will not be considered statistically significant. Where possible large sample 
sizes were used to avoid a Type II error (false negative: Field, 2009). Specific analyses for 
individual methods are presented alongside their findings throughout Chapter 5.  
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4.10 Study-wide ethical considerations 
4.10.1 Research Governance and approvals process 
Table 4-6 details the various peer reviews and governance checks that occurred during the study. 
The National Institute for Health Research (NIHR)/ Health Education England (HEE) provided 
funding. King’s College London acted as the sponsor. Research Ethics Committee (REC) Wales 
REC4 approval was obtained on the 28/05/2015 (Appendix W), with amendments on the 
21/09/2015 (minor amendment involving clarification of data processing: Appendix X) and 
21/03/2016 (substantial amendment changing source of records to be included in clinical record 
review: Appendix Y). The Coordinated System for gaining NHS Permission (CSP) provided initial 
Research & Development governance checks in August 2015 prior to obtaining local R&D 
approvals. The Caldecott Guardian requested clarification in the protocol, participant information 
sheets and consent forms on how data would be managed and stored; all clarifications were made 
as directed. The project was adopted by the NIHR Clinical Research Network (CRN) and the 
Health & Care Research Wales portfolios.  Data collection commenced with ‘Protocol Version 
6.1’; dated 09/07/2015. This was replaced by ‘Protocol Version 6.2’; dated 01/02/2016 which 
underwent appropriate governance authorisations to amend how the clinical notes were reviewed 
(see Section 5.8.2). The study passed King’s College London’s PhD Upgrade assessment on the 
16/12/2015. 
The unique ethical implications for each method are presented in the specific methods’ sections. 
The study wide ethical issues involved are presented in Box 4.2. 
Box 4.2 Study-wide ethical issues 
 Data protection and storage (section 4.10.2) 
 Participation of staff and patients (section 4.10.3) 
 Potential of observing/ discovering unsafe practice (section 4.10.4) 
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Table 4-6 Governance reference numbers and dates 
Approval type Approval reference Approval date 
NIHR funding CDRF-2013-04-052 18/11/2013 









NHS Site 1 Caldecott 
Guardian 
Staff interviews: 577736 13/07/2015 
Staff questionnaires: 577873 13/07/2015 
Clinical diary and notes review: 577900 30/07/2015 
Consultation observations: 577912 30/07/2015 
Patient questionnaires: 577924 30/07/2015 
NIHR CSP Study IRAS: 148264    Study ID: 15SM2609 
04/08/2015 & 
11/09/2015 
NIHR CRN Portfolio 19378 13/07/2015 
Health & Care 
Research Wales 
148264 22/09/2015 
NHS Research & 
Development 
Site 1: 15SM2609 01/09/2015 
Site 2: 148264/865710/6/743/279285/334156 23/10/2015 
Site 3: R04119 09/12/2015 
Site 4: 2015/0351 18/09/2015 
Site 5: 15/RPM/6281P 25/09/2015 
King’s College London 
PhD Upgrade 
Student ID: 0751254 16/12/2015 
NIHR= National Institute for Health Research; REC= Research Ethics Committee; NHS= National Health 
Service; CSP= Coordinated System for gaining NHS Permission; CRN= Clinical Research Network 
 
4.10.2 Data protection and storage 
Data protection and storage were the major considerations throughout the study. The main risks 
were associated with the potential breach of data protection, leading to a loss of data and/ or 
confidentiality. The Great Britain Data Protection Act (1998) was adhered to throughout, ensuring 
confidentiality of participants and legitimate access to information. The study was later registered 
with KCL Data Protection Register to ensure compliance with the introduction of the General Data 
Protection Regulation (EU, 2016) which came into effect on the 25th May 2018. Patient identifiable 
data did not leave NHS sites, and were only used were absolutely necessary. Identifiable data 
were not recorded on data collection tools, but were stored on an NHS secured server which was 
accessed through a secured Virtual Private Network, in line with Caldecott Guardian 
requirements. Hardcopy lists which detailed patient identifiable information or staff identifiers were 
stored in locked cabinets at each site. Authorised access to local NHS IT systems or clinical 
records was required to access further personal information. Demographic information collected 
included: ethnic origin, gender, sexual orientation, medical and sexual history, presenting 
complaint, diagnosis and treatment. No patients' names or addresses were recorded, other than 
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for the prize draw attached to the patient questionnaire (which were provided voluntarily). All 
references to patients or staff in this thesis are pseudonyms or study ID numbers.  
In line with the university’s research framework, research records will be kept for a period of 10 
years on completion of the study, archived in line with KCL policy. Where possible, paperwork 
was scanned and stored electronically on a secure server. All appropriate hardcopies were 
destroyed as NHS confidential waste. 
The researcher and the study supervisors met regularly to ensure high standards of data 
collection and analysis were maintained throughout. The study had direct health economics and 
statistician support to ensure rigour of quantitative data analysis.  
 
4.10.3 Participation of staff and patients  
The involvement, participation and goodwill of staff was required throughout the study. To avoid 
coercion, rationales for non-participation were not sought by the researcher. At all times, the 
voluntary nature of participation was emphasised, as was the ability to withdraw at any point 
without providing rationales. Written consent was required from staff prior to participating in 
interviews and the clinical diary, and from staff and patients for consultation observations. Two 
copies of the consent form were then signed, one for the participant, one for the research file. 
Written consent was not required for the patient or staff questionnaires, as completion and 
submission was deemed as implied consent. The clinical notes review was approved by the 
Caldecott Guardian as an audit and so individual staff or patient consent was not required.  
 
4.10.4 Potential for observing or discovering poor practice  
While undertaking data collection there was a risk of discovering or witnessing poor or unsafe 
practice. For all aspects of the study the researcher was to either (i) approach the nurse at an 
appropriate time to discuss the issue, preferably not in front of patients; or (ii) report the incident 
to a senior manager for further investigation and/ or training (HRA, 2016). 
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4.10.5 Accessing and assessing data where the researcher is not employed 
Appropriate local R&D authorisations were obtained prior to accessing data sources. In areas of 
uncertainty relating to patient management (e.g. local policy differs from national guidelines), the 
researcher used local governance documents, and discussed all queries with local departmental 
representatives. If practice was deemed appropriate locally (e.g. followed local guidance, policies 
or formularies) it was recorded as appropriate. 
 
4.10.6 Research Governance 
The study was conducted in compliance with the Declaration of Helsinki (World Medical 
Association, 1996) and the Research Governance Framework for Health and Social Care (2005). 
The researcher maintained a ‘Good Clinical Practice’ qualification throughout the study, and 
complied with University and NHS Trust research guidelines. Appropriate sponsorship, ethics and 
local Research & Development approval was in place prior to any data collection. Amendments 
were made through appropriate approval channels for all protocol changes. 
 
4.11 Defining medication errors in practice 
The provision of medication is a complex process that involves a range of considerations to 
achieve a desired pharmacological effect in a safe, cost effective and patient focussed way. Safe 
medication delivery goes beyond the actual provision of medication, but also incorporates the 
patient’s consultation, history and preferences. Safe prescribing is facilitated through accurate 
history taking and clinical assessment to determine medication necessity and appropriateness. 
Allergies and concurrent medications, including over-the-counter and herbal remedies, should be 
consistently checked (Latter et al., 2007a) to avoid potentially lethal or allergic reactions or drug 
interactions which may cause side effects, drug inactivation or toxicity (BNF, 2016). Awareness 
of recent medication changes may explain any new symptoms, side effects or adverse events; 
e.g. in sexual health antibiotic use may affect diagnostic tests or cause fungal infections (BASHH, 
2016). 
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Accurate documentation is a key component in medication safety to provide a legal and 
professional record of patients’ assessments and medication provision. Medication 
documentation should include: full details of the medication, prescribing rationale, drug name, 
dose, frequency and duration or review date (BNF, 2016). Prescribing decisions should be 
evidence based and/ or consistent with recommended practice (BASHH, 2016; FSRH, 2016). The 
BNF provides guidance on drug choice; unsuitable drugs; consideration of patients’ comorbidities 
(e.g. liver or renal disease); risk associated with pregnancy and breastfeeding; adverse drug 
reactions and side effects; consideration of drug interactions; dose options; routes of 
administration; cost and monitoring recommendations (Buppurt, 2011; Wagle, 2011). The BNF 
(Version 70), BNF Online and Medicines Complete 
(https://www.medicinescomplete.com/mc/alerts/current/drug-interactions.htm) were the primary 
resources for assessing drug safety (for UK licensed medications). The quality of prescription 
writing and PGD supply were measured against the expected documentation standards in Box 
4.3. 
 
4.11.1 Prescribing error definition and severity 
The definition of ‘prescription errors’ was based on Avery et al. (2012), and was used to evaluate 
prescription writing accuracy throughout this thesis (including PGD documentation):  
“A prescribing error occurs when, as a result of a prescribing decision or prescription-writing 
process, there is an unintentional, significant: reduction in the probability of treatment being 
timely and effective, or increase in the risk of harm when compared to generally accepted 
practice” (Avery et al., 2012, p. xvii). 
 
Box 4.3: Requirements of a prescription (BNF, 2016) 
 Patient’s details 
 Name of prescribed item/ formulation  
 Strength (if any) 
 Dosage 
 Frequency 
 Quantity/ duration 
 Signed and dated by prescriber or PGD user 
 Given by PGD, if applicable 
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This definition was devised through a Delphi Technique involving 35 prescribing experts, 
standardised over 26 alternative error definitions and provided the basis for comparisons between 
professionals and clinical groups (Avery et al., 2012). The term ‘significant’, within the definition, 
is intended to afford interpretation of the clinical impact of the error. This allowed flexibility to 
overlook minor errors that would not result in harm to patients; for example, minor misspelling of 
drug’s names (e.g. doxycycline vs. doxcycline). The phrase ‘generally accepted practice’ is also 
important given this thesis involved five sites, across three separate countries. As local practice 
may have differed from national guidelines, prescriptions that were accurate locally were not 
considered an error, unless there was a fundamental safety issue with the local policy.  
Where an error was identified, the frequency, nature and severity were assessed. Dornan et al. 
(2009) list of prescribing errors (see Box 4.4) initially guided the analysis of error categories, but 
ultimately this study generated a list relevant to its own findings. The main addition to prescribing 
errors in this study related to patients’ past medical history, concurrent medications, allergies and 
pregnancy risk not being documented in the clinical records, as these are essential components 
in assessing medication safety and appropriateness (BNF, 2016). Moreover, missing 
‘administration route’ in ‘prescriptions’ was recorded as an error, regardless of whether there was 
only one type of drug formulation, as this was considered good practice in prescription 
documentation (BNF, 2016) (excluding cryotherapy, inter-uterine devices and contraceptive 
implants). The severity of prescribing errors was assessed in line with a validated, reliable scoring 
tool (Dean and Barber, 1999) and practical application in another prescribing study (Avery et al., 
2012). A visual analogue scale of 0-10 (zero means no potential effects on the patient, and 10 an 
error that would result in death) had a generalisability coefficient of 0.8, detailing a reliable test 
with construct validity for assessing prescribing error severity (Box 4.4); scores less than three 
are considered minor, 3 to 7 are moderate and over 7 are severe (Dean & Barber, 1999). In line 
with the tool, five judges (one expert research pharmacist, two consultant sexual health physicians 
and two experienced INPs) independently scored each error (with similar errors grouped); the 
mean score was the taken as the index of severity. Dean and Barber (1999) detailed that a 
minimum of four judges were required to make the assessments reliable and valid. The 
researcher approached four external judges, with the aim of obtaining three further severity 
assessments in addition to the researcher’s, i.e. four in total. However, all four external judges 
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agreed to participate, therefore, five severity assessments were used in this study, surpassing 
the minimum requirement for reliable and valid assessments. 
 
Box 4.4: Prescribing error categories (Dornan et al., 2009) 
 [Omission on admission]* 
 Under-dose 
 Overdose 
 Strength/dose missing 
 [Omission on ‘to take away’ discharge prescriptions]* 
 Administration times incorrect/ missing 
 Duplication 
 Product/ formulation not specified 
 Incorrect formulation 
 No maximum dose documented (if an exact dose is not stated e.g. once only 
medicines) 
 Unintentional prescription of a drug 
 No signature 
 Clinical contra-indication 
 Incorrect route 
 No indication 
 [IV instructions incorrect/ missing]* 
 Drug not prescribed but initiated 
 Continuation for longer than needed 
 Route missing 
 Start date incorrect/ missing 
 [CD requirement incorrect/ missing]* 
 Drug interactions 
 Daily dose divided incorrectly 
 Significant allergy 
 Continuation after adverse drug reaction(s) 
 Premature discontinuation 
 Drug interaction not taken into account 
 No dosage alteration after levels out of range 
 Dose/ rate mismatch 
 
*not relevant to routine outpatient sexual health practice 
 
Error severity (Dean & Barber, 1999) 
0 to <3 = Minor (very unlikely to have any adverse effects) 
3 to < 7= Moderate (likely to cause some adverse effects or interfere with therapeutic 
goals but very unlikely to result in death or cause lasting impairment) 
7 to 10 = Severe (likely to cause death or lasting impairment) 
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4.12 Chapter summary 
This chapter has provided an overview of the research methods used in this mixed methods study 
designed to explore medication delivery by nurses in UK sexual health services. A description of 
the study’s aims and objectives was presented along with justification for the research design and 
methods used with consideration of the relevant ethical and governance requirements. This 
design collected data concurrently and sequentially. Given the complexity of the methods used, 
and their interaction with one another, further methodological justifications are presented 
alongside their corresponding results in the subsequent chapters. Data are then merged in the 
discussion chapter structured around the study’s objectives. The conclusions then specifically 
answer the research question with reference to: clinical application, patient experience and costs 
comparisons associated with INP and PGD utilisation by nurses in sexual health.  
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The preceding chapter, ‘Chapter 4: Methods’ provided an overview of the study’s methods. 
Chapter 5 expands on this by detailing method-specific features with their corresponding findings. 
Given the complexity of the interactions between the multiple methods adopted, presenting the 
findings in this manner was determined by the researcher to provide the greatest clarity and ease 
of reference, as agreed by study supervisors. The first topic is the staff interviews, which are 
followed by staff questionnaires, clinical diary, patient experience questionnaire, clinical notes 
review, observations of medication consultations and the cost & consequences. The findings from 
the individual methods are triangulated throughout the discussion chapter.  
 
5.2 Staff interviews: Task-specific methods 
 
5.2.1 Purpose 
Senior NHS stakeholder staff interviews facilitated a qualitative explanatory basis to the study. 
The interviews allowed the researcher to explore nursing leads’ perceptions on the strength and 
weaknesses of nurses’ independent delivery of medication, as well as the local governance and 
training processes. The interviews facilitated a deeper understanding of local practice(s) of how 
each site managed and used INP and/ or PGDs in clinical practice.  
 
5.2.2 Method design 
Face-to-face semi-structured interviews used open-ended questions to elicit a dialogue with 
participants. Further exploration of concepts raised during interviews then expanded on 
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participants’ opinions of local governance, training, and the benefits and barriers to nurses 
independently delivering medication from an organisational perspective. The use of a semi-
structured interview schedule enabled topic standardisation between all five participants while 
allowing flexibility in exploring individuals’ experiences and perceptions. This design provided the 
researcher the opportunity to clarify or expand on ideas raised (Moule and Goodman, 2009). The 
interview schedule, which was created based on the review of existing evidence and discussions 
between the study’s supervisors, is presented in Appendix A. 
 
5.2.3 Recruitment 
One senior NHS stakeholder from each site (n=5), with overall sexual health governance 
responsibility for INP and/ or PGDs, was invited to participate in an audio-recorded interview. 
During the formative stages of the project, the researcher approached five sexual health services 
to organise departmental participation based on the site inclusion criteria (see page 92). The 
researcher subsequently liaised with five senior nurses to obtain the necessary research 
governance approvals for each department. These senior nurses also identified themselves as 
having overall INP and/ or PGD governance responsibility for their service, and were 
subsequently invited to be interviewed.  
Participants were given a copy of the participant information sheet (Appendix B) and consent form 
(Appendix C) at least 48 hours prior to the interview. The voluntary nature of participation was 
highlighted, and an opportunity to ask questions was provided prior asking participants to sign the 
consent forms.  
 
5.2.4 Data collection 
Interviews were conducted in participants’ offices at times suggested by themselves to reduce 
the impact participation would have on their work routine. The researcher endeavoured to probe 
only on issues specifically raised by the participants to avoid leading the interview. Open ended 
questions and confirmation statements were used to corroborate understanding of concepts 
raised. All data protection and governance processes presented in Chapter 4 were adhered to. 
 




Audio recordings were transcribed verbatim and thematically analysed. References to specific 
people or sites were anonymised. Hardcopies of interview transcripts and NVivo 10 were used to 
support inductive analysis of the interview data. Transcripts were thematically analysed using 
codes that appropriately defined the data’s content. Codes were linked to create overarching 
themes. This process was undertaken across six stages, as described by Braun & Clarke (2006). 
The stages are shown in Table 5-1. 
Table 5-1 Stages of thematic analysis undertaken 
Stage Phase Analysis (for this study) 
1 
Familiarising yourself with 
the data 
The researcher listened to all the interviews and read the 
transcripts through. Transcripts were re-read and initial notes 
made 
2 Generating initial codes 
Transcripts were transferred into Nvivo (v.10), and each line/ 
subject/ topic was coded 
3 Searching for themes 
The codes were reviewed and gathered to determine emerging 
themes 
4 Reviewing themes 
The coded extracts, initial notes and transcripts were re-reviewed 
to determine validity of the draft themes 
5 
Defining and naming 
themes 
Themes and subthemes were refined into clear constructs 
6 Producing the report 
The findings were written focusing on how the transcripts 
addressed the research question/ objectives (see page 83) 
Adapted from Braun & Clarke (2006, page 87) 
 
To support methodological rigour, processes to enhance credibility, transferability and 
dependability were employed throughout data design, collection and analysis (Endacott, 2008). 
All three aspects were enhanced through supervisor support and feedback throughout the various 
research stages. Credibility was increased as each participant reviewed their transcript prior to 
analysis to ensure it accurately reflected their interviews and individual opinions. All participants 
agreed they did. One participant requested that a single phrase was removed from their transcript. 
While the clinical setting of the interviews was restricted to sexual health, the concepts and 
themes raised are transferable to other clinical areas given INP and PGDs are governed at 
organisational and national levels. According to Creswell (2014), transferability of evidence is 
achieved through rich, thick descriptions. As such, each theme and subtheme is confirmed using 
participants’ quotations. Dependability was enhanced by using Braun & Clarke’s (2008) stages of 
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thematic analysis, as presented in Table 5-1, which provided a clear framework for data analysis 
and formation of themes. An example of transcript coding is presented in Appendix W. 
Reflexivity is an essential consideration during analysis of qualitative data (Creswell, 2014; Ritchie 
et al., 2013). For transparency purposes, the researcher discloses that they are a senior sexual 
health nurse with personal experience of INP and PGD governance and training. Having personal 
experience inevitably influenced the questions posed, probing during the interviews and how data 
were subsequently analysed (Ritchie et al., 2013; Tufford & Newman, 2010). While the researcher 
made efforts to ensure inductive interview questioning and analysis, it was inevitable their 
experience influenced this process, perhaps even enhanced a deeper line of enquiry and 
analysis. However, use of the aforementioned process helped ensure themes were derived 
directly from the data and not the researcher’s personal opinion.  
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5.3 Staff interviews: Findings 
 
5.3.1 Coding 
Four sites used both INP and PGDs, and one site only used PGDs. All participants were lead 
nurses in the sexual health department. Demographics were not collected to protect participants’ 
anonymity. While all five provided overall responsibility for INP and/ or PGD governance, two had 
more extensive experience of integrating and managing the introduction and maintenance of both 
medication delivery methods. A total of 76 initial codes were generated across the five interview 
transcripts. Table 5-2 provides a summary of each interviews’ duration and number of initial and 
total codes that emerged during analysis.  




Number of initial unique codes 
identified per interview 
Total number of codes 
per interview 
P.1 46m 56 415 
P.2 20m 43 254 
P.3 18m 40 201 
P.4 63m 46 753 
P.5 20m 54 262 
P.= participant 
 
5.3.2 Overview of themes 
The findings are discussed under three main themes: ‘clinical governance’, ‘service delivery’ and 
‘training and resources’. Several sub-themes are explored within each themes, as presented in 
Table 5-3. Key points are illustrated using anonymised quotations from participants (P.). 
Table 5-3 Overview of themes for stakeholder interviews 
Themes Sub-themes 
Clinical governance 
 Advancing nursing practice with access to medication 
 Defining advanced practice 
 The influence of banding on clinical practice 
 Accessing medication: INP formularies 
 Accessing medication: creating and maintaining PGDs 
 PGD use in clinical practice 
Service delivery 
 Efficiency of service delivery 
 Provision of nurse-delivered clinics 
Training and resources 
 INP training 
 INP training resources 
 PGD training 
 PGD training resources 
INP= independent nurse prescriber; PGD=patient group directions 
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5.3.3 Theme 1: Clinical governance 
The ‘clinical governance’ theme emerged from all interviews. There was a strong sense of how 
nurses’ roles, medication legislation and clinical standards were applied to support medication 
delivery in practice. Participants highlighted how medication legislation had facilitated advanced 
practice for sexual health nurses; however, clear differences in clinical application were evident 
in terms of which medications were available and how these were accessed.  
 
5.3.3.1 Advancing nursing practice with access to medication 
All participants discussed advancing nursing practice and how the role of the sexual health nurse 
had evolved. As practice shifted towards increased autonomy, the nurses’ interaction with doctors 
had also changed: 
“When I first came here, we were doctors’ handmaidens, so to speak. So…the equivalent of say 
Band 6 nurses, chaperoned doctors, passing swabs to doctors, getting clinics ready for doctors.  
And then perhaps just doing wart treatments following a prescription written by a doctor.” P.5 
 
“nurses now deal with patients who have got infection, who are symptomatic, who have a wide 
range of infections, it’s not just the domain of the doctor...So they [nurses] can get on and treat 
without necessarily seeing a doctor.” P.4 
 
Nurses’ access to medication was a key component in facilitating advanced practice. When asked 
how important access to medication was for nurses’ roles, one participant responded: 
 “its fundamental, is completely fundamental to the role” P.1  
 
As the governance for accessing medication evolved, so did nurses’ scope of practice. One 
participant recalled that prior to the introduction of PGDs, there were difficulties accessing 
medication, even when patients could purchase certain items from pharmacy: 
“when I first came here, nurses couldn’t use any PGDs or prescribe or give any medication.  And 
it was really difficult because you were constantly chasing after doctors, even asking for a 
prescription for something like a Canesten pessary, which you can buy over a counter.” P.5 
 
Recalling practice prior to PGD introduction also raised questions from participants, related to the 
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governance surrounding doctors prescribing medications for patients managed by nurses, or from 
nurses using local medication ‘protocols’:  
“So, “I’ve seen the patient, I assess them, I think this is what they need, would you mind 
prescribing it?” And because the doctors knew us and trusted us, they would often say ‘yes’ 
without seeing the patient, you know.  And, so although you tried your hardest to build in good 
governance around that, it wasn’t robust.” P.4 
 
“We’ve had nurse practitioners working in sexual health here since 1996. And I started here in 
97, and we had group protocols within which we used to issue medication, but we subsequently 
discovered that legality of those may or may not have completely ideal. And that led on to 
obviously PGDs and then on to non-medical prescribing.” P.1 
 
The introduction of PGDs was, therefore, regarded as an advancement in terms of service 
delivery for patients and for safe clinical practice: 
“I think PGDs are, are hugely useful. And before we had prescribing, we just thought they were 
amazing because it was the first time that we’d had the freedom to complete an episode of care 
for a patient and to feel that we’d done that safely.” P.4 
 
The introduction of INP was seen as another significant milestone in advancing nursing practice 
in terms of governance and flexibility:  
“once those ones who had become prescribers began to put that [INP] into practice, we realised 
just how cumbersome the PGDs can be” P.4 
 
“I think for me personally it’s the thing [INP] that has completely opened up practice” P.1 
 
INP’s flexibility in clinical practice was highlighted by all participants. Two participants discussed 
the impact INP had on the management of persistent genital warts: 
“I’ve got my own, run my own treatment where it’s mainly patients with genital warts.  And they 
send me complex patients where – because when we treat genital warts, we tend to follow a 
guideline or a protocol on what the best treatment is for the different types of warts; whereas, 
when I see them, I can work a little bit outside the box, a little bit outside the protocol.” P.5 
 
However, not all participants agreed that INP was currently appropriate for their services. One 
participant highlighted PGDs were fully established within their service and were appropriate for 
nurses’ current practice. Nevertheless, it was acknowledged the benefits INP would bring for more 
advanced scope of nursing practice: 
“we started with PGDs and that works fine.  And nobody is coming forward saying that they want 
to be a non-medical prescriber…There is no need.  You know, if it’s not broken, why try and fix 
it, because it’s [PGDs] working really well” P.3 
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“it’s a drawback of our service and our nursing team and it’s something that I’m really mindful of 
and I want to promote, is more advanced nurse practitioners… I think that we should have more 
expertise in our sexual health nurses and have more advanced nurse practitioners, and that goes 
hand-in-hand maybe with non-medical prescribing.” P.3 
 
From an individual nurses’ perspective, it was highlighted that some nurses were content using 
PGDs, if they covered the required clinical presentations:  
“the majority of staff find, especially if we’re getting these treatments, like the gonorrhoea 
treatment on PGD, I think they find that’s enough for them” P.5 
 
5.3.3.2 Defining advanced practice 
Defining the concept of ‘advanced practice’ was raised. One participant felt this was a loosely 
defined term and needed to encompass a specific level of practice, academic achievement, 
incorporate INP and be formed around competency based assessment frameworks: 
“I personally feel that we should have system like in America, where you have to do a nurse 
practitioner course, that it’s a second registration…and depending on what area or field of 
practice, that you do placements and you have assignments and that non-medical prescribing 
should be part of that.” P.1 
 
“non-medical prescribing…needs to be seen within an educational framework, that is both broad 
in terms of…physical assessment, but specific in terms of discipline…because I am a complete 
advocate for advanced practice, I think it needs to be within a Masters framework. And I say 
‘framework’ as opposed to a Master’s degree because I think that different people, different 
specialities…will have different requirements for that, but I definitely think they should fit within, 
the national competencies for advanced practice” P.1 
 
 
While the achievement of such an academic standard was seen as desirable, it was 
acknowledged that this may not always be practical due to an individuals’ inability to study at the 
required level or, because of the resources required to obtain it: 
“We do want all our specialty nurse practitioners to get a degree, but it’s quite a big thing 
especially if you didn’t qualify, if you qualified back in the eighties or nineties.  And they’re not 
perhaps very academic.” P.5 
 
“There is a course they have to do [for INP]. And it’s expensive and it’s time-consuming and you 
have to write a huge piece of work for it.  Those who are academic don’t mind that.  Those who 
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5.3.3.3 The influence of banding on clinical practice 
Nurses’ banding was seen as an indication of their expected scope of practice. Three participants 
aligned banding with an expected level of skill, clinical competence and access to medication: 
“Band 5 nurses…they’re trained in their kind of foundation competences in sexual health, and 
the next thing we feel that they would benefit, and patients would benefit, and clinic would benefit 
from, is those Band 5 nurses having some access to some of the PGDs. A 6 will see symptomatic 
patients independently.  A 5 basically won’t see symptomatic patients independently, but will do 
everything else.  They’ll do treatments, nurse follow-up, cryotherapy, asymptomatic, complex 
asymptomatic, partner notification.  They will do everything else apart from independently see 
symptomatic patients.” P.3 
 
Participants consistently identified that Band 5 nurses should have access to PGDs, and some 
highlighted that PGDs were useful clinical training tools: 
“I think the PGDs are very targeted, so that’s quite useful for our junior staff, because it means 
that they can concentrate on learning one thing, like Hepatitis B vaccination; as opposed to 
having to learn the whole thing” P.1 
 
The clinical expectation of specific bands was raised by one participant in relation to a lack of 
PGD competence, despite their band: 
“She came to us as a trainee, as a Band 5, and was promoted to a Band 6, it’s probably at least 
a year, which is why I’m so surprised that she hasn’t yet got that [PGD sign-off].” P.3 
 
While participants agreed Band 5 nurses should be able to use PGDs, there wasn’t the same 
agreement with regards to INP banding, or the level of ‘coercion’ to complete INP training. One 
participant felt INP should be voluntarily introduced at Band 6, whereas another respondent was 
of the view that it should be expected, and protected, at a Band 7 nurse practitioner role: 
“we regularly identify who needs, who’s next to go on the prescribing course.  And nobody is 
coerced on to it.  So we tend to, our aim is to have all our Band 6s and above prescribing.” P.4 
 
“once you start as a nurse practitioner the first thing we are going to put you on, before your little 
feet touch the ground, is the non-medical prescribing course.” P.1 
 
“there is a thing about delineating practice between what a junior nurse can do and what a senior 
nurse can do; because it is the only way that we can then protect our senior nurses, because the 
junior nurses at some point will want to go into a Band 7, and if we’ve eroded that, then there will 
be no Band 7’s for them to go to” P.1 
 
5.3.3.4 Accessing medication: INP formularies  
The four participants utilising INP discussed their formularies (i.e. locally/ nationally approved 
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drugs available to practitioners).  INPs’ access to medication varied across different services. Two 
services had a clinic formulary that met nurses’ requirements for accessing medication, while 
another had the full range of medicines listed in the BNF: 
“We’ve got a clinic formulary.  We’ve got a second formulary, but I tend to stick to the drugs that 
we’ve got in our clinic.  I don’t think I’ve ever prescribed anything that isn’t a drug that’s one of 
our formulary drugs.” P.5  
 
“we have been very clear about not having a very tight formulary, so I know that historically within 
the Trust they’ve wanted to have like a really, really tight formulary saying that non-medical 
prescribers can prescribe A or B or C. And we resisted that and kept it quite broad…And as our 




The fourth service required individual nurses to keep a personal portfolio of specific drugs they 
could prescribe. Interpretation of legislation was the rationale for creating these formulary 
portfolios. The arduous nature of this was likened to individual nurses writing their own PGDs: 
“our understanding is from our training is that each of us should have our own core formulary.  
And that’s something that we can add to as we go along…we all had this core formulary that we 
did ourselves.  And we did it pretty much off the back of the course.” P.4 
 
 “so I would just go into my folder, get up a template and work through that, get all the information 
I need to fill that in.  It’s a bit like writing a PGD.” P.4 
 
‘Intention to practice’ forms (locally derived documents outlining drugs that practitioners intend to 
prescribe) were used by one service to determine the range of drugs INPs could access. The 
intention to practice forms made INP governance more straightforward, dynamic to change and 
manageable in comparison to the personal portfolios:  
 “[For the] intention to practice form…I’ve created a blurb that gives enough detail of what we 
would expect our nurses to prescribe, without having to list every single medication. Which 
means if there is slight change then that can be incorporated quite easily because you would just 
change your practice….some people list every single medication in the way that they would with 
the PGD. For us, ‘cause the practice changes quite a lot, that would be a complete pain…to 
actually administer. Because it would mean that I’d have to ensure that every…independent 
prescriber updates their forms if there’s a change in practice, and I haven’t got time for that” P.1 
 
The intensity and volume of work to create personal formulary portfolios in P.4’s service resulted 
in some INP reverting to PGDs to deliver medication. However, the concept of INP using PGDs 
was not seen as beneficial, or required by another participant 
“there were a couple of prescribers…and they were talking about PGDs that they use and I was 
saying, “Oh you use that PGD.”  “Oh yes I do…because I haven’t got it in my formulary. So, and 
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I know I should get it into my formulary and I will one day, but I haven’t yet, so I just use the 
PGD.”  And because the PGD is there, I suspect it means they never get it in their formulary 
because it’s just too easy to use the PGD.” P.4 
 
“So I’ve never given anything under PGD since qualifying as a non-medical prescriber, because 
I just don’t, I don’t really see the advantage of doing that.” P.2 
 
5.3.3.5 Accessing medication: creating and maintaining PGDs 
Three participants had direct involvement in creating, authorising and maintaining PGDs within 
their services. They were also members of their Trust’s Non-Medical Prescribing Committees. 
These three participants frequently used the terms (or variations of): “challenging”, “the problem”, 
“long”, “cumbersome”, “time”, “pain” and “complexity” to describe PGDs. The complex 
authorisation processes were discussed by participants: 
“we’ve just added wart treatments to the PGD, and then that had to…be disseminated locally for 
all of the medical consultants to comment on, then it had to go to our nurses meeting, it had to 
go to the local GU meeting, it had to go to the directorate meeting, it had to be signed off by a 
divisional director of nursing, it had to be signed off by the chief principal pharmacist, it has to go 
to the non-medical prescribing, because it has antibiotics it has to go to the drugs and 
therapeutics committee. So it’s just so long, and difficult to get people…first of all to even read 
the frigging thing” P.1 
 
“the initial work was fairly laborious in that, in getting the right template, getting it all written, 
getting it to the right committees by the right time.  If you missed the deadline, you waited another 
month until it went to the next committee. And, of course, having the pharmacists rewrite what 
you’ve written, it meant that, you know, from the thought of having a PGD, to actually having it in 
place, was probably something like six months.” P.4 
 
“we’d have a lead clinician…get that signed, the pharmacists sign it. So it gets batted around in 
the internal mail until it’s all completely signed off.  Once that’s done, it’s then put up on to the 
intranet, it goes live, it goes public, and then it’s sent back to us with that signing sheet 
photocopied and, and at that point, we tell our staff, “We’ve got this new PGD, or this updated 
PGD.” We have folders in various strategic places around the clinic, and all the nurses are told, 
“You need to sign for that new PGD.” So that takes a little time. We have nurses working who 
only work out in satellite clinics.  And we used to send the PGD, we still do actually if they are 
really remote, we send the PGD out to them and say, “You sign that and you keep that in your 
own place of work.”  But the central staff, we just have one copy here and everyone signs it here.” 
P.4 
 
Because of the protracted PGD approval process it was highlighted that PGDs were not as 
dynamic as INP to changes in practice or to the availability of new medications: 
“one of the big issues with PGDs…there’s a time lag. So if something changes in practice, you 
can change your individual practice, but in terms of actually issuing medication, you have to wait 
until the PGD has been re-ratified through that whole process.” P.1 
 
The chair of the non-medical prescribing committee was a key component for the efficiency of the 
approval process: 
 
  114 
 
“So I think that when a new chair came in, she inherited a bit of…a kind of mess, if I’m honest, 
with regards to PGD.  So there didn’t really seem to be much understanding of which PGDs were 
being used where and this kind of thing. And it’s taken her a while to kind of get the house in 
order.  And I think that she’s just very organised and efficient and works with a team of people 
who are also organised and efficient and have a real will to enable people to use PGDs safely in 
the organisation.” P.2 
 
The requirement for each drug to be presented in its own PGD document, and for each document 
to have to undergo a revalidation process added further frustration for participants: 
“I can’t remember how many we have.  But probably twenty or something, possibly more.  And 
they’ve been developed by different people at different times.  So they come up for review at 
different times...And so it’s just a bigger bit of work because of the sheer complexity of the 
number.” P.4 
 
“continual process of renewal. So every two years, they have to be re-validated, which means 
after the first year you then have to complete all the audits…and you have to do start that process, 
so that when it runs out in two years, the next one is ready to go, which is a logistical pain” P.1 
 
 
While overall participants thought PGDs were useful, some participants questioned whether the 
effort was worth the outcome: 
“[PGDs are]... incredibly useful. But the amount of time it takes is disproportionate” P.1 
 
To make the process simpler participants discussed the benefits of a suite of PGDs, rather than 
individual documents. A suite of PGDs combines similar drugs under a single PGD document, 
rather than individual documents for each drug. The ability to use PGD suites varied between 
sites: one site was already using them, another was in the process of approving them, but were 
completely rejected by a third: 
“I think we’re going to have one suite of PGDs, and I think that the reason for that, is that our 
colleagues have been able to demonstrate that this is custom and practice in other areas...in my 
NHS Trust, we have a very, very pragmatic chair of the PGD group.” P.2 
 
“I sat and combined them all, got this lovely one-size-fits-all PGD, and then it’s thrown back at 
me.” P.4 
 
In stark contrast, interviewees were much more appreciative of PGDs’ governance when the task 
was delegated to colleagues: 
“I delegated that [laughter]…It was really easy…one of the Band 8As actually was responsible 
for adding those parts. And they went off and got all of the information, and put into the format 
for the monograph…So for me it was quite straightforward, cause I just needed to review what 
they had written.” P.1 
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“one person took the lead, got it done, it was their pain, not ours.  And we just said, “Oh great 
we’ve got another one,” when it duly arrived and we signed for it.” P.4 
 
Moreover, where the PGD governance role was managed by a pharmacist, lead nurse 
participants were much less critical, one found it almost pleasant: 
“we gave her a list of what we wanted. I think she wrote them and then had to get it signed off by 
the chief pharmacist, the – possibly the chief executive and somebody else senior – a few senior 
people had to sign them off – medical director, I think, before we could start using them” P.5 
 
“And it all went through quite quickly [PGD approval process].  And, for me, it’s quite, it’s a very 
nice process because it happens around me very efficiently.  And people just seem to know what 
they’re doing and get it done.” P.3 
 
5.3.3.6 PGD use in clinical practice 
While all participants agreed that PGDs were beneficial within clinical practice, their restrictive 
nature was discussed. The main restrictions related to: PGDs’ lack of clinical flexibility; nurses 
inadvertently overlooking treatment exclusions; and the need to obtain doctors’ prescriptions for 
drugs covered by outdated PGD documents: 
“PGDs are fine to a point, but there are limits with the PGDs in, you know, in that you can only 
give it out in a particular situation with a particular type of patient” P.1 
 
“There are little funny exclusions sometimes that people just forget about.” P.4 
 
“One thing is Ceftriaxone for the treatment of gonorrhoea.  The reason it’s not [available as a 
PGD] is when our PGDs were written, ceftriaxone wasn’t a treatment for gonorrhoea.  So they 
are still constantly trying to find somebody to write that [a prescription] for them, which I feel could 
be on PGD really” P.5 
 
 
PGDs also created unnecessary differences in clinical practice between INP and PGDs. Despite 
certain PGD nurses having advanced contraception skills (e.g. intra-uterine coil insertions), they 
were limited to providing just three months pill supply; whereas INP could provide up to five years. 
This ultimately affected patients’ interactions with the service: 
“in our community clinics, where we’ve giving contraception, there was a barrier to PGDs. We 
can only prescribe three months’ worth of contraception to each patient, whereas with 
independent prescribing, we can write up a prescription which will last five years. And the patient 
just comes back in and gets reviewed once a year.  So a nurse prescriber, independent 
prescriber, could do that.  But the staff using PGDs can’t.  So it does mean more visits for the 
patients to see somebody that’s using PGDs.” P.5 
 
In sites where INP was used in clinical practice, the participants all agreed that INP removed 
these inherent PGD restrictions: 
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“some of us have done nurse prescribing, which…helps even more because we’re not stuck to 
strict protocols.” P.5 
 
 
5.3.4 Theme 2: Service Delivery 
The impact INP and PGDs had on service delivery was another strong theme that emerged from 
interviews. This theme explores the impact nurses access to medication had on how services 
could be delivered, and the noticeable effect when nurses couldn’t practice autonomously.  
5.3.4.1 Efficiency of service delivery 
All participants used the term ‘efficient’ with regards to independent access to medication and its 
impact on service delivery. This ultimately allowed increased capacity and improved patient 
journeys: 
“I think that our services are very positively affected. I think that it’s a much more efficient pathway 
for the journey, pathway for the patient if they’re not having to wait around for a doctor to prescribe 
for them, when they’ve had an episode of care completed by a nurse” P.2  
 
“So we’re able to see these extra patients now.  If we’d stuck as we were in 1999, we would not 
be getting through the patients, the sheer number of patients we’re getting through now, because 
we’d have to have a doctor there, we wouldn’t be able to see so many patients.” P.5 
 
Several personal/ professional benefits were also expressed by participants beyond the efficiency 
of service delivery. These included increased satisfaction for both patients and staff, and greater 
holistic care, i.e. nurses were enabled to deliver complete episodes of care: 
“I like the efficiency of it, I couldn’t stand…having to wait for someone, used to drive me mad, 
you know, you’d have a pile of notes and you’d think, “There’s all these people to see, and here 
I am standing here waiting for a doctor.”” P.4 
 
“I think that it’s really improved the patient journey and the patient satisfaction and I think it’s also 
improved staff morale and just kind of given people more of a sense of pride around their own 
work when they’re able to complete a whole episode of care.” P.2 
 
“It makes the patient experience better because of not seeing different clinicians and nurses and 
having to disappear to get prescriptions” P.3 
 
In circumstances where medication access was not available this had a noticeable impact on 
service delivery. Frustration was evident not only from nurses seeking prescriptions, but also from 
the doctors being asked to sign them. This was subsequently seen to affect service efficiency and 
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productivity: 
 “they’re [Practice nurses] having to go and ask for a GP to prescribe this drug which just is 
another step for them, but it’s quite a laborious step.” P.4  
 
 “Those doctors will get to know which nurses aren’t able to use PGDs and those are the doctors 
who will come back to me and say, “Oh such and such can’t do it, it’s slowing things down and 
it’s not as effective, it’s not as efficient,” you know, it’s taking up their time. So I get complaints 
maybe from doctors in terms of efficiencies.” P.3 
 
5.3.4.2 Provision of nurse-delivered clinics 
Nurses’ independently accessing medication was described as facilitating the growth of nurse-
delivered clinics, in both main service hubs and satellite/ outreach services. The ability to provide 
medication was seen as creating a more flexible approach to how services could be provided: 
“It just makes it run a much more flexible service delivery, you know, people can multitask and 
they can be put anywhere almost” P.4 
 
 “now we’ve got nurses running clinics without doctors even being there, and making autonomous 
decisions for the care of patients.” P.5 
 
Participants highlighted that as nurses’ ability to provide medication had increased, so had the 
expectation to manage more complex patient presentations. The integration of genitourinary and 
contraception specialities has created additional complexity to consultations, as historically these 
were distinct specialities. Moreover, patients were seen to be presenting with more complicated 
pre-existing health issues: 
“so we are seeing more patients for integrated appointments now than prior to integration.  So 
people needing sexual health care, sexual health screening and contraception. And that might 
be what people come for, but it might [also] be a bit of an incidental finding when we take people’s 
histories.” P.2 
 
“maybe there’s a temptation in sexual health to think that patients are young and well.  And 
actually that’s not necessarily the case.  In my area we have a growing population of people living 
with HIV for much longer.  So, you know, they may be on lots of, you know, they’ve got poly-
pharmacy, they’ve got chronic conditions that they’re living with, so actually this idea that people 




As nurses’ roles and expectation of autonomous practice had increased to manage more complex 
cases, the benefits and flexibility INP brings over PGDs was highlighted. This was particularly 
evident in satellite clinics and outreach services where PGDs were regarded as much less 
practical: 
 
  118 
 
“We do a lot of satellite clinics, peripheral local clinics and I think most of us who work in those, 
are prescribers. And we couldn’t really do it otherwise, because so many of our patients wouldn’t 
fit the PGD criteria.” P.4 
 
“I also work in a prison.  And in the prison I can use different drugs for patients I see there, that 
might be not, that we might not have on PGD.” P.5 
 
 
5.3.5 Theme 3: Training and resources 
Issues surrounding training and the resources required for training was the third key theme that 
was elicited from participants. This theme highlighted that while the provision of INP training was 
relatively consistent, there were vast differences in how PGD training was provided. 
 
5.3.5.1 INP training 
In the four services that applied INP, the predominant feature with regards to INP training was the 
difficulty of the course. The depth of knowledge acquired during the INP course was significant, 
but viewed as worthwhile. However, the level of academic assessment was regarded as higher 
than Master’s level study, even when taken at degree level: 
“I think that, for me, it’s been an incredibly positive thing. I think that my understanding of 
pharmacology and issues around diagnosis and management have just improved enormously 
since undertaking the course.  The course is really challenging and it’s the hardest thing I’ve ever 
done, ever!” P.2  
 
“it was…delivered at [degree level], with the option to do it at Masters level…But I did it at [degree 
level], because I already had a masters and I thought it was incredibly high level…I thought it 
was way beyond, assessed well beyond [degree level]” P.4 
 
 
Nevertheless, from a managerial perspective, assessment at such a high level was reported to 
produce safe nurse prescribers. This subsequently provided confidence for managers that 
individual nurses were competent to undertake the INP role. However, from an individual nurse’s 
perspective, the difficulty of the course was often seen as a barrier to undertake INP training: 
“In terms of non-medical prescribers, I mean it’s a very robust course anyway, you know, in terms 
of all their written assessments and their portfolio, and their exams and short answer papers and 
maths questions, so because of that I’m quite confident that once been through that, and that 
they have passed that they’re okay” P.1 
 
“I think a big barrier to them doing the prescribing course is the amount of work involved. I think 
we’ve all come back, those of us that have done it, we’ve all come back and said about how 
much work is involved and possibly, unfortunately, put some of them off.” P.5  
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Consistently, INPs across the four sites, were all very clear that the medical team were extremely 
supportive. Doctors were seen to be supportive as INP had an immediate impact on the service 
and their interaction with nurses: 
“my designated medical practitioner in the team was just very supportive, you know, he’s worked 
with non-medical prescribers before and I think, you know, he totally saw the value of members 
of the team who have got, you know, a degree of sexual health knowledge and skill and are 
managing, you know, starting to manage more complex needs and that kind of thing, I think he 
really saw the advantage of it.” P.2 
 
“it was only very small numbers of us that were doing it, and they could see the immediate benefit, 
because they were fed up being asked continually to prescribe” P.4 
 
5.3.5.2 INP training resources 
A predominant resource issue with INP training was the funding, length of the programme and 
time required for the university course. While INP funding was previously readily available, NHS 
education funding budgets had been reduced. This created uncertainty amongst participants with 
regards to whether the courses would be funded in the future. Nevertheless, costs associated 
with INP training were viewed as a worthwhile, cost-effective investment; particularly with regards 
to the flexibility INP provided compared to PGDs:   
“funding for non-medical prescribing courses comes separately, currently. I think that the amount 
of education budget that the Trust is going to get in the next financial year is going to be 
significantly reduced.” P.2 
 
“the current costs I think is £2,000 for non-medical prescribing at [university],…and actually it 
creates an incredibly robust practitioner at the end of it, and I think that’s a very small investment 
for that. And it means we don’t have to worry in terms of the minutia of if something changes, or 
if you change from one brand to another do we have to update the PGD, we don’t have to worry 
about any of that.” P.1 
 
 
In addition to costs, participants reported that nurses were taken out of clinical practice for 26 
days to complete mandatory university training. This was seen as a difficult resource to 
accommodate. While some services attempted to give the full 26 study days, others had already 
cut the number provided: 
“I’d be very keen to support people with a hundred percent study time for attending study days.” 
P.2 
 
“I had a full hundred percent study leave. I think now it’s probably fifty percent study leave.” P.5 
 
 
Participants recognised that to complete INP training, nurses had to invest far more than the 26 
university study days. Given the degree of personal commitment and amount of expected 
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knowledge acquisition, participants were keen to preserve the 26 study days as far as possible, 
particularly as nurses must complete a substantial proportion of INP training in their personal time: 
“The 26 study days is a challenge, but we work to that because we expect nurses in their 26 days 
to gain an inordinate amount of knowledge, that medical students probably take two or three 
years to assimilate. So I think the 26 study days is completely fair.” P.1 
 
“The hundreds of hours that you will do will not all be given to you within your contracted hours.  
It is a bit of a partnership really” P.2 
 
 
5.3.5.3 PGD training 
In comparison to the standardised national curriculum for INP, training for PGDs was reported to 
be inconsistent across the five sites. The level of pharmacology knowledge was considered 
superficial, in comparison to that provided on INP programmes. Yet despite the limited medication 
knowledge junior nurses could independently provide medication: 
 “The problem is they don’t necessarily get any in-depth pharmacology, pharmacokinetics, 
pharmacodynamics in relation to administering those. So the most junior people are 
administering medication, and we assess them robustly in terms of making sure they are safe 
and effective in what they do, but they don’t necessarily have the theoretical underpinnings for 
that” P.1 
 
Throughout individual interviews it became apparent that PGD training and assessment 
processes varied greatly across services. Table 5-4 summaries these vast differences, 
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Table 5-4 PGD competency assessments as reported during interviews 
Type of training/ assessment P.1 P.2 P.3 P.4 P.5 Total 
Competency based assessment      4 
Tutorials      3 
Observed practice      3 
One to one discussions      3 
Group meetings      3 
e-learning (PGD specific)      2 
Self-directed study      2 
Auditing of notes      1 
e-learning (general)      1 
Observed Structured Clinical Examination      1 
Reflections      1 
Examination      1 
Assigned mentor      1 
University courses (e.g. contraception)      1 
No formalised training      1 
P.= participant 
Participants reported that most sites utilised competency based assessment for PGD training; 
however, there was great variation in how this was undertaken. One service provided PGD 
training alongside asymptomatic screening assessments, integrating the ability to provide 
medication alongside clinical competence. Whereas another site had no formalised process for 
PGD training in place: 
“so when they do their clinical’, they do a week of clinical practice, ‘when they do the clinicals 
that at the end of that they’re signed off on their PGDs so that they’re hit the ground running, and 
it’s not something we have to think about afterwards’” P.1 
 
“usually a new member of staff coming to us, that’s going to be using them, has already trained, 
has done a course already to be able to work here and already knows the drugs anyway.  But 
we just make sure that they know the side effects and things like that.  But, and we go through 
the PGD, but they don’t actually have formal training now.” P.5 
 
5.3.5.4 PGD training resources 
‘Time’ was highlighted as the primary PGD training resource, but this was an extremely limited 
resource. Finding time varied from: difficulty having time to spare clinical staff to undergo training 
because of low staffing numbers; to trainers being busy with other components of their roles; or 
not having enough staff that require training to justify the trainer’s time: 
“I think that we’re in a situation at the moment where the clinic is very short-staffed.  So freeing 
staff up or being able to work alongside staff to support them in becoming confident and 
competent with more PGDs, is very challenging.” P.2 
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“most of my kind of stress around PGDs actually is self-engendered because I’m busy and I don’t 
get it done, it’s done piecemeal rather than all done at once. It’s not anybody’s fault, it’s just busy-
ness.” P.4 
 
“The pharmacist is so busy, she wouldn’t want to run a session just for one person.  So we have 
to make it worthwhile really.” P.5 
 
Another participant highlighted that if the importance of PGDs on service delivery was better 
understood at strategic levels, then additional resources may be made available to support 
training:  
“I think that maybe an increased awareness across the organisation of why we use PGDs, how 
we use them, how it improves the patient care, would be really helpful.  And I guess that’s up to 
us as people working within the speciality to do that, isn’t it?  And I think that maybe by affording 
PGDs and settings like this, with a higher profile, it may mean that we get more resources to do 
it” P.2  
 
In contrast to considering the cost-effectiveness of the resources required for INP training, one 
participant was much less confident on the cost-effectiveness of the PGDs. They identified the 
opportunity costs associated with PGD creation, training, assessment and maintenance could be 
better allocated:  
“I’m not sure if [PGDs] are cost-effective. If you think about that every department…has to go 
through this process. That’s a lot of senior nurse time that could be spent with patients, or training 
staff, or doing research or other stuff” P.1 
 
5.3.6 Staff interviews summary 
Participants consistently agreed that access to medication was fundamental for nurses to 
undertake their clinical roles. The integration of PGDs and INP was reported to have facilitated 
sexual health nurses to evolve from doctor’s ‘handmaidens’ to autonomous practitioners, able to 
provide complete episodes of safe, legal care. Service efficiency and accessibility, improved 
patients’ experience, and expanded nurses’ roles (which increased job satisfaction and career 
prospects) were all seen to be benefits that arose from independent access to medication by 
nurses.  
Nevertheless, there was a clear divide in how participants viewed INP and PGDs. From a 
stakeholder’s perspective, PGDs, although essential, were mostly regarded as ‘cumbersome’, 
‘restrictive’ and ‘painful’ to govern and use in clinical practice. In all services where INP was 
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applied, participants were clearly more favourable towards INP, as compared to PGDs, in terms 
of flexibility, robustness of training and benefits to service delivery. 
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5.4 Staff questionnaires: Task-specific methods 
 
5.4.1 Purpose 
The staff questionnaire explored the demographics of sexual health nurses who were 
independently delivering medication at the participating sites; nurses’ attitudes on how this 
impacted on their practice; and their awareness/ recall of resource implications. Distribution of the 
questionnaires also provided an opportunity to introduce the entire study to potential participants 
to support recruitment for subsequent stages.  
 
5.4.2 Method design 
Questionnaires are an economical and easily administrable method for collecting quantitative 
data (Moule & Goodman, 2009). The two questionnaires (INP and PGD versions) were designed 
specifically for the study based on existing nurse prescribing questionnaires and evidence 
presented in the ‘Background’, and ‘Review of Empirical Evidence’ chapters. The questionnaires 
were split into three distinct sections: background (demographics); views on independent 
medication delivery; and about becoming an INP/ PGD user. Relevant comparable background/ 
demographical data were predominantly based on existing questionnaires by prominent UK nurse 
prescribing researchers (Courtenay & Gordon, 2009; Courtenay & Carey, 2008; Courtenay et al., 
2007a; Courtenay et al., 2007b; Latter et al., 2007). The demographic data collected included: 
method of medication delivery, gender, age, nurse banding/ grade, highest educational 
qualification and clinical experience. The clinical scope of practice was also elicited, for sexual 
health this involved simple or advanced genitourinary medicine and/ or contraception. The second 
section involved responses to 11 positively worded attitude statements, which were based on 
themes presented throughout the ‘Background’ chapter. These statements were created 
specifically for the study and explored participants’ opinions on how medication delivery: impacted 
on their clinical practice (Qu. 1, 2, 3); influenced patient experience (Qu. 4); affected their personal 
confidence and satisfaction in practice (Qu. 5, 6, 9); how training and continuing professional 
development prepared them (Qu. 7, 8); and whether they felt it was a worthwhile intervention (Qu. 
10, 11). Participants were asked to circle a five-point ‘Likert-type scale’ detailing strong 
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disagreement (1) to strong agreement (5) to the statements. The last section of the questionnaire 
utilised governance and training legislation for medication delivery (NICE, 2014; DH, 2012; NMC, 
2006), and the expertise of a health economist, nurse prescribing researcher and a senior sexual 
health nurse to determine the resources required for integrating, training and maintaining INP and 
PGDs in clinical practice. Participants were prompted to provide estimates/ recall of the resource 
implications to independently deliver medications. Separate INP (Appendix E) and PGD 
(Appendix F) questionnaires focussed on the components specific to each method. Participants 
also had the opportunity to leave ‘comments’ to expand their responses. 
The benefit of using questionnaires in this way supported a standardised method of data collection 
across all participants, thus supporting quantitative analysis and the ability to create inferences. 
That being said, the questionnaires’ structure limited the respondents’ choices, and may have 
obliged participants to choose an option they may not have otherwise selected (Parahoo, 2006; 
Bowling, 2009; Moule & Goodman, 2009). Moreover, the questionnaires were not based on 
existing validated research tools; however, their content was based on existing evidence and 
were designed to collect specific data to answer the research question. The design was further 
enhanced as the aforementioned research team modified the content until full agreement was 
achieved. Once refined, the questionnaires were further peer reviewed by two separate senior 
sexual health nurses; who offered no further comments for refining or improvement. Following 
this process, questionnaires were  deemed to have face and content validity, as they were 
focussed on measuring what they intended to measure; despite not being tested for validity or 
reliability (Parahoo, 2006; Bowling, 2009; Moule & Goodman, 2009).  
 
5.4.3 Recruitment 
All sexual health nurses at the participating sites (n=95) who used INP (n=28) or PGDs (n=67) 
were invited to complete a questionnaire following a presentation of the study during routine team 
meetings. An email detailing the study was also sent to the minority of nurses who could not 
attend the study presentation. The researcher attended staff meetings on all sites and offered to 
meet any potential participants one-to-one if they had any queries or would like to discuss 
participation.  
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The presentation of the study provided an overview of the entire project, but primarily focussed 
on what participation would involve (i.e. staff questionnaire, clinical diary, patient experience 
questionnaire and observational study). At the end of the presentation questionnaire packs were 
left with the local representative to distribute among eligible staff (i.e. INP and/ or PGD users 
working within sexual health). The pack contained: the questionnaire; participant information 
sheets for the questionnaire (Appendix D); the researchers’ contact details for any queries; and a 
return envelope. At the end of the questionnaire there was an ‘Expressions of interest’ tear off 
sheet which invited staff to leave their contact details if they were interested in participating in the 
clinical diary. A participant information sheet for the clinical diary (Appendix I) was also included 
in the pack to facilitate an informed decision regarding further involvement. Once completed, 
participants were requested to seal their questionnaires in the envelopes provided and 
anonymously return them to the local representative. The researcher arranged personal bulk pick-
up to avoid questionnaires being lost in the post. 
 
5.4.4 Data collection 
As the questionnaire contained three separate sections that required time to consider responses, 
the researcher requested questionnaires were returned within a two-week period. The time delay 
provided nurses time to consider participation in the questionnaire and subsequent study aspects. 
To support further submissions at the two-week period, either the researcher or the local site 
representative sent out email reminders to encourage further responses; this extended the 
submission period for a further two weeks. Completion and return of questionnaires were 
regarded as implied consent.  
Upon receipt of the questionnaires, the ‘expressions of interest’ tear-off sheets were removed 
prior to reviewing any responses to enhance anonymity. These sheets were stored separately in 
a secure, locked drawer at the university and subsequently used for recruitment to the clinical 
diary.  Data from the questionnaire were manually transferred to a specifically designed Microsoft 
Access® database by the researcher. All aspects of research governance and responsibility 
presented in Chapter 4 were adhered to.  
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5.4.5 Analysis 
A power calculation was deemed unnecessary as the study capacity only allowed for five research 
sites. Therefore, a high response rate was sought to be able to infer and draw conclusions. Moule 
& Goodman (2009) suggest a response rate over 50% is generally deemed acceptable. 
Descriptive statistics were used predominantly in this section to describe nurses’ age, clinical and 
professional experience and opinions on the impact medication delivery had on their practice. 
Where statistical test assumptions were met, the Chi-squared test and Independent Samples t 
Test were used to infer differences between INPs and PGD users, as described in ‘Data analysis 
overview’ on page 94. Findings from the staff questionnaires relating to costs are presented in 
Section 5.14 and 5.15.  
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5.5 Staff questionnaires: Findings 
 
5.5.1 Response rate 
Of 95 questionnaires distributed, 61 (64.2%) responses were received (INP=26, 92.8%; PGD=35, 
52.2%). PGD users were less likely to respond than INPs (2= 14.178, df= 1, p<0.001). 
 
5.5.2 Demographic data 
5.5.2.1 Gender, age & educational qualifications 
Most staff participants were female (n=55, 90.2%) aged between 35 to 44 years (n=21, 34.4%). 
INPs were mostly aged between 35 and 54 years, Band 7 or above (n=18, 69%) and qualified to 
Masters Level (n=16, 61.5%). Whereas, PGD users were mostly Band 6 (n=24, 68.6%), but were 
more spread across all age categories and level of academic qualifications than INPs, see Table 
5-5. 
Table 5-5 Demographics of nurse questionnaire respondents   
Demographics 
INP (n=26) PGD (n=35) Total  (n=61) 
n % n % n % 
Gender 
Female 21 80.8 34 97.1 55 90.2 
Male 5 19.2 1 2.9 6 9.8 
Age range 
25-34 3 11.5 8 22.9 11 18.0 
35-44 13 50.0 8 22.9 21 34.4 
45-54 9 34.6 10 28.6 19 31.1 
55-64 1 3.8 9 25.7 10 16.4 
Band 
5 0 0.0 5 14.3 5 8.2 
6 8 30.8 24 68.6 32 52.5 
7 13 50.0 6 17.1 19 31.1 
8 & 9 5 19.2 0 0.0 5 8.2 
Qualification 
Diploma 5 19.2 13 37.1 18 29.5 
Degree 4 15.4 8 22.9 12 19.7 
Masters 16 61.5 10 28.6 26 42.6 
PhD 1 3.8 0 0.0 1 1.6 
Unanswered 0 0.0 4 11.4 4 6.6 
INP= independent nurse prescribing, PGD= patient group directions 
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5.5.2.2 Clinical experience 
There was no difference between the groups with regards to the mean number of years 
participants had been qualified as a nurse (INP= 19.9 vs. PGD= 20.0: t= 0.035, df= 58, p= 0.972) 
or practising in sexual health (INP= 13.0 vs. PGD= 10.1: t= 1.954, df= 56, p= 0.056). PGDs had 
been used longer than INP by participants (7.6 vs. 5.2 years, respectively: t= -2.157, df= 56, p= 
0.035: Table 5-6).  
Table 5-6 Clinical experience of sexual health nurses by group  
Clinical experience 
INP (n=26) PGD  (n=35) Total (n=61) 
n (%) n (%) n (%) 
Years as a 
qualified nurse 
 
No. of responses 26 (100) 35 (100) 61 (100) 
Range 6 to 35 3 to 45 3 to 45 
Mean  19.9 20.0 19.9 
Standard deviation 7.7 11.8 10.2 
Statistical testing 
t =-0.035 (df58.2) p=0.972* 





No. of responses 25 (96.2) 30 (85.7) 55 (90.2) 
Range 6 to 35 3.5 to 45 3.5 to 45 
Mean  18.8 19.6 19.0 





No. of responses 26 (100) 32 (91.4) 58 (95.1) 
Range 4.5 to 23 2 to 23 2 to 23 
Mean 13.0 10.1 11.4 
Standard deviation 5.3 5.9 5.7 
Statistical testing 
t = 1.954 (df56) p=0.056 






No. of responses 26 (100) 32 (91.4) 
 
Range 0.5 to 11 0.2 to 16 
 
Mean 5.2 7.6 
 
Standard deviation 3.5 4.5  
Statistical testing 
t = -2.157 (df56) p=0.035 
mean difference= -2.3 (95% CI: -4.5 to -0.2) 
INP previous 
use of PGD 
(yrs) 
No. of responses 24 (92.3) 
  




Standard deviation 4.4   
INP= independent nurse prescribing, PGD= patient group directions, t=Independent Samples t Test, 
No=number, CI= confidence interval. *Levene’s Test equal variances not assumed.  
 
Twenty-two (84.6%) INPs reported they had used PGDs for a mean of 5.9 years prior to 
undertaking the prescribing course (see Table 5-6). A third of INPs at site 4 continued to use 
PGDs despite being qualified prescribers (see Table 5-7).  
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Table 5-7 Methods of medication delivery used by sexual health nurses by site 
Medication delivery 
method 
Site 1 Site 2 Site 3 Site 4 Site 5 Total 
n % n % n % n % n % n % 
INP 
INP responses 11 42.3 1 3.8 0 0.0 12 46.2 2 7.7 26 100 
INP only 11 100 1 100 0 0.0 8 66.7 2 100 22 84.6 
INP & PGD 0 0.0 0 0.0 0 0.0 4 33.3 0 0.0 4 15.4 
PGD 
PGD responses 6 17.1 4 11.4 4 11.4 10 28.6 11 31.4 35 100 
PGD only 6 100 4 100 4 100 10 100 10 90.9 34 97.1 
PGD & PSD 0 0.0 0 0.0 0 0.0 0 0.0 1 0.1 1 2.9 
INP= independent nurse prescribing, PGD= patient group directions, PSD= patient specific directions (a 
medication treatment plan made specifically for individual/ specific patients) 
 
INPs and PGD users practiced across genitourinary medicine and contraception; however, a 
higher percentage of PGD nurses overall (n=10, 16.4%), did not have any contraception training 
compared to genitourinary medicine (n=1, 1.6%). INPs were more like to be trained to advanced 
practice level in genitourinary medicine, compared to PGD users (80.8% versus 48.6%, 
respectively; 2= 5.285, df=1, p= 0.022). There was, however, no difference with regards to 
whether or not INPs and PGD users practiced at advanced levels in contraception (46.2% vs. 
45.7%, respectively; 2= 0.001, df=1, p= 0.973). See Table 5-8. 
 
Table 5-8 Clinical competency of INPs and PGD users 
Sexual health competency 




(INP vs. PGD) 
Total (n=61) 
n % n % n % 
Advanced genitourinary  21 80.8 17 48.6 
2= 5.285, df=1, 
p= 0.022 
38 62.3 
Simple symptomatic 3 11.5 17 48.6 20 32.8 
Asymptomatic genitourinary 1 3.8 1 2.9 2 3.3 
Working towards 
genitourinary competencies 
1 3.8 0 0.0 1 1.6 
Advanced contraception 12 46.2 16 45.7 
2= 0.001, df=1, 
p= 0.973 
28 45.9 
Basic contraception 12 46.2 11 31.4 23 37.7 
No contraception 2 7.7 8 22.9 10 16.4 
*Statistical testing compared ‘advanced genitourinary’ practice with combined totals of non-advanced 
genitourinary practice between INPs and PGD users; and similarly for advanced contraception. INP= 
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5.5.3 Nurses’ attitudes to independent delivery of medication 
Both INP and PGD users provided positive responses to 11 attitude statements regarding the 
impact independent access to medication had on their practice. A detailed results breakdown is 
presented in Appendix AA. There were limited variations found between INPs and PGD users’ 
opinions. Participants highlighted the following: 
Clinical practice 
Respondents in both groups predominantly agreed that independent access to medication made 
their clinical roles easier (INP=25, 96.3%; PGD=35, 100%); was essential for their roles (INP=23, 
88.5%; PGD=33, 94.3%); and that their medication delivery skills were being used effectively 
(INP=24, 92.3%; PGD=29, 82.9%) 
Patients’ experience 
Respondents were of the belief that patients received a better quality of care because nurses 
could independently deliver medications (INP=24, 92.3%; PGD=35, 100%). 
Personal confidence and satisfaction 
Both INP (n=25, 96.1%) and PGD users (n=30, 85.7%) identified that they felt confident in their 
ability to deliver medication independently, and that confidence in their clinical practice had 
increased since delivering medications independently (INP=22, 84.6%; PGD=30, 85.7%).  
Training/ continuing professional development 
There was slightly less confidence from nurse participants regarding the adequacy of training to 
prepare them for delivering medication independently; with 21 (80.8%) INPs and 26 (74.3%) PGD 
users agreeing it was sufficient. There was even less satisfaction from INPs relating to support 
for continuing professional development, with only 17 (65.4%) agreeing it was enough. This was 
less apparent in responses from PGD users (n=27, 77.2% agreeing). 
Overall personal recommendations 
Respondents reported that they would recommend independent medication delivery to 
departments not enabling nurses to do this (n=56, 91.8%), and that the effort to become 
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competent in the independent delivery of medications was worthwhile (n=54, 88.6%). While no-
one disagreed with this final statement, four (11.4%) PGD users were neutral.  
 
5.5.4 Motivation for independently delivering medications 
INPs were predominantly motivated to prescribe to: enhance their clinical skills; improve patients’ 
journey/ experience and personal job satisfaction; and to overcome medication restrictions (n=24, 
92.3%). While these were also important motivations for PGD users, the main influencing factor 
for the majority of PGD users (n=30, 85.7%: see Table 5-9) was the expectation by their employer. 
Table 5-9 Motivation in training to become INP or PGD users 
Training motivation 
INP (n=26) PGD (n=35) Total (n=61) 
n % n % n % 
Enhance clinical skills 24 92.3 29 82.9 53 86.9 
Improve patient experience/ journey 24 92.3 28 80.0 52 85.2 
Expectation from role/ employer 16 61.5 30 85.7 46 75.4 
Increase knowledge of medicines/ pharmacology 20 76.9 22 62.9 42 68.9 
Facilitate service development 20 76.9 26 74.3 46 75.4 
Improve satisfaction in your role 24 92.3 29 82.9 53 86.9 
Remove existing restrictions to medication delivery 21 80.8 24 68.6 45 73.8 
Obtain academic credits 10 38.5 
    
INP= independent nurse prescribing, PGD= patient group directions 
 
5.5.5 PGDs likelihood to undertake INP training 
Over 40% (n=13, 40.6%) of PGD users reported they would be very likely/ likely to undertake INP 
training.  Similar numbers (n=13, 40.6%) reported they would be unlikely/ very unlikely to do so. 
See Table 5-10. The remaining 18.8% (n=6) could be encouraged to undertake INP training.  
Table 5-10 Likelihood of PGD users undertaking INP training 
Likelihood of 
INP training 
Number of responses (n=32) 
n % 
Very unlikely 6 18.8 
Unlikely 7 21.9 
Neutral 6 18.8 
Likely 5 15.6 
Very likely 8 25.0 
INP= independent nurse prescribing, PGD= patient group directions 
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Content analysis of PGD users’ free-text comments relating to INP training identified that of those 
PGD users keen to undertake the INP training course, three had experienced resistance from 
their managers, despite detailing potential clinical benefits. By contrast, in a site that fully 
supported INP, it was highlighted that a Band 6 was unable to become an INP because of local 
restrictions that determined INPs needed to be Band 7 (n=1). PGD users (n=5) reported that as 
they became more senior and began managing more clinically complex presentations, they 
started noticing inherent restrictions associated with PGDs, and saw the benefits of INP. Two 
respondents reported that they were happy to continue to use PGDs, as they were suitably “wide-
ranging and sufficient to cover their sexual health role.” 
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5.6 Clinical diary: Task-specific methods 
 
5.6.1 Purpose 
Diaries were used by nurses to keep a record of their clinical activities over a two-week period. 
Although diaries are more commonly used in qualitative research, they are useful for collecting 
structured quantitative data as a complementary research design (Bowling, 2009; Moule & 
Goodman, 2009). Within the context of this study, the diary supported the collection of 
standardised data on nurses’ consultations activity across all five sites. 
 
5.6.2 Method design 
The clinical diary (Appendix G) was specifically designed for the study, initially based on the 
researcher’s expert knowledge of sexual health and patients’ journeys through the service. The 
diary was further refined in conjunction with the study supervisors, who provided theoretical and 
practical research expertise to ensure only relevant data were collected. The circling of coded 
responses aimed to make diary completion quick, simple and efficient; however, it did rely on 
participant’s commitment to ensure reliable and accurate completion. The primary purpose was 
to determine the frequency of medication provision and consultation length to support cost and 
resource assessments. The aim of nurses delivering medication independently was to facilitate 
autonomy (NMC, 2006); however, clinical and/ or medication support is frequently sought through 
the multi-disciplinary team (Black, 2013). The diary recorded: patients’ clinic IDs and type of 
consultation (new or follow-up); frequency and independence of medication provision; whether 
any clinical and/ or medicinal advice was sought from a colleague; and an approximation of time 
required to manage individual care episodes. Explanatory notes (Appendix H) formed the front 
page of the diary to provide detailed guidance and act as a reference point for accurate 
completion.  
To improve the dairy’s validity and reliability it was piloted (Moule and Goodman, 2009) by four 
experienced sexual health nurse practitioners. During piloting, aspects associated with: recording 
durations of consultations; categorisation of type of advice sought (clinical management and/ or 
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medicinal); and instructions on how to complete the diary were raised. Those piloting it found it 
was difficult to provide precise consultation durations. Incorporating scales (e.g. 0-5; 6-10) made 
the chart overly encumbered. Following feedback and liaising between those piloting the diary 
and the study supervisors, three columns were agreed on for participants to handwrite an 
estimated consultation duration, specifically: ‘Patient-facing time’; ‘Non-patient facing’ and ‘Time 
with other professional’. A suggestion to differentiate between ‘clinical management’ and 
‘medicine’ advice was also added because of user feedback, thus producing practical information 
on the nature of advice sought. The diary’s explanatory notes (Appendix H) were also modified 
to be clearer in terms of phrasing and formatting. The definitive version of the diary incorporated 
all the suggested feedback, and was subsequently used in the study. 
The diary was also used to distribute the patient experience questionnaires (Appendix L) to 
patients who received medication from nurse participants (see section 5.12).  
 
5.6.3 Recruitment 
Respondents who submitted an expression of interest form from the staff questionnaire were 
contacted by the researcher to discuss participation in the clinical diary, initially by email then in 
person. A participant information sheet (Appendix I) and consent form (Appendix J) were emailed 
to each potential participant at least 48 hours prior to the researcher arriving on site. A discussion 
on the diary was undertaken on a one-to-one basis, with an opportunity to ask questions. Prior to 
asking the participants to sign the consent forms, the voluntary nature of participation was 
emphasised, as was the ability to withdraw at any point.  
 
5.6.4 Data collection 
Completion of diaries had the potential to alter behaviour as participants were aware they were 
being monitored. They could also lead to participant burden and fatigue (Moule and Goodman, 
2009). To achieve enough diary entries, but avoid overly burdening participants, a period of two 
weeks was decided and agreed by the study supervisors. This was defined as two normal working 
weeks for that individual; taking into consideration long days and part time hours, rather than 
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simply specifying 10 working days. If participants were sick or on annual leave during the data 
collection period they were asked to include additional days to represent two normal working 
weeks of data. Participants were free to select their own suitable two-week period.  
During data collection, some further issues became apparent that were not raised during piloting. 
There was initial confusion relating to which patients needed the questionnaire. This was clarified 
as per the instruction sheet on the front page. Once this aspect became apparent, the distribution 
of patient questionnaires was emphasised to all subsequent nurse participants to ensure accurate 
understanding. Initially some other nurses were only recording patients they gave medication to, 
the need to include all patient contact was also clarified with all participants. Some PGD users 
became confused with the words “independently completed” in the ‘Medication delivery’ column; 
assuming this referred to INPs, as opposed to independent medication delivery. Clarification was 
provided. The term ‘autonomous practice’ was subsequently used throughout the study to ensure 
this differentiation was clear.  
The diary recorded patient clinic numbers and dates of birth, however, did not include patient 
names or diagnoses. Patient confidentiality was of upmost importance and a consideration 
throughout the diary design and data collection processes. Upon completion, participants were 
requested to seal their diaries in the envelopes provided and anonymously return them to the site 
representative. The researcher arranged to collect them in bulk to avoid them getting lost in the 
post. Once received, the data from the diaries were transferred onto a specifically designed 
Microsoft Access® database. All aspects of research governance and responsibility presented in 
Chapter 4 were adhered to. 
 
5.6.5 Analysis 
Much of the data collected in the diaries was categorical, therefore the Chi-squared test was used 
to determine potential differences between INP and PGD users’ consultations in terms of: 
presentation type (new versus follow-up); medication delivery frequency; need to obtain support 
from professional colleagues. Patients’ age (where possible), consultation length and length of 
time other professionals spent supporting participants was presented in terms of mean, standard 
deviation, range. The Independent Samples t Test was the used to infer if any differences existed 
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between INPs and PGD users. PGD users were particularly underrepresented in the diary in 
relation to the overall percentage employed at each site. The relatively high number of actual 
diary entries from both groups should, however, reduce any potential differences being down to 
chance. The effects of ‘new’ versus ‘follow-up’ care episodes, medication delivery and study type 
(INPs or PGD users) on consultation length were tested statistically using a general linear model 
(GLM). To test whether study type moderated the effects of ‘new’ versus ‘follow-up’ and 
medication delivery on consultation length interaction (moderating) terms were added to the main 
effects model that already included ‘new’ versus ‘follow-up’, medication delivery and study type. 
If the moderating effects were not statistically significant the GLM without moderating effects was 
used to test the main effects (i.e. the effect of each independent variable adjusting for the two 
other variables in the model). F-tests (with degrees of freedom and p-values) for moderating 
effects and main effects have been presented in the results. 
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5.7 Clinical diary: Findings  
 
5.7.1 Response rate 
Expressions of interest for participation in the clinical diary were received from 17 (65.8%) INPs 
and 22 (62.9%) PGD users from the questionnaire. This represented 60.7% of INP and 32.8% of 
PGD nurses across the five sites. All respondents who expressed interest in the clinical diary 
consented to participate; 17 (100%) INPs and 19 (86.4%) PGD users subsequently returned their 
completed documents. Three PGD users withdrew.  
 
5.7.2 Nurses’ clinical diary activity 
The 36 submitted diaries provided 1,330 clinical entries (INP=737; PGD=593). See Table 5-11 
for a summary and Appendix BB for detailed breakdown. INPs were more likely to manage new 
episodes of care compared to PGD users (69.5% vs. 49.6%, respectively: 2= 47.75, df= 1, 
p<0.001: Table 5-11). There was no difference in the frequency of medication provision between 
INPs and PGD users (62.4% vs. 58.7%: 2 = 1.97, df = 1, p=0.168); however, INPs were more 
likely to deliver medication autonomously (91.1% vs. 70.4%: 2 = 57.88, df = 1 p<0.001) and less 
likely to seek advice from professional colleagues (10.2% vs. 13.8%: 2 = 3.97, df = 1, p=0.046) 
compared to PGD users. See Table 5-11. INPs (n=38, 50.7%) were more likely to seek clinical 
management advice compared to PGD users who equally sought medication (n=21, 25.6%) and 
clinical advice (n=20, 24.4%: 2 = 37.922, df= 2, p=0.019). Both groups predominantly consulted 
doctors when seeking advice. Thirty (8.6%) PGD users’ episodes required professional 
colleagues to write prescriptions. 
Patients managed by nurse participants during the diary were aged between 13 to 78 years, with 
a mean age of 28.6 years. There was no difference in patients’ ages between INPs and PGD 
users (t =0.826, df= 1170.5, p=0.409: Table 5-12). 
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Table 5-11 Summary of diary results  
Diary entries (n=1330) 
Total 
Statistical testing 
(INP vs. PGDs)* 
INP (n=737) PGD (n=593) 
n % n % 
Presentation 
New 512 69.5 294 49.6 2 =47.747, df =1, p<0.001 
Follow-up 220 29.9 280 47.2 
Both 0 0.0 1 0.2 
 
Missing 5 0.7 18 3.0 
Medications 
given? 
Med given 460 62.4 348 58.7 2  =1.972, df =1, p=0.168 
No meds 261 35.4 232 39.1 
Missing 16 2.2 13 2.2  
Advice sought 
Advice sought 75 10.2 82 13.8 2 =3.966, df =1, p=0.046 
No advice Sought 580 78.7 451 76.1 
Missing 82 11.1 60 10.1  
Type of advice 
Clinical 38 50.7 20 24.4 
2 =7.922, df =2, p=0.019 Medicine 12 16.0 21 25.6 
Both 13 17.3 12 14.6 
Missing 12 16.0 29 35.4  
Advice 
obtained from 
Doctor 42 56.0 60 73.2 
Doctor vs. others combined 
2 =0.532, df =1, p=0.466 
Nurse 3 4.0 6 7.3 
Pharmacist 5 6.7 1 1.2 
Health Adviser 2 2.7 3 3.7 
Missing 23 30.7 12 14.6  
Medications given  460 62.4 348 58.7  
Medication 
delivered? 
Autonomously 419 91.1 245 70.4 
2=57.878, df=1, p<0.001* 
 
Rx: Doctor 29 6.3 80 23.0 
Rx: Nurse 2 0.4 10 2.9 
Rx: Pharmacist 3 0.7 3 0.9 
Rx: Health Adviser 2 0.4 1 0.3 
Rx: Missing 5 1.1 9 2.6 
No PGD   30 8.6  
*Statistical testing does not include data from the grey sections (e.g. ‘Both’ or ‘Missing’) 
**combines prescriptions from all professions and compares against nurses’ autonomous practice 
INP= independent nurse prescribing, PGD= patient group directions, vs.= versus, 2= Chi-squared test, 
Meds= medications, Rx= prescription, No PGD= no valid PGD for care episode 
 
 
Table 5-12 Patients’ age demographics 
Data type INP PGD Total Statistical testing (INP vs. 
PGD) 
Mean (years) 28.8 28.3 28.6 t =0.826, df= 1170.5, p=0.409 
mean difference 0.6 (95% CI: -
0.6 to 1.5)* 
Standard deviation 9.5 10.8 10.1 
Range 13 to 78 13 to 74 13 to 78 
INP = independent nurse prescribing; PGD = patient group directions; t=Independent Samples t Test; CI= 
confidence interval. *Levene’s Test equal variances not assumed.
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5.7.3 Consultation length 
Overall, INPs statistically spent longer managing patient presentations compared to PGD users 
(mean of 24.9 vs. 22.8 minutes, respectively: t=2.597, df=1,144, p=0.010:  Table 5-13). However, 
when consultations were compared like-for-like there were no statistical differences found 
between INPs and PGD users’ new (mean 27.3 vs. 25.7 minutes respectively: t=1.434, df=694, 
p=0.152) or follow-up consultation lengths (mean 19.6 vs. 20.0 minutes, respectively: t=-0.338, 
df=448, p=0.736). These times also do not account for complexity of patients’ presentations.  
 




Total nurses’ time managing patients Statistical 
testing 
INP PGD  
Overall 
Number of entries 





t= 2.597, df= 
1144, p= 0.010 
Range (mins) 1** to 84 5 to 95 
Mean (mins) 24.9 22.8 
Standard deviation 12.9 13.9 
New 
Number of entries 412 284 
t=1.434, df=694, 
p=0.152 
Range (mins) 1** to 84 5 to 95 
Mean (mins) 27.3 25.7 
Standard deviation 13.0 15.1 
Follow-up 
Number of entries 177 273 
t= -0.338, 
df=448, p0.736 
Range (mins) 5 to 60 7 to 75 
Mean (mins) 19.6 20.0 
Standard deviation 10.8 12.0 
*number of episodes included in the diary where a face-to-face time was expected  
 **INP prescribed for another nurse, but did not physically manage the patient so entered ‘1’ minute 
INP=independent nurse prescribing, PGD= patient group directions, mins= minutes, t= Independent 
Samples t Test 
 
 
The effects of ‘new’ versus ‘follow-up’ care episodes (mean difference=6.8 minutes) and whether 
medication delivery (mean difference=1.9 minutes) impacted on consultation length is presented 
in Table 5-14. Neither new episodes of care (F[1,1141] = 1.31, p=0.25) nor provision of medication 
(F[1,1141] = 0.36, p=0.55) were moderated by study type. Unsurprisingly, new episodes of care 
(F[1,1143= 68.76, p<0.001) and the provision of medication (F[1,1143] = 4.13, p=0.042) 
increased consultation length. These outcomes were consistent regardless of whether the patient 
was managed by an INP or PGD (F[,1,1143] = 0.59, p=0.44).  
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Table 5-14 Face-to-face time (minutes) 
Face to face time* INP (n=591) PGD (n=563) Total (n=1,154) 
Missing entries 146 (19.8%) 30 (5.1%) 176 (13.2%) 
Face-to face time (mins) Total Range ** Mean 
St. 
Dev. 
Total Range Mean 
St. 
Dev. 
Total Range Mean 
St. 
Dev. 
Overall 14,701 1 to 84 24.9 12.9 12,859 5 to 95 22.8 13.9 27,560 1 to 95 23.9 13.4 
New episode 11,234 5 to 65 27.2 13.0 7,309 5 to 95 25.7 15.1 18,543 5 to 95 26.6 13.9 
Follow-up episode 3,467 1 to 60 19.5 10.9 5,465 5 to 75 19.4 12.0 8,932 1 to 75 19.8 11.5 
Medication given 10,193 1 to 65 25.7 12.7 7,876 5 to 95 23.3 14.2 18,069 1 to 95 24.6 13.5 
No medication given 4,493 5 to 84 23.3 13.1 4,983 5 to 90 22.1 13.3 9,476 5 to 90 22.7 13.2 
New WITH medication 7,965 1 to 65 28.1 12.8 4,498 5 to 95 26.5 15.6 12,463 1 to 95 27.5 13.9 
New WITHOUT medication 3,269 5 to 84 25.1 13.2 2,811 
10 to 
90 
24.7 14.2 6,080 5 to 90 24.9 13.7 
Follow-up WITH medication 1,224 5 to 60 19.4 12.2 2,162 5 to 60 19.7 11.8 3,386 5 to 60 19.6 11.9 
Follow-up WITHOUT medication 2,228 1 to 60 19.5 10.2 3,303 5 to 75 20.1 12.1 5,531 1 to 75 19.9 11.3 
*This table presents the same data presented in four separate ways: 
Overall : combines the total face-to-face times nurses spent with patients 
New or Follow-up: determines if differences in face-to-face times are related to whether a patient presented as a new episode of care or a follow-up 
Medication given or not given: determines if differences in face-to-face time are related to whether medication is given or not 
New/ follow up, with/without medication: determines if differences are related to a combination of both type of episode presentation and whether medication was delivered or not. 
**one INP participant put a value of ‘1’ minute in their diary when providing ‘adhoc’ prescriptions to patients they were not directly managing, identifying they supported another member 
of the team.  
INP=independent nurse prescribing, PGD = patient group directions, mins= minutes, St. Dev. = standard deviation
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5.7.4 Support from professional colleagues 
Although INPs required less support from professional colleagues than PGD users (10.2% vs. 
13.8% of consultations, respectively: 2 = 3.97, df = 1, p=0.046), when INPs sought help, their 
colleagues spent longer supporting them compared to PGD users (11 minutes versus 8.2 minutes 
respectively); however, this was not statistically significant (t = 1.707, df = 92.7, p=0.091: see 
Table 5-15).  
 
Table 5-15 Colleagues' time for advice or prescriptions (minutes) 
Measurement 
Total colleagues face to face time (minutes) 
INP (n=95*) PGD (n=152*) Total (n=247*) 
Number of entries 
(% of expected values) 
63 (66.3%) 87 (57.2%) 150 (60.7%) 
Range (minutes) 1 to 47 2 to 45 1 to 47 
Mean (minutes) 11.0 8.2 9.4 
Standard deviation 11.7 6.9 9.3 
Statistical testing 
t = 1.707, df=92.7, p=0.091** 
mean difference 2.8 (95% CI: -0.5 to 6.1) 
 
*number of episodes where either advice or medication was obtained from a professional colleague 
**Levene’s Test equal variances not assumed 
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5.8 Clinical notes review: Task-specific methods 
 
5.8.1 Purpose 
The clinical notes review enabled a quantitative exploration of the safety and appropriateness of 
medication delivery by sexual health nurses. This also enabled an evaluation of nurses’ scope of 
practice in terms of the conditions they managed and the range of medications they required 
access to. Patients’ diagnosis, existing medical history, medication provision and documentation 
within clinical records were used to assess overall safety and appropriateness of care for 
individual episodes. In addition, episodes of care where patients did not receive medication were 
evaluated to ensure it was appropriate not to provide it (e.g. it would be appropriate to offer 
emergency contraception after recent pregnancy risk). Undertaking a thorough investigation in 
this way was intended to increase the generalisability of the findings and the inferences regarding 
safety and appropriateness of medication delivery by UK sexual health nurses. Moreover, it may 
well have implications for other clinical fields where non-medical practitioners independently 
assess, diagnose, treat and discharge patients attending for episodic healthcare.  
 
5.8.2 Method design 
The initial governance approval (REC, 28/05/2015) intended to use the clinical diaries to locate 
the clinical notes. However, during the data collection in the preceding phases several factors 
became apparent which weakened the robustness of this design. These involved: fewer number 
of PGD participants than predicted; reduced number of diary entries as nurses had multiple non-
patient facing roles and part time hours; and each site undertook the diary’s data collection at 
different time points. This consequently meant the results may have been biased towards INP, 
non-comparable between sites, and under-powered as minimum sample sizes may not have 
been achieved. A substantial amendment was therefore agreed (REC, 21/02/2016), which 
sourced the patients’ notes from clinic attendance lists rather than the clinical diary. All sites 
provided lists of patient attendances between 01/07/2015-31/12/2015 (limited to all to INP and 
PGD users were possible), thus standardising the timeframe across all sites. This also had the 
 
  144 
 
benefit of including all INP and/ or PGD users, as an audit design was employed rather than 
relying on staff volunteering. Consequently, this design is more likely to represent actual practice 
and it provided enough data to achieve the minimum sample size targets (presented later in this 
section).  
Reviewing clinical documentation was incorporated as it provided key data components to assess 
safety and appropriateness of care as documentation was expected to provide accurate synopses 
of care provision (NMC, 2015). The use of existing documentation had the benefit of: not requiring 
additional staff participation; reduced researcher bias as conclusions were drawn from what was 
or was not documented; and the data were readily available (Moule and Goodman, 2009). Relying 
on data not specifically collected for research purposes may, however, impact on the specificity 
as this was not the primary function of the original documentation. Furthermore, clinical records 
only represented what was documented, rather than actual practice (Moule and Goodman, 2009). 
Nevertheless, the clinical notes were a valuable source of data to explore medication delivery.  
A sample size calculation for the minimum number of clinical notes to include identified 344 clinical 
episodes per group. This calculation, made in conjunction with a statistician, assumed 99% of 
care episodes from INP were appropriate, compared with 89% of PGD; based on Black’s (2013) 
study. An estimated six-month population size of 6,475 care episodes was based on a nurse 
practitioner managing three patients per hour, one four-hour clinical shift per day, five days a 
week, for two weeks by ten nurse participants per site. However, this figure, in retrospect, over-
estimated the population as many sexual health nurses have multiple roles that are not always 
patient facing, and it did not consider part time workers. Nevertheless, the power calculation 
identified: "ignoring the structure of the data, where patients are nested within nurses, and some 
nurses are probably better than others at prescribing. With 344 patients per group, we have 99% 
power at the 5% significance level to find a difference between rates of appropriate prescribing of 
90% compared to 98%, at the 5% significant level." (Personal communication with statistician, 
2013).  
Four distinct groups were determined to achieve a robust quantitative assessment of safety and 
appropriateness of nurses’ medication delivery. A minimum of 344 clinical episodes in each group 
was the minimum target, based on the power calculation, as presented in Box 5.1.  
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Box 5.1 Minimum sample size of notes for each research group 
1. Medication episodes primarily managed by INP (n=344: “INP med”) 
2. Medication NOT provided in episodes managed by INP (n=344: “INP no med”) 
3. Medication episodes primarily managed by PGD (n=344: “PGD med”) 
4. Medication NOT provided in episodes managed by PGD (n=344: “PGD no med”) 
 
Assessments of non-provision of medication was an essential component of study, as not 
providing medication to patients in certain circumstances may have been unsafe and/ or 
inappropriate.  Examples include: incorrect management of sexual infections or partner 
notification causing STI to remain infective; not offering vaccinations, thus leaving high risk 
patients susceptible to preventable infections; inappropriate advice/ provision of contraception or 
emergency contraception puts females at risk of unwanted pregnancies; and not appropriately 
offering post exposure prophylaxis, following high-risk sex, could lead to HIV acquisition (BASHH, 
2016; FSRH, 2016).   
The type of data collected ensured assessments could be made based on the patients’ 
demographic risk factors, existing medical conditions, concurrent medication, pregnancy risk and 
diagnosis. Assessments then reviewed drug choice, prescription documentation, drug 
appropriateness, unexpected re-attendance for the same issue and independence of practice. 
Data collected were based on: prescribing frameworks (RPS, 2016), local policies, relevant 
BASHH (2016) and FSRH (2016) guidelines, the BNF (2016), and legislation influencing how 
nurses deliver medications independently (DH, 2006; NMC, 2006; The Human Medicines 
Regulations 2012; NICE, 2014).  
Assessing clinical practice in this way adopted an implicit review, resulting in a single person’s 
interpretation of clinical practice, thus opening the study to bias. To reduce interpretation bias and 
improve validity and reliability, additional precautions were integrated within the study design. The 
researcher discussed every episode of substandard practice, plus any issues where uncertainty 
existed, with a local representative. Local representatives were all experienced senior sexual 
health nurse prescribers (except site 3, who was the PGD author). Consensus was achieved in 
all queries between the researcher and the local representative prior to final reporting. A further 
10% of each site’s clinical notes quota (see Recruitment 5.8.3) were also randomly checked by 
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the local representative. Randomisation occurred using the ‘Study IDs’ from each site, including 
only episodes where medication was delivered. The relevant list was exported into an Excel® 
spreadsheet, was allocated a random number, and then sorted lowest to highest. Clinical notes 
were then checked in ascending numerical order by the local representative until the original 10% 
quota was achieved.  An experienced in HIV/ sexual health pharmacist independently assessed 
the medication safety of a 10% random sample (same randomisation process) of clinical notes 
where patients had a documented medical condition, concurrent medication and/ or allergy. The 
pharmacist also provided advice on four complex medication cases.  
5.8.2.1 Measuring appropriateness of medication delivery with a validated research tool 
The Medication Appropriateness Index (MAI: Hanlon et al., 1992) was used in this study to 
measure appropriateness of prescribing (in conjunction with local and national guidelines, and 
prescribing error definitions). Multiple other tools existed to assess prescribing practice; however, 
given the vast variations in patient presentations, no single tool accurately assessed all types of 
medication provision (Kaufmann et al., 2014). Choosing the assessment resources to use in this 
study was an important methodological consideration to ensure accurate, meaningful evaluations 
that were based on valid and reliable tools (Latter et al., 2007). The ‘structured systematic 
overview of published assessment tools’ (Kaufmann et al., 2014) reviewed 46 different prescribing 
assessment tools. However, most of these targeted specific patient populations; most commonly 
elderly (n=36, 78%), in-patient (n=4, 8.5%) or ambulatory (n=9, 19.5%) care. Tools that 
specifically assessed older adults, drug-drug interactions or were disease specific (i.e. renal 
disease, liver disease, diabetes mellitus or other long-term conditions) were excluded as sexual 
health attendees are predominantly younger, less likely to have multiple comorbidities or 
polypharmacy and therefore required more generic assessments. This resulted in a choice 
between the ‘Medication Appropriateness Index’ (MAI: Hanlon et al., 1992), the ‘Robertson’s Flow 
Charts to prevent, identify and resolve Drug therapy Problems’ (Robertson, 1996) and the ‘Kaiser 
Permanente Model’ (Raebel et al., 2007). Based on the extensiveness and range of measurement 
factors (Kaufmann et al., 2014), the MAI appeared to be the most comprehensive tool. 
Furthermore, Latter et al. (2007) determined that the MAI was ‘relevant and meaningful in 
evaluating the clinical appropriateness of nurses’ prescribing decisions’ (p418), and it 
demonstrated good inter/ intra-rater reliability, content validity and had successfully assessed 
medical and pharmacy consultations (Latter et al., 2007). The MAI questions 10 specific areas 
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(see Box 5.2) related to medication choice; typically, with four responses: ‘indicated’, 










Latter et al., (2007b), Latter et al., (2012) and Naughton et al., (2012) have successfully used the 
MAI to assess nurse prescribing. Utilisation of the tool was not found to be time intensive. 
Naughton et al. (2012) found considerable differences between reviewers (Cohen’s kappa 
statistic for inter-rater reliability was 0.19, which is very poor: Naughton et al., 2012); but only used 
two ‘prescribing experts’ to assess a wide range of clinical specialities where a more specialist in-
depth clinical knowledge may have been required to make accurate assessments. Conversely, 
Latter et al. (2012) used 20 “experienced prescribers” to each assess 20 transcripts, and found 
little variation between the overall scores; an Analysis of Variance identified high level of positive 
agreement between raters (84.5%, n=3,381), which increased (93.7%, n=3748) when ambiguous 
‘not known’, ‘not applicable’ or ‘missing’ data were removed. The MAI has been shown to support 
exploration of the appropriateness of medication provision in nurse prescribing research (Latter 
et al., 2007; Latter et al., 2012).  
Consequently, the MAI was used in this study to assess the appropriateness of medication 
choices in the clinical notes review and the consultation observations. Components deemed 
Box 5.2: Medication Appropriateness Index (MAI: Hanlon et al., 1992)   
1. Is there an indication for the drug? 
2. Is the medication effective for the condition? 
3. Is the dosage correct? 
4. Are the directions correct?  
5. Are the directions practical? 
6. Are there clinically significant drug-drug interactions? 
7. Are there clinically significant drug-disease/ condition interactions? 
8. Is there unnecessary duplication with other drug(s)? 
9. Is the duration of therapy acceptable?  
10. Is this drug the least expensive alternative compared with others of equal utility? 
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‘inappropriate’ during assessments with the MAI were allocated a prescribing error category, as 
guided by Dornan et al. (2009); and allocated a severity rating (Dean and Barber, 1998; Avery et 
al., 2012). It should, however, be noted that the MAI is not effective with regards to the 
determination of appropriateness of ‘omitted drugs’ where medication is indicated for a patient, 
but not provided (Marie-West et al., 2012). The researcher used national and local guidelines and 
their own clinical expertise to determine if medication was inappropriately not provided. The 
researcher was an experienced senior sexual health advanced practice nurse, therefore had the 
expertise to make clinical judgements using the MAI and non-provision of medication. To enhance 
reliability and validity of the findings, a random selection of 10% of each sites’ sample size quota 
were independently re-assessed, as was all queries and omissions/ error categories, as 
previously described.  
Some patients received more than one drug, therefore analysis of prescription completeness and 
assessments using the Medication Appropriateness Index (MAI) undertook assessments for each 
individual drug. The MAI used mean, standard deviation, range and the Independent Samples t 
Test to demonstrate similarities between INP and PGD. MAI scores range from 0 (all appropriate) 
to 18 (all inappropriate). The closer to ‘0’, the more appropriate medication delivery is. The 
weighting to each MAI questions were grouped as detailed in Table 5-16. 








A Indication; effectiveness 0 3 
B 
Dosage; correct directions; drug-drug interactions; 
drug-disease interactions 
0 2 
C Practical directions; costs; duplication; duration 0 1 
(Hanlon, et al., 1992) 
 
5.8.3 Recruitment 
The clinic notes review adopted an audit design; therefore, individual staff or patient consent was 
not required, as authorised by Caldecott Guardian, REC and R&D approvals. Each site provided 
a list of patient attendances between 01/07/2015 and 31/12/2015, filtered to include eligible 
nurses where possible. If the clinic lists contained patients’ names or addresses these were 
immediately deleted, and not used in working documents. As the clinical notes data collection 
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was during a similar timescale to commencement of the entire study, the clinical notes review 
reflected the practice of nurses from the preceding tasks. The six month timescale standardised 
the recruitment of clinical records across all five sites.   
The minimum quota of clinical records required from each site was stratified to be proportionate 
to the percentage of INPs/ PGD users at each corresponding department. As demonstrated in 
Table 5-17, site 1 had 39.3% of the total INPs, therefore site 1 were allocated 39.3% of the 344 
quota for INPs (135.1 notes per INP group, rounded up to 136). Each site’s distinct clinic 
attendance lists were stored on a separate Microsoft Excel® spreadsheet, and each entry was 
allocated a random number by Microsoft Excel®. Each distinct list was then sorted into ascending 
numerical order, and the corresponding clinical notes were reviewed in that order. Recruitment 
continued to each of the four groups until the last group achieved the minimum quota (meaning 
three groups exceeded their minimum quota). The inclusion/ exclusion criteria are presented in 
Table 4-4 on page 92 in ‘Chapter 4: Methods’.  
 
Table 5-17 Stratified sample size quotas per site 
Site 
INP PGD 
No. at site % at site 
Notes 
/group 
No. at site % at site 
Notes 
/group 
1 11 39.3 135.1 14 22.2 76.4 
2 1 3.6 12.3 8 12.7 43.7 
3 0 0.0 0.0 10 15.9 54.6 
4 13 46.4 159.7 16 25.4 87.4 
5 3 10.7 36.9 15 23.8 81.9 
Total 28 100.0 344.0 63 100.0 344.0 
INP= independent nurse prescribing, PGD=patient group directions 
 
5.8.4 Data collection 
The researcher attended each site to collect data at mutually convenient times. Data from the 
clinical notes were recorded on a specifically designed Microsoft Access® database (Appendix 
K), which was adapted from a similar project undertaken by the researcher (Black, 2013). The 
original version was adapted to incorporate: the validated MAI tool; a review of the 
appropriateness of non-provision of medication; and unexpected re-attendance related to the 
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initial complaint. Data were recorded that were determined, by the researcher and their 
supervisors, to be relevant to make judgements on the safety and appropriateness of medication 
delivery, as presented in the ‘Method design’. The data collection tool was subsequently 
considered to have content and face validity; however, only the MAI had proven reliability and 
validity (Hanlon et al., 1992).  No structural changes were made to the tool during data collection. 
Appendix K presents the field list and purpose of that data. 
During data collection, no patient identifiable information were stored on the data collection tool, 
instead separate Microsoft Excel® sheets were used to record the automated ‘ID’ number 
generated by Microsoft Access® during data entry. Consequently, individual clinic numbers could 
be traced back without having them stored on the data collection tool. Relevant demographics 
regarding patients’ ethnicity, gender, sexuality and age were recorded as these had implications 
for the patients’ clinical management.  
There was an ethical clause that in the unlikely situation of discovering criminal activity, the 
researcher was to report this to an appropriate local manager, but this was not required. All 
aspects of research governance and responsibility presented in Chapter 4 were adhered to. 
 
5.8.5 Analysis  
Due to the various perspectives explored in this method, the sample sizes differ throughout based 
on the aspect under review (e.g. whether or not medication was delivered; specifically looking at 
medication consultations; or reviewing individual drugs delivered). The data analysis structure 
and associated sample sizes are summarised in Figure 5-1 on page 153. Analysis was split into: 
‘Medication delivery frequency’, ‘Clinical characteristics & activity’, ‘Review of medication 
consultations & Individual drug assessments’, ‘Synthesis of clinical errors, appropriateness & 
safety’.  
The sample size calculation identified that a minimum of 344 care episodes in each of the four 
research groups was required for statistical testing (see Table 5-17 on page 149). The PGD 
groups achieved their quota far quicker than INPs, but to accurately assess frequency of 
medication delivery, data collection continued until the smallest group neared completion. 
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Frequency analysis included 1,851 care episodes, whereas detailed consultation reviews only 
included 1,682 as detailed data collection on PGD users’ care episodes stopped to ensure a more 
equal spread of analyses between groups. Thirty-two INP clinical notes were not included in 
frequency analysis; as medication delivery frequency could not be calculated from site 2 (as clinic 
lists for patients who were delivered medication could not be obtained, n=14). Moreover, 18 
records where INPs did not deliver medication were sourced from the clinical diary rather than 
attendance lists (as it was not possible to source these last 18 from attendance lists at sites 2 and 
5 within the study’s timeframe).  
Data from the clinical notes reported on patients’ gender, age, ethnic origin, sexuality, 
presentation type, diagnoses, whether medication was delivered and if nurses completed care 
episodes autonomously. Descriptive data on the support resources from professional colleagues 
were also recorded. Consultations where medications were delivered explored the types of 
medication, potential risk factors (e.g. interactions with existing medical problems), 
appropriateness and safety. MAI assessments for each drug were undertaken as distinct 
measurements to allow clearer comparisons between INPs and PGD users. Clinical governance 
properties unique to PGDs were presented separately. Assessments of patient presentations 
were also made to determine if medication was not provided or offered, despite it being indicated 
(i.e. to ensure it was appropriate not to provide medication). Mean, standard deviation and range 
were presented for continuous measures and frequencies and percentages for 
nominal/categorical variables. The Chi-squared test (2) was used to test the association between 
two categorical variables and Independent Samples t Test (t) to compare means for statistical 
differences between INPs and PGD users. 
 The clinical notes review concludes by reporting an inter-rater review between the researcher 
with local representatives and with a pharmacist. Ten percent (n=77) of each sites’ clinical notes’ 
quota were independently checked by a local representative (this was based on the quota of 
notes, not the final number included). Inter-rater reliability could not be measured statistically as 
it was not possible to obtain a definitive decision on whose assessment was accurate as R&D 
permissions had expired when analysis was undertaken. Therefore, it was decided that a 
descriptive discussion around inter-rater reliability was more appropriate than statistical testing in 
this scenario. A pharmacist with specialist knowledge in HIV pharmacology reviewed a random 
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sample of 18 medication assessments where patients had pre-existing medical conditions, 
allergies and/ or concurrent medications (examples presented in Appendix II). The researcher 
incorporated the pharmacist’s feedback within the case notes assessments. All cases or queries 
where errors or omissions were identified were discussed locally during data collection, and 
agreement was reached with the local representative.  
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Figure 5-1 Structure and sample size of clinical notes review findings 
 
  154 
 
5.9 Clinical notes review: Findings 
 
Analysis of the clinical notes/ patient presentations focussed on the appropriateness of the medication 
related activities within the context of individual cases. This section presents data clinical notes’ inclusion/ 
exclusion and the frequency of medication delivery. A description of the patients for whom notes were 
sampled, and consultation characteristics, are then provided. An analysis of medication related activities is 
then presented, before concluding with an assessment of overall medication errors, appropriateness and 
safety, and the inter-rater comparisons findings. 
 
5.9.1 Clinical notes inclusion/ exclusion 
A total of 3,052 patient presentations were reviewed, 1,201 (39.4%) were excluded. Frequency of 
medication analysis included 1,851 presentations (INP=711, PGD=1,140); 201 of these records were not 
used in any further analysis as minimum quotas for detailed consultation analysis had been achieved (see 
Table 5-18). The detailed clinical records review included 1,682 (55.1%: INP=743, PGD=939) and involved 
879 patient presentations where medication was given (INP med=399, PGD med=480) and a further 803 
where medicines were not given (INP no med=344, PGD no med=459). Of the 1,370 patient presentations 
excluded from the detailed consultation review, the most frequent rationale was that patient care was 
delivered by staff who were not trained to prescribe or administer medicines by PGDs (n=857, 62.6%). 
 
Medication delivery frequency 
 
5.9.2 Frequency of medication delivery 
Of all the 1,851 patient presentations (INP=711, PGD=1,140), INP was used more frequently (n=385, 
54.1%) than PGDs (n=548, 48.1%: 2 = 6.47, df = 1, p=0.011) to deliver medications.  
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Table 5-18 Rationale for excluding patients’ notes from the clinical notes review 
Clinical notes exclusion rationale 
(n=number of notes excluded per site) 
Site 1 (n=262) Site 2 (n=6) Site 3 (n=92) Site 4 (n=655) Site 5 (n=355) Total (n=1370) 
n % n % n % n % n % n % 
Main type of clinical notes: Paper Electronic Electronic Electronic Paper   
Non-eligible staff member 195 74.4 6 100.0 91 98.9 282 43.1 283 79.7 857 62.6 
Additional data included for medication frequency only* 0 0.0 0 0.0 0 0.0 201 30.7 0 0.0 201 14.7 
Administration / virtual clinic/ telephone 0 0.0 0 0.0 0 0.0 134 20.5 0 0.0 134 9.8 
Unable to locate paper based notes 57 21.8 0 0.0 0 0.0 0 0.0 55 15.5 112 8.2 
Episode not found in notes 10 3.8 0 0.0 1 1.1 11 1.7 17 4.8 39 2.8 
Nurses’ initial documentation allocating patients’ to the relevant clinic 
for that presentation  
0 0.0 0 0.0 0 0.0 27 4.1 0 0.0 27 2.0 
*’Additional data included for medication frequency only’ (n=201), was used in frequency analysis (n=1851), but not in patient presentations review (n=1682), as minimum quotas had 
been achieved
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Consultation characteristics and activity  
5.9.3 Distribution of notes across research groups 
Data collection continued until each category achieved the target ‘344’ (based on sample size 
calculation Section 5.8.2), A total of 1,682 patient presentations (INP= INP=743, PGD=939: range 
344-480 across the four categories) were included for detailed review. More than half the records 
related to PGD users, rather than INPs (55.8% vs. 44.2%). The proportion of notes showing 
medication was delivered was over 50% for both INP and PGD (see Table 5-19). A total of 29 
INPs and 58 PGD users’ were involved in the consultations included.  
 
Table 5-19 Notes included in each group 
Group type INP PGD Total 





















INP= independent nurse prescribing, PGD= patient group directions 
 
5.9.3.1 Patient and consultation characteristics 
Over half (n=859, 51.1%) of the patient presentations reviewed were those of female patients. 
Overall, patients’ mean age was 30 years, 73.3% (n=1,232) were ‘White’ and 68.1% (n=1,145) 
were heterosexual (see Table 5-20 for patient demographics and consultation characteristics). 
Across all groups, patients most frequently presented for ‘new episodes of care’ (n=1,149, 
68.3%). There was no statistical difference between INP and PGD managing new (INP=517, 
69.6%; PGD=632, 67.3%) and follow-up (INP=226, 30.4%; PGD=307, 32.7%) presentations (2 
= 0.794, df =1, p=0.399); however, INP were statistically more likely to manage patients 
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Table 5-20 Demographics of patients included in the clinical notes review 
Patients’ demographics 










n % n % n % n % n % 
Gender 
Male 150 37.6 171 49.7 223 46.5 278 60.6 822 48.9 
Female 249 62.4 173 50.3 256 53.3 181 39.4 859 51.1 
Transgender 0 0.0 0 0.0 1 0.2 0 0.0 1 0.1 
Age at 
presentation 
Range 16 to 73 16 to 66 16 to 77 16 to 87 16 to 87 
Mean 29.5 31.7 29.8 30.6 30.2 
Standard deviation 11.3 11.6 11.2 11.3 11.4 
Ethnic origin 
White British, Irish 
& Other 
293 73.4 247 71.8 348 72.4 344 75 1232 73.3 
Unknown 20 5 19 5.5 26 5.4 24 5.2 89 5.3 
Black African 13 3.3 19 5.5 15 3.1 19 4.1 66 3.9 
Mixed 22 5.6 12 3.5 31 6.5 22 4.8 87 5.1 
Asian & Chinese 19 4.9 18 5.3 24 5.1 19 4.1 80 4.8 
Black Caribbean & 
Other 
12 3.1 14 4.1 24 5 18 3.9 68 4 
Other 20 5 15 4.4 12 2.5 13 2.8 60 3.6 
Sexuality  
Heterosexual 284 71.2 234 68.0 319 66.5 308 67.1 1145 68.1 
Homosexual 66 16.5 65 18.9 108 22.5 103 22.4 342 20.3 
Bisexual 9 2.3 16 4.7 29 6.0 29 6.3 83 4.9 





New 288 72.2 229 66.6 323 67.3 309 67.3 1149 68.3 
Follow-up 111 27.8 115 33.4 157 32.7 150 32.7 533 31.7 
Statistical testing* 2 =0.794, df = 1, p=0.399 (INP vs. PGD)   
Symptoms? 
Asymptomatic 120 30.1 185 53.8 220 45.8 333 72.5 858 51.0 
Symptomatic 182 45.6 103 29.9 201 41.9 63 13.7 549 32.6 
Unknown 97 24.3 56 16.3 59 12.3 63 13.7 275 16.3 
Statistical testing* 2 = 28.443, df =1, p<0.001 (INP vs. PGD)   
*Statistical testing compares INP (med and no med) with PGD (med and no med); ‘Unknown’ excluded from 
tests. INP= independent nurse prescribing, PGD= patient group directions, med= medication given, no med= 
no medication given, 2 = Chi-squared test 
 
5.9.4 Patient management and diagnoses in sexual health  
Patients’ management was categorised, by the researcher, as ‘Procedural tasks’ and/ or 
‘Diagnostic’. Within the 1,682 patient presentations there were 1,838 procedural tasks. These 
tasks most frequently involved sexual health screening (n=929, 50.5%), the remaining involved 
contraception provision (n=359, 19.5%), follow-up care (n=315, 17.1%) and specialist 
interventions (n=235, 12.9%: see Figure 5-2). 
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Figure 5-2 Procedural management of patients 
 
A total of 788 diagnoses were found from the review of patient presentations. These mostly 
included the diagnosis of bacterial sexual infections (n=319, 40.4%); the remainder included other 
genital infections (n=211, 26.8%), sexual contacts of a person with an infection (n=146, 18.5%) 
and viral sexual infections (n=112, 14.2%: see Figure 5-3). A detailed breakdown of procedural 
tasks and diagnoses are presented in Appendix CC.  
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5.9.5 Autonomous practice 
Of all the patient presentations reviewed (n=1,682), INPs were statistically more likely to complete 
episodes of care autonomously than PGD users, regardless of whether medication was delivered 
or not (83.0% vs. 76.0%, respectively: 2= 12.225, df= 1, p<0.001: see Table 5-21). When patient 
presentations were limited to cases where medication was delivered (n=879), both INP and PGD 
users were less likely to work autonomously compared to when all cases were included; however, 
INP were again overall more likely to complete care autonomously compared to PGD (77.7% vs. 
64.2%, respectively: 2= 19.099, df= 1, p<0.001: see Table 5-22). A number of reasons were 
provided in the clinical notes by nurses for seeking advice from others, and ‘obtaining medication 
advice’ was the most frequent reason reported (n=214, 12.7%: see Table 5-23). PGD users were 
more likely to seek medication advice compared to INP (INP=51, 6.9%; PGD=163, 17.4%: 2 = 
70.229, df = 1, p<0.001); however, there was no difference with regards to seeking clinical advice 
(INP=76, 10.2%; PGD=118, 12.6%: 2= 3.522, df= 1, p= 0.061). 
 
Table 5-21 Likelihood of autonomous practice, all patient presentations (medication delivered and not 
delivered) 






















Statistical testing: 2 =12.225, df = 1, p<0.001 (INP vs. PGD) 
INP= independent nurse prescribing, PGD=patient group directions, 2 = Chi-squared test 
 
Table 5-22 Autonomous practice limited to patient presentations where medication was delivered 






















Statistical testing: 2 =19.099, df =1,  p<0.001 (INP vs. PGD) 
INP= independent nurse prescribing, PGD=patient group directions, 2 = Chi-squared test 
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Table 5-23 Autonomous practice frequency and reasons for nurses seeking additional professional support 
 
Autonomous practice 
INP (n=743) PGD (n=939) 
Total (n=1682)  
Statistical testing** 
(INP vs PGD) 
Med (n=399)* No med (n=344) Med (n=480)* No med  (n=459) 
n % n % n % n % n % 
Autonomous practice 310 77.7 307 89.2 308 64.2 406 88.5 1331 79.1  
Medicine advice sought 49 10.3 2 0.6 157 32.7 6 1.3 214 12.7 2 = 70.229, df =1, p<0.001 
Clinical advice sought 41 12.3 35 10.2 71 14.8 47 10.2 194 11.5 2 =3.522, df = 1, p=0.061 
*Nurses in both ‘medication delivered’ groups may have sought both medicines and clinical advice 
**Statistical testing compares INP (med and no med) with PGD (med and no med) autonomous practice with ‘medicine advice sought’, and autonomous practice with ‘clin ical advice 
sought’.  
INP= independent nurse prescribing, PGD= patient group directions, med= medication given, no med= no medication given, 2 = Chi-Squared test 
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Review of medication consultations & Individual drug assessments 
 
5.9.6 Medications delivered 
From the patient presentations in which medication was delivered (n=879: INP=399, PGD=480: 
Table 5-19), 1,357 individual drug items were provided. This included 66 different drugs (INP=620 
items comprising 56 different drugs; PGD=737 items comprising 51 different drugs. For detailed 
list see Appendix DD). A description of the drug groups provided is presented in Table 5-24. Drugs 
were grouped, by the researcher, to demonstrate how they were being used specifically within 
sexual health, rather than their official medication categories. Antibiotics were the most frequently 
delivered medicines for both INPs (n=203, 32.7%) and PGD users (n=283, 38.4%). Azithromycin 
was the most frequently delivered drug overall (n=231, 17.0%).  
 
Table 5-24 Medication delivered drug categories 
Drug groups* (number of different products) 
INP (n=620) PGD (n=737) Total (n=1357) 
n % n % n % 
Antibiotics (n=15) 203 32.7 283 38.4 486 35.8 
Anaesthetics (n=2) 76 12.3 80 10.9 156 11.5 
Wart treatments (n=4) 56 9.0 60 8.1 116 8.5 
Vaccinations (n=3) 27 4.4 88 11.9 115 8.5 
Short acting contraception (pills, patch, ring: n=8) 59 9.5 54 7.3 113 8.3 
Long-acting reversible contraception (n=3) 52 8.4 53 7.2 105 7.7 
Antifungals (n=4) 49 7.9 42 5.7 91 6.7 
Termination of pregnancy regimens  
(n=4: excluding azithromycin) 
30 4.8 11 1.5 41 3.0 
Emergency contraception (n=2) 14 2.3 26 3.5 40 2.9 
Topical creams (n=10) 11 1.8 24 3.3 35 2.6 
Antiviral (n=1) 14 2.3 8 1.1 22 1.6 
HIV anti-retroviral (n=4) 14 2.3 4 0.5 18 1.3 
Erectile dysfunction treatments (n=4) 10 1.6 1 0.1 12 0.9 
Non-steroidal anti-inflammatory drugs (n=2) 1 0.2 1 0.1 2 0.1 
Total number of drugs delivered  620 100 737 100 1357 100 
*Drug groups categorised to demonstrate therapeutic treatment of sexual health presentations rather than 
official formulary classification. INP= independent nurse prescribing, PGD=patient group directions 
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5.9.7 Completeness of prescription documentation and provision of medication delivery 
Of the 1,357 drug items delivered, the medicine name was clearly documented on all but one 
record. The remaining five components of the ‘prescription’ were less consistently recorded (see 
Table 5-25): e.g. the administration routes were only completed in care delivered by 435 (74.3%) 
of INP documented medicines, and 569 (77.2%) of PGD users. PGD users were statistically more 
likely to document the full ‘prescription’ compared to INP (85.5% vs. 82.5%, respectively: 2= 
13.003, df= 1, p<0.001). Across both groups, medication was most frequently provided as pre-
packed ‘to-take-out’ treatment packs (n=462, 34.2%) or directly administered as injections 
(n=417, 30.7%: see Table 5-26).  
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Table 5-25 Completeness of documented 'prescription' in patients’ clinical notes 
Prescription 
component: 
Name Dose Route Frequency Duration Signature Summative score Statistical testing 
(INP vs. PGD) n % n % n % n % n % n % n % 
INP (n=620) 619 99.8 513 82.7 435 70.2 462 74.5 484 78.1 557 89.3 3070 (/3720) 82.5 2= 13.003, df =1, 
p<0.001 PGD (n=737) 737 100 612 83.0 569 77.2 578 78.4 613 83.2 670 90.9 3779 (/4422) 85.5 
INP= independent nurse prescribing, PGD=patient group directions, 2 = Chi-squared test 
 
Table 5-26 Method of delivering medication 
Method of medication delivery 
INP (n=620) PGD (n=737) Total (n=1357) 
n % n % n % 
‘To take out' pre-pack medication 187 30.2 275 37.3 462 34.0 
Injection 168 27.1 249 33.8 417 30.7 
Not known/ missing 94 15.2 67 9.1 161 11.9 
Directly observed therapy 66 10.6 80 10.9 146 10.8 
Procedure 67 10.8 51 6.9 118 8.7 
Collect from hospital pharmacy 22 3.5 5 0.7 27 2.0 
Other 16 2.6 10 1.3 26 1.9 
INP= independent nurse prescribing, PGD=patient group directions 
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5.9.8 Professionals who wrote prescriptions 
Of the 1,357 individual medication items provided, 306 (22.5%) prescriptions were written by 
doctors; therefore, nurses did not practice autonomously in these episodes. As might be expected 
PGD users (as compared to INP) were more likely to require the support of a colleague to deliver 
medications (33.6% vs. 13.1%, 2 =77.691, df =1, p<0.001 see Table 5-27). The most common 
reason doctors prescribed for INP was the provision of full drug regimens for the management of 
termination of pregnancies (n=44/81, 54.3%: made up of 29 individual termination of pregnancy 
drug items and 15 azithromycin ‘antibiotic’ items). Nurses cannot legally prescribe termination of 
pregnancy drugs (Abortion Act, 1967, RCN, 2017). Azithromycin (n=26/225, 11.6%) was the most 
frequent drug prescribed by a doctor for PGD users. These specific cases were usually because 
the doctor had some form of prior involvement with patient management, rather than the PGD 
user stopping consultations to seek a prescription. The categories of medications prescribed by 
doctors are summarised in Table 5-28 (see Appendix EE for the full list of these medicines). Of 
the 48 actual drugs prescribed by doctors, INP had the capability to prescribed 46 (95.8%), 
whereas PGD users could only have supplied/ administered 27 (56.3%), due to the availability of 
approved PGD documents across the five sites.  
 
Table 5-27  Professional group writing ‘prescriptions’ 
Prescription 
written by 
INP (n=620) PGD (n=737) Total (n=1357) Statistical 
testing (INP vs 
PGD) n % n % n % 
INP 539 86.9 23 3.1 562 41.4 
2 =77.691, df = 
1,  p<0.001 PGD 
    489 66.4 489 36.0 
Doctor 81 13.1 225 30.5 306 22.5 
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Table 5-28 Drug categories prescribed by doctors 
Drug groups* prescribed by doctor for INP & 
PGD (number of specific drugs) 
INP (n=81) PGD (n=225) 
n % n % 
Antibiotic (n=11) 27 32.5 89 39.5 
Vaccinations (n=3) 6 7.2 33 14.7 
Short acting contraception (pills n=6) 3 3.6 22 9.7 
Wart treatments (n=5) 2 2.4 17 7.4 
Anaesthetics (n=1) 6 7.2 13 5.8 
Antifungal (n=3) 4 4.8 13 5.7 
Termination of pregnancy drug regimens (n=7) 29 34.9 12 5.2 
Emergency contraception (n=2) 0 0.0 8 3.5 
Topical creams (n=4) 0 0.0 6 2.5 
Long-Active Reversible Contraception (n=2) 1 1.2 5 2.2 
HIV antiretroviral (n=2) 4 4.8 4 1.8 
Antiviral (n=1) 0 0.0 3 1.3 
Non-steroidal anti-inflammatory (n=1) 1 1.2 0 0.0 
*Drug groups categorised to demonstrate therapeutic treatment of sexual health presentations rather than 
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5.9.9 Safety of medication provision 
Across 879 patient presentations, involving the delivery of medications, patients’ past medical 
histories (n= 816, 92.8%), concurrent medications (n= 808, 91.9%), allergies (815, 92.7%), and 
in the 505 female patients, the pregnancy risk (n=481, 95.2%) documentation was relatively good. 
Overall, INP were statistically more likely to record these details compared to PGD users 
(INP=1,131/1,446, 78.2%; PGD=1,308/1,696, 77.1% potential documentations: 2 =14.401, df =1, 
p<0.001: Table 5-29).  
 
Table 5-29 Documentation of past medical history, concurrent medications, allergies and pregnancy risk 
Accuracy of documented risk 
assessment prior to delivering 
medication 
INP (n=399) PGD (n=480) Total (n=879) Statistical 
testing  
(INP vs PGD) n % n % n % 
Past medical 
histories 
Documented 380 95.2 436 90.9 816 92.8 2  =6.354, df = 1, 
p=0.012 Not clearly documented 19 4.8 44 9.2 63 7.2 
Concurrent 
medications 
Documented 374 93.7 434 90.5 808 91.9 2 =3.23, df =1, 
p=0.072 Not clearly documented 25 6.3 46 9.6 71 8.1 
Allergies 
Documented 377 94.5 438 91.3 815 92.7 2 =3.380, df = 1, 
p=0.066 Not clearly documented 22 5.5 42 8.8 64 7.3 
Female patients only INP (n=249) PGD (n=256) Total (n=505)  
Pregnancy 
risk 
Documented 240 96.4 241 94.1 481 95.2 2 =1.405, df = 1, 
p=0.236 Not clearly documented 9 3.6 15 5.9 24 4.8 
Overall documentation statistical testing 2 =14.401, df = 1, p<0.001 (INP vs. PGD) 
INP= independent nurse prescribing, PGD=patient group directions, 2 = Chi-squared test 
 
Specific details recorded, relating to the safety of medication delivery in patients, were pregnancy, 
breast-feeding, liver conditions or renal disease (see Appendix FF). A total of 8.5% (43/505) of 
female patients were pregnant; 75% (n=33) of these were seeking termination of pregnancy. 
Seven female patients were breastfeeding. Six patients had liver or renal infections/ conditions. 
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5.9.10 Medication appropriateness index 
Five hundred and forty three (40%) of the 1,357 items of medication delivered were given to 
patients with a pre-existing medical condition/ allergy [medication-disease/ condition interaction], 
and/ or 538 (39.6%) who were taking concurrent medications (see Table 5-30). No difference was 
found between INPs and PGD users with regards to patients reporting existing medical conditions 
and/ or allergies (40.5% vs. 39.6%, respectively: 2 =0.072, df =1, p=0.789) or concurrent 
medications (36.8% vs. 42.1%, respectively: 2=3.718, df =1, p=0.054).  
Across the 1,357 individual drug items, the medication appropriate index (MAI) demonstrated that 
both INP and PGD users consistently provided appropriate medication (Table 5-31). Overall, 
medication was predominantly clinically indicted and likely to be therapeutically effective for 
98.5% (n=1,336/1,357) of the condition(s) managed. As each of the 1,357 medications were 
scored against ten individual MAI questions, the opportunity for errors could have totalled 13,570. 
The main issue identified through the MAI, involved documentation omissions, or data being 
unavailable (n=626/13,570, 4.6%). It was, therefore, difficult to fully ascertain medicines’ 
appropriateness in these cases (Table 5-32). The main reason for ‘inappropriate’ categorisations 
(n=100/13,570, 0.7%) was related to prescription errors (n=86/100, 86%). This included one site 
that had inaccurate details of ‘dose’ and ‘directions’ for a metronidazole regimen in their electronic 
prescription template (errors in dose n=17; and directions n=17; overall 34/86, 39.5%); however, 
the appropriate medication pre-packs were available to supply the actual intended regimen as 
per local/ national guidance. Following this discovery by the researcher, steps were taken by the 
site to ensure the correct regimen was added to the template. Issues classified as ‘intermediate’ 
on the MAI classification (n=115/13,570, 0.8%) were mostly related to unclear documentation of 
whether cautions were given about potential minor drug interactions (n=53/115, 46.1%); e.g. 
concurrent use of azithromycin with some antidepressants may interfere with electrical cardiac 
signals (BNF, 2016).      
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Table 5-30 Number of patient with existing medical issues and/ or concurrent medication 
Existing medical issues & 
concurrent medication 
INP(n=620) PGD (n=737) Total (n=1,357) 
Statistical testing  
(INP vs. PGD) 
No Yes No Yes No Yes 
n  % n % n  % n % n  % n % 
Pre-existing medical issue/ allergy* 369 59.5 251 40.5 445 60.4 292 39.6 814 60.0 543 40.0 2 =0.072, df =1, p=0.789  
Concurrent medication 392 63.2 228 36.8 427 57.9 310 42.1 819 60.4 538 39.6 2 = 3.718, df =1, p=0.054 
* Allergies were considered alongside pre-existing medical conditions in ‘medication-disease/ condition interaction’ during medical appropriateness index assessments. INP= 
independent nurse prescribing, PGD=patient group directions, 2 = Chi-squared test  
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Table 5-31 Medication Appropriateness Index summary 
Medication 
Appropriateness Index* 
INP (n=620) PGD (n=737) 
Appropriate Intermediate Inappropriate Not known Appropriate Intermediate Inappropriate Not known 
n % n % n % n % n % n % n % n % 
Is there an indication for the 
medication? 
611 98.5 6 1.0 2 0.3 1 0.2 725 98.4 6 0.8 5 0.7 1 0.1 
Is the medication effective for 
the condition? 
609 98.2 8 1.3 2 0.3 1 0.2 727 98.6 6 0.8 4 0.5 0 0.0 
Is the dosage correct? 
 
543 87.6 11 1.8 11 1.8 55 8.9 687 93.2 3 0.4 14 1.9 33 4.5 
Are the directions correct? 
 
548 88.4 7 1.1 8 1.3 57 9.2 679 92.1 10 1.4 13 1.8 35 4.7 
Are the directions practical? 
 
549 88.5 6 1.0 8 1.3 57 9.2 699 94.8 5 0.7 0 0.0 32 4.3 
Are there clinically significant 
medication interactions? 
576 92.9 14 2.3 4 0.6 26 4.2 664 90.1 15 2.0 6 0.8 52 7.1 
Are there clinically significant 
medication-disease/ condition 
interactions 
578 93.2 11 1.8 0 0.0 31 5.0 671 91.0 9 1.2 6 0.8 51 6.9 
Is there any unnecessary 
duplication with other 
medication(s)? 
610 98.4 1 0.2 3 0.5 6 1.0 716 97.2 3 0.4 4 0.5 14 1.9 
Is the duration of therapy 
acceptable? 
560 90.3 6 1.0 0 0.0 54 8.7 691 93.8 10 1.4 14 1.9 22 3.0 
Is this drug the least 
expensive alternative 
compared to others of equal 
utility? 
615 99.2 1 0.2 1 0.2 3 0.5 735 99.7 2 0.3 0 0.0 0 0.0 
*Percentages relate to the categorisation of ‘appropriate’, ‘intermediate’, ‘inappropriate’ and ‘not known’ in response to each individual medication appropriateness index question by INP 
and PGD (i.e. INP=620, PGD=737:  INP= independent nurse prescribing, PGD=patient group directions) 
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Table 5-32 Rationale for medication appropriateness index scores not being classified as ‘appropriate’ 
Overall assessment (total potential issues=13,570) Number of individual issues based on MAI questions (% of individual issue based on MAI question) 
Rationale  for non-appropriateness 
scoring 
Total 



















Lack of documentation/ 
unable to access original 
notes 
617 4.5 2 (0.3) 4 (0.6) 96 (15.6) 99 (16.0) 99 (16.0) 78 (12.6) 82 (13.3) 79 (12.8) 75 (12.2) 3 (0.5) 




Error in prescription 65 0.5 1 (1.5) 1 (1.5) 22 (33.8) 21 (32.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 20 (30.8) 0 (0.0) 
Rationale for treatment 
unknown 
15 0.1 4 (26.7) 4 (26.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 7 (46.7) 0 (0.0) 0 (0.0) 
Unsafe/ inappropriate 13 0.1 2 (15.4) 2 (15.4) 2 (15.4) 0 (0.0) 0 (0.0) 4 (30.8) 0 (0.0) 0 (0.0) 3 (23.1) 0 (0.0) 
Potential moderate/ 
significant drug interaction 




Potential minor drug 
interaction 
53 0.4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 34 (64.2) 19 (35.8) 0 (0.0) 0 (0.0) 0 (0.0) 
Unclear treatment 
documentation 




22 0.2 3 (13.6) 1 (4.5) 3 (13.6) 3 (13.6) 3 (13.6) 0 (0.0) 0 (0.0) 0 (0.0) 5 (22.7) 4 (18.2) 
Documentation error 4 0.0 0 (0.0) 0 (0.0) 0 (0.0) 2 (50.0) 2 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Diagnostic tests not 
completed 
2 0.0 0 (0.0) 2 (100) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
INP= independent nurse prescribing, PGD=patient group directions
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Table 5-33 summarises the MAI scoring for INPs and PGD users. There was comparable 
medication appropriateness scoring between both groups (t = 1.032, df = 1,239.6, p=0.302). Due 
to the MAI’s weighted scoring system (which rates appropriateness 0-18, closer to 0 more 
appropriate, see page 148) had all aspects been weighted as ‘inappropriate’ or ‘not known’, a 
total score of 24,426 (i.e. 1,357*18) would have been achieved. Both INP (582) and PGD users 
(602) scored very low, i.e. demonstrating a high level of appropriate medication delivery for the 
conditions treated. Overall, 81% of medications scored ‘0’ (i.e. no inappropriate medication 
provision), with a mean score of 0.9/18. 
 
Table 5-33 Medication Appropriateness Index weighted scoring results  
Medication Appropriateness Index scoring INP (n=620) PGD (n=737) Total (n=1357) 
Potential highest MAI weighted score (n*18) 11160 13266 24426 
Combined MAI weighted score 582 602 1184 
Mean MAI weighted score (out of 18)* 0.9 0.8 0.9 
Standard Deviation 2.3 2.0 2.1 
Range of MAI weighted scores  0 to 14 0 to 11 0 to 14 
Number scoring ‘0’: most appropriate 505 (81.5%) 603 (81.8%) 1108 (81.7%) 
Statistical testing (INP vs PGD) 
t = 1.032, df = 1239.6, p=0.302** 
mean difference 0.1 (95% CI: -0.1 to 0.4) 
*Range 0-18, closer to 0 more appropriate. **Levene’s Test equal variances not assumed. INP= independent 
nurse prescribing, PGD=patient group direction, t= Independent Samples t Test 
 
5.9.11 Appropriateness of PGD medication delivery in clinical practice 
PGD documents across the five sites demonstrated that users had access to between 11 and 37 
different medications (mean per site= 20.4).  Contraception provision was inconsistent across all 
sites. Appendix GG demonstrates the variation of medications available via PGDs. 
There were 72 cases where PGDs were used inappropriately across the 480 patient presentations 
in which medication was delivered. An assessment of the associated clinical governance 
identified that appropriate clinical governance was in place for 407 (84.8%) of the 480 PGD 
medication delivery episodes. See Table 5-34. In 39 (40.6% of 96 errors/ omissions or 8.1% of 
all PGD presentations where medication was delivered) medicines were utilised outside their 
restrictions; however, these medicines were clinically appropriate for the patients’ presentations. 
A further ten (2.1%) patient presentations had medication prescribed by a doctor despite a 
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suitable PGD being available; although not technically an error, the need to obtain a prescription 
was not regarded as appropriate use of the PGD (classed as intermediate accuracy).  
Table 5-34 Appropriate delivery of medications using PGDs 






Correct 407 84.8   407 
Intermediate 34 7.1 
Procedural, but no PGD visualised by researcher 
(cryotherapy=9)* 
9 
Unclear clinical record documentation 11 
PGD covers, but separate prescription sought with 
no clear rationale why it was not delivered 
autonomously 
10 
Medication instructions inaccurate 4 
Incorrect 28 5.8 
Outside PGD restrictions* 13 
Patient symptomatic, excluded from PGD* 8 
No medicinal PGD visualised (aciclovir; Daktakort; 
Diprobase (twice); hydrocortisone; Femodette)* 
6 







Unclear who authorised medication delivery 9 
Brand of medicine unclear* 1 
Medication indication unclear* 1 
*These were clinically safe and appropriate medication choices for the patient and condition being treated; 
however, were given outside the PGD restrictions or a lack of documentation makes it difficult to ascertain 
if the patients’ presentations were included in the PGD. This constitutes 8.1% (n=39/480) of medication 
deliveries by PGD users. PGD= patient group direction.  
 
To further test the appropriateness of PGDs in clinical practice, INPs’ patient presentations 
(n=399) were compared against local site-specific PGDs (n=480). Just under half (n=185, 46.4%) 
of INPs’ patient presentations would not have been covered had they been governed by locally-
based PGDs (n=225, 46.9%). This percentage is similar across both groups, as presented in 
Table 5-35. Therefore, the availability and restrictions associated with PGD documents would 
have directly affected INPs’ practice autonomy, had they been restricted to using PGDs. 
Table 5-35 Appropriateness of PGDs to manage all patient episodes 
PGD clinical coverage for all patient 
presentations 
INP (n=399) PGD (n=480) Total (n=879) 
n % n % n % 
PGD covers patients’ presentation 214 53.6 254 52.9 468 53.2 
PGD does not cover patients’ presentation 136 34.1 186 38.8 322 36.6 
No PGD available for patients’ presentation 49 12.3 39 8.1 88 10.0 
Unable to assess 0 0.0 1 0.2 1 0.1 
INP= independent nurse prescribing, PGD=patient group direction 
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Synthesis of clinical errors, appropriateness & safety  
5.9.12 Where no medication was delivered, was this appropriate? 
From the 1,357 patient presentations reviewed, there were incidences were medication was 
‘potentially’ (n=19, 1.1%) or ‘specifically’ (n=25, 1.5%) indicated, for which there was no 
documentation that is was offered or given (see Table 5-36). This most commonly related to 
failure to offer appropriate prophylactic medications (n=14/25, 56.0% or 0.8% overall: Table 5-
37). There were a further 101 incidences in which the documentation highlighted that despite 
medication being indicated, the nurse appropriately did not provide any (see Table 5-38). This 
was most commonly because the required medication required was not within the sexual health 
remit, and so patients were signposted to alternative appropriate services (n=24, 2.8%). Another 
reason for this lack of provision was that the contacts of people with sexual infections declined 
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Table 5-36 Appropriate non-provision of medication 
Non-provision of medication 
INP (n=743) PGD (n=939) 
Total (n=1682) 
Med (n=399) No med (n=344) Med (n=480) No med (n=459) 
n % n % n % n % n % 
Medication not indicated 9 2.3 333 96.8 12 2.5 448 97.6 802 47.7 
Medication potentially indicated 5 1.3 6 1.7 4 0.8 4 0.9 19 1.1 
Medication indicated, but not given/ documented 5 1.3 5 1.5 8 1.7 7 1.5 25 1.5 
INP= independent nurse prescribing, PGD=patient group direction 
Table 5-37 Medication inappropriately not provided/ offered/ documented by nurses 
Treatment not given despite being indicated 
INP PGD 
Med No med Med No Med 
Appropriate prophylaxis medication not offered (e.g. emergency contraception, post exposure prophylaxis for sexual exposure, 
vaccination, sexual contact) 
1 3 4 6 
Clinical presentation indicates treatment was indicated (i.e. pelvic inflammatory disease, warts, bacterial vaginosis, proctitis, balanitis) 3 2 2 1 
Incorrect clinical management resulting in medication inappropriately not being given 1 0 1 0 
Doctor advised to give medication, no documentation that it was delivered 0 0 1 0 
INP= independent nurse prescribing, PGD=patient group direction 
Table 5-38 Medication indicated or acknowledged but appropriately not given 
Medication not given, but correctly acknowledged/ offered by nurse 
INP (n=743) PGD (n=939) 
n % n % 
Treatment not indicated/ appropriate for sexual health setting 9 1.2 15 1.6 
Patient would prefer to wait for results before being treated  6 0.8 14 1.5 
Patient declined or nurse appropriately discontinued hepatitis B vaccine prescription 9 1.2 10 1.1 
Already taking the appropriate treatment 6 0.8 9 1.0 
Patient offered and declined emergency contraception 5 0.7 6 0.6 
Patient offered and declined other treatments 5 0.7 5 0.5 
Patient was clinically managed by another, nurse didn't need to deliver medication 2 0.3 0 0.0 
INP= independent nurse prescribing, PGD=patient group direction   
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5.9.13 Unplanned repeat consultations for index condition or non-attendance to follow-
up 
Of the 1,682 patient presentations reviewed, 306 (18.2%) patients returned within three months 
for 400 specific issues (Table 5-39). The reasons for returning were relatively consistent across 
INP and PGD users (were medication was and was not given). There were 15 different reasons 
categorised under four headings (Table 5-40). There was no indication that any of these reasons 
were because nurses used INP or PGDs. The only difference between patients of INPs and PGD 
users’, relating to follow-up, was that INPs’ patients were more likely not to attend expected follow-
up, compared to PGD users (9.6% vs. 2.4%, respectively: 2 =8.890, df =1, p=0.003). 
 












n % n % n % n % n % 
Number of patients who didn't 
re-attend 
308 77.2 290 84.3 387 80.6 391 85.2 1376 81.8 
Number of patients re-attending 91 22.8 54 15.7 93 19.4 68 14.8 306 18.2 
Number of individual return 
rationales* 
135 65 125 75 400 
*patients can return for multiple rationales. INP= independent nurse prescribing, PGD= patient group 
directions, med= medication given, no med= no medication given 
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Table 5-40 Rationales for re-attending 
Rationale for unexpected return 
 





INP (n=91) No INP(n=54) PGD (n=93) No PGD (n=68) Total (n=306) 
n % n % n % n % n % 
Clinical/ diagnostic issue that was not known at initial visit (INP=99; PGD=101)** 
Positive test from diagnostics 25 27.5 17 31.5 35 37.6 25 36.8  
 
 




Developed new genital symptoms 19 20.9 6 11.1 11 11.8 1 1.5 37 12.1 
Repeat testing indicated/ required 10 11.0 5 9.3 4 4.3 8 11.8 27 8.8 
New sexual health issue (non-symptomatic) 2 2.2 8 14.8 4 4.3 3 4.4 17 5.6 
Low Hepatitis titre, booster/ course required 3 3.3 4 7.4 1 1.1 9 13.2 17 5.6 
Symptomatic or adverse issues that became apparent after initial visit (INP=59; PGD=56)** 
Symptoms not resolved/ worsened/ returned 14 15.4 2 3.7 10 10.8 8 11.8  
 





Drug/ contraception side effects 16 17.6 4 7.4 10 10.8 1 1.5 31 10.1 
Long-acting reversible contraception follow-up issues 5 5.5 5 9.3 7 7.5 3 4.4 20 6.5 
Wart treatment ineffective/ prolonged/ changed 6 6.6 1 1.9 10 10.8 2 2.9 19 6.2 
High risk sexual behaviour/ psychosocial support 5 5.5 1 1.9 1 1.1 4 5.9 11 3.6 
Behavioural or processing issue which potentially could have been avoided (patients’ behaviour was large component) (INP=28; PGD=39)** 
Re-treatment for same condition 11 12.1 0 0.0 21 22.6 0 0.0  
 
2 =0.150, df =1, 
p=0.698 
32 10.5 
Recalled due to service processing issues 3 3.3 6 11.1 2 2.2 7 10.3 18 5.9 
Partner notification/ sexual contact issues 1 1.1 1 1.9 5 5.4 2 2.9 9 2.9 
Subsequent/ repeat termination of pregnancy 4 4.4 2 3.7 2 2.2 0 0.0 8 2.6 
Unexpected non-attendance to follow-up (did not attend) (INP=14; PGD=4)** 
Did not attend expected follow-up 11 12.1 3 5.6 2 2.2 2 2.9 
2 =8.890, df =1, 
p=0.003 
18 5.9 
Total individual return rationales* 135 65 125 75  400 
*patients could return for multiple rationale (hence why overall statistical testing not completed); **Statistical testing compares INP (med and no med) with PGD (med and no med), 
combined into the four categories prior to testing. INP= independent nurse prescribing, PGD= patient group directions, med= medication given, no med= no medication given, 2 = Chi-
squared test 
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5.9.14 Medication error categories and rates 
A total of 1,844 (error rate=8.5%) individual information omissions or errors were identified 
throughout the full review of patient presentations (INP=879, 47.7%; PGD=965, 52.3%). Where 
error categories were identified, INPs were statistically more likely to make an error/ omission 
compared to PGD users (9.2% vs. 7.9%, respectively: 2=10.418, df = 1, p=0.001). Twelve of the 
17 error categories related to documentation omissions (see Table 5-41). The majority of errors 
were categorised as minor (INP=489, 55.6%; PGD=602, 62.4%); however, errors made by INPs 
as compared to PGD users were statistically more likely to be categorised as moderate severity 
(44.1% vs. 37.4%, Fisher’s Exact Test=8.805, p=0.007: see Table 5-42). There was no evidence 
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Table 5-41 Medication error categories and rates 
Error categories (source of error)* 






















Route missing (prescription)** 620 185 29.8 737 168 22.8 1357 353 26.0 
Administration frequency incorrect/ missing (prescription/ MAI) 620 147 23.7 737 158 21.4 1357 305 22.5 
Duration not clearly documented (prescription) 620 130 21.0 737 124 16.8 1357 254 18.7 
Strength/dose not clearly documented (prescription) 620 113 18.2 737 125 17.0 1357 238 17.5 
Method of drug supply not clearly documented (prescription)*** 620 116 18.7 737 67 9.1 1357 183 13.5 
No signature on ‘prescription’ (prescription) 620 63 10.2 737 67 9.1 1357 130 9.6 
Concurrent medication not clearly documented (safety)**** 399 25 6.3 480 46 9.6 879 71 8.1 
Allergy not clearly documented (safety) 399 22 5.5 480 42 8.8 879 64 7.3 
Past medical history not clearly documented (safety)**** 399 19 4.8 480 44 9.2 879 63 7.2 
Outside PGD restrictions (PGD appropriateness) 0 0 0.0 737 39 5.3 737 39 5.3 
Pregnancy risk assessment not clearly documented (safety)**** 249 9 3.6 256 15 5.9 505 24 4.8 
Medication indicated, but not given/ offered/ documented (synthesis) 743 21 2.8 909 23 2.5 1652 44 2.7 
Prescription error (MAI) 620 12 1.9 737 19 2.6 1357 31 2.3 
No indication for drug (MAI) 620 9 1.5 737 12 1.6 1357 21 1.5 
Consideration of drug interactions not clearly documented (MAI)**** 399 4 1.0 480 6 1.3 879 10 1.1 
Duplication of medication (MAI) 399 3 0.8 480 4 0.8 879 7 0.8 
Clinical contra-indication (MAI) 399 1 0.3 480 6 1.3 879 7 0.8 
Product/ formulation not clearly documented (prescription) 620 5 0.8 737 3 0.4 1357 8 0.6 
Overall error rates 9586 879 9.2 12152 965 7.9 21738 1844 8.5 
Statistical testing (INP versus PGD) 2=10.418, df= 1, p= 0.001   
*Medication categories where no errors were made were not included in this analysis. **route includes all prescriptions that had missing route regardless of whether there was only one type of 
formulation (excluding inter-uterine devices, contraceptive implants and cryotherapry).***supply of drug relates to how patients received it (for example as a pre-pack in the clinic or from 
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pharmacy) ****these prescribing errors may not have been considered as prescribing errors in comparable studies, but as they relate to prescribing safety were included in this study. This may 
influence comparability in the discussion. INP= independent nurse prescribing, PGD= patient group directions, MAI= Medication Appropriateness Index, 2 = Chi-squared test 
Table 5-42 Categorisation of error severity 
Severity based on mean scores* 
INP (n=879) PGD (n=965) Statistical 
tests 
Total (1844) 
n % n % n % 






Moderate (3 to <7: likely to cause some adverse effects or interfere with therapeutic 
goals but very unlikely to result in death or cause lasting impairment) 
388 44.1 361 37.4 749 40.6 
Severe (7-10: likely to cause death or lasting impairment) 2 0.2 2 0.2 4 0.2 
INP= independent nurse prescribers, PGD=patient group direction. *Each unique error was graded 0-10 for severity by five individual raters, a mean score calculated and used to 
categorised error frequencies as minor, moderate or severe, in-line with Dean & Barber (1999) 
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5.9.15 Assessment of safety and appropriateness of care for patient presentations 
Each patients’ care episode was assessed for appropriateness (appropriate, intermediate or not 
known) and safety (safe, unsafe or not known). The overall safety and appropriateness was then 
categorised in three ways: ‘safe & appropriate’, ‘not safe and/ or appropriate’, and ‘not known’. 
Across INPs and PGD users (with and without medication delivery, n=1,682) most episodes of 
care were assessed, by the researcher, to be predominantly ‘safe and appropriate’ overall 
(n=1,596, 94.9%: Table 5-43). INPs were found to provide significantly more appropriate care 
than PGD users (INP=714, 96.1%; PGD=883, 94.0%: Fisher’s Exact Test, p<0.001). The 
difference in appropriateness of care provision, was as a result of the provision of clinically 
appropriate care by PGD users, however medication was delivered outside of the PGDs’ 
restrictions (n=39/43, 90.7%). There was no significant difference in the safety of care provided 
between groups (INP=713, 96.0%; PGD=927, 98.7%: Fisher’s Exact Test, p=0.554). 
Nevertheless, INPs had higher frequencies of errors, being classed as ‘moderate’ severity 
compared with PGD users (44.1% vs. 37.4%; Fisher’s Exact Test, p=0.007). Only a very small 
minority of care episodes were deemed to be ‘unsafe and inappropriate’ (n=8, 0.4%: Box 5.3; 
INP=4, PGD=4), with four errors (INP=2; PGD=2) being classed as ‘severe’.   
Box 5.3: The eight cases of unsafe/ inappropriate practice involved: 
1. Potential drug interaction with ‘antihypertensive’. If this was ketanserin, when given 
with azithromycin could potentially cause fatal torsade de pointes arrhythmia [mean 
severity score 7.4; INP] 
2. Incorrect transcription of results in clinical records, resulting in delivery of incorrect 
treatment. The error was subsequently discovered by a local health care practitioner, 
the patient was informed, recalled and the correct results and treatment was issued. 
(INP) 
3. Two patient samples were attributed to the wrong patients. This was identified by a 
local health care practitioner, investigated and resolved. (INP) 
4. It was not documented that a patient, at high risk of HIV, had been offered post-
exposure prophylaxis (PEP). The patient attended follow-up as planned, and was 
found to be HIV positive, therefore the PEP would have been ineffective in this 
situation [mean severity score 7.4:INP]. 
5. A patient was given the combined oral contraception pill when the risks outweighed 
the benefits as diastolic blood pressure was slightly over 90 (UKMEC3: Risks 
outweigh the benefits (FSRH, 2016)) [mean severity score 7.4: PGD]. 
6. Patient given high dose penicillin (benzylpenicillin 2.4MIU) with documentation of 
penicillin allergy [mean severity sore 7.2: PGD) 
7. A PGD user signed for a drug but it was issued to the patient by another nurse.  
8. A symptomatic sexual contact of gonorrhoea was not offered treatment at 
presentation, in line with local and national guidelines. (PGD) 
While some of these issues had the potential to cause harm, there was no indication of adverse 
effects. 
 INP= independent nurse prescribing, PGD=patient group direction 
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Table 5-43 Overall categorisation of safe and appropriate medication delivery 
 
Appropriateness, Safety & Overall 
Assessment 





(INP vs. PGD) 
Med (n=399) No Med (n=344) Med (n=480) No Med (n=459) 
n % n % n % n % n % 
Appropriate 
Appropriate 372 93.2 342 99.4 426 88.8 457 99.6 1597 94.9 Fisher’s Exact Test 
p<0.001 Inappropriate 1 0.3 1 0.3 42 8.8 1 0.2 45 2.7 
Not known 26 6.5 1 0.3 12 2.5 1 0.2 40 2.4  
Safety 
Safe 372 93.2 341 99.1 469 97.7 458 99.8 1640 97.5 Fisher’s Exact Test 
p=0.554 Unsafe 1 0.3 2 0.6 2 0.4 0 0.0 5 0.3 
Not known 26 6.5 1 0.3 9 1.9 1 0.2 37 2.2  
Overall 
Safe and appropriate 372 93.2 341 99.1 426 88.8 457 99.6 1596 94.9 Fisher’s Exact Test 
p<0.001 Not safe and/ or appropriate 1 0.3 2 0.6 42 8.8 1 0.2 46 2.7 
Not known 26 6.5 1 0.3 12 2.5 1 0.2 40 2.4  
*Statistical testing compares INP (med and no med) with PGD (med and no med). Excludes ‘Not known’ 
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5.9.16 Interrater reliability and validity assessments  
 
Clinical record assessments 
Seventy-seven patient presentation assessments from the clinical notes were made by local 
representatives, to independently compare against the researcher’s interpretation. Across 
‘demographics’ and ‘presentation’ sections, there were high levels of agreement (see Table 5-44). 
The main disagreement related to the presence of symptoms (agreement=70/77 clinical records, 
90.9%). Locally, particularly for contraception services, no documentation of genital symptoms 
indicated the patient was asymptomatic; however, as the researcher could not see any 
documentation this was recorded as ‘not known’. Within the ‘MAI’ assessments, the reviewers 
were confident they understood the prescription regimens when assessing documentation; 
however, the researcher detailed that if the drugs’ dose, directions or duration or the patients’ 
past medical history or concurrent medication was not documented, a full assessment against the 
MAI could not be made. This represented a difference of opinion between the researcher and 
local representatives. These documentation issues accounted for the differences in agreement 
for ‘overall assessment’.  
A total of 161 (9.6%: see Table 5-45) further care episodes were discussed with a local 
representative to support conclusions.  
 
Pharmacist random review of medication assessments 
In 15/18 (83.3%) cases, the pharmacist completely agreed with the researcher. Two further 
episodes had slight differences in the assessment relating to concurrent HIV medications and use 
of antibiotics - the pharmacist identified one episode with insufficient documentation to make a 
full assessment, and in another case, highlighted a potential drug interaction that had a low 
evidence base. The final case involved advising the patient about when to take medication with 
concurrent use of multi-vitamins. An example of the assessment is presented in Appendix II.  
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Table 5-44 Inter-rater assessment between researcher and local representative  
Agreement between researcher and local 




Gender 77 100 
Age 77 100 
Ethnic origin 76 98.7 
Sexual orientation 77 100 
Presentation 
Episode type 77 100 
Symptoms present 70 90.9 
Medical history documentation 76 98.7 
Concurrent medication documentation 76 98.7 
Allergy documentation 75 97.5 
Pregnancy risk (n=46) 45 97.8 
Diagnosis 76 98.7 
Medication regimen 77 100 
Medication Appropriateness Index 
Indication 77 100 
Effective 77 100 
Dosage 67 87.0 
Directions correct 68 88.3 
Directions practical 71 92.2 
Drug-drug interactions 73 94.8 
Drug-disease interactions 72 93.5 
Unnecessary duplication 76 98.7 
Duration of treatment 71 92.2 
Cost 75 97.5 
Overall assessment 
Appropriate 67 87.0 
Safe 72 93.5 
Safe & appropriate  71 92.2 
 
 
Table 5-45 local clarification of clinical queries, safety and appropriateness 
Local clarification on 
individual episodes 










n % n % n % n % n % 
No clarification required 339 85.0 330 95.9 405 84.4 447 97.4 1521 90.4 
Local clarification obtained 60 15.0 14 4.1 75 15.6 12 2.6 161 9.6 
INP= independent nurse prescribing, PGD= patient group directions, med= medication given, no med= no 
medication given 
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5.10 Clinical observations: Task-specific methods 
 
5.10.1 Purpose 
Building observations into the study was undertaken to consolidate data collected from the 
preceding stages, and assess how organisational governance, staff expertise, policies and 
documentation influences clinical practice. Moreover, it facilitated an understanding of the nurse-
patient interaction during medication consultations that would be impossible to achieve from 
clinical records or questionnaires.  
 
5.10.2 Method design 
Observations are a suitable method for investigating nurse-patient interactions, communication 
and clinical performance (Parahoo, 2006). The observational study involved the researcher 
observing, audio recording and taking field notes of consultations where nurses delivered 
medication. Video-taping the observations would have facilitated exploration of subtleties missed 
during physical observation of consultations, and allow thorough critique of the researchers’ 
conclusions. However, as sexual health involves discussing intimate and personal issues, and 
patients had limited time to consider participation, it was decided by the researcher, the 
supervisors and the REC, that audio recording was more suitable and ethical (HRA, 2015).  
The Prescribing Framework (RPS, 2016) details that prescribing involves assessing the patient, 
considering treatment options and reaching a shared decision based on the associated 
governance, before prescribing can occur. The observational study was designed to determine if 
this process occurred in practice. Field notes (Appendix O) were made based on an earlier version 
of the Prescribing Framework (NPC, 2012), and the analysis utilised the updated version (RPS, 
2016). Both frameworks were designed to underpin prescribing practice with a common set of 
multi-professional competencies. The framework’s competencies were designed to support safe, 
effective prescribing which benefited patients’ medication outcomes. Centred on the patient, ‘the 
consultation’ and ‘prescribing governance’, domains had ten separate dimensions (see Table 5-
46) that those delivering medications should demonstrate during consultations (RPS, 2016). 
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Based on the data collection methods employed during observations, it was only practical to 
assess nurses against the 46 competencies under ‘the consultation’ domain. There are multiple 
other tools and methods available to explore healthcare consultations; however, to ensure this 
study remained focussed on the medication delivery aspect, only the prescribing framework 
(NPC, 2012; RPS, 2016) was used.  
Table 5-46 Competency framework for prescribers’ dimensions 
The consultation Prescribing governance 
1. Assess the patient 7. Prescribe safely 
2. Consider the options 8. Prescribe professionally 
3. Reach a shared decision 9. Improve prescribing practice 
4. Prescribe 10. Prescribe as part of a team 
5. Provide information  
6. Monitor and review 
(RPS, 2016) 
To further keep data collection and analysis components manageable within the study’s 
resources, the researcher and supervisors identified that undertaking multiple observations on a 
small number of nurses would be the most appropriate design. This had the benefit of recruiting 
fewer nurses, and allowed the participants to become more comfortable with the researcher’s 
presence. Three INPs, and three PGD users each had a quota of five medication consultations 
observed, totalling 30 observations. Short sessions, suitable for each nurse, were adopted to 
reduce observation fatigue and impact on service delivery. In order to reduce the number of 
unnecessary observations, participants were asked to select clinics in which they most frequently 
provided medication. While this may add bias, the purpose was to determine the interaction 
between nurses and patients during medication consultations. To support deeper analysis and 
triangulation, while remaining focussed on medication delivery, the observations were linked to 
preceding methods: i.e. the clinical diary, clinical notes review and patient experience 




All nurses who participated in the clinical diary across all five sites were invited to participate in 
the observational study. The first three INP and three PGD users who volunteered and met the 
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inclusion criteria (Table 4-4 on page 92 in ‘Chapter 4: Methods’) were selected. After volunteering, 
staff were given a minimum of 48 hours to read participant information sheet and consider their 
participation (Appendix P) and sign consent forms (Appendix Q). Two copies of the consent forms 
were signed, one for the participant and one for the research file. Observations took place at 
dates and times that were mutually suitable for the researcher and the nurse participants. Once 
the observer had observed and audio-recorded five consultations in which individual nurses 
delivered medication, recruitment for that nurse ceased.  
 
5.10.3.2 Patients 
Recruitment of patients was more complex as they had limited time to consider participation, thus 
making the validity of their consent an issue. Sexual health’s open access episodic nature made 
it difficult to predict patients’ attendance or which staff member would manage their care. 
Therefore, the researcher followed closely the Health Research Authority’s (HRA, 2015) advice 
and the REC to ensure appropriate measures were in place to protect patient participants. Where 
possible, patient participant information sheets (PIS: English version Appendix R, Welsh version 
Appendix S) and consent forms (English version Appendix T, Welsh version Appendix U) were 
distributed in reception areas to all patients who were likely to be managed by the nurse 
participants. Based on PPI feedback, these sheets were shortened to support reading in a shorter 
time period (see section 4.6 on page 91). Posters advertising the study (Appendix V) were placed 
in waiting rooms when the observational study was actively recruiting. This allowed additional 
time for patients to consider participation.  
At the beginning of the consultation nurse participants asked patients (in the absence of the 
researcher) if they would be willing to participate. This was to avoid coercion. Patients were 
advised that participation was voluntary and their care would not be affected if they declined this 
invitation. If the patient declined, the nurse continued with the consultation as normal. If the patient 
accepted, the nurse summoned the researcher who discussed the study, ensured patients’ 
questions were answered satisfactorily and obtained two signed copies of the consent form. The 
patient and the nurse were advised they could terminate participation at any point without 
providing a reason. Both the nurse and the patient also had up to 48 hours after the consultation 
to withdraw consent, permitting additional time for patients to consider participation. If consent 
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was withdrawn all data collected would have been destroyed as NHS confidential waste. If during 
the consultation the patient appeared visibly uncomfortable, distressed or presented 
safeguarding/ vulnerability issues (e.g. child protection, sexual assault), the researcher had 
arranged with the nurse to terminate observations. These aspects were added to ensure the study 
did not negatively impact on patients’ care. No nurse or patient withdrew their consent during or 
after observations. 
 
5.10.4 Data collection 
The initial data collection plan was to invite all patients managed by the nurse to participate. When 
it became apparent within the consultation that no medication would be required, the researcher 
terminated observations at an appropriate juncture. Audio-recordings were deleted, but consent 
forms kept. To avoid inappropriate observations, efforts were made to attend clinics more likely 
to deliver medication. The process became more streamlined when nurse participants first 
enquired why the patient had attended. If medication delivery was likely, then the nurse enquired 
if the patient would consider participation. Recruitment of patients was found to be easier in 
contraception clinics or follow-up treatment clinics than in those presenting for new episodes of 
GUM care.  
While the researcher endeavoured not to influence practice, their presence, and the participants’ 
awareness of audio-recording, was likely to have modified behaviour, i.e. the Hawthorne Effect. 
Changed behaviour is, however, difficult to maintain for extended durations (Parahoo, 2006; 
Moule and Goodman, 2009). The use of multiple consultations with nurses aimed to reduce the 
Hawthorne Effect, allowing nurse participants to get used to the observations. Nevertheless, short 
sessions suitable to nurses’ commitments were adopted to reduce observation fatigue and impact 
on service delivery. The researcher did not intervene in consultations; however, they were aware 
of their ethical duty to stop unsafe or inappropriate practice should it have occurred. During the 
observations, the researcher filled out field notes and completed the clinic diary. At the end of the 
consultation patients were asked to complete the patient questionnaire. The patient was provided 
with the opportunity to ask any questions they may have had about the research prior to their 
leaving the clinic. 
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During data collection, all participants’ identities were kept anonymous, replaced with study 
numbers and/ or pseudonyms, except on the consent form. Audio-recording staff or patients’ 
names was avoided where possible. Transcribing was undertaken by an NHS approved 
transcriptionist. Patient/ staff names or site names used during consultation dialogues were 
removed immediately after receiving the transcripts. Original unedited transcripts were not shared 
with anyone else. 
 
5.10.5 Analysis 
The findings for the observational study are split into Section A and Section B. Section A presents 
the findings from direct observations and researcher-completed clinical diary, Section B presents 
data yielded from the clinical notes and patient experience questionnaires.  
Under Section A, consultation characteristics were recorded in terms of patient demographics, 
presentation type, consultation length, attendance reason, diagnosis and medication given. Data 
are presented as number, percentages, mean, standard deviation and range where applicable. 
Chi-squared tests were used to compare categorical data, and the Independent Samples t Test 
was used to compare means.  
Transcription of audio recordings did not commence until a minimum of 48 hours had elapsed 
from the end of the consultation. Each consultations’ audio-recording and transcript was assessed 
against the 46 individual competencies from the Prescribing Framework (RPS, 2016). There was 
no specific scoring or weighting presented by RPS (2016); therefore, within this study to explore 
potential differences in practice between INPs and PGD users, a mean competency scoring 
system was used. Against each competency the transcripts were marked as ‘not achieved’ 
(scoring 0), ‘achieved’ (scoring 1), ‘implied’ competency (i.e. not directly observed, scoring 1) or 
‘not applicable’ (scoring 1).  Individual scores were totalled, the overall mean was calculated and 
compared to the potential top score of 46. Findings on the competencies achieved are presented 
as descriptive data. One of the researcher’s supervisors who is an expert in non-medical 
prescribing and has used a similar tool before, independently checked four transcripts (26.7%) 
and agreed with the researcher’s assessments. Inherent within these assessments was 
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compliance with local and national guidelines to ensure appropriate management of sexual health 
presentations.  
Section B offered a deeper analysis of the observations by incorporating the clinical diary (see 
page 136), clinical notes review (page 143) and patient experience questionnaire (page 209) to 
support triangulation with other aspects of the study. Observational data were analysed as per 
the relevant method.   
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5.11 Clinical observations: Findings 
The observational study’s findings are presented under two distinct sections. Section A presents 
the direct observations based on the consultation characteristics and the prescribing framework. 
Section B integrates the clinical notes review and patient satisfaction questionnaire (used in the 
wider study) to support deeper observation analysis.  
 
Section A: 
5.11.1 Characteristics of nurse-patient consultations 
Thirty nurse-patient medication delivery consultations were observed (INP=15; PGD=15) 
involving five INP and six PGD nurses. One PGD nurse participant withdrew, but requested their 
observation (n=1) was included; a sixth PGD nurse completed the four remaining observations to 
achieve the study’s quota. Seventeen consultations involved management of genitourinary 
conditions (56.6%), 12 (40.0%) provided contraception only and one (3.3%) integrated both. 
Consultation characteristics are summarised in Appendix JJ. 
There was no difference in the overall mean consultation length between INPs and PGD users 
(mean 19.9 vs. 16.9 minutes, respectively: t= 0.906, df= 28, p= 0.373), despite an overall mean 
difference of 3.0 minutes, see Table 5-47.  

















Range 13 to 44 5 to 30 5 to 44 8 to 35 7 to 27 7 to 35 5 to 44 
Total consultation time 180 118 298 171 83 254 552 
Mean 22.5 16.9 19.9 19 13.8 16.9 18.4 
Standard Deviation 9.8 8.1 9.2 8.9 7.6 8.5 8.8 
Statistical testing* 
t = 0.906, df = 28, p = 0.373 
mean difference 2.9 (95% CI: -3.7 to 9.6) 
 
* Statistical testing compared total mean consultation lengths of INP with PGD users. 
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5.11.2 Patient demographics 
Approximately two thirds of patients were female (n=19, 63.3%). INPs managed an equal gender 
split, whereas, PGD nurses managed more females (n=11, 73.3%). Patients’ mean age was 27 
years. INP had equal split of heterosexual and homosexual patients (both n=7, 46.7%), whereas 
PGD users’ managed mostly heterosexual patients (n=11, 73.3%). Consultations consisted of 17 
(56.7%) new care episodes and 13 (43.3%) follow-up in total, and most patients were 
asymptomatic (n=21, 70.0%).  
 
Table 5-48 Patient demographics 
Patients’ demographics 
INP (n=15) PGD (n=15) Total (n=30) 
n % n % n % 
Gender 
Male 7 46.7 4 26.7 11 36.7 
Female 8 53.3 11 73.3 19 63.3 
Age at 
presentation 
Range 16 to 53 16 to 45 16 to 53 
Mean 27.7 28.1 27.9 
Standard deviation 10.5 9.2 9.7 
Ethnic origin 
White British 8 53.3 8 53.3 16 53.3 
Unknown 2 13.3 5 33.3 7 23.3 
Black Caribbean 1 6.7 1 6.7 2 6.7 
Mixed White Caribbean 1 6.7 1 6.7 2 6.7 
Asian Pakistani 1 6.7 0 0.0 1 3.3 
White Other 1 6.7 0 0.0 1 3.3 
Other 1 6.7 0 0.0 1 3.3 
Sexuality  
Heterosexual 7 46.7 11 73.3 18 60.0 
Homosexual 7 46.7 0 0.0 7 23.3 
Bisexual 1 6.7 2 13.3 3 10.0 
Unknown 0 0.0 2 13.3 2 6.7 
Presentation 
New 8 53.3 9 60.0 17 56.7 
Follow-up 7 46.7 6 40.0 13 43.3 
Symptoms 
Asymptomatic 10 66.7 11 73.3 21 70.0 
Symptomatic 5 33.3 4 26.7 9 30.0 
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5.11.3  Assessment of consultations against the prescribing framework 
The prescribing framework has 46 individual competencies (RPS, 2016). INPs demonstrated a 
mean score of 44.7/46 and PGD users 45.4/46. There was no difference between INPs and PGD 
users in performance measured against the prescribing framework (Mann Whitney U= 94.500, 
p=0.407: Table 5-49). Detailed observational assessments against the prescribing framework are 
shown in Appendix KK. 
Across the 30 observations, nurses frequently demonstrated that they achieved the competencies 
in ‘Section 3: Reach a shared decision’ (sub-competencies= 6) and ‘Section 5: Provide 
information’ (sub-competencies= 5). These sections were directly observed by the researcher 
more often in the PGD group (Section 3: n=90/90, 100%; Section 5: n=70/75, 93.3%) than INP 
(Section 3: n=87/90, 96.7%; Section 5: n=62/75, 82.7%); however, there was no statistical 
difference (Section 5: Mann Whitney U= 2,662.500, p=0.230). Despite ‘Competency 1: Assess 
the patient’ ranking third across the six prescribing framework competencies in terms of direct 
observation, nurses in all consultations were clearly observed taking appropriate histories, clinical 
assessments and interpreting / using relevant investigations.  
Not all aspects of the prescribing framework components were applicable to all consultations/ 
presentations. For example, competency “1.7: Reviews adherence to and effectiveness of current 
medicines” applied to 10 contraception and three genitourinary consultations. However, sexual 
health nurses were not necessarily qualified to determine medication adherence for eight patients’ 
pre-existing medical conditions. Moreover, eight further patients were not on any other 
medications to measure adherence. Therefore, throughout the competency assessment ‘not 
applicable’ was not negatively marked.  
Other competencies, while not being directly observed, were obviously inherent within nurses’ 
knowledge and skill base. For example, competencies “2.7: Identifies, accesses, and uses 
reliable and validated sources of information and critically evaluates other information” and “2.8: 
Stays up-to-date in own area practice and applies the principles of evidence-based practice…” 
were consistently demonstrated by nurses when making medication decisions based on current 
national/ local guidance. In these cases nurses were not specifically observed undertaking the 
competency by the researcher, but they were clearly ‘implied’ within their clinical decision making. 
These were considered as observed (but presented separately in Appendix KK).  
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Table 5-49 Summary of Prescribing Framework scores 
*’Total points’ assumes one potential point for each subsection x 15 observed consultations in each group 
**Not observed scored ‘0’; observed, not applicable & implied scored ‘1’ to calculate mean scores out of a top score of 46. Statistical testing compared mean scores of INPs with PGD 






(number of subsections) 
Total 
points* 











n % n % n % n % n % n % n % n % 
1: Assess the patient (8) 120 96 80.0 0 0.0 1 0.8 23 19.2 99 82.5 0 0.0 0 0.0 21 17.5 
2: Consider the options (10) 150 68 45.3 57 38.0 1 0.7 24 16.0 72 48.0 55 36.7 0 0.0 23 15.3 
3: Reach a shared decision (6) 90 87 96.7 0 0.0 0 0.0 3 3.3 90 100 0 0.0 0 0.0 0 0.0 
4: Prescribe (13) 195 110 56.4 41 21.0 6 3.1 38 19.5 116 59.5 36 18.5 0 0.0 43 22.1 
5: Provide information (5) 75 62 82.7 0 0.0 8 10.7 5 6.7 70 93.3 0 0.0 4 5.3 1 1.3 
6: Monitor and review (4) 60 39 65.0 0 0.0 0 0.0 21 35.0 41 68.3 0 0.0 0 0.0 19 31.7 
TOTAL (46) 690 461 66.8 98 14.2 17 2.5 114 16.5 488 70.7 91 13.2 4 0.6 107 15.5 
Overall scores**  Total: 673; Range 41 to 46; Mean=44.7 (St. Dev 1.7) Total: 686; Range 44 to 46; Mean 45.4 (St. Dev 0.8) 
Statistical testing**  Mann Whitney U= 94.500, p=0.407 
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The few competencies that nurses did not achieve (n=20/1,380, 1.4%) are presented in Table 
5-50, alongside the researcher’s rationale for this judgement. Competencies “5.3: Guides 
patients/ carers on how to identify reliable sources of information about their medicines and 
treatments” and “5.4: Ensures that the patient/ carer knows what to do if there are any concerns 
about the management of their condition…” were the two least frequently observed. 
 
Patient public involvement concerns 
The PPI section of the framework identified that patients were most concerned about the effects 
of taking medications and the potential of side effects. There were five related RPS (2016) 
competencies, as presented in Table 5-51. Nurses predominantly addressed these concerns 
across all five competencies, with no differences between INPs and PGD users’ practice (92.0% 
vs. 97.4%, respectively; 2 = 2.113, df= 1, p= 0.146). 
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Table 5-50  Researcher’s rationale for scoring ‘not observed’ in prescribing framework competencies 





1.7 Reviews adherence to and effectiveness of current medicines. Did not undertake compliance for Trichomoniasis INP 1 
2.6 Takes into account any relevant patient factors (e.g. ability to swallow, religion) 
and the potential impact on route of administration and formulation of medicines. 
Patient reported difficulty swallowing tablets, suspension not 
offered; patient chewed the tablets. (No religion-specific 
aspects were identified during observations) 
INP 1 
4.2 Understands the potential for adverse effects and takes steps to avoid/minimise, 
recognise and manage them. 
Does not provide information on potential adverse effects, and 
what to do if there is an issue. Does mention stomach cramps 
may be a side effect 
INP 1 
4.9 Electronically generates or writes legible unambiguous and complete 
prescriptions which meet legal requirements. 
Written "COC" as prescription instead of full drug name/ 
prescription 
INP 1 
4.10 Effectively uses the systems necessary to prescribe medicines (e.g. medicine 
charts, electronic prescribing, decision support). 
INP 1 
4.12 Makes accurate legible and contemporaneous records and clinical notes of 
prescribing decisions. 
INP 1 
4.12 Makes accurate legible and contemporaneous records and clinical notes of 
prescribing decisions. Did not write in clinical notes the rationale for providing thrush 
treatment and there was no indication from the notes it was 
required 
INP 1 
4.13 Communicates information about medicines and what they are being used for 
when sharing or transferring prescribing responsibilities/ information. 
INP 1 
5.3 Guides patients/carers on how to identify reliable sources of information about 
their medicines and treatments. 




5.4 Ensures that the patient/carer knows what to do if there are any concerns about 
the management of their condition, if the condition deteriorates or if there is no 
improvement in a specific time frame. 
Follow-up booked, but did not discuss what to do if concerns 
in the meantime 
INP 3 
PGD 2 
INP= Independent nurse prescribing, PGD = patient group directions, COC = combined oral contraception 
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Table 5-51 Competencies based on patient and public involvement concerns 












n % n % n % n % n % n % 
3.3 Explains the rationale behind and the potential risks and benefits of management options 
in a way the patient/carer understands. 
15 100 0 0.0 0 0.0 15 100 0 0.0 0 0.0 
4.1 Prescribes a medicine only with adequate, up-to-date awareness of its actions, 
indications, dose, contraindications, interactions, cautions, and side effects. 
6 40.0 9 60.0 0 0.0 7 46.7 8 53.3 0 0.0 
4.2 Understands the potential for adverse effects and takes steps to avoid/minimise, 
recognise and manage them. 
14 93.3 0 0.0 1 6.7 15 100 0 0.0 0 0.0 
5.2 Gives the patient/carer clear, understandable and accessible information about their 
medicines (e.g. what it is for, how to use it, possible unwanted effects and how to report 
them, expected duration of treatment). 
15 100 0 0.0 0 0.0 15 100 0 0.0 0 0.0 
5.3 Guides patients/carers on how to identify reliable sources of information about their 
medicines and treatments. 
10 66.7 0 0.0 5 33.3 13 86.7 0 0.0 2 13.3 
Total 60 80.0 9 12.0 6 8.0 65 86.7 8 10.7 2 2.7 
INP= Independent nurse prescribing, PGD = patient group directions
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5.11.4 Autonomous practice 
Both INPs and PGD users predominantly managed episodes of care autonomously (n=25, 
83.3%), with no difference in autonomy between groups (Fishers Exact Test, p=1.000). Additional 
clinical/ medication support was required in five (16.7%) consultations, see Table 5-52. 
 
Table 5-52 Autonomous practice 
Autonomous practice 
INP (n=15) PGD (n=15) Total (n=30) 
n % n % n % 
Autonomous practice 13 86.7 12 80.0 25 83.3 
Complex contraception referral 2 13.3 0.0 0.0 2 6.7 
Medicine advice sought 0 0.0 1 6.7 1 3.3 
Clinical advice sought & prescription obtained 0 0.0 1 6.7 1 3.3 
Reduced duration of contraceptive pill supply due to 
PGD restrictions 
0 0.0 1 6.7 1 3.3 
Statistical testing (INP vs. PGDs) Fishers Exact Test, p=1.000 
INP= Independent nurse prescribing, PGD = patient group directions 
 
Section B: 
This section utilises methods applied in previous aspects of the study by triangulating the clinical 
notes review and patient experience questionnaire with observed practice.  
Clinical notes review: 
5.11.5 Completeness of prescription documentation and method of medication delivery 
Of the 47 drug items delivered during observations (INP=28; PGD=19), the medicine name was 
clearly documented in all but one record. Prescriptions’ route, frequency and duration were less 
consistently recorded (see Table 5-53). INPs were statistically more likely to document the full 
‘prescription’ compared to PGD users (INP=158, 94.0% vs. PGD=93, 81.6: 2= 10.791, df= 1, p= 
0.001). INPs most often administered medication by injection (n=15, 53.6%), whereas PGD users 
(n=13, 68.4%) mostly supplied medication as ‘to-take-out’ oral treatment packs (n=13, 68.4%: 
Table 5-54). 
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Table 5-53 Quality of completed 'prescription' documentation 
Completeness of 
‘prescription’* 
Name Dose Route Frequency Duration Signature Summative score Statistical testing 
(INP vs PGD) n % n % n % n % n % n % n % 
INP (n=28) 27 96.4 27 96.4 26 92.9 25 89.3 25 89.3 28 100 158 (/168) 94.0 2 = 10.791, df = 1, 
p = 0.001 PGD (n=19) 19 100 14 73.7 13 68.4 14 73.7 16 84.2 17 89.5 93 (/114) 81.6 
*some patients were prescribed more than one drug; 47 drugs delivered over 30 consultations. INP= independent nurse prescribing, PGD=patient group directions, 2 = Chi-squared 
test 
 
Table 5-54 Method of delivering medication 
Method of medication delivery INP (n=28) PGD (n=19) Total (n=47) 
n % n % n % 
‘To take out' provided 9 32.1 13 68.4 22 46.8 
Injection 15 53.6 3 15.8 18 38.3 
Directly observed therapy 2 7.1 1 5.3 3 6.4 
Pharmacy 1 3.6 1 5.3 2 4.3 
Missing documentation in notes 1 3.6 1 5.3 2 4.3 
INP= independent nurse prescribing, PGD=patient group directions 
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5.11.6 Safety in medication provision 
Documentation of patients’ past medical history, concurrent medication, allergies, and where 
applicable, pregnancy risk, were found in all consultations (Table 5-55). For two PGD cases these 
items were documented at a recent previous attendance; however, the nurse participants were 
observed asking these questions but it was not re-documented.  
   
Table 5-55 Documentation of past medical history, concurrent medication, allergy and pregnancy risk 
Accuracy of documented risk 
assessment prior to delivering 
medication (n=30) 
INP (n=15) PGD (n=15) 
n % n % 
PMH documented 
Documented 15 100 13 86.7 
Past documented 0 0 2 13.3 
Concurrent 
medications 
Documented 15 100 13 86.7 
Past documented 0 0 2 13.3 
Allergies 
Documented 15 100 13 86.7 
Past documented 0 0 2 13.3 
Female patients only (n=19) INP (n=8) PGD (n=11) 
Pregnancy risk Documented 8 100 11 100 
 INP= independent nurse prescribing, PGD=patient group directions 
 
5.11.7 Medication appropriateness index 
Twelve (40.0%) patients in the observation study had a pre-existing medical condition and/ or 
allergy, and 10 (33.3%) were taking concurrent medications (see Table 5-56). One patient was 9-
11 weeks pregnant. The researcher considered these pre-existing issues throughout medication 
safety and appropriateness assessments. 
Table 5-56 Number of patients with existing medical issues and/ or concurrent medication 
Existing medical 
issues & concurrent 
medication 
INP (n=15) PGD (n=15) Total (n=30) 
No Yes No Yes No Yes 
n  % n % n  % n % n  % n % 
Pre-existing medical 
issue/ allergy* 
10 66.7 5 33.3 8 53.3 7 46.7 18 60.0 12 40.0 
Concurrent 
medication  
11 73.3 4 26.7 9 60.0 6 40.0 20 66.7 10 33.3 
* Allergies were considered alongside pre-existing medical conditions in ‘medication-disease/ condition 
interaction’ during medical appropriateness index assessments. INP= independent nurse prescribing, 
PGD=patient group directions 
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Across the 47 individual drug items, the MAI demonstrated that both INPs and PGD users 
consistently provided appropriate medication (Table 5-57), in line with local and national treatment 
guidelines (BASHH, 2016; FSRH, 2016). Based on documentation alone, INPs provided two 
drugs that appeared not to be indicated for the conditions being managed (i.e. patient was 
prescribed clotrimazole cream and pessary when there was no apparent fungal infection). 
However, when triangulated with observational data the reason was clear i.e. the patient 
frequently suffered from antibiotic related thrush and was prescribed an antibiotic. Similarly, for 
PGD users, omissions on the documented ‘prescriptions’ led to poorer MAI scores for dosage 
(n=14, 73.7%) and directions (n=13, 68.4%). However, when triangulated with observational data 
there were no concerns related to medication appropriateness. Table 5-58 summarises the MAI 
scoring for INP and PGD based on documentation alone, then triangulated with observational 
data. There was comparable medication appropriateness scoring between both groups based on 
documentation alone (t = -1.367, df = 32.7, p= 0.181). Due to the MAI’s weighted scoring system 
(which rates appropriateness 0-18, closer to 0 more appropriate, see page 146) had all aspects 
of the MAI been ‘inappropriate’ or ‘not known’ a total score of 846 (i.e. 47*18) could have been 
achieved. Both INP (score=19) and PGD users (score=31) scored very low, demonstrating a high 
level of appropriate medication delivery. Overall, based on documentation alone, 38 (80.9%) of 
medications scored ‘0’, with a mean score of 1.0/18. Subsequent triangulation of observational 
data with documentation determined that all drugs were clinically indicated and likely to be 
therapeutically effective (n=47, 100%; MAI score 0/18 for INP and PGD users). Therefore, 
although documentation raised some concerns in relation to practice appropriateness, 
triangulation with the observations demonstrated that all observed consultations provided safe 
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Table 5-57 Medication Appropriateness Index assessment (documentation & observations) 
Medication Appropriateness Index Source 
INP (n=28)* PGD (n=19)* 
Appropriate Intermediate Inappropriate Not known Appropriate Not known 
n % n % n % n % n % n % 
Is there an indication for the medication? 
Documentation 26 92.9 0 0 2 7.1 0 0 19 100 0 0 
Observation 28 100       19 100   
Is the medication effective for the 
condition? 
Documentation 26 92.9 0 0 2 7.1 0 0 19 100 0 0 
Observation 28 100       19 100   
Is the dosage correct? 
Documentation 27 96.4 0 0 0 0 1 3.6 14 73.7 5 26.3 
Observation 28 100       19 100   
Are the directions correct? 
Documentation 25 89.3 0 0 0 0 3 10.7 13 68.4 6 31.6 
Observation 28 100       19 100   
Are the directions practical? 
Documentation 27 96.4 0 0 0 0 1 3.6 13 68.4 6 31.6 
Observation 28 100       19 100   
Are there clinically significant medication 
interactions? 
Documentation 26 92.9 2 7.1 0 0 0 0 19 100 0 0 
Observation 26 92.9 2 7.1 0 0 0 0 19 100   
Are there clinically significant medication-
disease/ condition interactions 
Documentation 28 100 0 0 0 0 0 0 19 100 0 0 
Observation 28 100       19 100   
Is there any unnecessary duplication with 
other medication(s)? 
Documentation 26 92.9 0 0 2 7.1 0 0 19 100 0 0 
Observation 28 100       19 100   
Is the duration of therapy acceptable? 
Documentation 25 89.3 2 7.1 0 0 1 3.6 16 84.2 3 15.8 
Observation 26 92.9 2 7.1 0 0 0 0 19 100   
Is this drug the least expensive alternative 
compared to others of equal utility? 
Documentation 28 100 0 0 0 0 0 0 19 100 0 0 
Observation 28 100       19 100   
*number of individual medications delivered (not consultations). INP = independent nurse prescribing, PGD= patient group directions. 
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Table 5-58 Medication Appropriateness Index weighted scoring results of documentation, then triangulated with observational data  
Medication Appropriateness Index (MAI) 
Weighted scoring  
Documentation & triangulation with observational data^ 
INP (n=28) PGD (n=19) Total (n=47) 
Documentation Triangulation Documentation Triangulation Documentation Triangulation 
Potential highest MAI weighted score (n x 18) 504 342 846 
Combined MAI weighted score 19 0 31 0 50 0 
Mean MAI weighted score (out of 18) 0.7 0 1.6 0 1.0 0 
Standard Deviation 2.0 0 2.5 0 2.3 0 
Range of MAI weighted scores  0 to 7 0 0 to 6 0 0 to 7 0 
Number scoring ‘0’: most appropriate 25 (89.3%) 28 (100%) 13 (68.4%) 19 (100%) 38 (80.9%) 47 (100%) 
Statistical testing (INP= 0.7 vs. PGD=1.6: Documentation only) 
t = -1.367, df = 32.7, p= 0.181* 
mean difference -1.0 (95% CI: -2.4 to 0.5)  
  
  
*Range 0-18, the closer to 0 more appropriate **Levene’s Test equal variances not assumed. INP = independent nurse prescribing, PGD = patient group directions, t= Independent 
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5.11.8 Patient experience feedback  
 
Of the 30 observations, 27 patient experience questionnaires were distributed. A 96.3% (n=26: 
INP=14; PGD=12) response rate was achieved. From the 26 eligible responses, patients 
overwhelmingly reported a positive experience during their interactions with the nurse (see Table 
5-59). INP and PGD nurses were reported as being: friendly and approachable (n=26, 100%); 
that they instilled confidence and trust for patients (n=25, 96.2%); explained the reasons for 
medication clearly (n=26, 100%); and were able to suitably answer questions (n=25, 96.2%). 
Where patients were aware the nurses provided medication autonomously, they all had 
confidence in the nurse doing so (n=14, 100%). While only 14 patients identified that nurses 
provided medication independently, in practice 25 (83.3%) of them actually received medication 
independently from the nurse.  
 
Table 5-59 Patients’ satisfaction with their consultation with nurses 
Patients' satisfaction with nurses medication 
consultations 
Observation 
INP (n=14) PGD (n=12) Total (n=26) 
n % n % N % 
1. Was the nurse you saw today 
friendly and approachable? 
Definitely, yes 14 100 12 100 26 100 
2. Did you have confidence & trust 
in the nurse you saw today? 
Definitely, yes 14 100 11 91.7 25 96.2 
Missing answer 0 0.0 1 8.3 1 3.8 
3. Did the nurse explain the reasons 
for the medicine in a way you could 
understand? 
Completely, yes 14 100 12 100.0 26 100.0 
4. If you had any questions to ask, 
were you satisfied with the 
answers? 
Definitely, yes 14 100 11 91.7 25 96.2 
No opportunity 0 0.0 1 8.3 1 3.8 
5A Did the nurse give you 
medication without speaking to a 
Dr? 
Yes 8 57.1 6 50.0 14 53.8 
No  3 21.4 2 16.7 5 19.2 
Don't Know 3 21.4 0 0.0 3 11.5 
Missing answer 0 0.0 4 33.3 4 15.4 
5B If YES did nurse have necessary 
skills 
Number  8 6 14 
Definitely, yes 8 100 6 100 14 100 
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5.11.8.1 Satisfaction with Information about Medicines Scale (SIMS) 
Patients predominantly reported that they were satisfied with the information they received about 
medicines (Table 5-60). The most common areas patients reported being less satisfied with 
information provision, related to medication potentially making them feel drowsy (positive score 
17, negative score 7), whether they could drink alcohol (positive score 19, negative score 4) and 
the risks of getting side effects (positive score 19, negative score 4). 
 
Table 5-60 Summary of satisfaction with information on medicines scale categories 
SIMS category 
INP (n=13)* PGD (n=10)* Total (n=23)* 
n % n % n % 
Total potential score* 208 100 160 100 368 100 
Too much (+0) 4 1.9 16 10.0 20 5.4 
About right (+1) 154 74.0 135 84.4 289 78.5 
Too little (+0) 5 2.4 4 2.5 9 2.4 
No medication information 
received (+0) 
15 7.2 2 1.3 17 4.6 
Not applicable (+1) 29 13.9 3 1.9 32 8.7 
Missed (+0) 1 0.5 0 0.0 1 0.3 
*percentages based on the total potential scores, not the number of completed SIMS. SIMS: Satisfaction 
with Information about Medicines Scale, INP =independent nurse prescribing, PGD= patient group directions 
 
There was no difference in patients’ satisfaction in relation to whether they were managed by 
INPs or PGD users (mean=13.1 vs. 10.7/16, respectively: Mann Whitney U=87.000, p=0.836: see 
Table 5-61). Patients reported marginally less satisfaction with information on the ‘potential 
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(INP vs. PGD) 
SIMS potential score  224 208 432 
 Mann Whitney U= 87.000, 
p=0.836 
SIMS score achieved 184 139 323 
SIMS mean score (/16) 13.1 10.7 12.0 
SIMS standard deviation  4.5 7.5 6.1 
AU total potential score  112 104 216 
Mann Whitney U= 83.000, 
p=0.662 
AU score achieved 95 70 165 
AU Mean score (/8) 6.8 5.4 6.1 
AU standard deviation 2.1 3.8 3.0 
PPM total potential score  112 104 216 
Mann Whitney U= 82.000, 
p=0.630 
PPM score achieved 89 69 158 
PPM Mean score (/8) 6.4 5.3 5.9 
PPM standard deviation 2.5 3.7 3.1 
*SIMS potential score is the highest score had every participant been completely satisfied with the 
medication information they received. **Statistical testing compared INP with PGD 
SIMS: Satisfaction with Information about Medicines Scale, AU: Action and usage of medicines score; PPM: 
Potential problems of medicines score. INP =independent nurse prescribing, PGD= patient group directions. 
 
 
5.11.8.2 Content analysis of patients' handwritten comments 
 
Nine patients (INP=5; PGD=4) left handwritten comments which covered several feedback 
content categories, as shown in Table 5-62. All comments were positive.  
 
Table 5-62 Content analysis of patients’ comments 
Comment content category INP PGD Total 
Helpful 2 2 4 
Informative/ knowledgeable 1 2 3 
Lovely nurse 0 3 3 
Approachable 2 0 2 
Existing medication, no advice needed 1 0 1 
Comfort/ put at ease 1 0 1 
Would return to service 0 1 1 
Reassuring 0 1 1 
INP =independent nurse prescribing, PGD= patient group directions  
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5.12 Patient experience questionnaire: Task-specific methods 
 
5.12.1 Purpose 
Nurses providing medication independently is intended to improve patient care and experience; 
therefore, it is essential to obtain patients’ feedback. The questionnaire (Appendix L) explored 
patients’ satisfaction with their consultation and level of medicines’ information received. 
 
5.12.2 Method design 
The patient experience questionnaire was a two-page document based on two validated research 
tools: Birmingham’s sexual health service satisfaction questionnaire (Weston et al., 2010) and the 
Satisfaction with Information about Medicines Scale (SIMS; Horne et al., 2001). The first section 
enquired about patients’ experience, confidence and opinion on nurses independently managing 
their care, using ‘tick’ boxes to highlight pre-determined responses. To facilitate a focussed line 
of enquiry only five questions from Weston et al.’s (2010) tool were used; those which were 
deemed by the researcher and supervisors to have face validity. While this may affect the overall 
validity, the questionnaire’s phrasing was used to enhance the design of the tool used in this 
project. Moreover, Birmingham’s questionnaire involved redundant enquires regarding all aspects 
of service interaction from initial contact through to leaving the clinic. The validity of this tool may, 
therefore, only be applicable to Birmingham’s local service, as not all services will manage patient 
journeys in the same way (e.g. walk-in versus appointment). That being said, Weston et al.’s 
(2010) tool was specifically designed and tested to target sexual health patients, based on the 
speciality’s unique governance requirements and patient demographics. Design and validation of 
the tool involved a systematic literature review, patient experience interviews and use of a Delphi 
technique to create the questionnaire’s content. High levels of internal consistency were found 
(Cronbach’s alpha 0.88) ‘during your appointment’ and ‘overall impression’. Weston et al. (2010) 
concluded the questionnaire had good levels of content validity and was feasible to deliver in a 
sexual health setting. Patients reported they preferred completing the questionnaire in the clinic, 
rather than posting (Weston et al., 2010). Therefore, patients within this study were requested to 
complete the questionnaire before leaving the clinic.  
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The second page of the patient questionnaire incorporated the SIMS validated tool which posed 
17 questions regarding safe self-management of medication. The SIMS is based on research tool 
designed by Horne et al. (2001) to test how satisfied patients were in relation to medication 
information received. Their paper determined through using additional research tools (Medication 
Adherence Report Scale (MARS) and Beliefs about Medicines Questionnaire (BMQ)) in eight 
different clinical settings, that the SIMS had good levels of internal consistency (Cronbach’s alpha 
coefficient 0.81-0.91), test-retest reliability (Pearson correlations 0.67-0.76, p<0.05) and ease of 
use. Moreover, a higher SIMS score related to higher levels of medication adherence (Horne et 
al., 2001). The original scale had 17 questions; however, one question (question 8: How to use 
your medicine) was accidentally omitted during questionnaire printing. Therefore this study only 
included 16 questions. The SIMS has been evaluated for its acceptability (ease of use), internal 
consistency, test-retest reliability and criterion related validity. Therefore, this tool was used to 
determine sexual health patients’ satisfaction with information and medication.  
 
The draft questionnaire used for this project was sent to six patient representatives. They were 
informed of the questionnaire’s context as receiving medication from a nurse in sexual health. 
Suggestions on formatting were provided, and one person, an experienced patient representative, 
reported that the participant information sheet was too long; consequently, this was shortened 
based on their suggestions.  
 
5.12.3 Recruitment 
Nurses undertaking the clinical diary were requested to distribute the patient experience 
questionnaires at the end of all consultations in which medicines had been delivered, regardless 
of whether this had been autonomously or otherwise. The recruitment phase was the same two-
week period in which the nurses completed the diary. Questionnaires were distributed at the end 
of consultations and, to avoid coercion, deposited in a designated box placed in the reception. 
Return of completed questionnaire was regarded as implied consent.  
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5.12.4 Data collection 
Patients who received medication from nurses completing the clinical diary were expected to 
receive a uniquely referenced questionnaire and a participant information sheet (English version 
Appendix M, Welsh version Appendix N) from the nurse. Questionnaire references were logged 
on the nurses’ clinical diaries. Recording questionnaires in this way facilitated calculation of the 
response rate, and allowed further investigation should patients report inappropriate levels of 
advice; acknowledging not all SIMS’s measurements are applicable to every medication. 
However, this did rely on nurses remembering to distribute questionnaires. Distributing the 
questionnaires in this way was deemed the most appropriate method; however, as Latter (2011) 
identified, self-selecting questionnaire distribution potentially creates a large bias. While the 
researcher acknowledged the distribution bias, it was the only feasible option based on 
governance, resources and clinical assessment. Given the confidential nature of sexual health, it 
was not possible for the researcher to retrospectively post questionnaires to eligible patients from 
the diaries’ data. The number of sites (including satellite) and nurses participating, meant that the 
researcher was unable to personally distribute questionnaires. Moreover, not all patients fulfilled 
inclusion criteria (see ‘Inclusion and exclusion criteria’ on page 92). Nurses therefore identified 
whether or not patients fulfilled inclusion criteria. The diary did, however, record which patients 
did not receive a questionnaire which to some extent, addressed the bias issue.  
 
The researcher collected the patient questionnaires in bulk when attending each site to collect 
the nurses’ diaries. Data from the questionnaires were then transferred onto a specifically 
designed Microsoft Access® database. During the clinical notes review, the researcher also 
collected data on patients’ diagnoses and medications where the questionnaire reference 
numbers could be traced back to specific patient episodes. All aspects of research governance 
and responsibility presented in Chapter 4 were also adhered to. 
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5.12.5 Analysis 
Data related to Weston et al.’s (2010) patient experience questionnaire are presented as 
frequency distribution across the pre-determined responses. Due to the homogeneity in 
responses between both groups, and the obvious positive skew, statistical testing was not 
undertaken on consultation feedback. The SIMS is analysed on three different levels: firstly an 
overall picture providing general areas where medication information is lacking. The next section 
then provides a score on participants satisfaction levels, this is done be applying a score to each 
response: SIMS score ‘1’ if ‘about right’ or ‘not applicable’; ‘0’ if ‘too much’, ‘too little’ or ‘not 
received’ as this suggests information wanting. Scores will range from 0-16, the higher the score, 
the higher the satisfaction. The full scale is then split into two further sub-categories: satisfaction 
relating to “Action and usage of medication” (questions 1-8); “Potential problems of medication” 
(questions 9-16). Cronbach’s alpha coefficients for SIMS was tested on each of the SIMS scales 
and sub-scales to measure internal consistency/ reliability. The Cronbach’s Alpha score is from 0 
to 1, anything over 0.6 is considered to have a good level of internal consistency (Horne et al., 
2001). The Independent Samples t Test was undertaken based on the mean SIMS scores 
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5.13 Patient experience questionnaire: Findings 
 
5.13.1 Response rate 
Of the 808 eligible patients who received medication from nurses during the clinical diary data 
collection, 393 (48.6%) were issued with a questionnaire; 380 were returned (96.7% response 
rate); consisting of INP=180 (47.4%), PGD=173 (45.5%), not known=7 (1.8%) and not 
completed=20 (1.1%). The overall usable response rate was 91.6%; however, this only 
represented 44.6% (360/808) of the overall eligible clinical diary patients. Table 5-63, presents 
the reasons questionnaires were not distributed, where this data was recorded.  
 
Table 5-63 Distribution of patient questionnaires during clinical diary 
Questionnaire eligibility 
Comments and reasons for not 
distributing 
Number % 
Eligible & given (n=393) 
Traceable questionnaires 366 93.1 
Questionnaire reference missing/ illegible 27 6.9 
Eligible, not given 
questionnaire (n=415) 
No rationale 264 63.6 
Patient declined 29 7.0 
Forgot 26 6.3 
Patient in a rush 25 6.0 
Safeguarding/not appropriate 24 5.8 
Limited English 14 3.4 
AdHoc prescribing 13 3.1 
No questionnaire supply 11 2.7 
Referred to doctor 5 1.2 
Patient had eyesight issues 3 0.7 
Previous participation 1 0.2 
NOT eligible & given Not eligible for questionnaire but traceable 16 




5.13.2 Patient’s experience of the consultation  
From the 360 eligible questionnaires returned, respondents overwhelmingly reported a positive 
patient experience during their interaction with nurses (see Table 5-64). INP and PGD nurses 
were reported as being: friendly and approachable (n=359, 99.7%); that they instilled confidence 
and trust for patients (n=357, 99.2%); explained the reasons for medication clearly (n=349, 
96.9%); and were able to suitably answer questions (n=335, 93.1%). 
 
Table 5-64 Patient's satisfaction with their consultations with nurses 








n % n % n % n % 
1. Was the nurse 
you saw today 
friendly and 
approachable? 
Definitely, yes 179 99.4 172 99.4 6 85.7 357 99.2 
Some extent, yes 1 0.6 0 0.0 1 14.3 2 0.6 
Missing answer 0 0.0 1 0.6 0 0.0 1 0.3 
2. Did you have 
confidence & 
trust in the nurse 
you saw today? 
Definitely, yes 177 98.3 171 98.8 6 85.7 354 98.3 
Some extent, yes 1 0.6 1 0.6 1 14.3 3 0.8 
No 1 0.6 0 0.0 0 0.0 1 0.3 
Missing answer 1 0.6 1 0.6 0 0.0 2 0.6 
3. Did the nurse 
explain the 
reasons for the 
medicine in a way 
you could 
understand? 
Completely, yes 171 95.0 167 96.5 7 100.0 345 95.8 
Some extent, yes 1 0.6 3 1.7 0 0.0 4 1.1 
No 2 1.1 0 0.0 0 0.0 2 0.6 
Didn't need 5 2.8 2 1.2 0 0.0 7 1.9 
Missing answer 1 0.6 1 0.6 0 0.0 2 0.6 
4. If you had any 
questions to ask, 
were you 
satisfied with the 
answers? 
Definitely, yes 174 96.7 151 87.3 7 100.0 332 92.2 
Some extent, yes 1 0.6 2 1.2 0 0.0 3 0.8 
Did not have 4 2.2 18 10.4 0 0.0 22 6.1 
No opportunity 1 0.6 1 0.6 0 0.0 2 0.6 
Missing answer 0 0.0 1 0.6 0 0.0 1 0.3 




to a doctor? 
Yes 90 50.0 73 42.2 4 57.1 167 46.4 
No 36 20.0 38 22.0 2 28.6 76 21.1 
Don't Know 42 23.3 56 32.4 1 14.3 99 27.5 
Missing answer 12 6.7 6 3.5 0 0.0 18 5.0 
 
5B* If ‘YES’ did 
the nurse have 
necessary skills? 
Number: 90 73 4 167 
Definitely, yes 89 98.9 68 93.2 4 100 161 96.4 
Some extent, yes 0 0.0 1 1.4 0 0 1 0.6 
No 1 1.1 0 0.0 0 0 1 0.6 
Missing answer 0 0.0 4 5.5 0 0 4 2.4 
*Question 5A asked patients to only complete question 5B if they answered ‘yes’. INP=Independent nurse 






When patients were asked “Did the nurse give you medication WITHOUT speaking to a doctor?”, 
only 90 (50%) managed by INPs and 73 (42.2%) managed by PGD users answered ‘yes’. In 
comparison, the analysis of patients’ clinical notes found 160 (89.1%) INPs and 127 (83.0%) PGD 
users’ medications were delivered to patient participants independently by the nurse. 
Nevertheless, 161 (96.4%) of the patients that were aware nurses delivered their medication 
independently ‘definitely’ had confidence in the nurse doing so, see Table 5-64. 
 
5.13.3 Satisfaction with Information about Medicine Scale 
Of the returned questionnaires, 348 (96.7%) fully or partially completed the SIMS section 
(INP=174, 96.7%; PGD=169, 97.7%; unknown=5, 71.4%). The summary of the SIMS results are 
shown in Table 5-65, detailed responses are presented in Appendix LL. 
 
Table 5-65 Summary of satisfaction with information on medicines scale categories 
SIMS category 
INP (n=174)* PGD (n=169)* Not known (n=5)* Total (n=348)* 
n % n % n % n % 
Total potential score 
(n*16) 
2784 100 2704 100 80 100 5568 100 
Too much (+0) 223 8.0 187 6.9 0 0 410 7.4 
About right (+1) 2062 74.1 1987 73.5 59 73.75 4108 73.8 
Too little (+0) 57 2.0 56 2.1 5 6.25 118 2.1 
None received (+0) 169 6.1 163 6.0 16 20 348 6.3 
Not applicable (+1) 241 8.7 285 10.5 0 0 526 9.4 
Missed (+0) 31 1.1 25 0.9 0 0 56 1.0 
*percentages based on the total potential scores, not the number of completed SIMS. INP= independent 
nurse prescribing, PGDs= patient group directions, SIMS= Satisfaction with Information about Medicines 
Scale, (+0) = no score, (+1) = score of 1 per patients reporting about right or not applicable to the question. 
The higher the score the higher the satisfaction (maximum score =16 per full response) 
 
Nurses consistently scored very highly throughout, demonstrating high levels of patient 
satisfaction with medication information, as summarised in Table 5-65. About right (n=4108, 
73.8%) and not applicable (n=526, 9.4%) were the highest scoring categories. From the ‘negative’ 
rated categories, nurses tended to provide ‘too much’ information (n=410, 7.4%), as opposed to 
not giving enough. Information components where patients were less satisfied related to: whether 
patients could drink alcohol while on treatment (positive score 251, negative score 95); whether 
the medication would make them feel drowsy (positive score 254, negative score 91); and what 
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they should do if they experienced side effects (positive scores 276, negative score 72). 
Nevertheless, these components still scored highly overall. 
 
There was no difference in patients’ satisfaction in relation to whether they were managed by 
INPs or PGD users (mean=13.3 vs. 13.5/16, respectively: t= -0.482, df= 341, p= 0.630: see Table 
5-66). Patients reported marginally less satisfaction with information on the ‘potential problems’ 
with medications (mean=6.4/8) than with information on action and usage of medicines 
(mean=7.0/8), but there was no statistical differences between INPs and PGD users for these 
groups.   
 











(INP vs PGD) 
SIMS potential score* 2784 2704 80 5568 Cronbach’s = 0.944 
t = -0.482, df = 341, 
p=0.630 
mean difference=-0.2 
(95% CI: -1.1 to 0.6) 
 
SIMS score achieved 2303 2272 59 4634 
SIMS mean score (/16) 13.3 13.5 11.8 13.4 
SIMS standard deviation 4.3 4.2 6.0 4.3 
AU total potential score 1392 1352 40 2784 Cronbach’s = 0.914  
t = -0.960, df 341, 
p=0.338 
mean difference=-0.2 
(95% CI: -0.7 to 0.2) 
 
AU score achieved 1196 1196 33 2425 
AU mean score (/8) 6.9 7.1 6.6 7.0 
AU standard deviation 2.2 2.0 2.2 2.1 
PPM total potential score 1392 1352 40 2784 Cronbach’s = 0.900  
t = -0.022, df 341, 
p=0.983 
mean difference=-0.0 
(95% CI: -0.5 to 0.5) 
 
PPM score achieved 1107 1076 26 2209 
PPM mean score (/8) 6.4 6.4 5.2 6.4 
PPM standard deviation 2.4 2.5 3.9 2.4 
*SIMS potential score is the highest score had every participant been completely satisfied with the 
medication information they received; SIMS: Satisfaction with Information about Medicines Scale, AU: Action 
and usage of medicines score; PPM: Potential problems of medicines score. INP =independent nurse 
prescribing, PGD= patient group directions, t= Independent Samples t Test, CI= confidence interval 







5.13.4 Content analysis of patients’ handwritten comments  
One-hundred and two patients (INP=59; PGD=43) left additional comments at the end of their 
questionnaires, some covering multiple topics, as presented in Table 5-67. Every comment left 
was positive. Service delivery (n=44), professional knowledge (n=32), nurses’ approachable 
nature (n=28) and their ability to put patients at ease (n=23) were valued by patient respondents. 
 








Great or excellent service/ positive experience of service  30 14 44 
Informative/ knowledgeable 20 12 32 
Pleasant/ friendly/ approachable 15 13 28 
Put at ease/ comfortable 11 12 23 
Polite/ lovely/ kind/ nice 17 5 22 
Very helpful 10 10 20 
Thank you 6 4 10 
Unrushed/ able to ask questions 4 6 10 
Confidence in practice/ safe 4 5 9 
Professional/ diplomatic 7 0 7 
Perfect/ 10/10 4 1 5 
Existing medication, no advice needed 3 2 5 
Non-judgemental 3 1 4 
Adequate/ OK/ satisfied 2 2 4 
Great doctor or consultant 3 0 3 
Answered all questions 3 0 3 
Cared for 2 0 2 











Use of alternative service delivery models has the potential to affect resource requirements and 
costs, as well as the processes and outcomes of care.  It may also impact on the job satisfaction 
and career progression opportunities of health professionals involved.  This section explores the 
economic implications of use of INP vs. PGDs for the delivery of medications in sexual health 
clinics from the perspectives of the NHS (provider of care) and of individual nurses.  It adopted a 
cost-consequences analysis (CCA) framework (Mauskoff et al., 1998) to compare INP and PGDs 
across various outcomes.  In this way, this section has synthesised findings from the across 
different components of this study.  
CCA was determined to be most suitable health economics evaluation methodology for this study 
because of the multiple influences, perspectives and potential effects associated with nurses’ 
delivery of medication. Whilst cost-effectiveness and cost-utility analyses are the more frequently 
advocated approaches to economic evaluation (Drummond et al., 2015), these focus on a single 
clinical or health-related quality of life outcome which is less appropriate in the context of a service 
delivery intervention (Sutton et al., 2018) such as the comparison of INP and PGDs.  CCA, on the 
other hand, supports the inclusion of non-health related factors, and processes of care. Outcomes 
of interest in the comparison of INP and PGDs included the appropriateness and safety of 
prescribing, impact on other health professionals in the team and the patient experience.  CCA 
presents a costs balance sheet alongside the consequences, providing a broader and more 
comprehensive perspective of considerations and outcomes from an intervention, compared to 
other health economics methods. Data are presented as non-aggregated information rather than 
an overall cost-effectiveness or cost-utility ratio (Mauskopf et al., 1998). Hence, organisations and 
individuals can review specific aspects of the same dataset to determine whether the issues under 
consideration are likely to be economically beneficial from their perspective. Although a largely 
descriptive approach, CCA provides a framework for generating a clear summary of the 
differences between INP and PGDs for all stakeholders. In line with other approaches, drawbacks 
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of CCAs include their limited generalisability outside the organisation(s) or specialities being 
investigated, and vulnerability to bias when deciding which aspects to include. 
The potential economic implications and consequences of INP vs. PGDs were identified at the 
outset to ensure relevant data were gathered throughout the study. Both INP and PGDs have 
benefits and barriers which ultimately affect resourcing, access of nurses to training, patient 
experience and service delivery. The main resource considerations from the perspective of the 
NHS and individual nurses are summarised in Table 5-68. These include, for the NHS, differences 
between INP and PGD in: set up/ staff training costs; medication prescribing; consultation 
duration; and impact on the workload of other professionals in the team.  From the nurses’ 
perspective, gaining an INP qualification, rather than using local PGD may involve: dedication of 
personal time to study and out-of-pocket expenses.  Consequences arising in the context of these 
resource considerations were: patient experience of care (satisfaction with information received 
and the consultation) and career prospects and job satisfaction of nurses. Data captured for each 
item was embedded in other aspects of the study. Where resources were implicated, costs were 
subsequently attributed as appropriate, and where a statistical difference was demonstrated 
between INP and PGDs and compared between both groups. Further details of data capture, 




Table 5-68 Components and data sources for cost-consequence analyses  












Higher Education Institutes fees 
Senior staff 
supervision time 
Apply unit costs of appropriate grade, according to time spent 
Study time & back fill 
Not applicable 
Time to write PGDs 
Committee approval 
time 




Costs of medications prescribed 
Review of clinic records BNF Costs of wrong / under / over prescribing 
Costs of inappropriate activity 
Consultation duration Nurse diaries  
Apply unit costs of appropriate grade, according to time spent 
Impact on workload of other professionals Nurse diaries, clinical records 
Unplanned repeat consultation for index 
condition 






Patient questionnaire Not quantified 





Personal study time and loss of leisure 
Staff interview & questionnaires 
Unit costs of appropriate grade 





Promotion prospects, lifetime earnings Estimated, discounted 
Subjective benefits, job satisfaction Not quantified 
INP= independent nurse prescriber, PGD= patient group direction, NHS= National Health Service, HEI= Higher Education Institute 
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5.14.2 Methods and costing 
 
This section presents how resource data were sourced throughout the study and subsequently 
attributed within the CCA to identify differences in costs between INP vs. PGDs from the 
perspective of the NHS and individual nurses.  
 
5.14.2.1 NHS perspective implications 
 
Implications of INP vs. PGD from the perspective of the NHS are considered in two categories, 
‘Training & governance’ and ‘Clinic processes’. The investment in both INP and PGDs is intended 
to improve clinical processes (i.e. more efficient delivery of medications to patients and reducing 
demands on doctor time for prescribing). The key consequences thus have ‘cost’ as well as 
‘experience’ implications, as under ‘clinic processes’ and ‘patient experience’. See Figure 5-4. 
 
 




























5.14.2.1.1 Training & governance 
Training and governance for INPs and PGDs have different resource implications for the NHS. 
Data relating to this were gathered through staff interviews (Section 5.2 and 5.3), questionnaires 
(Section 5.4 and 5.5) and documentary reviews (Section 5.6 through to 5.9). 
INP 
Nurses wishing to embark on INP training needed to be sponsored by their local service. The 
decision to train was instigated by local teams or individual nurses. The NMC (2015) detailed that 
HEIs must provide INP training at Degree level or above over a minimum of 26 days, with a further 
12 days (7.5 hours/day) of supervised clinical practice. The local NHS Trust provides a designated 
medical practitioner (DMP), who is expected to work with INP students in practice for the majority 
of these 12 days (which may have been alongside normal clinical activities) and provide support 
and guidance as required (NMC, 2015). Costs associated with INP training were applicable to 
individual nurses undertaking the training course. For some nurses who had previously used 
PGDs, the move to INP could involve incremental training costs.  
Mean university fees were calculated based on the response to staff questionnaires that asked 
when and where nurses studied for INP. Each named university was contacted (or their website 
visited) to determine the current fees applicable during data collection (i.e. 2015/16). Every 
participant that answered this question was used to calculate the mean HEI costs. The DMP and 
clinical support hours were calculated where questionnaire respondents completed a time entry 
alongside the level of support they received (missing answers not included). This method will not 
be truly accurate as it was based on nurses’ recall and self-reporting rather than accurate data 
recording. Moreover, it needs to be borne in mind that support provided by the DMP may have 
formed part of the DMP and/ or nurse’s normal clinical responsibilities/ roles; therefore, the entire 
DMP/ nurses’ time commitment may not have been additional work on top of normal duties. 
Staffing resources (dedicated DMP time) and study time were calculated based on hourly costing 
data from validated NHS unit costs for health and social care professionals, inclusive of all on-
costs and overheads 2016 (Curtis & Burns, 2016). Whether nurses’ roles were backfilled while 
undertaking training was not captured during data collection; however, this should be borne in 
mind as provision of study days meant clinical duties had to be covered by other staff members 





PGDs can be used by large numbers of nurses deemed locally competent. However, senior 
members of the NHS needed to invest considerable time and effort to obtain the required 
governance for PGD integration into practice. According to staff interviews and NICE (2013) this 
process involved creation, approval and implementation (see Figure 5-5). The time required to 
undertake this process will vary between authors, approval processes, governance restrictions, 
complexity of the drug / clinical management and availability of relevant stakeholders. During data 
collection the researcher’s department required a new PGD for the contraceptive implant to be 
written, and nine further individual contraception PGDs to be updated following clinical guideline 
updates from FRSH (2016). The researcher was tasked with doing this which provided an 
opportunity to assess the resource implications of undertaking the PGD governance process. The 
researcher kept a log of the time taken to write and update the PGDs. The relevant stakeholders 
who edited/ authorised the PGDs (including clinical leads and Non-medical Prescribing 
Committee members) were also asked to log the time taken to review and edit the documents. 
Cost of staff times were attributed to nationally validated unit costs for the relevant health 
professionals 2016 (Curtis & Burns, 2016). With regards to updating the PGDs, it should be noted 
that nine PGDs were presented as a suite (i.e. single document with all PGDs contained within it) 
rather than individually. Subsequently time updating PGDs was divided by nine to obtain an 
estimate for updating an individual PGD; however, had they been individual documents the 




Figure 5-5 PGD approval process 
 
5.14.2.1.2 Impact on clinic processes  
The impact on clinical processes and patient experience are presented in Box 5.4 
Box 5.4 Impact on clinical processes and patient experience: 
 
Clinic processes included: 
 Medications delivered 
 Provision of safe medication delivery that was considered therapeutically effective for the 
conditions being managed (i.e. avoidance of wrong, under or over prescribing).  
 Differences in consultation duration, after standardisation for differences in case load/ types of 
consultation. 
 Differences in autonomous practice and the associated workload of other professionals.  
o Frequency of professional support required and reason (i.e. clinical management or 
medication advice) 
o Differences in impact on workload of other professionals in routine practice (including 
time that professional needed to spend).  
 Differences in medical delivery appropriateness such that there are implications for costs of 
medications delivered or resource ramifications of inappropriate medications 
 Differences in unplanned repeat consultations for the index condition.  
 
Patient experience included: 
 Ability to provide a high-quality service where patients have a positive experience following 
consultation by an INP or PGD user.  




Data to explore clinic processes were accessed through a variety of methods (see Table 5-68). 
Medications delivered were sourced through the clinical notes review. It was predicted that both 
INPs and PGD users would be working with locally procured medication formularies based on 
222 
 
local and national policies; consequently, they were likely to have limited ability to deliver 
unnecessarily expensive medication regimens. Costing medication choices were based on the 
BNF (2016) prices; even though local services may have secured better rates with manufacturers. 
The extent of wrong, under or over prescribing was established through the expert record review, 
as described in Section 5.9. Inappropriate medication activity was costed using the BNF (2016) 
as above. Wrong and over prescribing was taken as an indication of wastage and the cost of 
‘wasted’ medication was estimated. For under-prescribing the medications that should have been 
prescribed were also estimated. The severity of prescribing errors, as presented in the clinical 
notes review, was also considered.   
Consultation durations were recorded through observation (Section 5.11) and clinical diaries 
(Section 5.7). While observations were accurately timed, they were less likely to reflect actual 
practice as patients were purposively selected (as opposed to being normal practice) as delivery 
of medication was expected within the consultation. Also, only a small number of participants 
were involved. The clinical diary provided more quantitative data based on nurses’ actual practice, 
although durations were based on estimates. Nevertheless, the diary was deemed likely to be 
more accurate for the purposes of costing consultation duration as it reflected actual practice. A 
mean consultation duration for INPs and PGD users was considered based on new, follow-up 
and overall consultations.  
The impact of nurse delivery of medications on the workloads of other health professionals was 
also quantified (e.g. nurses obtaining prescriptions or clinical advice from doctors). This was 
based on data from the clinical diary (Section 5.7.4). Participants were prompted to record: the 
frequency of professional support required; who they sought support from; and how long that 
professional spent supporting them. The mean duration of support from different professionals 
was calculated and costed using validated unit costs for the relevant professional group 2016 
(Curtis & Burns, 2016) to obtain an overall mean unit cost for professional support.  
Unplanned re-consultation rates for the index condition were used as measure of the 
effectiveness of the initial treatment received. The number of unnecessary re-consultations due 
to sub-standard practice was calculated and compared between INPs and PGD users. 
Differences between re-attendance as consequence of test results, patients experiencing 
unexpected symptoms or adverse events (e.g. medication side effects) or relapses likely 
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attributable to patients’ behaviour were counted but not analysed further for the purposes of cost 
as these were unlikely to have been influenced by whether the patient was manged by an INP or 
a PGD user.  
 
5.14.2.2 NHS patient outcomes 
 
The patient perspective was assessed in terms of their experience of their consultation and 
satisfaction with medicines information provided by INPs and PGD users. These data were 
collected from the patient experience questionnaires, see Section 5.13.  
 
5.14.2.3 Nurses’ private costs 
Nurses undertaking medication delivery training may incur loss of leisure time to study, and some 
out-of-pocket expenses for travel and purchase of materials. There may also be employer 
expectations to expand their practice. As the NHS is primarily funding the course fess and study 
leave, it is expected that individual nurses invest personal commitment and time to achieve 
qualifications that improve their professional confidence, job satisfaction and career prospects. 
These components were included in narrative form in this CCA. See Figure 5-6.  
 

























Information on each of these elements was collected through the staff interviews (Section 5.3) 
and questionnaires (section 5.5).  Loss of leisure time was calculated from the mean number of 
days respondents reported undertaking training in their personal time (mean did not include 
missing answers). The mid-point was taken where a range was provided. The cost was then 
calculated based on how much it would have cost the NHS to fund the nurse training in their 
personal time, using nationally validated unit costs 2016 (Curtis & Burns, 2016). Participants also 
reported a range of out-of-pocket expenses to complete training. Where values were reported by 
respondents, these were used to calculate the mean out-of-pocket expenses for INPs and PGD 
users which were then compared.  
 
Nurses’ private benefits  
The potential financial returns to investment in training was estimated by comparing the promotion 
pathways for INP and PGD nurses based on respondents’ current pay bands. Whilst a money 
value cannot be given to subjective benefits (e.g. job satisfaction) the opinions of INPs and PGD 
users from the staff questionnaires were considered in narrative form in this CCA.  
 
Synthesis 
The cost-consequences analysis (CCA) uses a balance sheet approach to present the range of 
costs and consequences, for the NHS, nurses and patients. Where possible costs and 
consequences are presented in quantitative form, otherwise a descriptive narrative is used. This 
provides a broader, more comprehensive perspective with inclusion of resource implications, 
costs, health and non-health related factors. The overriding purpose of the CCA was to compare 
INPs vs. PGDs as methods of medication delivery. The exploration of the costs and the returns 
aimed to determine the impact of the different medication delivery mechanisms on patient 
outcomes, clinic processes and costs to inform future service delivery decisions (Sutton et al., 
2018). Only components with a statistical significance or clear resource differences (e.g. training 
resources and governance were clearly different for INP vs. PGDs) were included in the final CCA 
synthesis.   
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5.15 Economic analysis: Findings 
 
5.15.1 NHS cost implications 
 
This section presents the findings from the NHS resource and cost implications associated with 
INP and PGDs’ ‘training’ and ‘clinic processes’. 
 
5.15.1.1 INP training resources 
Higher Education Institution course fees 
HEI fees were predominantly fully paid by employers or government health education grants 
(n=25/26, 96.2%), the remaining nurse partially self-funded. The staff questionnaires (Section 
5.5.2) indicated that 26 INPs used ten different HEIs for prescriber training; 19 (73%) respondents 
reported that they trained between 1995 and 2015. Module fees were available from seven out 
the ten HEIs in 2016 (year of data collection) which identified a mean cost of £1,695.25; however, 
a wide range was noted (£900 to £3,555). Fees varied based on the number of academic credits 
offered (i.e. 15, 30, 40 or 60), level of study (i.e. Degree or Masters) and geographical location of 
the university. See Table 5-69.  
 
Table 5-69 Higher education institution INP course fees 
Measure Cost during data collection 
Year(s) 2016 
Number of HEIs 7 
Range (£) £900 to £3,555 
Mean (£) £1,695.25 
Standard deviation 779.10 





Supervision time with DMP and other senior staff 
All 26 respondents to the staff questionnaire (Section 5.4) identified the grade of doctor who acted 
as their DMP (see Table 5-70). Based on the 23 (88.5%) respondents that reported duration of 
DMP supervised practice, it was determined that consultant doctors most frequently undertook 
the DMP role, providing a mean of 6.8 days (range 2 to 11). Consultants were the most expensive 
resource and, based on respondents in this study, cost the NHS a mean of £6,885.00 per student. 
However, five respondents reported that they spent the majority of clinical supervision with their 
consultant DMP (i.e. up to 12 days). Therefore, this potentially increased the DMP resource cost 
to £12,150 for each of these five students.  
While clinical supervision was predominantly provided by DMPs, some respondents (n=14, 
53.8%) reported additional support from other professional colleagues; 10 (71.4%) of whom 
provided the duration (see Table 5-70). Clinical supervision from nurse practitioners was the most 
frequently reported (n=4, 40.0%), aside from the DMP. Nurse practitioners were reported to have 
provided a mean of 1.9 days (range 1 to 3 days), costing £755.25. Based on the reported 
durations, inclusive of all professional colleagues that supported INP clinical supervision, a mean 
of 7.4 days (range 2 to 13.7) was provided, costing the NHS a weighted mean of £6,451.20 per 
INP student (range £1,282.50 to £11,137.50). It should, however, be borne in mind that the costs 
quoted are unlikely to be additional NHS expenditure as the majority of clinical support provided/ 










Table 5-70 Clinical supervision reported by INP respondents during training 
Participant 
(n=26) 
Designated Medical Practitioner (n=26) (7.5 hour days) Other supervision (n=14 from the 26 respondents)(7.5 hour days) Overall 
clinical 
supervision 











1 5   5      5 £5,062.50 
2 11   11      11 £11,137.50 
3 8   8      8 £8,100.00+ 
4 4.5   4.5    1.5 1.5 6 £5,253.75 
5 4.5   4.5      4.5 £4,556.25 
6 8   8      8 £8,100.00 
7 8   8      8 £8,100.00 
8 11   11      11 £11,137.50+ 
9   8 8      8 £3,540.00 
10   11 11      11 £4,867.50 
11 11   11      11 £11,137.50 
12 11   11      11 £11,137.50+ 
13 2   2 1.5    1.5 3.5 £3,465.00 
14 2   2      2 £2,025.00 
15   8 8      8 £3,540.00 
16 8   8  2.7 3  5.7 13.7 £10,487.25 
17   2 2   1  1 3 £1,282.50 
18  5  5      5 £4,800.00 
19 2   2      2 £2,025.00 
20 11   11      11 £11,137.50 
21 5   5  1 2 1 4 9 £6,765.00 





Designated Medical Practitioner (n=26) (7.5 hour days) Other supervision (n=14 from the 26 respondents)(7.5 hour days) Overall 
clinical 
supervision 











23 5   5      5 £5,062.50 
24    N/A      N/A N/A 
25    N/A     N/A N/A N/A 
26    N/A      N/A N/A 
Measure 














Mean 6.8 5.0 7.3 6.8 1.5 1.9 1.9 1.3 2.5 7.4 £6,451.20 
SD 3.3 0.0 3.8 3.3 0.0 1.2 0.9 0.4 1.9 3.3 3308.8 





£1,012.50 £960.00 £442.50 
£904.86 
(221.84) 




Mean cost £6,885.00 £4,800.00 £3,230.25 £6,153.05 £1,440.00 £840.75 £755.25 £604.50 £1,215.45 £6,391.45  
 = Support from professional group obtained, but no duration reported by participants. + = time on top of this entry, but no additional duration provided by respondent. N/A= unable to 
ascertain duration. *Missing durations entries (n=3/26) not included in this dataset. **Cost calculations: daily cost = [hourly cost] x7.5, mean costs= unit costs/day x total mean supervised 
days for each section.  Hourly costs: Cost of specialist training support was obtained from ‘Hospital-based health care staff’ in Curtis & Burns (2016); page 191 for doctors:  consultant 
doctor £135/hour; registrar £59/hour; associate specialist £128/hour. Page 188 for nurse practitioner band 7 nurse £53/hour; pharmacist Band 8 £62/hour (pharmacist was considered 
as Band 8 hospital nurse). ***where range given mid-point used: 0 to 3 was considered 2 days; 10 or over considered 11 days (full DMP supervision is 12 days; this range considered 
as 10-12). Overall supervision includes DMP time and additional supervision so overall range increases (however, these costs may be over-inflated as supervision was likely provided 
as part of clinicians’ normal clinical roles) ****Total and total costs are weighted based on full data set (i.e. not a mean of means). SD= standard deviation. ^cost per nurse calculated 
from unit daily costs of DMP + other supervision. 
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Study time & backfill 
Twenty-four staff questionnaire respondents (seven ‘Band 6’, twelve ‘Band 7’ and five ‘Band 8’: 
section 5.5.2.1) identified a mean of 20.1 NHS provided study days to complete the INP training 
course, range 1 to 31 days. Based on all respondents’ nursing bands, each study day cost the 
NHS a weighted mean of £394.50 per nurse/day. Considering all respondents’ nursing bands, 
their associated daily rate (£330-£465.50) and the number of study days reported, it cost the NHS 
an additional weighted mean of £7,929.45 per nurse in study leave. Moreover, this weighted mean 
increased to £10,257 per nurse had the full 26 days HEI allocation been given (i.e. £394.50 x 26), 
which 12 (63.2%) respondents reported. See Table 5-71. Higher bands reported receiving more 
study days than more junior ones; however, it should be borne in mind respondents may not have 
been this band at the time they undertook the training. Moreover, these findings are specific to 
this cohort of respondents. Costs relevant to the range of study days provided per band are 
presented in Table 5-71.    
 






























n 26 26 0 130 











£7,929.45 n/a £192,537.50 
*Day cost= hourly costx7.5.  Costs were based on from ‘Hospital-based health care staff’ in Curtis & Burns 
(2016); page 188 for Band 5 nurse £35/hour, Band 6 nurse £44/hour, Band 7 £53/hour, Band 8 nurse 
£62/hour **All means calculated from full relevant dataset (i.e. not based on mean of means).  INP= 
independent nurse prescriber, SD= standard deviation 
 
Data on whether backfill was required to cover INPs while on study leave was not recorded; 
however, it is likely that at least some clinical services would require additional cover. It needs to 
be borne in mind that backfill could have been provided at lower or higher cost than the nurse on 
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study leave (e.g. junior nurse vs. doctor), but may not have been necessary for the entire period 
of absence. 
 
5.15.1.2 PGD resources 
This section sets out the resources with regards to the: time to write PGDs; committee time to 
approve PGDs; and training reported by nurses for them to use PGDs.  
Time to write PGDs 
Based on the approximate time in the researcher’s log for writing, reviewing and obtaining 
departmental approval for a new contraceptive implant PGD, it took 7.8 hours. Using a similar 
process, the approximate duration to update a suite of nine PGDs averaged 1.7 hours per PGD. 
In each case this involved the researcher writing/ amending each PGD. In addition a consultant 
doctor and two band 8 nurses reviewed each document, provided feedback and approved each 
PGD from the department’s perspective, as summarised in Table 5-72. Applying appropriate unit 
costs resulted in a total cost of £535.80 to write a PGD, ready for approval by the wider Directorate 
and Non-medical Prescribing Committee. Using a similar approach the cost to update each 
individual PGD was £106.50 (Table 5-72).  
 
Table 5-72 Time to write PGDs based on staff resource log 
Resource 
Write PGD Update PGD* 
Hours** Cost** Hours** Cost** 
Primary PGD author (Band 8 nurse/ researcher) 5.1 £316.20 1.3 £80.60 
Consultant doctor 0.8 £108.00 0.1 £13.50 
Combined resource from department’s Band 8 team (2x 
nurses) 
1.8 £111.60 0.2 £12.40 
Total 7.8 £535.80 1.7 £106.50 
*The total time to update a suite of nine PGDs was divided by nine to give an approximate time to update 
each individual PGD. **Duration to write PGDs were approximations based on the researcher’s log. Costs 
were based on from ‘Hospital-based health care staff’ in Curtis & Burns (2016); page 188 for Band 8 nurse 
£62/hour (and pharmacist was considered as Band 8 hospital nurse), page 191 for doctors £135/hour. PGD= 






Committee time to approve 
Following local departmental approval, PGDs required Trust approval, initially from the 
Directorate leads, then the Non-medical Prescribing Committee. Durations in this section were 
based on individuals detailing how long it took them or estimations. It was determined to take 
approximately 30 minutes to review a new PGD and 15 minutes for an updated one (as the same 
staff had previously approved existing PGDs). Consequently, a new PGD took 5.0 hours for 
Directorate approval, and an updated one took 2.3 hours. The Directorate approval process 
involved a Band 8 pharmacist, Band 9 nurse and a consultant doctor. The Non-medical 
Prescribing Committee involved seven Band 8 nurses. The approval duration for each member is 
summarised in Table 5-73. Applying appropriate unit costs resulted in a total cost of £376.50 for 
Trust approval of a new PGD, and £169.20 to update a PGD. 
It should be borne in mind that that these case studies of PGD development and updating maybe 
be under-estimates, as it was an experienced team who were also members of the Non-medical 
Prescribing Committee, so were aware of the pitfalls that stop PGDs being approved. Secondly, 
these PGDs only contained contraception. Had the PGDs included antibiotics it would have 
required additional committee approval (i.e. Antibiotic Resistance Committee). Therefore, the 
durations and costings for creating and approving PGDs cannot be deemed accurate for all 
approval processes.  
 
Table 5-73 Committee time to approve PGDs 
Resources 
New PGD Update PGD* 
Hours** Cost** Hours** Cost** 
Lead pharmacist (Band 8) 0.5 £31.00 0.2 £12.40 
Lead directorate nurse (Band 9) 0.5 £61.00 0.2 £24.40 
Lead directorate clinician (consultant doctor) 0.5 £67.50 0.2 £27.00 
Non-medical prescribing committee (x7 Band 8 nurses) 3.5 £217.00 1.7 £105.40 
Total 5.0 £376.50 2.3 £169.20 
*The total time to update a suite of nine PGDs was divided by nine to give an approximate time to update 
each individual PGD. **Duration to write PGDs were approximations based on the researcher’s log or 
estimations. Costs were based on from ‘Hospital-based health care staff’ in Curtis & Burns (2016); page 188 
for Band 8 nurse £62/hour (and pharmacist was considered as Band 8 hospital nurse) and Band 9 nurse 





Time for local training of nurse 
Twenty-nine/35 (82.9%) PGD user respondents in the staff questionnaire (Section 5.4) reported 
a high level of variability with regards to how they were trained to become competent to use PGDs. 
Table 5-74 demonstrates the range of training methods reported. The most frequent method was 
classroom with a range of 1 to 30 students for a mean duration of 5.2 hours (however, this 
included two respondents reporting a full contraception HEI module where PGDs were only one 
section of the wider syllabus). One-to-one training was reported by 11 respondents, which was 
regarded as the most resource intensive method. However, self-directed learning was undertaken 
by 20 and e-learning by 10, which was cheaper, but it is not clear whether this was completed 
during work or personal time.  
The high degree of variability in such a small sample led to skewed data on training duration. 
Based on all recorded responses (n=29), each PGD user spent a mean of 5.1 (SD 6.5) training 
hours (median and mode of 2.0 training hours). Whilst there is no requirement for the NHS to 
provide study days for PGD training, 30 respondents identified a mean of 0.9 NHS study days 
(6.4 study hours, range 0 to 85.2 hours); however, 16 (53.3%) were given no study time. The 
inclusion of the contraception university module skewed the mean study leave to be higher than 
mean training; however, the university module did facilitate supply of contraception through 
PGDs. Considering all respondents’ nursing bands, their associated hourly rate (£35-£53/hr) and 
the number of study hours reported, it cost the NHS a mean of £332.25 per day/ nurse for PGD 
training, which pro-rata (6.4 hours*£44.30/hr) was £283.52 per nurse. Table 5-75 provides 
additional data on NHS provided study leave for PGD training. Similar to INPs, more senior PGD 
users were given a larger amount of study leave compared to more junior bands. It should, 
however, be borne in mind that these senior respondents were more likely to have been involved 
in the initial implementation of INP and PGDs into clinical practice when they were in more junior 
roles and when these extended clinical skills were in their infancy. Now INP and PGD governance 
has become fully integrated within services, and NHS resources have become more restricted, 
the amount of study leave offered to those new INP and PGDs appears to be reducing.  
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Table 5-74 Formal PGD training resources 
Category of PGD training 
reported* 
Responses from formal 
PGD teaching (n=29) 









n % n  % n % 
Class teaching 23 79.3 14 60.9 1 to 30 10.9 7.8 14 60.9 0.5 to 30 5.2 8.6 
Question & answer 20 69.0 7 35.0 1 to 15 9.1 4.7 5 25.0 0.5 to 8 2.7 3.0 
Workshops 6 20.7 3 50.0 5 to 12.5 8.5 3.8 2 33.3 1 to 2 1.5 0.7 
Self-directed learning 20 69.0           7 35.0 2.5 to 15 6.9 5.1 
e-learning 10 34.5           4 40.0 1 to 5 2.1 1.9 
One-to-one training 11 37.9           4 36.4 1 to 20 7.0 8.8 
*Respondents may have had multiple methods of PGD training. Calculations based on completed entries in the staff questionnaires; mid-points used when a range given. Skewed results 
as a large amount of training involved lone training or classroom teaching with multiple students (i.e. e-learning 10 respondents reported lone personal training, whereas two respondents 
detailed classroom teaching with 30 students undertaking a contraception course which involved PGDs as one part of a larger syllabus). Interquartile range not used due to small sample 









Study hours (hours) 
Measure Range Mean* SD Median Mode Total 
5 4 £35/hr 
n 0 to 15 4.3 7.2 1 0 17 
£ £0 to £525 £150.50 £252.00 £35.00 £0.00 £595.00 
6 21 £44/hr 
n 0 to 11.3 2.1 2.9 0 0 44.3 
£ £0 to £497.20 £92.40 £127.60 £0.00 £0.00 £1949.20 
7 5 £53/hr 
n 0 to 85.2 26 38.4 0 0 130.2 
£ £0 to £4,515.60 £1,378.00 £2,035.20 £0.00 £0.00 £6,900.60 
All reported** 30 £44.30/hr 
n 0 to 85.2 6.4 17.2 0 0 191.5 
£ £0 to £3,774.36 £283.52 £761.96 £0.00 £0.00 £8,483.45 
* Costs were based on from ‘Hospital-based health care staff’ in Curtis & Burns (2016); page 188 for Band 5 nurse £35/hour, Band 6 nurse £44/hour, Band 7 £53/hour. This includes 
data from a university contraception training module that was not specific to PGDs, but did facilitate delivery of contraception through PGDs. **All results calculated and weighted from 
full relevant dataset (i.e. not based on mean of means).  PGD= patient group direction, SD= standard deviation. 
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5.15.1.3 Clinic processes 
Costs of medications prescribed 
The total cost for medication regimens delivered in the clinical notes review (see Section 5.9.6) 
across six months (01/07/2015 to 31/12/2015) was £20,053.67, based on the BNF (2016) prices. 
Some nurses managed HIV medication regimens. Given the high drug costs associated for 
managing HIV (£6,726.53), Table 5-76 presents the regimen costs both with and without HIV 
drugs. Without HIV medications the mean cost per patient was £9.82 (INP= £10.45; PGD= £9.29). 
However, these costs were not standardised for the potential differences between INPs and PGD 
users’ caseloads. 
  
Table 5-76 Medication regime costs 
Total drug costs over 6 months INP (n=620) PGD (n=737) Total (n=1357) 
Total inc. HIV drugs (£) £11,741.66 £8,312.01 £20,053.67 
Mean cost per drug (£) £18.94 £11.28 £14.78 
HIV drug costs (£) £5,264.79 £1,461.74 £6,726.53 
Total exc. HIV drugs (£) £6,476.87 £6,850.27 £13,327.14 
Mean cost per drug (£) £10.45 £9.29 £9.82 
INP= independent nurse prescribers, PGD= patient group direction, n= number of individual drugs delivered 
 
Costs of wrong/ over/ under prescribing 
Overall, the expert clinical record review (Section 5.9.10) revealed that in the majority of instances 
INPs and PGD users provided appropriate medication regimens. However, there was a small 
number of instances where drugs were wrongly or over ‘prescribed’. The cost of these medication 
regimens were estimated to give total wastage cost. The cost of the drugs that should have been 
prescribed were estimated for under-‘prescribing’, however, were not considered as a saving as 
patients may have needed to re-attend creating additional workload and poor patient experience. 
These sums are very small in comparison to overall drug expenditure and were similar between 





Table 5-77 Costs of wrong/ under/ over prescribing 
Costs of wrong/ under/ over 
prescribing 
INP (n=620) PGD (n=737) 
n % Cost n % Cost 
Wrong prescribing (wasted) 12 1.9 £102.87 19 2.6 £103.72 
Over-prescribing (wasted) 12 1.9 £77.41 16 2.2 £48.02 
Under-prescribing 25 4.0 £144.03 19 2.6 £137.46 
INP= independent nurse prescribers, PGD= patient group direction, n= number of individual drugs 
 
Inappropriate medication delivery based on prescribing error severity (excluding wrong/ under/ 
over prescribing) found that any differences between INPs vs. PGDs were based on 
documentation quality as opposed to known harm to patients (Table 5-78). Therefore, there was 




Table 5-78 Summary of inappropriate activity 
Type of inappropriate medication delivery  
INP (n=879) PGD (n=965) 
Minor error Moderate Severe error Minor error Moderate Severe error 
n % n % n % n % n % n % 
Considerations of drug interactions not documented 0 0.0 2 0.2 1 0.1 1 0.1 6 0.6 0 0.0 
Inappropriate use of PGDs 0 0.0 0 0.0 0 0.0 34 3.5 29 3.0 0 0.0 
Medication risk assessment 10 1.1 67 7.6 0 0.0 35 3.6 115 11.9 2 0.2 
Prescription documentation omission 458 52.1 292 33.2 0 0.0 514 53.3 175 18.1 0 0.0 
TOTAL 489 55.6 388 44.1 2 0.2 602 62.4 361 37.4 2 0.2 








As presented in Section 5.7.3, despite an overall statistical difference being found in consultation 
duration between INPs vs. PGD users in the clinical diary (mean of 24.9 vs. 22.8 minutes, 
respectively, p=0.010), when adjusted for type of presentation (i.e. new vs. follow-up) there were 
no statistical differences found (i.e. new: 27.3 vs. 25.7 minutes, respectively, p=0.152). 
Consequently, cost analyses were not considered further.  
 
Impact on workload of other professionals 
Findings from the clinical diary (Section 5.7.4) demonstrated that when professional support was 
required, colleagues spent more time supporting INPs compared to PGD users (11.0 vs. 8.2 
minutes, respectively); however, INPs required professional support less frequently than PGD 
users (12.9% vs. 25.6%, respectively, p<0.001). Both INPs and PGD users predominantly sought 
support from doctors (80.7% vs. 85.4%, respectively). Based on the weighted mean duration that 
the relevant professional groups provided support in the clinical diary, and cost data sourced from 
Curtis & Burns (2016), it was determined that it cost the NHS £10.41 per unit of professional 






Table 5-79 Impact on workload for other professionals’ support 
Clinical diary: Impact on workload of other 
professionals 
INP PGD 
n % n % 
Consultations where professional support sought 
(includes advice and prescriptions) 
95/737 12.9 152/593 25.6 
Statistical testing (diary) 
2= 35.281, df= 1, p<0.001 
Consultations with professional's time recorded 63/95 66.3 87/152 57.2 
Range (minutes) 1 to 47 2 to 45 
Mean (SD) (minutes) 11.0 (11.7) 8.2 (6.9) 
Professional groups that provided support 
(where data recorded): Frequency of support 
INP (n=88) PGD (n=164) 
n % n % 
Doctor 71 80.7 140 85.4 
Nurse 5 5.7 16 9.8 
Pharmacist 8 9.1 4 2.4 
Health adviser 4 4.5 4 2.4 
Estimated time & cost with each professional* Minutes Cost (£) Minutes Cost (£) 
Doctor (Consultant: £135/hour; £2.25/minute) 369.6 £831.60 640.5 £1,441.13 
Nurse (Band 7: £53/hour; £0.88/minute) 26.1 £22.97 73.5 £64.68 
Pharmacist (Band 8A: £62/hour; £1.03/minute) 41.7 £42.95 18 £18.54 
Health adviser (Band 7: £53/hour; £0.88/minute) 20.6 £18.13 18 £15.84 
Total weighted cost for professional support £915.65 £1,540.19 
Unit cost of professional support (based on mean) £10.41 £9.39 
*Estimated time & cost calculated based on percentage of occasions a professional group’s advice was 
sought from the ‘total time for support’ (e.g. Doctor’s advice sought 80.7% of occasions; 80.7% of 458 
minutes is 369.6minutes). Costs obtained from ‘Hospital-based health care staff’ in Curtis & Burns (2016); 
page 191 for doctors:  consultant doctor £135/hour; page 188 for nurse practitioner (& health adviser) band 
7 nurse £53/hour; pharmacist Band 8 £62/hour (pharmacist was considered as Band 8 hospital nurse).Unit 
cost for support calculated: Total weighted cost / number of occurrences where time data was recorded (e.g. 
INP: £915.65/88= £10.41). INP= independent nurse prescriber, PGD= patient group direction.  
 
Unplanned repeat consultation for index condition 
Based on the clinical notes review (Section 5.9.13) 18.2% (n=306/1,682; INP= 145/743, 19.5%; 
PGD= 161/939, 17.1%) of patients returned in relation to their index condition, involving 400 
reasons (INP=200; PGD= 200). The main reason was related to diagnostic laboratory tests being 
positive, which could not have been known at initial presentation. See Table 5-80. There were no 
indications that unplanned re-attendance was as a result of sub-standard care by either INPs or 
PGD users. Moreover, there were no statistical differences found between INPs vs. PGD users 
with regards to unplanned re-attendances, therefore, no costing analyses were made.  
It was noted that patients being managed by an INP were statistically more likely not to attend 
planned follow-up appointments compared with PGD users (7.0% vs. 2.0%, respectively). 
However, this is unlikely to have been associated to whether they were managed by an INP or a 
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PGD user, but it does demonstrate potential difference in wastage of follow-up appointments. 
Based on previously presented weighted daily cost calculations for INPs (Table 5-71) and PGD 
users (Table 5-75) in this study, and follow-up consultations taking INPs a mean of 19.6 minutes 
and PGD users 20.0 minutes (Section 5.7.3) this resulted in a cost difference of £182.27 between 
the groups in potentially wasted staff time. This does not include on-costs, resources or recall 
attempts, nurses are likely to have undertaken other duties when patients failed to attend. See 
Table 5-80. 
 
Table 5-80 Staffing resources for unexpected return for the index condition 




n % n % 
Clinical/ diagnostic issue that was not known at initial visit* 99 49.5 101 50.5 
Symptomatic or adverse issues that became apparent after initial visit * 59 29.5 56 28.0 
Behavioural or processing issue which potentially could have been avoided 
(patients’ behaviour was large component)* 
28 14.0 39 19.5 
Unexpected non-attendance to follow-up (did not attend) 14 7.0 4 2.0 
Potentially wasted staffing costs (excludes resource, recall, on-costs)** £241.47 £59.20 
*No statistical differences, costing analysis not undertaken. **statistical difference noted in did not attend 
(p=0.003, Section 5.9.13). Costs for wasted staff time calculated based on weighted daily cost for INP 
£394.50 (£52.60/hr; £0.88/minute) (Table 5-71) and PGD daily cost of £332.25 (£44.30/hr; £0.74/minute) 
(Table 5-75). Follow-up times based on mean of 19.6 minutes for INP, 20.0 minutes for PGD users from 
clinical diary (Section 5.7.3). INP= independent nurse prescriber, PGD= patient group direction.  
 
 
5.15.2 NHS patient outcomes 
Patient experience: consultation experience 
As presented throughout Section 5.13 there was no statistical difference in patients’ experience 
of medication consultation or satisfaction with information about medicines between INPs vs. 
PGD users.  
 
5.15.3 Nurses’ private costs 
Personal study time and loss of leisure 
Twenty-one INP respondents to the staff questionnaire (Section 5.5) reported spending an 
additional mean of 26.3 ‘days’ (i.e. 7.5 personal study hours per day), range 8 to 60 days, of their 
own personal time undertaking INP training. By comparison, 26 PGD users reported spending 
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1.6 ‘days’ of their own personal time undertaking training, but most respondents did not undertake 
any PGD training in their personal time (mode: 0 days).  Undertaking studying in personal time 
impacts on leisure time, and could be regarded as saving to the NHS as this time is unlikely to be 
recompensed. It should, however, be borne in mind that the NHS is funding the course fees and 
supporting university study leave, as such some personal commitment is expected from individual 
nurses for continuing personal and professional development for their own academic and 
professional career development. Associated costs were based on previously presented weighted 
daily cost calculations for INPs (Table 5-71) and PGD users (Table 5-75) in this study. This 
equated to saving the NHS a mean of £10,375.35 per nurse had the NHS paid all for all INPs’ 
training requirements. PGD users undertaking training in their personal time saved the NHS 
£531.60 per nurse. See Table 5-81. 
Table 5-81 Nurses' personal study time & loss of leisure 
Loss of personal time  
(7.5-hour days) 
Self-study days 
INP (n=21) PGD (n=26) 
Range 8 to 60 0 to 10 
Mean days (standard deviation) 26.3 (13.9) 1.6 (2.8) 
Daily cost per nurse* £394.50 £332.25 
Mean personal study costs £10,375.35 £531.60 
Mode (days) 30 0 
Mode personal study costs £11,835.00 £0.00 
*Costs for staff personal time calculated to determine how much it would cost the NHS to have paid for their 
time. These were based weighted daily cost for INP £394.50 (Table 5-71) and PGD daily cost of £332.25 
(Table 5-75). INP= independent nurse prescribing, PGD= patient group direction 
 
Out-of-pocket expenses 
Respondents in the staff questionnaire detailed additional out-of-pockets expenses they incurred 
to complete training. Predominantly across both INPs and PGD users there were no additional 
personal expenses reported. However, when expenses were incurred this was most frequently 
attributed to purchasing books (mean INP= £53.33; PGD= £5.00). Overall, INPs reported 
spending a mean of £32.02, compared to £1.49 by PGD users. These costs were not reimbursed 
by employers. See Table 5-82. However, one INP reported having travel, accommodation and 
childcare expenses as their university was situated in another city. Considering their expenses, 
this increased INPs’ mean out-of-pocket expenses to £40.19, but as this specific respondent had 
£200.00 travelling expenses reimbursed, the mean reimbursement for INPs was £8.33. 
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Table 5-82 Out-of-pocket expenses 
Out-of-pocket 
expenses  
INP (n=26)* PGD (n=35) 
Responses 




Range Mean (SD) 
Mode 
(frequency) n % n % 
Books 22 84.6 £0 to £250 £53.33 (60.50) £0 (x6) 19 54.3 £0 to £40  £5.00 (11.36) £0 (x16) 
Additional travel 14 53.8 £0 to £150 £47.57 (47.55) £0 (x3) 20 57.1 £0 to £3 £0.15 (0.67) £0 (x19) 
Stationary 17 65.4 £0 to £80 £19.26 (18.45) £20 (x5) 21 60.0 £0 to £5 £0.71 (1.79) £0 (x18) 
Accommodation 14 53.8 £0 £0 (0) £0 (x14) 18 51.4 £0 £0 (0) £0 (x18) 
OVERALL  67   £0 to £250 £32.02 (46.09) £0 (x24) 78   £0 to £40 £1.49 (6.05) £0 (x71) 
*One INP respondent reported that their university was a considerable distance from their home, this required additional travel, accommodation and child care costs, some of which were 
refunded. As an outlier this was excluded from main analysis; however, their additional £400 expenses increased the overall mean cost of INP training from £32.02 to £40.19 (SD=61.70), 






5.15.4 Nurses’ private benefits  
 
Promotion prospects, lifetime earnings 
The staff questionnaire (Section 5.5.2) highlighted that INPs (band 7= 13, 50.0%) were employed 
at higher bands compared to PGD users (band 6= 24, 68.6%). Based on respondents banding 
and unit costs for hospital nurses’ salaries (Burns & Curtis, 2016) there was a difference of 
£5,519.42 in the annual salaries between INPs and PGD user respondents in this study (see 
Table 5-83). These differences have the potential to be compounded over the working lives of the 
respondents.  
 
Table 5-83 Mean salary differences between INPs and PGD users 
Mean salary difference* 
INP (n=26) PGD (n=35) 
n % n % 
Band 5 £25,902 0 0.0 5 14.3 
Band 6 £32,114 8 30.8 24 68.6 
Band 7 £38,550 13 50.0 6 17.1 
Band 8A £45,204 5 19.2 0 0.0 
Overall weighted mean salary (SD) £37,849.31 (4,647.54) £32,329.89 (3,596.76) 
Difference in mean salary £5,519.42 
*Salaries calculated based on responses to current band in the staff questionnaire and the annual nursing 
salaries presented in ‘Hospital-based health care staff’ in Curtis & Burns (2016), page 188. INP= independent 
nurse prescribing, PGD= patient group directions, SD= standard deviation.   
 
Subjective benefits, job satisfaction  
INPs and PGD users provided very similar responses to subjective benefits and job satisfaction 




Table 5-84 Costing subjective benefits, job satisfaction to INP and PGDs 
Staff responses to subjective benefits of INP/ PGDs 
INP PGD 
Positive Neutral/ negative Positive Neutral/ negative 
n % n  % n % n  % 
Impacted on respondents' clinical practice 72 92.3 3 3.8 97 92.4 5 4.8 
Influenced patient experience  24 92.3 1 3.8 35 100 0 0.0 
Affected respondents' personal confidence and satisfaction in practice  68 87.2 7 9.0 90 85.7 14 13.3 
How training and continuing professional development prepared respondents 38 73.1 12 23.1 53 75.7 17 24.3 
Whether respondents felt INP/PGDs were worthwhile interventions 46 88.5 4 7.7 64 91.4 6 8.6 







As the study progressed it became apparent that INPs and PGD users where highly comparable 
in a number of areas: safe and therapeutically appropriate delivery of medications; range of 
medications used, and diagnoses managed; unplanned repeat consultation for index condition; 
similar consultation lengths; professional experience; and provision of high quality care with high 
levels of patient satisfaction. Consequently, there would be minimal implications related to cost 
differences between these components. Therefore, the CCA balance sheet focussed specifically 
on aspects where statistical differences were found between INP vs. PGD users (see Table 5-85). 
The clear, but not unexpected, difference was related to the resource implications for training and 
governance. It should, however, be borne in mind that the significant costs for each individual INP 
trained are a single cost that can be discounted over several years following qualification. 
Whereas, the PGD costs are recurring for each individual PGD every three years, but PGDs have 
the benefit of being used by multiple staff members. Consequently, the more frequently INPs and 
PGD users use their medication delivery skills in clinical practice, the overall mean cost per patient 
will reduce. 
When considering implementation of INP and PGDs, the CCA balance sheet can show the range 
of costs and consequences to different stakeholders. A worked example on the training 
implications is presented in Table 5-86.  This demonstrates that although the mean cost to train 
an INP was £16,075.90, the actual cost could range from £900 to £27,808. The only fixed INP 
training cost was the university module. The subsequent allocation of DMPs’ clinical supervision 
and number of study days provided are then decided locally between departmental stakeholders 
and individual nurses. However, as staff questionnaire respondents reported that the time spent 
with their DMPs was less than those expected of the NMC (2015), and nurses were likely to be 
autonomously managing patients during their DMP clinical supervision (as opposed to DMPs 
providing the entire supervision as dedicated training), these INP training costs may be 
overestimated. Whereas, in comparison to INP training, PGD creation, approval and training 
appeared to have relatively modest costs (Table 5-85). However, the PGD costs accumulated 
rapidly when applied to practical situations (Table 5-86). Across the five research sites a mean of 
20.4 PGDs were in place (range 11 to 37, see Appendix GG) which were used by 13.4 nurses 
per site (range 8 to 18, see Section 4.8). Consequently, PGDs cost £17,998.92 to integrate, then 
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a further £3,799.17 for local internal training. Moreover, a three yearly recurring cost of £5,624.28 
was required to maintain PGDs’ governance. A further consideration with PGDs relates to the 
number of different drugs PGD users delivered in the clinical notes review (n=51). Creating a 
PGD for every drug required would increase PGD creation and approval costs to £44,997.30, with 
a three-yearly recurring cost of £14,060.70.  
From the individual nurses’ perspective, the primary difference between INP vs. PGDs was INPs 
undertook a significant amount of study in their personal time, which was not reported to the same 
level by PGD users. However, INPs were found to work at higher salary bands compared to PGD 
users but this cannot be solely attributed to being able to prescribe. Nevertheless, individual 
nurses can consider whether their personal time investment in continuing personal and 





Table 5-85 Cost consequence analysis balance sheet 





Higher Education Institute course (per nurse) £1,695.25 £0.00 £1,695.25 Required for each individual INP student 
Senior staff supervision time (per nurse) £6,451.20 £0.00 £6,451.20 
If part of routine clinical duties costs may be 
significantly less than what are cited 
NHS study leave (per nurse) £7,929.45 £283.52 £7,645.93 
Not including backfill. Staff study leave may 
differ depending on amount locally allocated. 
Write each individual PGD £0.00 £535.80 £535.80 
Required for each PGD initially, but supports 
multiple staff to deliver medications. 
Update each individual PGD £0.00 £106.50 £106.50 
Each individual PGD is reviewed and updated 
on a 3 yearly cycle. Benefits multiple staff to 
deliver medications. 
Committee approval time for each new individual 
PGD 
£0.00 £346.50 £346.50 
Required for each PGD initially, but supports 
multiple staff to deliver medications. 
Committee approval time for updating each 
individual PGD 
£0.00 £169.20 £169.20 
Each individual PGD is reviewed and updated 




Costs of medications prescribed/ patient N/A N/A N/A 
No statistical difference in therapeutically 
appropriate medication 
Costs of wrong / under / over prescribing N/A N/A N/A No statistical difference 
Costs of inappropriate activity N/A N/A N/A No statistical difference 
Consultation duration N/A N/A N/A No statistical difference 
Impact on workload of other professionals £10.41 £9.39 £1.02 
Unit cost of professional colleague per episode 
of support 
Unplanned repeat consultation for index condition N/A N/A N/A No statistical difference 
Unexpected non-attendance to follow-up N/A N/A N/A 
Difference not likely to be attributed to whether 





Consultation experience N/A N/A N/A No statistical difference 




Personal study time and loss of leisure £10,375.35 £531.60 £9,843.75 
Mean weighted cost of staff time had they been 
paid for studying in their own time per nurse (i.e. 
potential saving to the NHS).  
Out-of-pocket expenses, e.g. travel, materials £32.02 £1.49 £30.53 Mean cost per nurse 
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Promotion prospects, lifetime earnings £37,849.31 £32,329.89 £5,519.42 
Salary difference/ year based on weighted 
bands and NHS salary costs from Curtis & 
Burns (2016); i.e. not the salary actually 
received by nurses. This difference cannot be 
solely attributed nurses being able to prescribe 
or use PGDs 
Subjective benefits, job satisfaction N/A N/A N/A No statistical difference 
INP= independent nurse prescribing, PGD= patient group directions; NHS= National Health Service, N/A= not applicable 
 
Table 5-86 Application of costs and consequences analysis balance sheet to compare training and governance 
INP/ 
PGD 
Resource Requirement Mean Range Total mean cost Total cost range 
INP 
University fees Mandatory university module £1,695.25 £900 to £3,555 
£16,075.90  
(per nurse) 
£900 to £27,808^ 
(per nurse) 
NHS study days Locally determined (0-26 days) £6,451.20 £0 to £12,103 
Clinical supervision 
Locally determined (12 clinically 
supervised days expected)* 
£7,929.45 £0 to £12,150 
PGD 
Write & approve a PGD** 
Number locally determined n=20.4 n=11 to 37 
£17,998.92 
(per site) 
£9,705.30 to £32,645.10 
(per site) 
Update a PGD*** 
£5,624.28 
(per site) 
£2,834.70 to £9,534.90 
(per site) 
Local training**** 
Local training required, can be one-
to-one or large groups 
n=13.4 n=8 to 18 
£3,799.17 
(per site) 
£2,268.16 to £5,103.36 
(per site) 
*12 clinical days expected, but this can be alongside normal clinical duties, as well as one-to-one additional training/ supervision. **For unit costs see Table 5-85: writing a PGD and 
committee approval time unit cost: £882.30 (£535.80 + £346.50). ***updating a PGD and committee approval time unit cost: £257.70 (£106.50 + 169.20), required every three years. 
****unit cost of PGD training £283.52 per nurse, number of PGD nurses at all sites=67. ^£27,808 total cost is based on a Band 8 nurse undertaking the most expensive university course, 









This chapter presents the overall contribution to knowledge, before discussing the study’s findings 
under each of the research objectives. Each objective is subcategorised, as presented in Box 6.1. 
Table 4.1 on page 85 presents an overview of the data used to address each objective. Each 
category is then discussed individually. The study’s limitations, practice implications are then 
discussed before concluding with recommendations for future research, and the overall 
conclusion on how INP and PGDs compare in sexual health.  
Box 6.1 Study objectives & categories  
1. Determine the extent to which nurses’ professional experience and scope of practice 
affect prescribing practice or PGD use  
o Professional experience of those delivering medication 
o INPs & PGD users’ scope of practice 
 
2. Explore INP practice and the use of PGDs by nurses working in sexual health 
services; investigating frequency, range, appropriateness, safety and outcomes of 
medicines delivery. 
o Frequency of medication delivery 
o Range of medication 
o Appropriateness of medication delivery 
o Safety of medication delivery 
o Outcomes of medication delivery 
 
3. To assess whether and how local application of INP and/ or PGD has benefited 
patients, health professionals and the NHS, with reference to quality of care, 
appropriate management of genitourinary and reproductive healthcare, and value for 
money 
o Benefits to patients 
o Benefits to health professionals  
o Benefits to the NHS 
o Quality of patient care 
o Appropriate management of genitourinary & reproductive care 






6.2 Contribution to knowledge 
This study has further contributed to the existing knowledge base through a robust exploration of 
INP and PGD medication delivery with regards to clinical application, patient experience and 
costs. This is the first multi-site study known to have compared INP with PGDs, and the most 
detailed to investigate advanced nursing practice within sexual health. The use of mixed methods 
has triangulated findings from multiple perspectives creating a robust and thorough research 
design. Although restricted to sexual health, it is expected these findings are generalisable to 
other services where patients present for episodic healthcare, and in which nurses utilise INP 
and/ or PGDs.  
Due to the robust nature of this study’s design, use of validated research tools, and comparability 
of research methods to existing large scale prescribing studies (Dornan et al., 2009; Avery et al., 
2012), it has been demonstrated that sexual health nurses are similar to other non-medical 
prescribers and doctors with regards to medication safety and error rates/ types. Moreover, this 
study has given confidence that nurses predominantly practice safely within their scope of 
practice, and appropriately seek support from the multi-disciplinary team when required. 
However, the findings also highlighted that PGD users sometimes exceeded their governance 
and legislation restrictions, albeit clinically appropriately. Nevertheless, patients were equally 
satisfied, and had confidence in both INPs and PGD users, and both groups provided appropriate 
levels of medication information.  
An unexpected finding was the extent to which PGDs users were similar to INPs in managing 
sexual health conditions and provision of contraception. PGD users were highly comparable to 
INPs in terms of professional demographics, the type of sexual health conditions they were 
involved in managing and the range of medications they required access to; however, PGD users 
needed professional support from colleagues more frequently than INPs. Nevertheless, PGD 
users often performed better than INPs, with regards to completeness of documentation and 
medication errors, despite significant differences in medication training and assessment. A further 
outcome related to the variability in the number of PGDs, how they were integrated and provision 
of staff training across the five sites, which suggests further variability also exists across other 





university-based education associated with INP meant NHS managers overall were more 
confident and supportive of INP as compared to PGDs. However, there were also locally imposed 
restrictions that prevented some nurses becoming INP (i.e. based on their banding or confidence 
that PGDs suitably covered nurses’ scope of practice). Nevertheless, both medication delivery 
methods were clearly shown to have extensive benefits in sexual health, despite resource and 
governance barriers.  
Throughout the discussion, findings from this study are compared with existing literature. 
Although these comparisons are made, this project was the first known to explore INP application 
within clinical services to such depth, incorporating multiple lines of investigation, a costs 
assessment and validated research tools within a single study. Through triangulation, the 
strengths and weaknesses of the various research methods were highlighted, and demonstrated 
how findings and conclusions differed, based on how data were collected. Moreover, the 
geographical spread of participants and research sites across England, Scotland and Wales, 
provide an additional perspective on existing literature. Recent evidence specifically exploring 
PGD use in any clinical setting, and the current advanced practice role within sexual health, is 
lacking; therefore, this research has contributed to the current knowledge base in these areas. 
Despite growth in nurses’ independent delivery of medications, there is scarce evidence available 
that has addressed the costs and consequences of integrating these skills. This study contributes 









6.3  Objective 1 
 
Determine the extent to which nurses’ professional experience and scope of practice affect 
prescribing practice or PGD use.  
This objective is addressed under two distinct categories: 
o Professional experience of those delivering medication 
o INPs & PGD users’ scope of practice 
 
6.3.1 Professional experience of those delivering medications 
INPs and PGD users in this study were found to be comparable in relation to the number of years 
they had worked as registered nurses, and their professional experience in sexual health. In-line 
with the prescribing literature (Courtenay et al., 2007a; Courtenay et al. 2007c; Latter et al., 2007c; 
Sibley et al., 2011; Carey et al., 2014; Cashin et al., 2014; Courtenay et al., 2017a), respondents 
were primarily female and aged between 33-55years. Most INPs (62%) were trained to Master’s 
level, which is consistent with the most recent INP studies (Wilkinson et al., 2013; Courtenay et 
al., 2017a) but higher than the Degree level previously reported (Courtenay et al., 2007a; 
Courtenay et al., 2007c; Latter et al., 2007c; Smith et al., 2014). By contrast, the majority of PGD 
users were at Diploma level. In-line with the literature (Baileff, 2007; Courtenay et al., 2007c; 
Pontin and Jones, 2007) high numbers of INPs in this study (85%) reported that they had used 
PGDs prior to undertaking their prescribing role. However, despite having the prerequisite 
requirements for prescribing training (i.e. 3 years qualified experience and degree level 
qualifications: NMC 2006), many PGD users (41%) reported that they did not intend to become a 
prescriber. Not wanting to prescribe and no need to prescribe were reasons given for this. 
Conversely, other PGD users were keen to prescribe but were unable to obtain support from their 
employers.  Reasons given by INPs for undertaking prescribing training included the desire to 
enhance their clinical skills, improve satisfaction with their role, and enhance patients’ experience. 
By contrast, PGD users were more frequently required to use PGDs because of employers’ 





From an organisational perspective, independent delivery of medication was found to have 
shaped nurses’ roles and facilitated autonomous practice and nurse-led clinics e.g. outreach 
services for vulnerable groups (e.g. prisoners) or specialist treatment clinics (e.g. management of 
genital warts). Consistent with the literature (Black and Dawood 2013), independent delivery of 
medications was reported to be fundamental to the sexual health nurses’ role. However, most 
participants reported that to make INP a prerequisite for certain roles within sexual health nursing 
(e.g. ‘Advanced Practitioner’) would be detrimental to the roles of PGD users and to sexual health 
service delivery, i.e. many skilled and capable nurses, for whom PGDs are effective, would be 
excluded from the role. From the employers’ perspective, it was evident from the findings, that 
there were clear reasons why INP was preferable over PGDs. Independent prescribing was 
reported to provide greater flexibility with regards to meeting the dynamic needs of patients, 
prescribing was reported to be easier to manage (i.e. there was no need for PGD governance), 
and INPs had more in-depth knowledge of the medications they delivered. These benefits were 
a positive consequence of policies that supported prescribing practice (Human Regulations, 2012; 
NMC, 2015); however, INP training required significant initial investment which was not as high 
as that required for integrating PGDs. By contrast, PGDs were reported by employers to be 
clinically restrictive, ‘cumbersome’ to manage, and training was unregulated and regarded as 
‘superficial’ in comparison to prescribing training. That being said, one service restricted INP for 
use by senior grades only, while another preferred PGDs, and did not see how INP would benefit 
the service if the provision of specific medication was within nurses’ scope of practice.  
It was evident from the findings that nurses’ banding (i.e. Registered Nurses are put into a ‘band’ 
with 5 = lower band; Band 8 or 9 = higher band, and a higher commensurate salary/ managerial 
responsibility/ clinical expertise) was indicative of their expected clinical skills. Band 5 was 
regarded by employers as those roles leading into autonomous practice including varying abilities 
to utilise PGDs. Although the expectations of band 6 nurses varied across sites, all band 6 nurses 
were able to use every locally available PGD. Most case sites (sites 2-5) regarded band 6 nurses 
as fully autonomous practitioners who could become INPs. The remaining site (site 1) restricted 
nurses’ ability to become an INP to band 7 and higher. This banding segregation was also evident 
in the findings of the staff questionnaires, i.e. there were no band 5 INPs and most PGD users 





INPs were mostly banded higher than those who didn’t prescribe. Similar banding variations have 
also been found across England’s Mental Health organisations where INP training was reported 
to be primarily available for band 6 nurses (Dobel-ober and Brimblecombe, 2016), and concerns 
have been raised by some INPs that the prescribing skill will be expected of lower grades in the 
future to save money (Carey et al., 2014). 
 
6.3.2 INPs and PGD users’ scope of practice 
 
The staff interviews highlighted that expanding nurses’ ability to deliver medication facilitated the 
development of sexual health nurses’ scope of practice, moving them from ‘doctors’ 
handmaidens’ to autonomous practitioners. Although PGDs were positively regarded when first 
introduced in case study sites, their restrictive nature became increasingly apparent as nurses’ 
scope of practice expanded to include prescribing. However, some restrictions were also reported 
with regards to prescribing. For example, some INPs were restricted by local formularies (i.e. lists 
of medicines to which all prescribers must adhere), whilst others had to create personal formulary 
portfolios (likened to writing personal PGDs) in which evidence had to be recorded (including 
drugs’ indications, contraindications, regimens and side effects) for each drug they could 
prescribe. Consequently, some INPs reverted back to using PGDs where drugs were not included 
in their portfolios, thus losing the benefits of prescribing and the value of the investment in training 
INPs. However, a paper detailing the integration of a prescribing formulary within a mental health 
service identified that a local drug formulary supported particularly new prescribers and enhanced 
their confidence in taking on the prescribing role and improved communication with service users 
(Dobel-Ober et al., 2013). This, therefore, could indicate potential benefits for personal 
formularies for new INPs, although, as found in this study, these formularies can be overly 
restrictive for more experienced INPs.  
The results differed somewhat between the two subgroups of nurses within sexual health (i.e. 
genitourinary care and reproductive health). INPs’ scope of practice in genitourinary care was 
found to be overall more advanced than PGD users (i.e. INPs were trained to manage more 





supported advanced clinical practice, which had a positive impact on service delivery i.e. 
participants reported improved efficiency by reducing time spent obtaining prescriptions; helping 
services to run smoothly and managing more patients through nurse delivered clinics. This 
facilitated convenient patient access to medicines and information. However, a similar finding 
relating to advanced practice was not found between INPs and PGDs users in reproductive health 
(i.e. both groups mostly provided simple contraception). This is most likely because advanced 
practitioner roles in reproductive health requires further competency-based assessments through 
supervised practice, to achieve the Faculty of Sexual & Reproductive Health’s ‘Letter of 
Competence’. Moreover, three sites (sites 1, 2 and 3) had not yet fully integrated reproductive 
healthcare with genitourinary care. This restricted the level at which nurses could practice due to 
the sites’ local governance processes which affected the availability of services locally.    
Sexual health nurses reported that they felt confident delivering medications independently and 
this subsequently increased their job satisfaction. A similar increase in nurses’ confidence in 
medication delivery has also been found in other clinical areas (Gumber and Gajebasia, 2012; 
Carey et al., 2014; Creedon et al., 2015). While most respondents reported that the prescribing 
programme adequately prepared them for their prescribing role, several respondents felt 
unprepared. The reasons for this were not explored. Commonly cited reasons include a lack of 
pharmacology knowledge, advanced clinical/ assessment skills and specific practice-area skills 
(Latter et al., 2007c). Furthermore, a small number of INPs and PGD users in this study felt 
unsupported with regards to continuing professional development (CPD) as they were unable to 
access training. This supports previous literature in which time to access CPD has been identified 
as a barrier to independent medication delivery (Creedon, 2010; Smith et al., 2014).  
 
6.3.3 Objective 1 summary 
 
Independent delivery of medications is fundamental to the role of sexual health nurses, and it was 
evident that both INPs and PGD users in this study were highly experienced professionals. INPs’ 
desire to enhance their clinical skills, improve satisfaction with their role, and enhance pat ients’ 





driven to use PGDs as a result of their employers’ expectations for them to. Although many PGD 
users possessed the necessary knowledge and experience to become prescribers, they chose 
not to do so. Employers heavily influenced both INPs and PGD users’ ability to deliver medication 
and scope of practice. This was often based on nursing ‘bands’. Subsequently, scope of practice 
of INPs and PGD users varied not only between users, but also between organisations. Although 
the modern sexual health nursing role was consistently found to be reliant upon independent 
delivery of medicines, a need for CPD was identified by both INPs and PGD users.  
 
 
6.4 Objective 2 
 
Explore INP practice and the use of PGDs by nurses working in sexual health services; 
investigating frequency, range, appropriateness, safety and outcomes of medicines 
delivery. 
This objective is addressed under five distinct categories: 
o Frequency of medication delivery 
o Range of medication 
o Appropriateness of medication delivery 
o Safety of medication delivery 
o Outcomes of medication delivery 
 
 
6.4.1 Frequency of medication delivery 
 
The clinical notes review identified INPs and PGD users frequently delivered medications in 
sexual health (54% vs. 48% of care episodes, respectively). This is consistent with Black’s (2012) 
findings from a single site sexual health service. Such frequent medication delivery reduces the 





return from the initial investment in INP and PGD training and governance becomes. Moreover, 
findings from the clinical diary suggested nurses with greater confidence in their clinical practice 
delivered medications more frequently than the overall nursing team. Although it was evident from 
the clinical notes review that the frequency of medicines delivery between INPs and PGD users 
was statistically significantly different, both groups delivered medications to approximately every 
second patient. Given that 2.7million patients in England attend sexual health clinics each year 
(PHE 2017), this highlights the important role nurses play with regards to medicines delivery. 
 
6.4.2 Range of medication 
 
It was evident from the clinical notes, that both INPs and PGD users delivered a similar range of 
medications, totalling 66 different drugs (56 vs. 51, respectively). INPs were found to be able to 
deliver a flexible and extensive range of medications autonomously. However, the inflexible 
nature of PGDs meant that users frequently sought prescriptions from colleagues, the arduous 
and cumbersome nature of PGDs making it impossible to create individual PGDs for the extensive 
range of drugs and clinical presentations manged by sexual health nurses. Therefore, local 
managers need to weigh the resource implications of creating multiple PGDs for frequently used 
medications versus PGD users’ need to obtain prescriptions from colleagues. Nevertheless, 
evidence from this study suggests that independent access to some medicines is better than no 
access at all, in line with previous research (Black and Dawood, 2013).  
Bacterial infections were the conditions for which medicines were required most frequently, and 
unsurprisingly antibiotics were delivered most often across both groups. The most common drug 
delivered was azithromycin. This was delivered by both INPs and PGD users to treat chlamydia, 
the most common bacterial STI (PHE, 2017). This highlights that antibiotic stewardship is a key 
responsibility for those delivering medicines in sexual health. Documentary evidence and 
observation data demonstrated that sexual health nurses delivered antibiotics responsibly and in 
line with guidelines (BASHH, 2016). This aligns with research that has explored the prescription 
of antibiotics by nurse and pharmacist prescribers for patients with respiratory tract infections 






6.4.3 Appropriateness of medication delivery 
 
It was evident from the findings that sexual health INPs and PGD users delivered clinically 
appropriate medications. Although not specifically exploring sexual health, this is in-line with 
previous nurse prescribing research that has used the Medication Appropriateness Index (MAI: 
Latter et al., 2007b; Latter et al., 2012; Naughton et al., 2012). The low mean MAI weighted score 
(clinical notes= 0.9/18; observations= 1.0/18) established that INPs and PGDs users made highly 
comparable and appropriate medication choices, with many medications delivered with no 
inappropriate scores; i.e. clinical notes= 82%; observation documentation= 81%, which increased 
to 100% when triangulated with observed data. This is higher than MAI assessments reported 
previously (Latter et al., 2012). 
 
From the MAI’s ten points of enquiry, both INPs and PGD users scored most appropriately on the 
question relating to using most cost efficient medication regimens being delivered. This concurs 
with previous research (Latter et al., 2012) and is perhaps unsurprising given that sexual health 
nurses in this study worked with a range of detailed evidence-based guidelines (BASHH, 2016; 
FSRH, 2016) and locally procured formularies. INPs and PGDs users also scored very highly on 
the components ‘indication for the medication’, and ‘medicines effectiveness for the condition’ 
managed. This is in-line with work by Naughton et al. (2012), investigating nurse prescribing in 
multiple clinical specialities across eight hospitals. These researchers concluded that there were 
no clinical benefits for the medication if these components were not met. There was some 
variability between INPs and PGD users with regards to the areas with the most inappropriate 
MAI scores. For INPs these related to appropriateness of dose, correct medication directions and 
directions being practical, whereas, for PGD users this was related to drug-drug interactions, 
medical condition-drug interactions and correct medication directions. Similar inconsistencies 
amongst prescribers have been reported previously (Latter et al., 2007b; Latter et al., 2012; 
Naughton et al., 2012). It is important to note that the primary reason INPs and PGD users scored 





practice. However, when this information was triangulated with observation and documentary 
evidence, every aspect of the MAI reached 100%. This demonstrates the importance of 
comprehensive documentation, and the limitations of using clinical records for assessing 
medication appropriateness.  
 
Appropriate use of PGDs? 
From a clinical governance perspective, INPs and PGDs users were comparable, and both groups 
appropriately delivered medications expected to be therapeutically beneficial. However, PGD 
users were more likely to practice outside of their restrictions (i.e. evident in 8% of medication 
deliveries). This has been reported previously (Williams and Knox, 2011; Black and Dawood, 
2013).  Interview data highlighted that in some instances, PGD users inadvertently overlooked 
exclusion criteria included in the direction. For example, some patients were appropriately 
supplied doxycycline for the management of proctitis or cervicitis; however, these conditions were 
either excluded (i.e. proctitis) or not listed in the inclusion criteria (i.e. cervicitis).   This finding 
raises concerns over authorisation and training. It is important to ensure that PGD users are 
educated to ensure safe practice and are compliant with PGD governance. However, it is also 
important, given that medicines delivered outside of PGD restrictions were clinically appropriate, 
that PGDs also correctly reflect users’ scope of practice. This became particularly apparent in site 
1 when all symptomatic patients infected with gonorrhoea were unnecessarily excluded from 
being managed by PGD users. As PGD users had the clinical competence to manage 
gonorrhoea, there was no obvious requirement for patients to be managed by a prescriber. This 
specific PGD restriction was subsequently removed. Overall, despite some cases where the 
boundaries of PGDs were pushed, there were many more cases of appropriate, safe clinical 










6.4.4 Safety of medication delivery 
 
Patients’ pre-existing risk factors 
It was evident from the findings that both INPs and PGD users did not consistently document their 
medication safety assessments in terms of patients’ pre-existing risk factors (i.e. medical history, 
concurrent medication, allergies, pregnancy risk). INPs were statistically more likely to fully 
document these factors compared to PGD users. Although not in sexual health, this lack of 
documentation has been highlighted previously in the general prescribing literature (Latter et al., 
2007a; Carey et al., 2009; Williams and Know, 2011; Price et al., 2012; Black, 2012). However, 
observational data demonstrated that risk factors were always fully discussed during 
consultations. 
Both INPs and PGD users managed similarly complex clinical presentations in terms of patients 
pre-existing medical conditions, allergies and/ or concurrent medication, which could have 
influenced medications’ safety or effectiveness. Although the findings demonstrated potential 
drug-drug or drug-disease interactions, both INPs and PGD users predominantly provided 
medications safely; i.e. the medication benefits outweighed their risks. However, four cases of 
potentially unsafe drug-drug interactions were identified based on the patients’ documented 
concurrent medications, and the new medications delivered by INPs and PGD users in this study; 
however, no patients were known to be harmed.  
 
Completeness of the prescription 
The most frequent medication errors made by both INPs and PGD users related to incomplete 
information on prescriptions. This concurs with findings by Avery et al. (2012) in research 
exploring medication errors by prescribers in general practice. Although both groups omitted 
information on drug dose, routes, administration frequencies and durations, PGD users provided 
significantly greater details than INPs. Nevertheless, findings in this study identified that both INPs 
and PGD users provided less complete ‘prescriptions’ than the findings reported in the general 





2011) but this comparison may be influenced by varying authors definition of what constitutes a 
complete prescription. For example, this study considered that if the ‘route of administration’ was 
missing it constituted an error, whereas, other studies may not have counted this as an error if 
there was only one formulation of a drug.  
 
Medication errors 
The Medication Protection Society (2016) reported that medication errors were the second most 
common cause for healthcare litigation; citing contraindicated drugs (most commonly antibiotics), 
providing the wrong drug or selecting an incorrect dose as most frequent. Dose related errors 
have also been reported in the prescribing literature (9.4%: Carey et al., 2008; 30.6%: Dornan et 
al., 2009; 5%: Bates et al., 2010; 17.8%: Avery et al., 2012; 20.6%: Seden et al., 2013). In 
contrast, the findings from this study identified that contraindicated drugs only accounted for 0.9% 
of errors, no indication for drug given 1.1%, and dose errors 0.8%. These findings were 
comparable across both INPs and PGD users.  
While on the whole medication delivery occurred safely, errors did occur. The overall 8.5% error 
rate in this study was marginally lower than in three large scale prescribing safety studies, which 
predominantly focussed on doctors; i.e. medication error rates of 8.9% (Dornan et al., 2009), 
12.2% (Avery et al., 2012) to as much as 43.8% (Seden et al., 2013). However, variations in what 
was defined as an error influence these comparisons, e.g. not documenting patient’s past medical 
history, concurrent medications and allergies was not considered an error by Dornan et al. (2009) 
and Avery et al. (2012). However, this study regarded the inability to assess the potential impact 
of a medication on pre-existing conditions as a risk to patient safety, and thus an error in 
prescribing safety governance. Moreover, Seden et al.’s (2013) study appears to artificially inflate 
the error rate as their study reported the percentage of prescriptions that had one or more error, 
and not the actual percentage of individual drug errors. Nevertheless, this study gives overall 
reassurance that sexual health nurses were comparable to their medical counterparts in 
prescribing safety. INPs were statistically more likely to make ‘moderate’ graded medication 
errors, compared to PGD users. However, errors predominantly related to omitted documentation, 





to patients being harmed. However, there were eight occurrences of medication errors 
categorised by the researcher as unsafe, demonstrating that ongoing medication safety vigilance 
is indicated. The spread of severity of prescribing errors across ‘minor’, ‘moderate’ and ‘severe’ 
is consistent with existing literature (Dornan et al., 2009; Avery et al., 2012). This study, therefore, 
provides evidence that both INPs and PGD users are likely to be comparable to other prescribers 
with regards to the safe delivery of medicines.  
 
6.4.5 Outcomes of medicines delivery 
 
6.4.5.1 Consultation characteristics 
 
Prioritisation of new episodes of sexual health care, over follow-up, as deemed by the DH (2013) 
to improve patient access, cost-efficiencies and reduce resources associated with re-attendance. 
Findings from the clinical notes review identified both INPs and PGD users were comparable with 
regards to the number of new care episodes managed (70% vs. 67% of consultations, 
respectively); however, this is less than that reported in sexual health services nationally (i.e. 
79%: (PHE, 2017)). Moreover, clinical diary data found PGD users were statistically more likely 
to manage follow-ups than INPs (47% vs. 30% of their caseload, respectively). 
The presence of symptoms increases the complexity of patients’ assessment and management 
(MedFASH, 2014; BASHH, 2017). It was evident from observation data that participants regularly 
enquired about patients’ symptoms. This is important given that the recent integration of online/ 
postal services is expected to reduce the number of asymptomatic patients presenting to 
specialist services (London Councils, 2017; SH:24, 2017). However, in line with Black (2012), the 
findings of this study identified that most patients managed by sexual health nurses were 
asymptomatic and where patients had documented symptoms, they were statistically more likely 
to be managed by INPs as compared to PGD users (38% vs. 28% of caseloads, respectively), 






6.4.5.2 Autonomous practice 
 
INPs were statistically more likely to complete care episodes autonomously, compared to PGD 
users. This contrasts with Black and Dawood (2013) who found no difference in autonomous 
practice between INPs and PGD users in an emergency department, but is consistent with 
Courtenay et al. (2015) who found non-INPs frequently needed GP support for prescriptions. The 
findings of this study identified that the restrictive nature of PGD governance was the primary 
reason PGD users were unable to practise autonomously; i.e. 46% of INPs’ prescriptions would 
have been restricted had INPs used local PGDs. While PGD restrictions were found to benefit 
training roles and purposely limit scope of practice, nurse prescribing clearly facilitated 
autonomous practice for experienced practitioners. 
Practitioners working autonomously have less resource and cost implications as they do not need 
to involve other professional colleagues in managing individual patient caseloads. INPs were less 
likely to seek medication support from professional colleagues compared to PGD users. When 
INPs obtained doctors’ prescriptions this most frequently related to the legal requirement of 
doctors signing termination of pregnancy prescriptions (Abortion Act 1967). Conversely, PGD 
users most frequently sought support for the prescription of antibiotics. Both INPs and PGD users 
required support for patients’ clinical management (which frequently related to management of 
patients with complex symptoms or presentations outside nurses’ scope of practice), which has 
also been reported previously in the nursing literature (Black, 2012; Wilkinson et al., 2013; 
Kroezen et al., 2014). Although autonomous practice does facilitate efficient service delivery, 
particularly as each query required colleagues’ time (INP = mean 11minutes; PGD= mean 
8minutes), the finding that participants sought support from medical colleagues is reassuring as 








6.4.5.3 Consultation duration 
 
Although the consultations of INPs were statistically longer than those of PGD users, when 
adjusted for type of consultation (i.e. new or follow-up), there were no differences found. This is 
likely due to local clinic processes which schedule a certain number of appointment slots per 
clinical session. Unsurprisingly new care episodes and the provision of medication increased 
consultation duration, but there were no differences between INPs and PGDs when moderated 
for consultation type (i.e. comparing similar consultation characteristics between the groups). 
Courtenay et al. (2015) identified that INPs spent longer with patients than non-INPs which 
impacted on the number of patients being managed in general practice; however, the complexity 
of patients’ presentations were not considered as part of this. 
 
6.4.6 Objective 2 summary 
 
Both INPs and PGD users were found to deliver medications frequently, to approximately every 
second patient. While both groups required a similar range of medications (mostly antibiotics), 
INPs were more likely to manage more clinically complex patients and deliver medications 
independently compared to PGD users. Consequently, nurse prescribing was found to be more 
flexible as nurses’ scope of practice increases. While INPs were more consistent at documenting 
patients’ medical risk assessments, PGD users documented ‘prescriptions’ more thoroughly, and 
were less likely to make ‘moderate’ graded medication errors than INPs. Nevertheless, both 
groups were comparable overall with regards to the safe and appropriate delivery of medicines. 
Where errors were identified, these predominantly related to omitted documentation, rather than 
patients being at risk of harm. When observation data were triangulated with documentary 
evidence, many errors were resolved. However, there were cases where PGD users exceeded 
the documents’ restrictions, and both INPs and PGD users were found to have provided 
potentially unsafe practice, albeit extremely rarely; ongoing vigilance is therefore indicated. 
Although INPs were found to practice more autonomously, having the ability to deliver 





6.5 Objective 3 
 
To assess whether and how local application of INP and/ or PGD has benefited patients, 
health professionals and the NHS, with reference to quality of care, appropriate 
management of genitourinary and reproductive healthcare, and value for money.  
 
This objective is addressed under six distinct categories: 
o Benefits to patients 
o Benefits to health professionals  
o Benefits to the NHS 
o Quality of patient care 
o Appropriate management of genitourinary & reproductive care 
o Value for Money 
 
6.5.1 Benefits to patients 
INPs and PGD users reported that patients benefited from safer, better-informed, efficient 
services because nurses could independently deliver medications. In turn, patients reported 
extremely high levels of satisfaction with their medication consultations, with no differences found 
between INPs and PGD users. Patients clearly valued nurses’ approachability; had confidence in 
their clinical management; were highly satisfied with medication explanations; and were given 
opportunities to ask questions. Positive patient feedback is a consistent finding in the general 
nurse prescribing literature (Drennan et al., 2011; Stenner et al., 2011; Bergman et al., 2013; 
Tinelli et AL., 2013, Courtenay et al., 2017b), as is patients’ confidence in nurses’ consultation 
skills and medication knowledge (Courtenay et al., 2010; Dhalivall, 2011; Banicek, 2012; 
Bergman et al., 2013; Ross et al., 2013; Courtenay et al., 2015). Interestingly more than half of 
patients were unaware nurses independently delivered medications, but those that did, were 
confident in nurses’ abilities.  
The initial PPI feedback that informed this study’s design, identified patients’ main medication 
concerns related to side effects, reluctance in taking medicines, and medication effectiveness. 
This is in-line with other nurse prescribing literature (Banicek, 2012; Riley et al., 2013). While 
observational data highlighted both INPs and PGD users addressed these concerns, findings 





‘reliable sources of information’ and ‘what to do if there are any concerns about the management 
of their condition’. However, this was not consistent across all observed practitioners.  
 
Satisfaction with medication information 
Patients in this study were also very satisfied with the level of medication information received, 
with responses to the Satisfaction with Information on Medication Scale’s (SIMS) scoring 
positively (i.e. ‘about right’ or ‘not applicable’). This demonstrated from the patients’ perspective 
that investment in both INP and PGDs was an effective use of resources. Patients were marginally 
more satisfied with the information received about action and usage of medications (i.e. its name, 
how to take it, how much and when) than the potential problems (i.e. what to do if the forget a 
dose, potential side effects, what to do if they experienced side effects, and concurrent use of 
other medications). This is in-line with Latter et al. (2007d), these researchers suggesting that 
prescribers inadvertently focusing on medication usage, rather than their associated risks, may 
encourage adherence by avoiding mentioning the negative aspects of medications. It was evident 
from the findings of this study that when patients were less satisfied with medication information, 
this most frequently was associated with concurrent alcohol use (26%); whether the medication 
would cause drowsiness (24%); and side effects (18%). As many sexual health related drugs are 
unlikely to be affected by moderate alcohol use, or cause drowsiness (BNF, 2016; Local 
handbook, 2016), nurses may have been less inclined to routinely discuss these issues. 
Moreover, nurses may have been unfairly criticised here. If the SIMS had not specifically asked 
about these areas, patients may not have considered them necessary information, particularly as 
patients otherwise reported opportunities to ask questions in the first section of the patient 
experience questionnaire.   
 
6.5.2 Benefits to health professionals 
 
It was evident from the findings that INPs and PGD users considered that the ability to deliver 





holistic autonomous practice. Moreover, INP and PGDs provided the ‘freedom and confidence’ 
(Participant 4) to safely manage patients. Despite PGDs’ restrictive nature, many nurses (and 
services) were content using them. PGDs were reported to complement clinical roles and provide 
enough scope for those who did not want to undergo INP training. The personal and professional 
benefits highlighted also included improved job satisfaction, self-esteem, specialist knowledge 
and clinical assessment skills. Similar health professional benefits have been reported elsewhere 
in the nurse prescribing literature (Stenner and Courtenay, 2008; Wilkinson et al. 2013; Carey et 
al., 2014; Courtenay et al., 2017a). The additional stress, and accountability and responsibility 
associated with delivering medications were highlighted as potential barriers to independent 
medicines delivery. Moreover, the intensity of the INP training was regarded as a major barrier. 
This was particularly evident in those not academically orientated, and those unwilling or unable 
to invest a large amount of personal time in the training programme who had managers unwilling, 
or unable, to invest time and/ or resources. INPs also had to invest a significant amount of their 
personal leisure time in completing the university training course, which was not found in the PGD 
user cohort. Although INPs’ personal investment is unlikely to be recompensed (Hobson et al., 
2010; Earle et al., 2011), INPs were more frequently on higher salaries compared to PGD users 
which suggested personal investment in the INP course could improve their career prospects; 
therefore, as the NHS is funding university fees and providing study leave, it is not unreasonable 
to expect nurses’ personal commitment and time to achieve such long-term benefits. However, 
the differences in salary cannot be solely attributed to whether nurses used INP vs. PGDs. Higher 
salaries/ banding for INPs has also been found in other literature, compared to those who could 
not prescribe (Kroezen et al., 2012; Courtenay et al., 2015; Creedon et al., 2015); however, 
Kroezen et al. (2012) identified that this often related to other academic achievements and not 
the ability to prescribe. 
The professional benefits of INP and PGDs expanded beyond nurses. Findings identified that 
although medical colleagues were initially hesitant about nurses delivering medicines 
independently, they were reported now to be consistently supportive. This is in line with findings 
of a national survey of non-medical prescribers in Wales (Courtenay et al., 2017a). In fact, where 
nurses were unable to provide medication independently, doctors commented on the service 





from this study are in-line with the general consensus of nurse prescribing literature with regards 
to: enhanced nurse-medical relationships (Bradley and Nolan, 2007; Earle et al., 2011; Ross, 
2015, Hopia et al., 2016; Lim et al., 2017); a reduction in nurses seeking prescriptions (Courtenay 
et al., 2009b; Price et al., 2012; Wilkinson et al., 2013); and doctors’ increasing confidence in the 
ability of nurses to manage more clinically complex cases (Wilkinson et al., 2013; Ross, 2015; 
Hopia et al., 2016). 
 
6.5.3 Benefits to the NHS 
 
It was evident from the findings that INP and PGDs supported efficient service delivery through 
improved capacity, access to services and a more streamlined patient journey. These findings 
are consistent with the wider nurse prescribing literature (Courtenay et al., 2010; Jones et al., 
2010; Courtenay et al., 2011; Price et al., 2012; Wilkinson et al., 2013; Carey et al., 2014; Creedon 
et al., 2015; Ross, 2015). There was also significant support for medication delivery from INPs 
and PGD users with regards to supporting service delivery. The findings also identified that 
nurses’ independent delivery of medications facilitated the creation of nurse-led clinics. Although 
senior participants reported that they preferred INP over PGDs (primarily because clinical 
presentations often exceeded PGDs’ restrictions), as PGDs are locally governed they can be 
amended to reflect practice need (NICE, 2013).  
While there are clear NHS benefits for independent medicines delivery by nurses, resource 
barriers were also highlighted. INP barriers related to the cost of the training course, the release 
of staff for university training days, and doctors’ Designated Medical Practitioners’ (DMP) time 
(discussed further under ‘Value for money’). Barriers reported in relation to PGD governance was 
its laborious and time-consuming nature and complexity. Such barriers have been reported 
previously (Price et al., 2012). It was also apparent from the findings that the chair of the non-
medical prescribing committee heavily influenced the approvals process for both PGDs and INP. 
The influence of these committees over nurses’ independent delivery of medication, has been 
reported previously (Dobel-Ober and Brimblecombe, 2016). The local influence of non-medical 





qualified INPs to maintain detailed personal portfolios of each drug they intended to prescribe. 
Not only did this create a barrier to practice, it made INPs revert back to using PGDs, undermining 
the benefits associated with being a qualified prescriber. 
 
6.5.4 Quality of patient care  
 
It was evident from the findings that there were no differences in the quality of care provided 
between INPs and PGD users. Based on documentary and observational data, nurses performed 
well on taking appropriate clinical histories and assessments; interpreting relevant investigations, 
understanding the conditions being treated, and how to effectively manage them. The 
observational findings also highlighted that both INPs and PGD users consistently listened to 
patients and sensitively managed their concerns. This is consistent with the findings on nurse 
prescribers working in the area of diabetes (Courtenay et al., 2009b). In the eight cases where 
quality of care was suboptimal (see section 5.9.15 on page 180) incidents were reported and 
investigated in line with local protocols, including patients being informed and corrective actions 
taken. Based on documentary evidence there were no known official patient complaints. 
Ultimately, patient’s experience is a key indicator of quality of care, and patients in this study 
reported very high levels of satisfaction with care. Moreover, content analysis of patients’ 
questionnaires clearly identified a high quality of care, with participants commenting on the 
excellent service, and knowledgeable and friendly/ approachable staff. Observational data 
supported this finding with nurses interacting with patients in a non-judgemental manner, and 
patients appearing comfortable talking about their sexual health with the nurse.  
 
6.5.5 Appropriate management of genitourinary and reproductive healthcare 
 
6.5.5.1 STI diagnoses and management  
Chlamydia, genital warts, gonorrhoea, non-specific genital infections and the management of 





INPs and PGD users in this study. This concurs with national evidence (PHE, 2017). It was 
evident from the findings that PGD users were involved in the management of 27 diagnosed 
conditions and INPs 25 conditions (i.e. INPs had no patient presentations involving 
Trichomoniasis vaginalis or Hepatitis C management) i.e. most of the sexual health diagnoses 
reported in national data (PHE, 2017). Ongoing management of people living with HIV was not 
routinely undertaken as part of sexual health nurses’ roles within this study (however, some senior 
nurses did have dual sexual health & HIV roles).  It was evident from the findings that these 
conditions were appropriately managed by INPs and PGD users, and, where appropriate, support 
was sought from doctors. 
 
6.5.5.2 Reproductive healthcare 
Navigating the wide range of contraception choices, their benefits and potential risks can be a 
challenging process for patients and healthcare workers (FSRH, 2017). However, observational 
data demonstrated that both INPs and PGD users appropriately discussed the range, risks and 
benefits of contraception methods with patients. In cases where patients’ contraception choices 
were contraindicated, the reasons for these contraindications were discussed with patients and 
appropriate options provided. It was evident from the findings that both INPs and PGD users 
appropriately delivered a range of advice, education and contraception methods (e.g. oral 
contraceptive pills, patches, long-acting reversible contraceptives). Both groups also managed 
termination of pregnancies alongside doctors. The only contraception method not managed by 
INPs and PGD users in this study was sterilisation. This demonstrates the extensive range of 
skills INPs and PGD users have with regards managing patients’ reproductive healthcare.  
It was evident in both genitourinary and reproductive observed practice that INPs and PGD users 
had advanced levels of knowledge and skills that enabled them to work autonomously and 






6.5.5.3 Non-provision of medication 
The findings highlighted a total of 126/1,682 cases where medication was indicated, but not 
delivered. Of these cases this was appropriate in 101 cases, most of which related to the 
medication not being delivered due to the condition not being a sexual health condition, or, the 
decline of treatment by patients until pathology results were available. There were a further 25 
cases in which the treatment indicated was not offered. These cases included situations in which 
prophylactic medicines had not been offered to patients at recent risk of pregnancy, patients at 
high risk of STIs, or patients who could have been protected through vaccination programmes 
(e.g. hepatitis B). While the cost of the drugs were saved in these circumstances, the long-term 
consequences of not providing medications in these circumstances could potentially lead to 
health outcomes that are expensive to manage in the future (e.g. managing hepatitis B infection).  
 
6.5.5.4 Unplanned re-attendances 
A total of 306 (18%) patients re-attended services within three months. The most common reason 
(33%) for this was a positive diagnostic test. Other reasons included the development of new 
symptoms, or patient behavioural issues (such as unprotected sex with an untreated partner and 
re-infection with an STI) that required re-treatment. Therefore, it is unlikely that re-attendance in 
these circumstances was linked to inappropriate practice; particularly given that re-infection from 
untreated partners is a common occurrence (BASHH, 2015). Medication-related re-attendances 
most frequently involved unresolved/ worsening/ returned symptoms (n=34, 11%), side effects to 
medications (n=31, 10%) or issues with long-acting reversible contraception (n=20, 6.5%). 
Despite approximately one fifth of patients returning within a three-month period, there was no 
indication that this was attributed to the level of care provided by INPs or PGDs users.  
 
6.5.6 Value for money 
It was evident from the costs and consequences analysis (CCA) that many clinic processes had 
no statistical differences between INPs and PGD users, and therefore, both methods were 
beneficial. However, consideration of which method offers the better value for money is less clear 





between the groups were attributed ‘training and governance’; however, the INP training costs 
may be over-inflated as much of the DMP staffing resources were likely provided during existing 
clinical responsibilities (see section 6.6.2.7 Costs). While PGDs were able to be used by multiple 
staff members at relatively small investment, they were considered difficult to govern, required 
frequent revalidation and were restrictive in practice. Whereas INP offered flexibility and 
streamlining of service delivery but involved significant investment from the NHS and individual 
nurses. INPs subsequently managed more complex cases and required less professional support 
from colleagues compared to PGD users; however, when INPs did require support they required 
it for longer duration than PGD users (11 minutes vs. 8 minutes, respectively), further suggesting 
INPs managed more complex patients. Courtenay et al. (2015) also found that nurses who could 
not prescribe sought support more frequently than INPs, however, the additional support obtained 
incurred less additional cost than the longer consultation duration and higher banding of INPs. In 
this study, there was no difference in consultation duration, but comparably, INPs were on higher 
bands than PGD users. However, as this study demonstrates, the impact INP has on service 
delivery and the flexibility to manage increasingly complex patient presentations provides long-
term returns for the NHS.  
As such initial INP training investments can be discounted over the term INPs continue to 
prescribe, and further discounted if the skill is used frequently. While PGDs were comparably less 
expensive, they were impractical to write for every type of sexual health presentation and for every 
drug required. Consequently, PGDs offered best value for money when nurses worked with 
predictable and frequent patient presentation types but as nurses’ scope of practice increased 
INP was more useful in clinical practice. However, the investment required for nurse prescribing 
training concerned 40 INP interviewees, with regards to the sustainability of funding for university 
courses, and, to save money, they were concerned the NHS would revert to using PGDs (Carey 
et al., 2014). This indicates that further assessments are required on the costs and consequences 
of nurses’ medication delivery.  
While the costs associated with training are important factors as NHS nursing education budgets 
are becoming restricted, the priority should remain on the value added benefits associated with 
investments. As clearly demonstrated nurses’ independent access to medication has benefits to 





nurse education and training investment (Willis, 2015). Moreover, with regards to value added 
benefits of INP, nurses unlike doctors (where prescribing is included in undergraduate training), 
require additional postgraduate training investment to prescribe. Therefore, when comparing 
costs, consequences and value added benefits further research into comparing INPs with doctors 
may demonstrate that INP training is not as expensive as it appears when compared with PGD 
governance.  
 
6.5.7 Objective 3 Summary 
 
The implementation of both INP and PGDs have benefited sexual health patients, health 
professionals and the NHS, allowing nurses to provide high quality, appropriate genitourinary and 
reproductive healthcare. Patients have benefited from a safer, better informed, efficient service 
because nurses were able to use INP or PGDs. Although a small number of patients were 
dissatisfied with regards to the information they received on medicines’ side effects, most patients 
were very satisfied with this information and the overall nurse consultations. From the staff 
perspective, there were many personal and professional benefits highlighted for using INP and 
PGDs, but the training requirements for INP and PGD users created barriers. The NHS was found 
to have invested significant costs and resources into INP and PGD training and governance, with 
the consequences of this investment leading to efficient, accessible sexual health services with 
smoother patient journeys. Moreover, INPs and PGD users were skilled to such a level they were 
able to appropriately manage an extensive range of genitourinary conditions and reproductive 
healthcare interventions required of modern day sexual health services. However, INP training 
was considered a more effective investment than PGDs as nurses’ scope of practice increased 







6.6 Study limitations and implications 
 
6.6.1 Representativeness of study  
 
6.6.1.1 Sites 
The study’s findings were based on five NHS sexual health services across England, Scotland 
and Wales. Three operated solely from city centre locations, and the other two provided additional 
outreach services. Consequently, rural and primary care services were underrepresented in this 
study; however, the focus was on specialist level 3 sexual health providers (which are 
predominantly situated in cities). In line with NHS Framework (2013), all services were in the 
process of integrating, or had fully integrated, genitourinary and reproductive healthcare 
(previously distinct specialities).  
 
6.6.1.2 Nurse participants (across all methods) 
The clinical notes review represented practice from all the INPs, and 87% (58/67) of PGD users 
that were invited to complete the staff questionnaire. However, PGD users were 
underrepresented in the staff questionnaire overall compared to INPs (response rate 52% vs. 
93%, respectively). Nevertheless, as both INPs and PGD users’ questionnaire response rates 
exceeded 50% in line with guidance (Moule and Goodman, 2009), they were considered 
representative. As potential participants who used the clinical diary were aware that the diaries 
were to be used to explore medication delivery practice, nurses who volunteered to participate 
were more likely to be more confident and experienced practitioners. By contrast, the clinical 
notes review included the patients of all INPs or PGD users. Therefore, while the clinical notes 
review provided an overview of actual practice, the clinical diary was more likely to compare 
clinically confident PGD users with similarly confident INPs. The consultation observations 
involved a non-randomised, convenience sample of nurses and patients who volunteered to 
participate, which allowed unique and privileged insights into nurse-patient interactions but may 
have altered participants’ behaviour as detailed by the ‘Hawthorn Effect’ (Moule and Goodman, 







While the patient experience questionnaire yielded a high response rate (93%), only 49% of 
eligible patients were offered the questionnaire as a result of it failing to be distributed to them by 
nurses, or, the patients declining the invitation to participate. The findings may, therefore, not be 
truly representative of patients’ experience. 
 
6.6.2 Study methods and design 
 
6.6.2.1 Staff interviews 
Although staff interviews provided an in-depth exploration of independent medication delivery 
practice and processes, only a small number of participants were interviewed, therefore, findings 
may not be representative of the wider population. 
  
6.6.2.2 Staff questionnaire 
Although the staff questionnaire was deemed to have face and content validity (due to its design, 
as presented in section 5.4.2), it was not tested for validity or reliability which affects confidence 
in its ability as a research tool (Parahoo, 2006; Bowling, 2009; Moule & Goodman, 2009). 
Moreover, during data collection two issues became apparent with regards to the attitude 
statements in Section 2. Firstly, the ‘likert-type scales’ were not intermingled with positive and 
negative-worded statements. This left Section 2 open to “rhythm…ticking boxes in the same 
column” (Parahoo, 2009, p.294). Secondly, there was a transcribing error which asked PGD users 
about ‘prescribing’ rather than ‘medication delivery’. This may have confused respondents, which 
possibly explains why three PGD users did not answer this specific question.  
Section 3 of the questionnaire (which explored costs) was limited as it relied on nurses’ recall and 
estimations on training resources, which may have been used years earlier. Therefore, the costs 
are not accurate representations of expenditure (i.e. may be over or under estimations), rather, 





several questions within section 3 were not completed by all respondents and so may not be truly 
representative of the sample.   
 
6.6.2.3 Patient questionnaires 
Although the questions used in the patient experience questionnaire were based on validated 
tools, there were some limitations which may have affected their overall validity. The questions 
designed to explore consultation satisfaction only (out of the 38 from the original validated tool 
(Weston et al., 2010)) that were deemed by the researcher as relevant for this study. There were 
three further issues associated with the SIMS tool that became apparent during data collection. 
Firstly, question 8 (i.e. “how to use your medication?”) was inadvertently omitted during design of 
the questionnaire. Secondly, the presentation of the SIMS tool in this study used a 1 to 5 
numbered scale to represent responses to questions. This could have been misinterpreted as a 
Likert scale. The use of dots, instead of a scale, would have been a more appropriate way to 
present this tool. Thirdly, some of the SIMS’s questions relating to adverse medication effects, 
may have unfairly criticised information provided by clinicians, particularly if the adverse effect 
was not relevant to the medication that was delivered, e.g. many drugs used in sexual health are 
unlikely to cause drowsiness, therefore, and it is unlikely to be routinely discussed, unless the 
patient asks. Consequently, the SIMS may be better applied, in some clinical areas, if questions 
not relevant to the medication supplied are not integral to the scoring. 
 
6.6.2.4 Clinical diary  
The clinical diary required nurses to remember to complete entries and code responses. While 
overall this was done well, multiple data points were omitted by participants. Moreover, data 
entries on consultation durations, and time spent with other professionals could have been over 
or under estimated and were frequently missing. While overall the diary yielded valuable data, in-
line with Moule and Goodman’s (2009) methodological suggestion, it complimented the other data 






6.6.2.5 Clinical notes review 
The original study design intended to use the clinical diary to source patients’ records for the 
clinical notes review. However, it became apparent that the minimum sample size quota would 
not be achieved using this method. This limitation subsequently strengthened the overall study 
design as sourcing of clinical notes was amended to come from patient attendance lists instead 
of the diary. Consequently, data collection became standardised between the five participating 
sites (in terms of dates) and explored actual practice rather than being limited to nurses who 
volunteered to participate in the diary. Nevertheless, relying on data not collected specifically for 
research was an issue as the clinical records only represented what was documented, rather than 
actual practice. Omitted documentation was the main limitation of using clinical records, and at 
times impacted on the researcher’s ability to draw conclusions. Moreover, there were difficulties 
in locating clinical notes in 2 out of 5 sites. In site 2 patient attendance lists could only be aligned 
to patients who received medication. Site 5 were unable to align patient attendances to those 
managed by nurses. Subsequently, each record had to be individually checked to determine 
which clinician managed the episode. Due to time constraints, it was not possible to obtain site 2 
& 5’s minimum quota for ‘INPs care episodes where medication was not given’.  To achieve these 
minimum sample size quotas within the study time frame, the clinical diary was used to source 
the remaining 18 records required. Overall, a total of 3,052 clinical records had to be reviewed by 
the researcher to achieve the 1,682 clinical records included in this study, which proved to be a 
time consuming and labour intensive task.  
A further limitation of the clinical notes review involved the researcher interpreting practice at sites 
with which they were unfamiliar. To strengthen the design, all aspects of substandard care/ 
documentation were confirmed with a local representative. Moreover, 10% of medication delivery 
records were independently checked by a local representative. However, there were some minor 
variations between the researcher and the independent reviewer. Most of these variations related 
to omitted documentation i.e. the researcher determined that a lack of documentation made 
aspects difficult to accurately assess, whereas local representatives were confident they 






6.6.2.6 Observational study 
While the researcher endeavoured not to influence practice, his presence, including participants’ 
awareness of audio-recording, was likely to have modified behaviour. This was, in some way, 
mitigated with nurse participants by undertaking multiple observations with the same nurse, 
behaviour change reported to be difficult to maintain for prolonged periods (Moule and Goodman, 
2009; Creswell, 2014). Moreover, the researcher’s presence may have affected patients’ ability 
to fully discuss their health concerns. A further limitation of this method was that audio-recording 
was used instead of video-recording. Consequently, subtleties and non-verbal communication 




The costs analysis used a descriptive approach which is generally considered the norm for 
exploring service delivery interventions (Sutton et al., 2018).The case study design limits the 
generalisability of the findings. There was some variability in practice between the research sites 
which was not explored in depth within the remit of this study as the focus was on an overall 
comparison between INP vs. PGDs. Therefore, the findings may not be generalisable to all sexual 
health services. 
It was evident from the findings that the resource implications of INP training and governance 
were significantly higher than those of PGD governance. However, it should be borne in mind that 
INP costs included time INPs spent with their DMPs as an additional resource. It is expected that 
INP students undertook much of the DMP supervision alongside their normal clinical duties, with 
their DMP being available as required (perhaps providing medication discussions at the end of 
clinics). Therefore, the DMP clinical supervision is unlikely to have incurred the full additional 
resources, time or costs reported. It was also evident from the findings that not all INPs obtained 
the full 12 DMP clinical supervision days expected as determined by the NMC (2015). A further 
consideration for INP training costs relates to the allocation of study days for attending university. 
Costing of study days was based on respondents’ current banding; however, respondents may 





captured in this study, was the resources and costs associated to backfill while undertaking INP 
training which may increase costs or affect the provision of service delivery.  There may also be 
cumulative costs associated with INP training which includes PGD training as 22 (85%) INPs 
reported using PGDs prior to becoming prescribers.  
Sections on PGD governance are very limited as the researcher was only able to track the 
process at one single time-point from one site. While the researcher’s input was logged, other 
stakeholders may not have been as diligent with the time they spent reviewing PGD 
documentation. Moreover, the researcher was a member of the non-medical prescribing 
committee and knew the PGD approval process very well. Someone less informed may have 
taken longer to navigate the pathway. Further tracking of multiple PGDs are required to obtain a 
more accurate cost assessment for PGD governance.  
Medication costs presented were based on BNF 2016 prices, but local services may have 
negotiated better prices. However, this is unlikely to impact on the findings as there were no 
statistically significant differences in the therapeutically appropriate delivery of medications.  
 
 
6.6.3 Implications for practice 
 
Findings from this research have several potential implications for policy and practice from the 
perspective of the NHS, managers and individual nurses.   
 
NHS perspective 
This study has demonstrated that the independent delivery of medication is an essential 
component of the sexual health nurse practitioner role. Consequently, it is essential that the NHS 
continues to provide funding and professional support to facilitate medication delivery training, 
integration and CPD. Where clinically appropriate, nurse practitioners should be offered the 





skills. While INP was found to offer greater flexibility and responsiveness to patients’ 
requirements, PGDs clearly offered medication delivery benefits for nurses not willing, or able, to 
become INPs. Moreover, PGDs were also found to support junior staff training to become 
autonomous practitioners prior to undertaking INP roles. As both INP and PGDs facilitate 
autonomous practice doctors’ time can be released to allow doctors to manage more clinically 
complex patient presentations. Therefore, ongoing clinical integration of both INP and PGDs are 
indicated within sexual health.  
With regards to PGDs, it was evident that a great amount of variability existed in a small number 
of sites with regards to how PGD training was conducted and how nurses were deemed 
competent to use PGDs. To provide greater structure and consistency for PGD training, it is 
recommended that the NHS creates a national standardised PGD training and assessment 
programme. This could be divided into two parts. Part 1 providing information on general PGD 
legislation and use, and Part 2 tailored to provide speciality-specific medication training. Part 2 
could be created in collaboration with NHS-approved clinical speciality working groups to align 
PGD training with the relevant national standards and guidelines. These same speciality working 
groups could also write, approve, and update national PGDs that could be adaptable for local 
use. For example, PGD documents could be designed so their indications for use and exclusions 
were optional to allow local services to customise how they were used in clinical practice. 
Moreover, if the overall oversight of the PGDs were at a national level, this would standardise 




NHS managers’ perspective 
The study’s findings identified a number of issues which had implications for practice from a 
manager’s perspective. These included (i) considerations of nurses’ scope of practice and what 
access to medication is required; i.e. PGDs or INP (ii) the use of PGDs outside of their restrictions; 





ensure nurses have the correct access to medication as required by the local patient population 
and service delivery model. PGDs were used outside of their restrictions by participants in this 
study. It is, therefore, important for managers to ensure that medication delivery method(s) are fit 
for purpose and undertaken safely and appropriately. Furthermore, the incomplete documentation 
identified in this study highlights the need for improvement in documentation skills. This could be 
achieved through discussions in local team meetings, appraisals and routine documentation 
audits or increased use of electronic proformas.  
 
Nurses’ perspective 
While the NHS local managers have a responsibility to support nurses delivering medications, 
ultimately, individual nurses have accountability and responsibility over their own practice. 
Consequently, nurses should ensure they are aware of their scope of practice and understand 
the implications of delivering medications. The NHS has restricted educational budgets, and 
therefore, nurses should seek CPD such as self-directed learning, peer teaching, journal clubs 
and engagement with organisations and professional communities involved in creating national 
guidelines (e.g. BASHH or FSRH). 
 
6.6.4 Future research 
 
This study has explored nurses’ medication delivery in sexual health and confirmed the safety 
and appropriateness of INP and PGD use within this speciality. However, further exploration of 
medication safety is required across other specialities and professions, particularly as the non-
medical prescribing powers are being widened to other healthcare professional groups. This study 
design could be repeated in other clinical areas, specifically those that utilise more complex drug 
regimens (e.g. chemotherapy), or where patients frequently have multiple co-morbidities and/ or 
polypharmacy. Moreover, as nurses have become independent practitioners in their own right, 
further research into how INP compared with doctors’ prescribing practice, and how nurses’ 





Are nurses becoming maxi-nurses or mini-nurses? (ii) How do professional models of care 
(nursing vs. medical) influence consultation skills, patient care, patient experience and prescribing 
practice? 
There is limited evidence that has explored the benefits and resources of nurses working in 
advanced practice roles. In the studies that are available (Norman et al., 2010; Courtenay et al., 
2015) the findings go against expectations that nurses in advanced practice roles offer greater 
cost-effective healthcare delivery. As INPs in this study were also found to be more expensive, 
further research into the resource and cost implications of nurses working in autonomous roles is 
required throughout a range of advanced practice skills and clinical areas. It should be borne in 
mind that cost should not always be the primary focus rather the value added benefit of nurses 
working in advanced practice roles.  
Another area for research includes further in-depth interviews and focus groups with NHS 
stakeholders to (i) provide a deeper analysis of their perceptions of medication delivery 
governance, (ii) formulation of a more streamlined approach to approval of INP and PGDs from 
an organisational, departmental and individual’s perspective, (iii) support standardisation of 








The robust multiple mixed methods approach employed throughout this study has generated new 
epistemological and ontological knowledge with regards to how INP and PGDs influence sexual 
health nurses’ practice from: experts in the field; detailed empirical research methods; and the 
exploration of how nurses work for the well-being of patients, the NHS and themselves. It was 
evident throughout this study that independent access to medication is fundamental to the modern 
sexual health nurses’ role. Moreover, INP and PGDs have facilitated a paradigm shift for nurses, 
moving from doctors’ handmaidens to autonomous advanced clinical practitioners who 
independently manage patient care episodes, run their own clinics and hold high levels of 
academic achievement (i.e. Masters Degrees and PhD). Consequently, nurses were found to 
hold a range of positions, from providers of day-to-day service delivery to advanced practitioners, 
to clinical leaders, researchers and innovators to those that hold senior strategic policy making 
and governance positions. While limited to sexual health, when considered against the existing 
literature, it is expected the findings from this study can be generalised to other specialities where 
nurses autonomously manage patient care episodes.  
This study found a highly comparable level of clinical practice between INPs and PGD users with 
regards to the range of conditions managed and medications required. However, INPs were found 
to be more responsive, autonomous and flexible in delivering medications compared to PGD 
users. Moreover, INPs, as compared to PGD users, often benefited by working at higher salary 
bands, but this cannot be solely attributed to becoming an INP. The benefits and barriers between 
INP vs. PGDs varied between sites and individual nurses. While most NHS stakeholders regarded 
PGDs as both cumbersome and time-consuming to govern, in-line with their purpose (NICE, 
2013), PGDs were less expensive to incorporate within clinical teams and were highly suitable for 
situations where patients had predictable presentations. However, as nurses began to manage 
more clinically complex presentations, the restrictive nature of PGDs was apparent, and INP 
enabled nurses to work more autonomously and be responsive to patients’ medication needs. 
Nevertheless, PGDs offer a suitable alternative to INP where nurses cannot, or do not wish to, 





Given the trailblazing approach the UK has, to providing non-medical healthcare professionals 
with independent access to medications, this study has further re-enforced the safety, 
appropriateness and professionalism that nurses have with regards to their medication delivery 
powers. Such findings should provide additional reassurance to other countries looking to expand 
legislation with regards to non-medical prescribing. Moreover, this study has also demonstrated 
that specialist sexual health nurses are comparably as safe as their medical counterparts (of note 
this study employed stricter criteria for ‘errors’ in comparison to other studies; however, this study 
was within a specialist area while previously doctor comparisons were usually based on evidence 
from more generalised settings). Consequently, further consideration should be given to: how 
nurses’ medication access has influenced the nursing and medical roles/ relationship; the effects 
on patient interactions and outcomes; and the impact on service delivery. These are important 
considerations, in order to determine the value added benefits of how INP and PGDs facilitate 
nurses in managing increasingly complex patient presentations, and how nurses’ practice 
compares with that of their medical colleagues. Such exploration of value added benefits would 
be meaningful given the apparently substantial cost differences reported between INPs and PGD 
users (which may provide over-inflated comparisons that deter NHS managers from embracing 
INP within their services). Nevertheless, both INP and PGDs were found to be highly suitable, 








6.8 Post-script: about the researcher and his PhD journey 
I qualified as a nurse in 1999 and worked in sexual health nursing since 2002 in various roles 
including staff nurse, charge nurse, health practitioner, nurse practitioner and consultant nurse. 
Through my advanced clinical practice roles, I became more inquisitive with regards to evidence 
based practice, the development of clinical guidelines and auditing performance against 
standards of practice. I became a qualified INP in 2008. During my INP training I had noted that 
there was limited literature on advanced practice in sexual health, and despite a growing non-
medical prescribing evidence base, I felt more research was needed with regards to its clinical 
application. Subsequently, I used my NIHR Masters of Research in clinical practice fellowship in 
2010 to explore how nurse practitioners delivered medication in sexual health and accident and 
emergency. That project formed the basis of this study and also created a personal academic 
interest with regards to how nurses work at advanced levels, particularly related to medication 
delivery.  
This project was further shaped through my consultant nurse clinical role. I often attended 
meetings with senior NHS stakeholders, and I noticed three key components that were raised 
frequently: (i) how aspects of care were integrated within clinical practice and how safe were they? 
(ii) What was the patient experience of using the service? (iii) How much did it cost and could we 
make savings? Therefore, to ensure this study had relevance back to clinical practice, I 
considered these three themes essential components when designing this project. Also within the 
consultant nurse role I experienced first-hand how ‘cumbersome’ and ‘stressful’ the PGD 
governance, approval and training process could be. 
This project was awarded funding as part of an NIHR/ HEE clinical doctoral research fellowship. 
Given the opportunities associated with the training fellowship, I was very keen to experience 
undertaking different research methods while receiving expert supervision. While I feel the project 
warranted the multiple mixed methods approach, I also personally benefited from practically 
experiencing the strengths and weaknesses of the various methods adopted throughout this 
study. Although it presented challenging issues by creating vast amounts of data and how best 





research projects in the future. However, I would seek more efficient processes to obtain the 
required data (e.g. avoiding the need to review 3,000 sets of notes).  
While undertaking this PhD process I greatly valued the expertise in the team around me, the 
level direction provided by my supervisor team and support from colleagues, family and friends. 
One colleague did pass on some great advice: ‘if something is taking you a long time, then there 
is probably an easier way to do it’. This was never as true as when I considered the weeks and 
months I was undertaking data analysis doing multiple calculations on Microsoft Excel®, and then 
my statistician repeated many of my calculations in SPSS® in just a few clicks. While this gave 
me confidence in the accuracy of my calculations, I have learned to go to the person who knows 
much sooner to save a lot of unnecessary work.  
The main aspect that I have taken from this project is how willing people were to support me and 
how generous they were with their time. This was particularly evident at the research sites where 
nobody knew me, yet many colleagues were very proactive and extremely welcoming. Sometimes 
this went beyond participation in the project. One such example of kindness was when I was 
camping for a week during data collection as all the hotels were fully booked and staying in the 
5-star luxury spa hotel would have exceeded my entire subsistence budget. Upon hearing I was 
staying in a tent (which I rather enjoyed) many of the team offered their spare rooms. While I was 
very touched, I politely declined; however, one nurse was adamant that I came over for dinner to 
ensure I had at least one home cooked meal. I have very fond memories from all the sites and 
I’m forever grateful to everyone who supported me.  
Throughout this process people often commented to me that you must be really intelligent to 
undertake a PhD. I do not feel that is the case, rather to complete a PhD I feel you need to be 
able to focus on a single topic for a very long time, take direction well, take criticism constructively, 
smile and trust in your own expertise and in that of your team.  This has been a difficult but 
rewarding journey that has provided me with the tools and experience to continue my clinical 
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Appendix A. Staff interviews: Interview schedule 
Stakeholders Interview Outline 
Version 2: 31st October 2014 
 
Participants:  
Stakeholders within organisations that are involved on a managerial/ governance level for 
incorporating independent nurse prescribing and patient group directions within sexual health 
services.  
Venue: 
If the researcher is able to easily attend the participants’ preferred address then they will be given 
the choice of a face to face or telephone interview. If travelling to the participants’ address is 
difficult then they will be invited to a telephone interviews. Interviews will take place at the most 
convenient times for the participants.  
Agenda: 
 Thank participants for their interest in the study and their time.  
 Introduce myself and give brief explanation of the research project. 
 General housekeeping  
o Ensure the participant has read the information sheet before the interview and has 
signed the consent form.  
o confirmation that the following section will be audio taped,  
o anonymity of participants within the written section of the study   
o freedom of expressing personal opinions without prejudice.  
o Opportunity to ask any further questions before beginning.  
[5 minutes] 
Question prompts: 
1. Can you discuss your perception of how your service(s) are affected by nurses being able to 
provide medication by independent nurse prescribing and/ or patient group directions?  
[20 minutes] 
2. What are the benefits and concerns of integrating independent nurse prescribing within 
your organisation(s)?  
[20 minutes] 
3. What are the benefits and concerns of integrating and maintaining patient group directions 
within your organisation(s)?  
[20 minutes] 
Maximum total duration: 65 minutes. 






Appendix B. Staff interviews: Participant information sheet 
 
Task 1: Stakeholder Interviews Participant Information Sheet 
Version 4.2: 9th July 2015 
 
Study title 
A comparison in the clinical application, patient experience and health economics between 
independent nurse prescribing and patient group directions in sexual health services 
Invitation and brief summary 
We’d like to invite you to take part in a research study because you are a senior NHS stakeholder 
involved with integrating nurse prescribing and/ or patient group directions within the sexual health 
department. Joining the study is entirely up to you, before you decide we would like you to 
understand why the research is being done and what it would involve for you. The researcher will 
go through this information sheet with you, to help you decide whether or not you would like to 
take part and answer any questions you may have. We’d suggest this should take about 10 
minutes. Please feel free to talk to others about the study if you wish. 
 
Available evidence on how nurses’ ability to independently deliver medicines affects services and 
patient experience is limited. This study aims to explore these issues in the context of sexual 
health clinics. The study involves mixture of seven methods to explore this topic from different 
perspectives. You are being invited to participate in Task 1: NHS Stakeholders’ Interview; either 
face to face or by telephone lasting approximately 1 hour. Your experiences in these areas will 
be audio taped and used to provide valuable information to form the basis of the study.  
What’s involved? 
You will be asked to participate in a face-to-face or telephone interview at a convenient time for 
you. There are a total of 5 research sites; a senior NHS stakeholder at each site will be invited to 
participate. You will be asked to share your experiences relating to the governance related to the 
integration of nurse prescribing and/ or PGDs into clinical practice, which will be audio taped, 
transcribed verbatim and compared against the other participants.  
You will be requested to sign a consent form prior to participation and after a period of 48 hours 
has passed following reading this information sheet.  
 
What are the possible benefits of taking part? 
There is no direct benefit but your help may allow us to have a deeper understanding of the 
governance issues relating to the integration of nurses delivering medication independently.  
 
What are the possible disadvantages and risks of taking part?  
There is a time commitment issue, however a telephone based meeting aims to reduce the impact 
on your workload. Should you prefer a face-to-face interview this will be done at a time and venue 
to cause minimal disruption to your work load. As part of that review unsafe practice may be 
discovered. Any such occurrences will be discussed with you, and if appropriate a senior 
manager. Your opinion may not be shared among other participants that are interviewed, however 
all opinions are valuable, and it is recognised not all users will have the same experience.  
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researcher 
who will do their best to answer your questions. In the first instance please contact Adam Black 
(Researcher) on 07XXXXXXXXX or adam.black@kcl.ac.uk. Should you have any further 
concerns, please contact: Professor Christine Norton (Principle Investigator) by email: 
Christine.norton@kcl.ac.uk  
If you have a complaint, you should talk to Adam Black who will do his best to answer your 
questions. If you remain unhappy, you may be able to make a formal complaint through the NHS 
complaints procedure.  Details can be obtained through the Patient Advice & Liaison Service 





This study is sponsored by King’s College London. The sponsor will at all times maintain adequate 
insurance in relation to the study independently. Kings College London, through its own 
professional indemnity (Clinical Trials) and no fault compensation. 
What will happen if I don’t want to carry on with the study? 
Participation is entirely voluntary. Should you decide that you do not wish to participate, or later 
withdraw, you do not need to provide a rationale and you will not be penalised in any way. 
 
Will my information be kept confidential? 
Your participation will be treated confidentially. Your interview will have a study ID allocated to it, 
traceable only by the researcher. The device used to record the interview will encrypt the data. 
The audio recording will be transcribed verbatim and undergo thematic analysis. Both the audio 
file and transcription will be securely stored on a Virtual Private Network at Imperial College 
Healthcare NHS Trust, which is accessible only by Adam Black and Professor Christine Norton.  
Responses from all participants will be combined for analysis and you will not be named in any 
reports or publications. All information which is collected during the course of the research will be 
kept confidential, in accordance with the Data Protection Act 1998. Should you wish a copy of 
your transcribed interview please contact Adam Black.   
 
What will happen to the results of this study? 
The results of the study will be reviewed against other participants and undergo descriptive 
analysis, statistical testing and a health economics review. The data will be used to write up a 
PhD thesis and be disseminated in relevant professional journals and conferences.  
 
Who is organising and funding the research? 
The study is organised by Adam Black, a Consultant Nurse in Sexual Heath prior to undertaking 
a PhD fellowship. This study is funded through a Clinical Doctoral Research Fellowship by the 
National Institute of Health Research & Health Education England (NIHR/HEE). The study forms 
part of a PhD programme at the King’s College London undertaken by Adam Black. 
 
Who has reviewed this study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable opinion 
by Wales 4 Research Ethics Committee, ref: 15/WA/0120. The study was also reviewed by the 
department’s Research & Development prior to starting.  
 
Further information and contact details 
Specific advice about this research study: please contact Adam Black on 07XXXXXXXXX or 
by email at adam.black@kcl.ac.uk. Should you have any further concerns please contact the 
Principal Investigator at King’s College London, Professor Christine Norton, by email: 
christine.norton@kcl.ac.uk 
 
Advice as to whether they should participate: Should you require any independent advice 
on participating in research please speak to your line manager or your organization’s 
Research & Development team. 
 














Appendix D. Staff questionnaire: Participant information 
sheet 
Task 2 Staff Questionnaire Participant Information Sheet 
Version 6.1; 9th July 2015 
 
Study title 
A comparison in the clinical application, patient experience and health economics between 
independent nurse prescribing and patient group directions in sexual health services. 
 
Invitation and brief summary 
We’d like to invite you to take part in a research study because you are a nurse using independent 
nurse prescribing or patient group directions in a sexual health department. Joining the study is 
entirely up to you, before you decide we would like you to understand why the research is being 
done and what it would involve for you. The researcher will go through this information sheet with 
you, to help you decide whether or not you would like to take part and answer any questions you 
may have. We’d suggest this should take about 10 minutes. Please feel free to talk to others 
about the study if you wish. 
Available evidence on how nurses’ ability to independently deliver medicines affects services and 
patient experience is limited. This study aims to explore these issues in the context of sexual 
health clinics. You are being invited to participate in a study designed to explore how independent 
nurse prescribing and patient group directions are used by nurses in sexual health services. The 
study involves mixture of methods to explore this topic from different perspectives. You are being 
invited to participate in Task 2: Staff Questionnaire because you have been identified as a nurse 
working within sexual health who uses independent nurse prescribing or patient group directions. 
All nurses that are able to independently deliver medication in your department are being invited 
to participate.  
What’s involved? 
If you agree to take part in this study, you are requested to complete a questionnaire which asks 
about your skills, experience and opinions of how nurses’ independent delivery of medication 
affects practice. This questionnaire will take approximately 20 minutes to complete. 
What are the possible benefits of taking part? 
There is no direct benefit but your help may allow us to have a deeper understanding of how 
nurses in sexual health are able to independently deliver medications.  
 
What are the possible disadvantages and risks of taking part? 
It is expected only to take approximately 20 minutes to complete.  
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researcher 
who will do their best to answer your questions. In the first instance please contact Adam Black 
(Researcher) on 07XXXXXXXXX or adam.black@kcl.ac.uk. Should you have any further 
concerns, please contact: Professor Christine Norton (Principle Investigator) by email: 
Christine.norton@kcl.ac.uk  
If you have a complaint, you should talk to Adam Black who will do his best to answer your 
questions. If you remain unhappy, you may be able to make a formal complaint through the NHS 
complaints procedure.  Details can be obtained through the Patient Advisory Liaison Service 
[insert local details]. 
This study is sponsored by King’s College London. The sponsor will at all times maintain adequate 
insurance in relation to the study independently. Kings College London, through its own 







What will happen if I don’t want to carry on with the study? 
Participation is entirely voluntary. Should you decide that you do not wish to participate you do 




Will my information be kept confidential? 
Your participation will be treated confidentially. Your questionnaire will be analysed with other 
responses from all participants and combined for analysis. You will not be named in any reports 
or publications. The back page inviting you to participate in the next stages will be removed before 
the questionnaire is reviewed. All information which is collected during the course of the research 
will be kept confidential, in accordance with the Data Protection Act 1998. All electronic data 
generated will be stored on a secure Virtual Private Network at Imperial College Healthcare NHS 
Trust, accessible only by Adam Black and Professor Christine Norton. All hardcopies will be 
destroyed as NHS confidential waste after being scanned and electronically stored. 
 
What will happen to the results of this study? 
The results of the study will be reviewed against other participants and undergo descriptive 
analysis, statistical testing and a health economics review. The data will be used to write up a 
PhD thesis and be disseminated in relevant professional journals and conferences.  
 
Who is organising and funding the research? 
The study is organised by Adam Black, a Consultant Nurse in Sexual Heath prior to undertaking 
a PhD fellowship. This study is funded through a Clinical Doctoral Research Fellowship by the 
National Institute of Health Research & Health Education England (NIHR/HEE). The study forms 
part of a PhD programme at the King’s College London undertaken by Adam Black. 
 
Who has reviewed this study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable opinion 
by Wales 4 Research Ethics Committee, ref: 15/WA/0120. The study was also reviewed by the 
department’s Research & Development prior to starting.  
 
Further information and contact details 
 
Specific advice about this research study: please contact Adam Black on 07XXXXXXXXX or 
by email at adam.black@kcl.ac.uk. Should you have any further concerns please contact the 
Principal Investigator at King’s College London, Professor Christine Norton, by email: 
christine.norton@kcl.ac.uk 
 
Advice as to whether they should participate: Should you require any independent advice 
on participating in research please speak to your line manager or your organisation’s 
Research & Development team. 
 








































































































Appendix H. Clinical diary: Explanatory notes 
Sexual Health Nurse Activity Diary: Explanatory Notes V6.1: October 2014   
Dear Colleague,  
 
Thank you for agreeing to complete a brief clinical diary for the above study. The diary has been 
designed to gather data on your clinical activity, frequency and independence of medication 
provision, and to record the distribution of patient questionnaires.  I would be grateful if you would 
complete the diary every time you conduct a patient-facing clinical session, over a period of 2 
weeks. 
  
This sheet provides explanatory notes to assist you in completing the diary. Should you have any 
further questions please contact Adam Black on 07XXXXXXXX or adam.black@kcl.ac.uk 
Subject 
heading Pre-set data Explanation 
Sexual Health 
Clinic Site 
 Name  of the department /  clinic where your patient facing session is 
occurring  
Nurse code  Check that a code has been added to identify you 
INP/PGD 
 Circle as appropriate to indicate if you are an independent nurse 
prescriber or PDG user 
Session date/ 
start time 
 State the date of the clinic session and its start time 




For each new patient please provide ‘Clinic ID Number’ & date of birth 
or an ID sticker 
New / FU 
New Circle if a new episode of care 
FU Circle if it’s a follow-up episode of care 
Medication 
provided 
Yes CIRCLE IF MEDICATION WAS DELIVERED 
No CIRCLE IF MEDICATION WAS NOT DELIVERED 
Advice 
No Circle if you did not require any advice from a colleague  
CM Circle if you needed advice on the clinical management of the patient 
Med Circle if you needed advice on any form of medication delivery 
D  N  P  HA Circle the appropriate abbreviation relating to what colleague you 
obtained advice from: 
D: Doctor  N: Nurse  P: Pharmacist  HA: Health Advisor 
Medication 
delivery 
Independent Circle if you independently delivered the medication 
Rx from: 
D  N  P  HA 
Circle the appropriate abbreviation relating to what colleague you 
obtained a prescription from: 
D: Doctor  N: Nurse  P: Pharmacist  HA: Health Advisor 
No PGD 
Circle only if you use PGDs where medication was indicated but NOT 
covered by the PGD. 
Time (minutes) 
patient related 
 Please provide an estimate of how many minutes spent on the patient in 
relation to ‘Face-to-face’; ‘Non pt facing’ & time with other professional 
Face-to-face 
 How long (minutes) you spent in consultation with the patient (inc. 
history, examination and results) 
Non Pt facing  How long (minutes) you spent on this patient, but NOT face –to –face 
(e.g. writing notes, referral letters, etc.) 
With other 
profession 
 How long (minutes) you spent with the other professional indicated in 
the ‘Advice’ column.  Record 0 (zero) minutes if you sought no advice 
for this patient.  
Please hand a questionnaire to patients you deliver medication to at the end of the consultation 
Patient 
questionnaire 
Yes, ref: Detail if you gave the patient a questionnaire when delivering 
medication; record the questionnaire number 
Not given Circle if you did not give a questionnaire. If possible please detail reason 








Appendix I.   Clinical diary: Participant information sheet 
 
Task 3A Clinical Diary: Participant Information Sheet 
Version 8.2:  1st February 2016 
 
Study title 
A comparison in the clinical application, patient experience and health economics between 
independent nurse prescribing and patient group directions in sexual health services 
 
Invitation and brief summary 
We'd like to invite you to take part in a research study because you are a nurse who is using 
independent nurse prescribing or patient group directions in the sexual health department. 
Following completion of the questionnaire you expressed an interest in taking part in this next 
phase of the research. Joining the study is entirely up to you, before you decide we would like 
you to understand why the research is being done and what it would involve for you. The 
researcher will go through this information sheet with you, to help you decide whether or not you 
would like to take part and answer any questions you may have. We'd suggest this should take 
about 10 minutes. Please feel free to talk to others about the study if you wish. 
Available evidence on how nurses’ ability to independently deliver medicines affects services and 
patient experience is limited. This study aims to explore these issues in the context of sexual 
health clinics. The study involves a mixture of methods to explore this topic from different 
perspectives. You are being invited to participate in Task 3A: Clinical Diary. This involves 
recording simple information during your normal clinical duties for a period of 2 weeks. You will 
also be requested to hand out patient experience questionnaires if you deliver medication 
 
What’s involved? 
If you agree to take part in this study, you are requested to complete a simple diary for a period 
of two weeks to record your normal clinical duties. Completion of the diary requires the patient’s 
clinic number, approximate consultation times and ‘circling’ responses to questions relating to 
how medication was given and if you received any support from any of your colleagues. Diary 
booklets can be handed to the researcher at the end of the two week data collection period, or 
posted in the freepost envelope provided. You will also be requested to distribute a patient 
experience questionnaire. The researcher will then use the diaries to explore how nurses deliver 
medication in terms of frequency and independence, and may be used to identify a sample of 
patient records. 
 
What are the possible benefits of taking part? 
There is no direct benefit but your help may allow us to have a deeper understanding of how 
independent nurse prescribing and patient group directions are used in clinical practice by sexual 
health nurses.  
 
What are the possible disadvantages and risks of taking part?  
It is expected to take less than 1 minute to complete the diary at the end of every patient facing 
consultation. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researcher 
who will do their best to answer your questions. In the first instance please contact Adam Black 
(Researcher) on 07XXXXXXXXX or adam.black@kcl.ac.uk. Should you have any further 
concerns, please contact: Professor Christine Norton (Principle Investigator) by email: 
Christine.norton@kcl.ac.uk  
If you have a complaint, you should talk to Adam Black who will do his best to answer your 
questions. If you remain unhappy, you may be able to make a formal complaint through the NHS 
complaints procedure.  Details can be obtained through the Guy’s and St Thomas’ Patient 
Advisory Liaison Service (PALS) on 0207 1887188, address: PALS, KIC, Ground floor, north 






This study is sponsored by King’s College London. The sponsor will at all times maintain adequate 
insurance in relation to the study independently. Kings College London, through its own 
professional indemnity (Clinical Trials) and no fault compensation. 
What will happen if I don’t want to carry on with the study? 
Participation is entirely voluntary. Should you decide that you do not wish to participate, or later 
withdraw, you do not need to provide a rationale and you will not be penalised in any way. 
 
Will my information be kept confidential? 
Your participation will be treated confidentially. Your participation in the clinical diary will be coded 
using a study ID, traceable only by the researcher. Responses from all participants will be 
combined for analysis and you will not be named in any reports or publications. All information 
which is collected during the course of the research will be kept confidential, in accordance with 
the Data Protection Act 1998. In cases where queries about your practice exists may result in the 
researcher discussing this with you or your manager for further clarification, however you will not 
be named in the research reports. All electronic data generated from the study will only be stored 
on a secure Virtual Private Network at Imperial College Healthcare NHS Trust, accessible only 
by Adam Black and Professor Christine Norton. Hardcopies will be destroyed as confidential NHS 
waste after they have been scanned and electronically stored.  
 
What will happen to the results of this study? 
Data from the clinical diary will be collected on a specifically designed database. The results will 
be reviewed against other participants and undergo descriptive analysis, statistical testing and a 
health economics review. The data will be used to write up a PhD thesis and be disseminated in 
relevant professional journals and conferences.  
 
Who is organising and funding the research? 
The study is organised by Adam Black, a Consultant Nurse in Sexual Heath prior to undertaking 
a PhD fellowship. This study is funded through a Clinical Doctoral Research Fellowship by the 
National Institute of Health Research & Health Education England (NIHR/HEE). The study forms 
part of a PhD programme at the King’s College London undertaken by Adam Black. 
 
Who has reviewed this study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable opinion 
by Wales 4 Research Ethics Committee, ref: 15/WA/0120. The study was also reviewed by the 
department’s Research & Development prior to starting.  
 
Further information and contact details 
 
Specific advice about this research study: please contact Adam Black on 07XXXXXXXXX or 
by email at adam.black@kcl.ac.uk. Should you have any further concerns please contact the 
Principal Investigator at King’s College London, Professor Christine Norton, by email: 
christine.norton@kcl.ac.uk 
 
Advice as to whether they should participate: should you require any independent advice 
on participating in research please speak to your line manager or your organisation’s 
Research & Development team. 














Appendix K. Clinical notes review: Data collection field list 
 
Field name Description/ rationale for data collection 
ID Unique entry number 
Entry date Automated date of entry's creation 
Site Details of entry's research site 
Entry purpose 
Differentiation of data collected for clinical notes, observations or local random 
review 
Delivery method Was care delivered by INP or PGD user, and was medication given? 
Participant ID Coded nurse identifier  
Gender What is the patients’ gender? 
Age How old was the patient on date of attendance? 
Ethnic origin What was the patient's registered ethnic origin? 
Sexual orientation What was the patient's registered sexual orientation? 
Attendance date What date did the patient attend? 
Episode type Was the patient attending for new or follow-up care episode? 
Symptoms Was the patient attending with symptoms? 
PMH Was the patient's past medical history documented? 
Meds Was the patient's concurrent medication documented? 
Allergy Was the patient's allergies (or lack of) documented? 
PT risk Where applicable, was pregnancy/ breast feeding risk documented 
PMH comments Detail any PMH, meds, allergies, pregnancy issues 
Diagnosis (1-5) Details of diagnose(s); five entry fields given 
Diagnosis 
comments 
Further details/ comments related to diagnosis 
Drug name (1-4) Name of the drug delivered; four entry fields given 
Dose (1-4) Dose of the drug delivered; four entry fields given 
Frequency (1-4) Frequency of the drug delivered; four entry fields given 
Length (1-4) Duration of the drug's regimen; four entry fields given 
Signature 
Signature on the page where documentation of the drug delivered; four entry 
fields given 
INP/ PGD Was the drug delivered through INP or PGD 
Drug comments Further details/ comments related to medication 
Advice Was there any documentation that the nurse sought advice 
Independent 
completion 
Was the episode of care completed autonomously?  
Clinical advice 
obtained 
Did the nurse seek clinical advice? 
Medication advice Did the nurse seek medication advice? 
Specialist referral Did the nurse make a specialist referral for the patient? 
Non-provision Was medication indicated but not given? 
Non-provision 
comments 
Further details/ comments related to non-provision of medication when it was 
indicated 
Indication MAI: Is there an indication for the drug? 
Effective MAI: Is the medication effective for the condition? 
Dosage MAI: Is the dosage correct? 
Directions correct MAI: Are the directions correct? 





Field name Description/ rationale for data collection 
Drug-drug 
interaction 
MAI: Are there clinically significant drug-drug interactions? 
Drug-disease 
interaction 
MAI: Are there clinically significant drug-disease interactions? 
Duplication MAI: Is there unnecessary duplication with other drugs? 
Duration MAI: Is the duration of therapy acceptable 
Cost 
MAI: Is this drug the least expensive alternative compared to others of equal 
utility? 
MAI comments Each MAI question had a separate section to add further details/ comments 
PGD limits Was the medication delivered within the PGD's restrictions (PGD users only) 
PGD limits 
comments 
Further details/ comments related to PGD use 
INP vs PGD 
Was the PGD suitable for PGD users / if an INP used a PGD could they have 
managed the patient? 
Appropriate Overall, was the episode of care and medication delivery appropriate? 
Safe Overall, was the episode of care and medication delivery safe? 
Overall Overall, was the episode of care and medication delivery safe & appropriate? 
Overall comments Further details/ comments related to overall safety and appropriateness 
Clarification Was further clarification/ discussion needed/ sought? 
Unplanned re-
attendance 
Did the patient return for an unplanned visit relating to the episode of care? 
Unplanned 
comment 
Further details/ comments related to unplanned visit 
ID= identifier, INP= independent nurse prescriber, MAI= Medication Appropriateness Index, 
meds= concurrent medications, PGD= patient group direction, PMH= past medical history, PT= 

















Appendix M. Patient experience questionnaire: Participant 
information sheet (English version) 
 
Task 5 Patient Experience Questionnaire Participant Information Sheet 
Version 4.1: 9th July 2015 
 
Study title 
A comparison in the clinical application, patient experience and health economics between 
independent nurse prescribing and patient group directions in sexual health services 
 
Invitation and brief summary 
We'd like to invite you to take part in a research study because you received medication from a 
nurse who was able to provide medication without speaking to a doctor. Available evidence on 
how nurses independently deliver medicines affects services and patient experience is limited. 
This study aims to explore these issues in the context of sexual health clinics. You are being 
invited to participate in Task 5: Patient Experience Questionnaire as you received medication 
from a nurse today and we would like feedback on your experience.  
 
What’s involved? 
If you agree to take part in this study, you are requested to complete a questionnaire about your 
experience and confidence in receiving your medication. This questionnaire will take 
approximately 10 minutes to complete. 
 
What are the possible benefits of taking part? 
You have the option to enter into a prize draw to potentially win one of ten £20 ‘High Street 
Vouchers’. There may be no benefit to you; however we aim to get a better understanding of 
patients’ experience in using the sexual health service.  
 
What are the possible disadvantages and risks of taking part? 
It is expected only to take approximately 10 minutes to complete.  
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to in the first instance please 
contact Adam Black (Researcher) on 07XXXXXXXXX or adam.black@kcl.ac.uk. Should you have 
any further concerns, please contact: Professor Christine Norton (Principle Investigator) by email: 
Christine.norton@kcl.ac.uk .If you have a complaint about your care you should ask to speak to 
the nurse in charge who will do their best to answer your questions. If you remain unhappy, you 
may be able to make a formal complaint through the NHS complaints procedure.  Details can be 
obtained through Patient Advisory Liaison Service [insert local details]. 
This study is sponsored by King’s College London. The sponsor will at all times maintain adequate 
insurance in relation to the study independently. Kings College London, through its own 
professional indemnity (Clinical Trials) and no fault compensation. 
 
What will happen if I don’t want to carry on with the study? 
Participation is entirely voluntary. Your medical care will not be affected should you decide that 
you do not wish to participate. 
 
 
Will my information be kept confidential? 
Your participation will be treated confidentially. All information which is collected during the course 
of the research will be kept confidential, in accordance with the Data Protection Act 1998. If you 
complete the back page inviting you to participate in the optional prize draw please remove this 





will be transferred onto an electronic database. All electronic data will be stored on a secure 
Virtual Private Network at Imperial College Healthcare NHS Trust, accessible only by Adam Black 
and Professor Christine Norton. Your questionnaire will be scanned and stored electronically. 
Hardcopies of the questionnaire and prize draw sheets will be destroyed as confidential NHS 
waste. 
 
What will happen to the results of the study? 
The results of the study will be reviewed against other participants and undergo descriptive 
analysis, statistical testing and a health economics review. The data will be used to write up a 
PhD thesis and be disseminated in relevant professional journals and conferences.  
 
Who has reviewed this study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable opinion 
by Wales 4 Research Ethics Committee, ref: 15/WA/0120. The study was also reviewed by the 
department’s Research & Development prior to starting.  
 
Further information and contact details 
 
Specific advice about this research study: please contact Adam Black on 07XXXXXXXXX or 
by email at adam.black@kcl.ac.uk. Should you have any further concerns please contact the 
Principal Investigator at King’s College London, Professor Christine Norton, by email: 
christine.norton@kcl.ac.uk 
 
Further advice relating to participating in research or about your clinical care: Should you 
require any independent advice on participating in research please speak to the nurse you 
were managed by, the nurse in charge or the Patient Advisory Liaison Service. 
 






Appendix N. Patient experience questionnaire: Participant 
information sheet (Welsh version) 
 
Taflen Wybodaeth i Gyfranogwyr am Dasg 5, Holiadur Profiad Cleifion 
Fersiwn 4.1: 9fed Gorffennaf 2015 
 
Teitl yr astudiaeth 
Cymhariaeth rhwng nyrs yn rhagnodi presgripsiwn yn annibynnol a chyfarwyddiadau grŵp cleifion 
mewn gwasanaethau iechyd rhywiol o ran cymhwyso clinigol, profiad y claf ac economeg iechyd. 
 
Gwahoddiad a chrynodeb byr 
Hoffem eich gwahodd i gymryd rhan mewn astudiaeth ymchwil oherwydd ichi dderbyn 
meddyginiaeth oddi wrth nyrs a oedd yn gallu darparu meddyginiaeth heb siarad â meddyg. Mae’r 
dystiolaeth sydd ar gael yn brin ynglŷn ag effaith nyrsys yn darparu meddyginiaethau’n annibynnol 
ar wasanaethau a phrofiad y claf. Nod yr astudiaeth hon yw edrych ar y materion hyn yng nghyd-
destun clinigau iechyd rhywiol. Rydym yn eich gwahodd i gymryd rhan yn Nhasg 5: Holiadur 
Profiad Cleifion gan ichi dderbyn meddyginiaeth oddi wrth nyrs heddiw ac fe hoffem ni gael eich 
adborth ar eich profiad.  
 
Beth y mae hyn yn galw amdano? 
Os byddwch chi’n cytuno i gymryd rhan yn yr astudiaeth hon, mae gofyn ichi gwblhau holiadur 
ynglŷn â’ch profiad a’ch hyder wrth dderbyn eich meddyginiaeth. Fe fydd hi’n cymryd rhyw 
10 munud i gwblhau’r holiadur hwn. 
 
Beth yw manteision posibl cymryd rhan? 
Mae gennych chi’r opsiwn i roi cynnig ar raffl lle gallech chi ennill un o ddeg ‘Taleb Stryd Fawr’ 
gwerth £20. Efallai na fydd yr astudiaeth o unrhyw fudd i chi; fodd bynnag, ein nod yw dod i ddeall 
yn well profiad cleifion o ddefnyddio’r gwasanaethau iechyd rhywiol.  
 
Beth yw anfanteision a risgiau posibl cymryd rhan? 
Y disgwyl yw y bydd hi’n cymryd rhyw 10 munud yn unig i’w gwblhau.  
 
Beth os oes yna broblem? 
Os oes gennych chi bryder ynglŷn ag unrhyw agwedd ar yr astudiaeth hon, fe ddylech chi yn y lle 
cyntaf gysylltu ag Adam Black (Ymchwilydd) ar 07XXXXXXXXX neu adam.black@kcl.ac.uk. Os 
oes gennych chi unrhyw bryderon pellach, yna cysylltwch â’r Athro Christine Norton (Pen 
Ymchwilydd) trwy e-bost: Christine.norton@kcl.ac.uk  
 
Os oes gennych chi gŵyn ynglŷn â’ch gofal, fe ddylech chi siarad â’r nyrs sydd wrth y llyw a fydd 
yn gwneud ei (g)orau i ateb eich cwestiynau. Os byddwch chi’n dal i fod yn anhapus, mae’n bosibl 
y gallwch chi ddefnyddio gweithdrefn y GIG i wneud cwyn ffurfiol. Mae manylion i’w cael trwy’r 
Adran Gwynion ym Mwrdd Iechyd Prifysgol Caerdydd a’r Fro ffôn: 02920744095, e-bost: 
concerns@wales.nhs.uk, cyfeiriad: Adran Gwynion, Bwrdd Iechyd Prifysgol Caerdydd a’r Fro, 
Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XW. 
Noddir yr astudiaeth hon gan King’s College London. Bydd y noddwr, sef King’s College London, 
bob amser yn cynnal yswiriant digonol yn annibynnol o ran yr astudiaeth, trwy ei yswiriant 
indemniad proffesiynol (Treialon Clinigol) a’i iawndal ‘dim bai’ ei hun. 
Beth fydd yn digwydd os na fydda’ i eisiau bwrw ymlaen â’r astudiaeth? 
Byddwch chi’n cymryd rhan yn yr astudiaeth hon yn llwyr o’ch gwirfodd. Ni fydd unrhyw effaith ar 






A fydd fy ngwybodaeth yn cael ei chadw’n gyfrinachol? 
Caiff y rhan y byddwch chi’n ei chwarae yn yr astudiaeth ei thrin yn gyfrinachol. Caiff yr holl 
wybodaeth a gesglir yn ystod yr ymchwil ei chadw’n gyfrinachol, yn unol â Deddf Diogelu Data 
1998. Os byddwch chi’n llenwi’r dudalen gefn sy’n eich gwahodd i gymryd rhan yn y raffl ddewisol, 
yna datgysylltwch hi o’r holiadur a phostio’r ddwy eitem yn y blwch yn y dderbynfa. Caiff data o’r 
holiadur hwn eu trosglwyddo i gronfa ddata electronig. Caiff yr holl ddata electronig eu storio ar 
Rith-rwydwaith Preifat yn Imperial College Healthcare NHS Trust, a dim ond Adam Black a’r Athro 
Christine Norton a fydd yn gallu eu cyrchu. Caiff eich holiadur ei sganio a’i storio’n electronig. 
Caiff copïau caled o’r holiadur a dalenni’r raffl eu dinistrio fel gwastraff cyfrinachol y GIG. 
 
Beth fydd yn digwydd i ganlyniadau’r astudiaeth? 
Caiff canlyniadau’r astudiaeth eu hadolygu yn erbyn cyfranogwyr eraill a byddan nhw’n destun 
dadansoddiad disgrifiadol, profion ystadegol ac adolygiad economeg iechyd. Caiff y data eu 
defnyddio i ysgrifennu thesis PhD a’u rhannu mewn cynadleddau a chyfnodolion proffesiynol.  
 
Pwy sydd wedi adolygu’r astudiaeth hon? 
Mae grŵp o bobl annibynnol, o’r enw Pwyllgor Moeseg Ymchwil, yn edrych ar yr holl ymchwil yn 
y GIG i warchod eich buddion. Mae Pwyllgor Moeseg Ymchwil Cymru 4 wedi adolygu’r astudiaeth 
hon ac mae’n ffafriol ei farn arni, cyf: 15/WA/0120. Adolygwyd yr astudiaeth hefyd gan dîm 
Ymchwil a Datblygu’r adran cyn ei chychwyn.  
 
Gwybodaeth bellach a manylion cyswllt 
 
Cyngor penodol ynglŷn â’r astudiaeth ymchwil hon: cysylltwch ag Adam Black ar 
07XXXXXXXXX neu drwy e-bost yn adam.black@kcl.ac.uk. Os oes gennych chi unrhyw bryderon 
pellach, cysylltwch â’r Pen Ymchwilydd yn King’s College London, yr Athro Christine Norton, drwy 
e-bost: christine.norton@kcl.ac.uk 
 
Cyngor pellach ynglŷn â chymryd rhan mewn ymchwil neu ynglŷn â’ch gofal clinigol: Os 
oes angen unrhyw gyngor annibynnol arnoch chi ynglŷn â chymryd rhan mewn ymchwil, yna 
siaradwch â’r nyrs fu’n eich rheoli, y nyrs wrth y llyw neu’r Adran Gwynion. 
 






Appendix O. Observational study: Observational schedule 
 
Data Collection and Analysis for Observational Study  
Version 2.1: October 2014 
 
The observational study will include 5 medication delivery consultations from 3 nurse prescribers 
and 3 PGD users, totally 30 observations for analysis. Each nurse should have more than 1 year 
experience of independently delivering medications and should be able to manage patients 
presenting to sexual health services with symptoms. The first 3 nurses in each group who meet 
these criteria, and who agree to participate, will be selected to undertake the observational phase 
of the study. The first 5 consultations where medication is delivered will be included and 
recruitment will stop for that individual nurse. Patients’ consultations will be excluded if they: 
 Are attending solely as a follow-up attendance (nurse to undertake full consultation) or 
there is a handover involved (e.g. out of scope or end of shift). If clinical advice is sought 
this will not be excluded 
 Have poor English 
 Are aged under 16 years 
 Present with safeguarding issues 
 Are deemed vulnerable during the consultation (e.g. child abuse, FGM, sexual assault).  
 
Posters will be placed in the waiting rooms advising patients that the study is underway. Patients 
will be given information leaflets on arrival at the clinic, prior to seeing the nurse, thus allowing 
them time to consider participating in the study whilst awaiting their consultation. The nurse will 
ask the patient if they are in agreement that the consultation will be audio-taped before the 
researcher is invited into the room. Formal written consent from the patient will be obtained, 
including for the consultation to be audio recorded.  
 
Audio tapes will be transcribed verbatim by the researcher and/ or NHS approved transcribing 
services that are bound to confidentiality protocols. They will undergo analysis in relation to the 
following documents: 
 A field assessment schedule 
 Local policies and documents for the management of sexual health conditions, 
contraception and patient group directions  
 Comparison between consultation transcripts and the clinical records 
 Transcripts will be analysed using the Medicines Appropriateness Index 
 The SIMS tool used in the patient experience questionnaire will be applied to determine 
if these items were addressed in observed consultations. 
 
It is expected the Hawthorne Effect will be an issue in this section of the study, however as there 





Assessment Schedule for Sexual Health Nurse Consultations 




Accurate, confident,  safe practice/ knowledgeable 
carrying out techniques 
0 Not done/omitted/not seen/ 
unsafe practice 
N/A Not applicable to this patient/condition 
Assessment Schedule: 
Assessment & Diagnosis: Takes a comprehensive history of the patients presenting problem including: 
 Behavioural indicator competence 1 0 N/A Comments 
1 Identifies a chief complaint     
2 Explores presenting symptoms     
3 Explores management of presenting problem to date     
4 Determine previous episodes of  presenting problem     
5 Explores past medical history     
6 Explores family/social history     
7 Determines any known allergies & nature of allergic response     
8 Explores current prescribed medication     
9 Explore OTC /herbal products not prescribed     
10 Makes a working or final diagnosis/ decision  by considering and 
systematically deciding between the various possibilities 
    
11 Identifies a relevant physical examination     
12 Considers psychological, social and environmental factors when 
establishing treatment options 
    
13 Considers non-pharmacological treatment options     
14 Requests relevant diagnostic tests     
15 Selects the most appropriate treatment option and/or drug, dose and 
formulation for the individual patient, assessing the risks and benefits to 
the patient 
    
16 Established a plan for reviewing the therapeutic objective/end point of 
treatment 
    





Communication with the patient 
 
 Behavioural indicator competence 1 0 N/A Comment 
1 Listens to and understands patients beliefs and expectations 
 
    
2 Deals sensitively with patients emotions or concerns 
 
    
3 Helps patient to make informed choice about their treatment 
 
    
4 Explains the nature of the patients’ condition and the potential risks and 
benefits of treatment options 
    
5 Gives clear instructions to the patient about their medication and how to 
apply if required (dose, use and duration) 
    
6 Gives clear instructions to the patient about possible side-effects, and 
action to take in event of side effects 
    
7 Shows evidence of understanding the cultural, language and religious 
implications of prescribing 
    
8 Shows evidence of using health education initiatives (e.g. avoiding sex and 
partner notification) 
    
9 Identifies the present and future needs of the patient/client and shows 
evidence of planning a strategy with them to meet these needs 
    
TOTAL SCORE 
 
    
 
Medication issued Advice sought Direct dispensing Medication Delivery Duration 















Component Yes No N/A Comment 
Field assessment schedule completed; 
based on NPC 
    
Episode of care complies with local 
guidance (inc. PGD) 
    
Appropriateness of medication; based on MAI 
Is there an indication for the drug     
Is the medication effective for the 
condition 
    
Is the dosage correct     
Are the directions correct     
Are the directions practical     
Are there clinically significant drug-drug 
interactions 
    
Are there clinically significant drug-
disease/ condition interactions 
    
Is there any unnecessary duplication 
with other drugs? 
    
Is the duration of therapy acceptable     
Is the drug the least expensive 
alternative compared with others of 
equal utility  
    
Has the medication been delivered 
within the limits of the PGD 
    
Medicines information; based on SIMS 
Name of the medication     
What the medicine is for     
What it does     
How it works     
How long it will take to act     
How can you tell if it is working     
How long you will need to be on your 
medicine 
    
How to get a further supply     
Whether the medicine has any 
unwanted effects (side effects) 
    
What are the risks of you getting side 
effects 
    
What you should do if you experience 
unwanted side effects 
    
Whether you can drink alcohol whilst 
taking this medicine 
    
Whether the medicine interferes with 
other medicines you are currently 
taking 
    
Whether the medication will make you 
feel drowsy 
    
Whether you were able to have sex 
while taking the medicine 
    
What you should do if you forget to 
take a dose 





Appendix P. Observational study: Staff participant 
information sheet 
Task 4 Staff Observational Study Participant Information Sheets 
Staff Version 4.1: 9th July 2015 
 
Study title 
A comparison in the clinical application, patient experience and health economics between 
independent nurse prescribing and patient group directions in sexual health services 
 
Invitation and brief summary 
We'd like to invite you to take part in a research study because you are a nurse who is using 
nurse prescribing and/ or patient group directions within the sexual health department. Joining 
the study is entirely up to you, before you decide we would like you to understand why the 
research is being done and what it would involve for you. The researcher will go through this 
information sheet with you, to help you decide whether or not you would like to take part and 
answer any questions you may have. We'd suggest this should take about 10 minutes. Please 
feel free to talk to others about the study if you wish. 
 
Available evidence on how nurses’ ability to independently deliver medicines affects services and 
patient experience is limited. This study aims to explore these issues in the context of sexual 
health clinics. This study involves mixture of methods to explore this topic from different 
perspectives. You are being invited to participate in Task 4: Observational Study exploring nurse-
patient interactions during clinical consultations where medication is delivered. You have been 
invited because you can deliver medications independently while managing patients 
 
What’s involved? 
If you agree to take part in this study, you are requested to allow the researcher to observe 5 of 
your consultations where medication is delivered. It is not possible to know which consultations 
will result in patients receiving medication, therefore you may be asked to participate in the 
consultations which may not be included in the study (i.e. if no medication was required). The 
consultation will be audio taped and the researcher will be taking notes. The content of the 
consultation will be compared alongside clinical and prescribing protocols and guidelines to 
explore if guidelines are adhered to during medication delivery.  
 
What are the possible benefits of taking part? 
There is no direct benefit but your help may allow us to have a deeper understanding of how 
nurses independently deliver medication in sexual health.  
 
What are the possible disadvantages and risks of taking part?  
Obtaining consent for patients to participation may mean that the consultation may take a little 
longer. As part of the observations, it may be found that medication was not appropriately or safely 
provided. In the unlikely event of this occurring the researcher will intervene at an appropriate 
point to ensure patient safety is maintained.  
 
What if there is a problem? 
Should you consider during the consultation that the patient is vulnerable (e.g. sexual assault, 
abuse, etc.) or they appear uncomfortable with the research please ask the researcher to 
terminate the observations. 
If you have a concern about any aspect of this study, you should ask to speak to the researcher 
who will do their best to answer your questions. In the first instance please contact Adam Black 
(Researcher) on 07XXXXXXXXX or adam.black@kcl.ac.uk. Should you have any further 
concerns, please contact: Professor Christine Norton (Principle Investigator) by email: 
Christine.norton@kcl.ac.uk  
 
If you have a complaint, you should talk to Adam Black who will do his best to answer your 





complaints procedure.  Details can be obtained through the Patient Advisory Liaison Service 
[insert local details] 
This study is sponsored by King’s College London. The sponsor will at all times maintain adequate 
insurance in relation to the study independently. Kings College London, through its own 
professional indemnity (Clinical Trials) and no fault compensation. 
What will happen if I don’t want to carry on with the study? 
Participation is entirely voluntary. Should you decide that you do not wish to participate, or later 
withdraw, you do not need to provide a rationale and you will not be penalised in any way. 
 
Will my information be kept confidential? 
Your participation will be treated confidentially. Your interview will have a study ID allocated to it, 
traceable only by the researcher. The device used to record the interview will encrypt the data. 
The audio recording will be transcribed verbatim and will be compared against the National 
Prescribing Centre’s Prescribing Framework. Both the audio file and transcription will be securely 
stored on a Virtual Private Network at Imperial College Healthcare NHS Trust, which is accessible 
only by Adam Black and Professor Christine Norton.  Responses from all participants will be 
combined for analysis and you will not be named in any reports or publications. All information 
which is collected during the course of the research will be kept confidential, in accordance with 
the Data Protection Act 1998. Should you wish feedback or a copy of your transcribed 
consultation(s) please contact Adam Black. The prescribing framework field notes will be scanned 
and stored securely on the VPN, hardcopies will be destroyed as confidential NHS waste.   
 
What will happen to the results of this study? 
The results of the study will be reviewed against other participants and undergo descriptive 
analysis, statistical testing and a health economics review. The data will be used to write up a 
PhD thesis and be disseminated in relevant professional journals and conferences.  
 
Who is organising and funding the research? 
The study is organised by Adam Black, a Consultant Nurse in Sexual Heath prior to undertaking 
a PhD fellowship. This study is funded through a Clinical Doctoral Research Fellowship by the 
National Institute of Health Research & Health Education England (NIHR/HEE). The study forms 
part of a PhD programme at the King’s College London undertaken by Adam Black. 
 
Who has reviewed this study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable opinion 
by Wales 4 Research Ethics Committee, ref: 15/WA/0120. The study was also reviewed by the 
department’s Research & Development prior to starting.  
 
Further information and contact details 
Specific advice about this research study: please contact Adam Black on 07XXXXXXXXX or 
by email at adam.black@kcl.ac.uk. Should you have any further concerns please contact the 
Principal Investigator at King’s College London, Professor Christine Norton, by email: 
christine.norton@kcl.ac.uk 
 
Advice as to whether they should participate: Should you require any independent advice 
on participating in research please speak to the nurse manager, the Research & 
Development team or the Patient Advisory Liaison Service.  
 













Appendix R. Observational study: Patient participant 
information sheet (English version) 
 
Task 4 Patient Observational Study Participant Information Sheets 
Version 5.1: 9th July 2015 
 
Title: Nurses independently delivering medication in sexual health 
 
Invitation & summary: A research project is being undertaken in the clinic today, and you may 
be invited to participate. The study involves a researcher observing and audio-taping nurses’ 
consultations. The purpose of the research is to gain a further understanding of the role of nurses 
in the delivery of medication in sexual health. 
 
What’s involved: If the nurse you see is included in the research, he/she will ask you at the start 
of the consultation if you are willing to have your consultation observed and audio-recorded. You 
do not need to do anything extra from a normal visit to the department. If you agree to having 
your consultation observed and audio-recorded, you will be asked to sign a consent form 
(attached). Participation is completely voluntary. 
What are the possible benefits: There is no specific benefit to you, but it will help us better 
understand how nurses deliver medication independently.  
What are the possible disadvantages: This may slightly increase the time you spend in the 
department.  
What if there is a problem: Please speak to Adam Black (researcher) in the first instance on 
07XXXXXXXXX or adam.black@kcl.ac.uk. If you have further concerns please contact Professor 
Christine Norton (Principle Investigator) by email: Christine.norton@kcl.ac.uk. If you remain 
unhappy, you may be able to make a formal complaint through the NHS complaints 
procedure.  Details can be obtained through Patient Advisory Liaison Service [insert local details]. 
This study is sponsored by King’s College London. The sponsor will at all times maintain adequate 
insurance in relation to the study independently. Kings College London, through its own 
professional indemnity (Clinical Trials) and no fault compensation. 
 
What if I don’t want to carry on with the study: You do not have to agree to your consultation 
being observed. The care you receive today will not be affected by a decision not to participate. 
If you later decide you would like to withdraw you can contact the researcher (details below) up 
to 48 hours after your visit. All information collected for research purposes during your visit will 
then be destroyed and not used in the study.  
 
Will my information be kept confidential:  
Your participation will be treated confidentially. Your interview will have a study ID allocated to it, 
traceable only by the researcher. The device used to record the interview will encrypt the data. 
The audio recording will be transcribed and compared against a national prescribing framework. 
Data will be securely stored on a Virtual Private Network at Imperial College Healthcare NHS 
Trust, accessible only by Adam Black and Professor Christine Norton.  Responses from all 
participants will be combined for analysis. You will not be named in any reports or publications. 
All information which is collected during the course of the research will be kept confidential, in 
accordance with the Data Protection Act 1998. Should you wish a copy of your transcribed 
consultation please contact Adam Black.  
 
What will happen to the results of the study:  
The researcher will only analyse the information collected if medicines are provided. If medicines 
are not provided, the information will be destroyed. The results of the study will be reviewed 
against other participants and undergo descriptive analysis, statistical testing and a health 
economics review. The data will be used to write up a PhD thesis and be disseminated in relevant 






Who has reviewed this study: The study has been given a favourable opinion by an 
independent group of people called a Research Ethics Committee (Wales 4, Ref: 15/WA/0120).  
 
Further contact: Researcher: Adam Black t: 07XXXXXXXXX e: adam.black@kcl.ac.uk 
Further query Chief Investigator: Professor Christine Norton e: christine.norton@kcl.ac.uk 
 
Further advice relating to participating in research or about your clinical care: nurse-in-
charge or PALS (details above) 
 






Appendix S. Observational study: Patient participant 
information sheet (Welsh version) 
 
Taflen Wybodaeth i Gyfranogion am Dasg 4, Astudiaeth Arsylwi ar Gleifion 
Fersiwn 5.1: 9fed Gorffennaf 2015 
 
Teitl: Nyrsys yn darparu meddyginiaeth yn annibynnol ym maes iechyd rhywiol 
 
Gwahoddiad a chrynodeb: Mae prosiect ymchwil yn mynd rhagddo yn y clinig heddiw, ac mae’n 
bosibl y cewch eich gwahodd i gymryd rhan. Yn ystod yr astudiaeth, bydd ymchwilydd yn arsylwi 
ar ymgynghoriadau nyrsys ac yn eu recordio (sain). Diben yr ymchwil yw dod i ddeall rôl nyrsys 
yn well wrth ddarparu meddyginiaethau ym maes iechyd rhywiol. 
 
Beth y mae hyn yn galw amdano: Os bydd y nyrs y byddwch chi’n ei (g)weld wedi’i chynnwys/ei 
gynnwys yn yr ymchwil, fe fydd yn gofyn ichi ar ddechrau’r ymgynghoriad a ydych chi’n fodlon i’r 
ymchwilydd arsylwi ar eich ymgynghoriad a’i recordio. Nid oes angen ichi wneud unrhyw beth 
ychwanegol at ymweliad arferol â’r adran. Os byddwch chi’n cytuno i’r ymchwilydd arsylwi ar eich 
ymgynghoriad a’i recordio, fe fydd gofyn ichi lofnodi ffurflen gydsynio (wedi'i hatodi). Byddwch 
chi’n cymryd rhan yn llwyr o’ch gwirfodd. 
Beth yw’r manteision posibl: Nid oes unrhyw fantais benodol i chi, ond fe fydd yn ein helpu ni i 
ddeall yn well sut mae nyrsys yn darparu meddyginiaethau’n annibynnol.  
Beth yw’r anfanteision posibl: Mae’n bosibl y bydd hyn yn golygu y byddwch chi’n treulio 
ychydig yn fwy o amser yn yr adran.  
Beth os oes yna broblem: Siaradwch ag Adam Black (ymchwilydd) yn y lle cyntaf ar 
07XXXXXXXXX neu adam.black@kcl.ac.uk. Os oes gennych chi unrhyw bryderon pellach, yna 
cysylltwch â’r Athro Christine Norton (Pen Ymchwilydd) trwy e-bost: Christine.norton@kcl.ac.uk. 
Os byddwch chi’n dal i fod yn anhapus, mae’n bosibl y gallwch chi ddefnyddio gweithdrefn y GIG 
i wneud cwyn ffurfiol. Mae manylion i’w cael trwy’r Adran Gwynion ym Mwrdd Iechyd Prifysgol 
Caerdydd a’r Fro ffôn: 02920744095, e-bost: concerns@wales.nhs.uk, cyfeiriad: Adran Gwynion, 
Bwrdd Iechyd Prifysgol Caerdydd a’r Fro, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, 
Caerdydd, CF14 4XW. Noddir yr astudiaeth hon gan King’s College London. Bydd y noddwr, sef 
King’s College London, bob amser yn cynnal yswiriant digonol yn annibynnol o ran yr astudiaeth, 
trwy ei yswiriant indemniad proffesiynol (Treialon Clinigol) a’i iawndal ‘dim bai’ ei hun. 
Beth os na fydda’ i eisiau bwrw ymlaen â’r astudiaeth: Nid oes yn rhaid ichi gytuno i’r 
ymchwilydd arsylwi ar eich ymgynghoriad. Ni fydd penderfynu peidio â chymryd rhan yn effeithio 
ar y gofal y byddwch chi’n ei dderbyn heddiw. Os byddwch chi’n penderfynu yn nes ymlaen eich 
bod chi eisiau tynnu yn ôl, gallwch chi gysylltu â’r ymchwilydd (manylion isod) hyd at 48 awr ar ôl 
eich ymweliad. Yna caiff yr holl wybodaeth a gasglwyd at ddibenion ymchwil yn ystod eich 
ymweliad ei dinistrio ac ni chaiff ei defnyddio yn yr astudiaeth.  
 
A fydd fy ngwybodaeth yn cael ei chadw’n gyfrinachol:  
Caiff y rhan y byddwch chi’n ei chwarae yn yr astudiaeth ei thrin yn gyfrinachol. Dyrennir ID 
astudiaeth i’ch cyfweliad, a dim ond yr ymchwilydd fydd yn gallu olrhain hwn. Bydd y dyfais a 
ddefnyddir i recordio’r cyfweliad yn amgryptio’r data. Caiff y recordiad ei drawsgrifio a’i gymharu â 
fframwaith rhagnodi cenedlaethol. Caiff y data eu storio ar Rith-rwydwaith Preifat yn Imperial 
College Healthcare NHS Trust, a dim ond Adam Black a’r Athro Christine Norton fydd yn gallu eu 
cyrchu.  Caiff ymatebion oddi wrth bawb sy’n cymryd rhan eu cyfuno i’w dadansoddi. Ni fyddwch 
chi’n cael eich enwi mewn unrhyw adroddiadau neu gyhoeddiadau. Caiff yr holl wybodaeth a gesglir 
yn ystod yr ymchwil ei chadw’n gyfrinachol, yn unol â Deddf Diogelu Data 1998. Os byddwch chi 
eisiau copi o’r trawsgrifiad o’ch ymgynghoriad, yna cysylltwch ag Adam Black.  
 
 
Beth fydd yn digwydd i ganlyniadau’r astudiaeth:  
Dim ond pan ddarperir meddyginiaethau y bydd yr ymchwilydd yn dadansoddi’r wybodaeth a 





astudiaeth eu hadolygu yn erbyn cyfranogwyr eraill a byddan nhw’n destun dadansoddiad 
disgrifiadol, profion ystadegol ac adolygiad economeg iechyd. Caiff y data eu defnyddio i 
ysgrifennu thesis PhD a’u rhannu mewn cynadleddau a chyfnodolion proffesiynol.  
 
Pwy sydd wedi adolygu’r astudiaeth hon: Mae grŵp annibynnol o bobl o’r enw Pwyllgor 
Moeseg Ymchwil (Cymru 4, Cyf: 15/WA/0120) wedi edrych ar yr astudiaeth ac mae’n ffafriol ei 
farn arni.  
 
Cyswllt pellach: Ymchwilydd: Adam Black ffôn: 0XXXXXXXX e-bost: adam.black@kcl.ac.uk 
Prif Ymchwilydd ar gyfer ymholiadau pellach: Yr Athro Christine Norton e-bost: 
christine.norton@kcl.ac.uk 
 
Cyngor pellach ynglŷn â chymryd rhan mewn ymchwil neu ynglŷn â’ch gofal clinigol: y 
nyrs wrth y llyw neu’r Adran Gwynion (manylion uchod) 
 














Appendix U. Observational study: Patient consent form 



















Appendix X. Research Ethics Committee Non-substantial 







Appendix Y. Research Ethics Committee Substantial 















Appendix AA. Nurse questionnaire: Participants’ attitudes to 















n % n % n % n % n % n % 
1 







INP 21 80.8 4 15.4 0 0.0 0 0.0 0 0.0 25 96.2 
PGD 28 80.0 7 20.0 0 0.0 0 0.0 0 0.0 35 100.0 
Total 49 80.3 11 18.0 0 0.0 0 0.0 0 0.0 60 98.4 
2 







INP 13 50.0 10 38.5 1 3.8 1 3.8 0 0.0 25 96.2 
PGD 24 68.6 9 25.7 2 5.7 0 0.0 0 0.0 35 100.0 
Total 37 60.7 19 31.1 3 4.9 1 1.6 0 0.0 60 98.4 
3 
I feel my skills 
in prescribing 
are being used 
effectively 
INP 18 69.2 6 23.1 1 3.8 0 0.0 0 0.0 25 96.2 
PGD 13 37.1 16 45.7 2 5.7 1 2.9 0 0.0 32 91.4 










INP 17 65.4 7 26.9 0 0.0 1 3.8 0 0.0 25 96.2 
PGD 25 71.4 10 28.6 0 0.0 0 0.0 0 0.0 35 100.0 
Total 42 68.9 17 27.9 0 0.0 1 1.6 0 0.0 60 98.4 
5 
I am confident 




INP 14 53.8 11 42.3 0 0.0 0 0.0 0 0.0 25 96.2 
PGD 21 60.0 9 25.7 5 14.3 0 0.0 0 0.0 35 100.0 






since I have 




INP 14 53.8 8 30.8 3 11.5 0 0.0 0 0.0 25 96.2 
PGD 14 40.0 16 45.7 5 14.3 0 0.0 0 0.0 35 100.0 
Total 28 45.9 24 39.3 8 13.1 0 0.0 0 0.0 60 98.4 
7 
Training 





INP 10 38.5 11 42.3 3 11.5 1 3.8 0 0.0 25 96.2 
PGD 13 37.1 13 37.1 6 17.1 3 8.6 0 0.0 35 100.0 









INP 4 15.4 13 50.0 4 15.4 4 
15.
4 
0 0.0 25 96.2 
PGD 10 28.6 17 48.6 7 20.0 1 2.9 0 0.0 35 100.0 






















resulted in me 
feeling more 
satisfied in my 
role 
INP 14 53.8 7 26.9 4 15.4 0 0.0 0 0.0 25 96.2 
PGD 17 48.6 13 37.1 4 11.4 0 0.0 0 0.0 34 97.1 







PGD to a 
department 
not using it 
INP 18 69.2 5 19.2 1 3.8 1 3.8 0 0.0 25 96.2 
PGD 21 60.0 12 34.3 1 2.9 1 2.9 0 0.0 35 100.0 
Total 39 63.9 17 27.9 2 3.3 2 3.3 0 0.0 60 98.4 
1
1 









INP 18 69.2 5 19.2 2 7.7 0 0.0 0 0.0 25 96.2 
PGD 19 54.3 12 34.3 4 11.4 0 0.0 0 0.0 35 100.0 
Total 37 60.7 17 27.9 6 9.8 0 0.0 0 0.0 60 98.4 
Grand total (from potential 
671 responses):          
366 54.5 221 32.9 55 8.2 14 2.1 0 0.0 656 97.8 







Appendix BB. Clinical diary: Detailed diary activity by site 
 
Diary entries 
























n % n % n % n %  n % n % n % n % n % n % n % 
Presentation 
New 317 74.8 49 59.8 6 37.5 25 62.5  23 69.7 154 65.3 82 76.6 35 57.4 115 34.7 512 69.5 294 49.6 
Follow-up 105 24.8 33 40.2 10 62.5 15 37.5  10 30.3 79 33.5 21 19.6 26 42.6 201 60.7 220 29.9 280 47.2 
Both 0 0.0 0 0.0 0 0.0 0 0.0  0 0.0 0 0.0 0 0.0 0 0.0 1 0.3 0 0.0 1 0.2 
Missing 2 0.5 0 0.0 0 0.0 0 0.0  0 0.0 3 1.3 4 3.7 0 0.0 14 4.2 5 0.7 18 3.0 
Medications 
given? 
Med given 267 63.0 50 61.0 9 56.3 25 62.5  18 54.5 148 62.7 69 64.5 36 59.0 186 56.2 460 62.4 348 58.7 
No meds 143 33.7 32 39.0 7 43.8 15 37.5  15 45.5 87 36.9 38 35.5 24 39.3 132 39.9 261 35.4 232 39.1 
Missing 14 3.3 0 0.0 0 0.0 0 0.0  0 0.0 1 0.4 0 0.0 1 1.6 13 3.9 16 2.2 13 2.2 
Advice 
sought? 
Advice sought 27 6.4 18 22.0 0 0.0 7 17.5  0 0.0 44 18.6 26 24.3 4 6.6 31 9.4 75 10.2 82 13.8 
No advice Sought 324 76.4 57 69.5 12 75.0 19 47.5  29 87.9 191 80.9 70 65.4 53 86.9 276 83.4 580 78.7 451 76.1 
Missing 73 17.2 7 8.5 4 25.0 14 35.0  4 12.1 1 0.4 11 10.3 4 6.6 24 7.3 82 11.1 60 10.1 
Type of 
advice? 
Clinical 9 33.3 11 61.1 0 0.0 0 0  0 0.0 25 56.8 5 19.2 4 100 4 12.9 38 50.7 20 24.4 
Medicine 2 7.4 5 27.8 0 0.0 0 0  0 0.0 10 22.7 4 15.4 0 0.0 12 38.7 12 16.0 21 25.6 
Both 6 22.2 0 0.0 0 0.0 0 0  0 0.0 7 15.9 10 38.5 0 0.0 2 6.5 13 17.3 12 14.6 




Doctor 11 40.7 6 33.3 0 0.0 7 100  0 0.0 29 65.9 23 88.5 2 50.0 22 71.0 42 56.0 60 73.2 
Nurse 1 3.7 2 11.1 0 0.0 0 0  0 0.0 2 4.5 1 3.8 0 0.0 3 9.7 3 4.0 6 7.3 
Pharmacist 1 3.7 0 0.0 0 0.0 0 0  0 0.0 4 9.1 0 0.0 0 0.0 1 3.2 5 6.7 1 1.2 
Health Adviser 2 7.4 0 0.0 0 0.0 0 0  0 0.0 0 0.0 1 3.8 0 0.0 2 6.5 2 2.7 3 3.7 
Missing 12 44.4 10 55.6 0 0.0 0 0  0 0.0 9 20.5 1 3.8 2 50.0 3 9.7 23 30.7 12 14.6 






























n % n % n % n %  n % n % n % n % n % n % n % 
Medication 
delivered? 
Independently 253 94.8 30 60 8 88.9 10 40  10 55.6 126 85.1 39 56.5 32 88.9 151 81.2 419 91.1 240 69.0 
Rx: Doctor 5 1.9 12 24 1 11.1 9 36  7 38.9 21 14.2 25 36.2 2 5.6 27 14.5 29 6.3 80 23.0 
Rx: Nurse 2 0.7 8 16 0 0.0 0 0  0 0.0 0 0.0 1 1.4 0 0.0 1 0.5 2 0.4 10 2.9 
Rx: Pharmacist 2 0.7 0 0 0 0.0 0 0  0 0.0 1 0.7 3 4.3 0 0.0 0 0.0 3 0.7 3 0.9 
Rx: Health Adviser 2 0.7 0 0 0 0.0 0 0  0 0.0 0 0.0 1 1.4 0 0.0 0 0.0 2 0.4 1 0.3 
Rx: Missing 3 1.1 0 0 0 0.0 6 24  1 5.6 0 0.0 0 0.0 2 5.6 7 3.8 5 1.1 14 4.0 
No PGD   4 8   1 4  1 5.5   5 7.2   19 10.2   30 8.6 





Appendix CC. Clinical notes review: Breakdown of nurses’ 
procedural and diagnostic activity 
 
 
Table 0-1 Procedural management of patients 
Procedural 










n % n % n % n % n % 






Symptomatic screen 106 26.6 44 12.8 102 21.3 37 8.1 289 17.2 




Vaccine 24 6.0 0 0.0 80 16.7 0 0.0 104 6.2 
Health Adviser support 7 1.8 15 4.4 35 7.3 38 8.3 95 5.6 
Contraception: maintain 43 10.8 0 0.0 47 9.8 0 0.0 90 5.4 
Contraception: change 38 9.5 9 2.6 31 6.5 3 0.7 81 4.8 
Contraception: new 40 10.0 0 0.0 35 7.3 1 0.2 76 4.5 
Contraception: advice only 14 3.5 25 7.3 12 2.5 19 4.1 70 4.2 
Termination of pregnancy 24 6.0 14 4.1 9 1.9 8 1.7 55 3.3 
Emergency contraception 14 3.5 0 0.0 28 5.8 0 0.0 42 2.5 
Safeguarding 8 2.0 10 2.9 10 2.1 6 1.3 34 2.0 
Test of cure 3 0.8 6 1.7 5 1.0 20 4.4 34 2.0 
Specialist follow-up 1 0.3 16 4.7 7 1.5 5 1.0 29 1.7 
HIV Test only 1 0.3 7 2.0 0 0.0 9 2.0 17 1.0 
Advice only 0 0.0 4 1.2 0 0.0 5 1.1 9 0.5 
Cervical smear 0 0.0 3 0.9 1 0.2 4 0.9 8 0.5 
HIV post exposure 
prophylaxis 
3 0.8 0 0.0 1 0.2 1 0.2 5 0.3 
INP= independent nurse prescribing, PGD= patient group directions, med= medication given, no med= no 







Table 0-2 Diagnoses managed by nurses 
Diagnoses 










n % n % n % n % n % 
Chlamydia 53 13.3 12 3.5 69 14.4 20 4.4 154 9.2 
Genital warts 38 9.5 3 0.9 39 8.1 1 0.2 81 4.8 
Gonorrhoea 22 5.5 3 0.9 49 10.2 7 1.5 81 4.8 
Contact chlamydia 33 8.3 0 0.0 39 8.1 0 0.0 72 4.3 
Non-specific urethritis (NSU) 24 6.0 0 0.0 23 4.8 0 0.0 47 2.8 
Bacterial vaginosis 21 5.3 1 0.3 21 4.4 2 0.4 45 2.7 
Vulval-vaginal candidiasis 23 5.8 0 0.0 20 4.2 2 0.4 45 2.7 
Contact gonorrhoea 12 3.0 2 0.6 25 5.2 3 0.7 42 2.5 
Herpes 14 3.5 3 0.9 8 1.7 1 0.2 26 1.5 
Other/ unknown 8 2.0 3 0.9 4 0.8 4 0.9 19 1.1 
Dermatoses 4 1.0 5 1.5 9 1.9 0 0.0 18 1.1 
Balanitis 5 1.3 2 0.6 9 1.9 1 0.2 17 1.0 
Contact of NSU, PID or TV 8 2.0 0 0.0 9 1.9 0 0.0 17 1.0 
Pelvic Inflammatory Disease 
(PID) 
6 1.5 1 0.3 7 1.5 0 0.0 14 0.8 
Epididymo-orchitis 6 1.5 0 0.0 4 0.8 1 0.2 11 0.7 
Contact of syphilis 1 0.3 0 0.0 6 1.3 2 0.4 9 0.5 
Urinary tract infection 4 1.0 1 0.3 4 0.8 0 0.0 9 0.5 
Contact of HIV 0 0.0 3 0.9 2 0.4 1 0.2 6 0.4 
Proctitis 4 1.0 0 0.0 1 0.2 0 0.0 5 0.3 
Syphilis 1 0.3 0 0.0 4 0.8 0 0.0 5 0.3 
Cervicitis 2 0.5 0 0.0 2 0.4 0 0.0 4 0.2 
Lymphogranuloma venereum 1 0.3 0 0.0 2 0.4 0 0.0 3 0.2 
Molloscum contagiosum 2 0.5 0 0.0 1 0.2 0 0.0 3 0.2 
Trichomoniasis vaginalis (TV) 0 0.0 0 0.0 2 0.4 1 0.2 3 0.2 
Hepatitis B 0 0.0 1 0.3 0 0.0 1 0.2 2 0.1 
Human Immuno-deficiency Virus 
(HIV)  
0 0.0 1 0.3 0 0.0 1 0.2 2 0.1 
Hepatitis C 0 0.0 0 0.0 0 0.0 1 0.2 1 0.1 
INP= independent nurse prescribing, PGD= patient group directions, med= medication given, no med= no 





Appendix DD. Clinical notes review: Specific medications 
delivered by INPs and PGD users 
 
Specific drug delivered by INP & 
PGD (number of products) 
INP (n=620) PGD (n=737) Total (n=1357) 
n % n % n % 
Antibiotic (n=15) 203 32.7 283 38.4 486 35.8 
Azithromycin 107 17.3 124 16.8 231 17.0 
Benzathine penicillin G 2 0.3 10 1.4 12 0.9 
Cefixime 1 0.2 2 0.3 3 0.2 
Ceftriaxone 25 4.0 57 7.7 82 6.0 
Ciprofloxacin 1 0.2 0 0.0 1 0.1 
Co-amoxiclav 1 0.2 0 0.0 1 0.1 
Doxycycline 26 4.2 50 6.8 76 5.6 
Erythromycin 0 0.0 1 0.1 1 0.1 
Flucloxacillin 2 0.3 1 0.1 3 0.2 
Metronidazole 26 4.2 31 4.2 57 4.2 
Nitrofurantoin 2 0.3 0 0.0 2 0.1 
Ofloxacin 7 1.1 3 0.4 10 0.7 
Procaine penicillin 0 0.0 1 0.1 1 0.1 
Spectinomycin 2 0.3 0 0.0 2 0.1 
Trimethoprim 1 0.2 3 0.4 4 0.3 
Anaesthetics (n=2) 76 12.3 80 10.9 156 11.5 
Lidocaine 75 12.1 71 9.6 146 10.8 
Xylocaine® 0 0.0 9 1.2 9 0.7 
Wart treatments (n=4) 56 9.0 60 8.1 116 8.5 
Cryotherapy 35 5.6 39 5.3 74 5.5 
Imiquimod 4 0.6 12 1.6 16 1.2 
Podophyllotoxin 14 2.3 8 1.1 22 1.6 
Trichloracetic acid 3 0.5 1 0.1 4 0.3 
Vaccinations (n=3) 27 4.4 88 11.9 115 8.5 
Hepatitis A vaccine 2 0.3 9 1.2 11 0.8 
Hepatitis B vaccine 16 2.6 66 9.0 82 6.0 
Twinrix (Hepatitis A&B) vaccine 9 1.5 13 1.8 22 1.6 
Short acting contraception  
(pills, patch, ring: n=8) 
59 9.5 54 7.3 113 8.3 
Cerazette®/ Cerelle®/ Zelleta® 15 2.4 15 2.0 30 2.2 
Cilest® 2 0.3 6 0.8 8 0.6 
Evra (3M) ® 2 0.3 1 0.1 3 0.2 
Femodette®/ Millinette 20® 0 0.0 2 0.3 2 0.1 
Gedarel® 2 0.3 2 0.3 4 0.3 
Microgynon®/ Rigivedon® 35 5.6 27 3.7 62 4.6 
Micronor® 2 0.3 1 0.1 3 0.2 
Nuvaring® 1 0.2 0 0.0 1 0.1 
Long-Active Reversible 
Contraception (n=3) 
52 8.4 53 7.2 105 7.7 





Specific drug delivered by INP & 
PGD (number of products) 
INP (n=620) PGD (n=737) Total (n=1357) 
n % n % n % 
Intra-uterine device/ system 10 1.6 15 2.0 25 1.8 
Nexplanon® 33 5.3 22 3.0 55 4.1 
Antifungal (n=4) 49 7.9 42 5.7 91 6.7 
Canesten HC® 0 0.0 5 0.7 5 0.4 
Clotrimazole 40 6.5 29 3.9 69 5.1 
Fluconazole 9 1.5 8 1.1 17 1.3 
Termination of pregnancy regimens 
(excluding azithromycin: n=4) 
30 4.8 11 1.5 41 3.0 
Anti-D immunoglobulin 3 0.5 1 0.1 4 0.3 
Cyclizine 3 0.5 0 0.0 3 0.2 
Mifepristone 8 1.3 5 0.7 13 1.0 
Misoprostol 15 2.4 5 0.7 20 1.5 
Ondanstron 1 0.2 0 0.0 1 0.1 
Emergency contraception (n=2) 14 2.3 26 3.5 40 2.9 
Levonorgestrel 12 1.9 23 3.1 35 2.6 
Uilpristal Acetate 2 0.3 3 0.4 5 0.4 
Topical creams (n=10) 11 1.8 24 3.3 35 2.6 
Aqueous Cream 0 0.0 4 0.5 4 0.3 
Fusidic Acid 1 0.2 0 0.0 1 0.1 
Instilligel® 3 0.5 10 1.4 13 1.0 
Daktacort® 0 0.0 3 0.4 3 0.2 
Dermol 500® 2 0.3 1 0.1 3 0.2 
Diprobase® 2 0.3 4 0.5 6 0.4 
Eumovate® 0 0.0 1 0.1 1 0.1 
Hydramol 1 0.2 0 0.0 1 0.1 
Hydrocortisone 0 0.0 1 0.1 1 0.1 
Permethrin® 2 0.3 0 0.0 2 0.1 
Antiviral (n=1) 14 2.3 8 1.1 22 1.6 
Aciclovir 14 2.3 8 1.1 22 1.6 
HIV anti-retroviral (n=4) 14 2.3 4 0.5 18 1.3 
Atripla 1 0.2 0 0.0 1 0.1 
Raltegravir 6 1.0 2 0.3 8 0.6 
Triumeq 1 0.2 0 0.0 1 0.1 
Truvada 6 1.0 2 0.3 8 0.6 
Erectile dysfunction treatments (n=4) 10 1.6 1 0.1 12 0.9 
Alprostadil 6 1.0 1 0.1 7 0.5 
Caverjet® 1 0.2 0 0.0 1 0.1 
Sildenafil 1 0.2 0 0.0 1 0.1 
Tadalafil 3 0.5 0 0.0 3 0.2 
Non-steroidal anti-inflammatory (n=2) 1 0.2 1 0.1 2 0.1 
Ibuprofen 0 0.0 1 0.1 1 0.1 
Mefeanic acid 1 0.2 0 0.0 1 0.1 
INP= independent nurse prescribing, PGD= patient group directions, med= medication given, no med= no 





Appendix EE. Clinical notes review: Specific medications 
prescribed by doctors for INPs and PGD users 
 
Drug groups prescribed by 
doctor for INP & PGD 
INP (n=81) Can INP 
provide? 
PGD (n=225) Can PGD 
provide? n % n % 
Antiviral (n=1) 0 0.0   3 1.3   
Aciclovir 0 0.0 Yes 3 1.3 Yes 
Antibiotic (n=11) 27 32.5   89 39.5   
Azithromycin* 17 20.5 Yes 26 11.6 Yes 
Benzathine penicillin G 1 1.2 Yes 10 4.4 No 
Cefixime 0 0.0 Yes 1 0.4 Yes 
Ceftriaxone 3 3.6 Yes 16 7.1 Yes 
Co-amoxiclav 1 1.2 Yes 0 0.0 No 
Doxycycline 2 2.4 Yes 22 9.8 Yes 
Erythromycin 0 0.0 Yes 1 0.4 No 
Metronidazole 2 2.4 Yes 8 3.6 Yes 
Ofloxacin 1 1.2 Yes 2 0.9 No 
Procaine penicillin 0 0.0 Yes 1 0.4 No 
Trimethoprim 0 0.0 Yes 2 0.9 No 
HIV antiretroviral (n=2) 4 4.8   4 1.8   
Raltegravir 2 2.4 Yes 2 0.9 No 
Truvada 2 2.4 Yes 2 0.9 No 
Antifungal (n=3) 4 4.8   13 5.7   
Canesten HC 0 0.0 Yes 5 2.2 No 
Clotrimazole 3 3.6 Yes 5 2.2 Yes 
Fluconazole 1 1.2 Yes 3 1.3 Yes 
Topical creams (n=4) 0 0.0   6 2.5   
Daktacort 0 0.0 Yes 3 1.3 No 
Dermol 500 0 0.0 Yes 1 0.4 No 
Diprobase 0 0.0 Yes 1 0.4 No 
Eumovate 0 0.0 Yes 1 0.4 No 
Termination of pregnancy 
regimens (excluding 
azithromycin; n=7) 
29 34.9   12 5.2   
Anti-D immunoglobulin* 3 3.6 Yes 1 0.4 No 
Antibiotic cover* 1 1.2 Yes 0 0.0 No 
Cyclizine* 1 1.2 Yes 0 0.0 No 
Mifepristone* 8 9.6 No 5 2.2 No 
Misoprostol* 15 18.1 No 5 2.2 No 
Ondanstron* 1 1.2 Yes 0 0.0 No 
Other 0 0.0 Yes 1 0.4 No 
Anaesthetics (n=1) 6 7.2   13 5.8   
Lidocaine 6 7.2 Yes 13 5.8 Yes 
Short acting contraception (pills 
n=6) 
3 3.6   22 9.7   





Drug groups prescribed by 
doctor for INP & PGD 
INP (n=81) Can INP 
provide? 
PGD (n=225) Can PGD 
provide? n % n % 
Cilest® 0 0.0 Yes 3 1.3 Yes 
Femodette®/ Millinette 20® 0 0.0 Yes 1 0.4 Yes 
Gedarel® 1 1.2 Yes 2 0.9 Yes 
Microgynon®/ Rigivedon® 0 0.0 Yes 12 5.3 Yes 
Micronor® 1 1.2 Yes 0 0.0 Yes 
Wart treatments (n=5) 2 2.4   17 7.4   
Condyline® 0 0.0 Yes 1 0.4 Yes 
Cryotherapy 1 1.2 Yes 10 4.4 Yes 
Imiquimod 0 0.0 Yes 4 1.8 Yes 
Podophyllotoxin 1 1.2 Yes 1 0.4 Yes 
Trichloracetic acid 0 0.0 Yes 1 0.4 Yes 
Long-Active Reversible 
Contraception (n=2) 
1 1.2   5 2.2   
DepoProvera® 0 0.0 Yes 4 1.8 Yes 
Intra-uterine device/ system 1 1.2 Yes 1 0.4 Yes 
Emergency contraception (n=2) 0 0.0   8 3.5   
Levonorgestrel 0 0.0 Yes 7 3.1 Yes 
Uilpristal Acetate 0 0.0 Yes 1 0.4 Yes 
Vaccinations (n=3) 6 7.2   33 14.7   
Hepatitis A vaccine 0 0.0 Yes 2 0.9 Yes 
Hepatitis B vaccine 4 4.8 Yes 23 10.2 Yes 
Twinrix (Hep A&B) 2 2.4 Yes 8 3.6 Yes 
Non-steroidal anti-inflammtory 
(n=1) 
1 1.2   0 0.0   
Analgesia cover* 1 1.2 Yes 0 0.0 No 
*Included in termination of pregnancy drug regimens, mifepristone and misoprostol must be 





Appendix FF. Clinical notes review: Medication safety assessments based on risk assessments 
Condition Medication delivered 
Frequency 
BNF safety comments for specific medical/ medication consideration 
Appropriate 
use? INP PGD 
Pregnancy 
(n=10) 
Azithromycin 1 0 Use only if adequate alternatives not available  
Ceftriaxone 1 0 Use if benefits outweigh risks; not known to be harmful in animal studies  
Clotrimazole 1 2 
Pregnant women need longer duration of treatment; oral antifungal treatment should be avoided. Topically minimal 
absorption from skin, not known to be harmful 
 
Cryotherapy 4 0 No data in British National Formulary   
Cyclizine 1 0 Advised to avoid, however, there is no evidence of teratogenicity  (appropriate for patient’s presentation)  
Lidocaine 1 0 Use if benefits outweigh risks; not known to be harmful in animal studies  
Metronidazole 1 1 Use only if potential benefit outweighs risk, avoid high-dose regimens  
Breastfeeding 
(n=7) 
Azithromycin 1 1 Present in milk, use only if no suitable alternatives  
Ceftriaxone 1 0 Compatible with breastfeeding; present in milk in low levels, but limited effects to infant  
Cerazette® 1 0 Does not affect lactation  
Depo Provera® 1 0 Present in milk, no adverse effects reported. First dose should be delayed until 6 weeks post-partum  
Lidocaine 2 2 Present in milk but amount too small to be harmful  
Metronidazole 1 0 Significant amount in milk, avoid large single doses, but otherwise compatible   




Aciclovir 1 0 Use normal oral dose every 12 hours if eGFR less than 10 mL/minute/1.73 m2**  
Azithromycin & ceft. 0 1 Use in reduced dose if eGFR less than 10 mL/minute/1.73m2**  
Cryotherapy 1 0 No data in British National Formulary  
Doxycycline 0 1 Use with caution, avoid excessive doses  
Hepatitis B vaccine 0 1 No data in British National Formulary   
Instillagel® 1 0 No data in British National Formulary   
Lidocaine 0 1 Use with caution in severe renal impairment  
Podophyllotoxin 1 0 No data in British National Formulary   
Liver (n=1) Aqueous cream 0 1 No data in British National Formulary   
*patients may have received multiple drugs. INP= independent nurse prescribing, PGD= patient group directions, med= medication given, no med= no medication given, eGFR= estimated glomerular filtration 





Appendix GG. Specific medication available through PGDs by 
site 
 
PGD medications active during study Site 1 Site 2 Site 3 Site 4 Site 5 
Anti-infective 
Aciclovir           
Azithromycin           
Cefixime           
Ceftriaxone (& lidocaine) x2* x2*       
Ciprofloxacin           
Clotrimazole (cream & pessary)   x2* x2* x2*   
Co-trimoxazole           
Doxycycline           
Fluconazole           
Hepatitis A vaccine       x2*   
Hepatitis B vaccine           
Imiquimod           
Liquid nitrogen           
Malathion           
Metronidazole x2*         
Paracetamol           
Podophyllotoxin           
Trichloracetic acid           
Twinrix (Hepatitis A&B)           
Contraception 
Cerazette®, Cerelle® or Zelleta ®           
Cilest®           
Depo-Provera®           
Depo-Provera® (sub-cutaneous)           
Femodene ED®           
Femodene®, Katya 30/75® or Millinette 30/75®           
Femulen®           
Levonorgesterel            
Lidocaine 1% for contraceptive implants           
Loestrin 20®           
Loestrin 30®           
Logynon®           
Logynon ED ®           
Marvelon® or Gedarel® 30/150           
Mercilon® or Gedarel 20/150®           
Microgynon 30 ED®           
Microgynon®, Ovranette®, Levest® or 
Rigevidon®           
Micronor® or Noriday®           
Nexplanon®           





PGD medications active during study Site 1 Site 2 Site 3 Site 4 Site 5 
Norimin®           
Norinyl-1®           
Ovysmen®           
TriNovum®           
Ulipristal acetate           
Total 20 (+2) 11 (+2) 12 (+1) 22 (+2) 37 
   PGD added after the study 
*x2 – demonstrates different medication preparations in separate PGD documents (e.g. clotrimazole 
topical cream and clotrimazole vaginal pessary). PGD = patient group direction 
 
Mean number of PGDs= 20.4 (SD: 10.4) 





Appendix HH. Clinical notes review: Detailed rationales for 













Unclear treatment rationale 1   2   3 
Incorrect treatment/ results given 1       1 
PEPSE indicated but not offered/ 
documented   1     1 
Combined oral contraceptive pill given 
with UKMEC 3     1   1 
PGD user signed medicine, but drug 
administered by another nurse     1   1 
Potential drug-drug interaction     1   1 
Symptomatic gonorrhoea contact not 
treated       1 1 
Intermediate 
Further investigation of symptoms 
indicated 6 5 7 4 22 
Lack of documentation 3 6 10 1 20 
Error in 'prescription' documentation  2   5   7 
Pregnancy risk unclear 3 1 1   5 
Condition not treated 1   4   5 
Indicated medication not offered   1   4 5 
Medication not indicated 1   1   2 
Medication advice not accurate 1       1 
Not known 
Limited summary of TOP attendance  26   8   34 
Lack of documentation   1 4 1 6 
Safety 
Unsafe 
Incorrect treatment/ results given 1       1 
COCP given on UKMEC 3     1   1 
Potential drug-drug interaction     1   1 
Samples mixed up (investigated and 
resolved)   1     1 
PEPSE indicated but not offered/ 
documented   1     1 
Symptomatic gonorrhoea contact not 
treated       1 1 
Intermediate 
Lack of documentation  11 1 20 1 33 
Potential drug-condition/ allergy 
interaction 3       3 
Further investigation of symptoms 
indicated 1   2 1 4 
Not known 
Limited summary of TOP attendance 26   8   34 




Incorrect treatment/ results given 1       1 
Combined oral contraceptive pill given 
with UKMEC 3     1   1 
Samples mixed up (investigated and 
resolved)   1     1 
PEPSE indicated but not offered/ 
documented   1     1 
Potential drug-drug interaction     1   1 
PGD user signed medicine, but 














Symptomatic gonorrhoea contact not 
treated       1 1 
Undetermine
d 
Limited summary of TOP attendance 26   8   34 
Lack of documentation 8 2 17 0 27 
Further assessment of symptoms 
indicated 2 1 3 4 10 
Unclear pregnancy risk assessment 3   2 2 7 
Condition not treated 1   4 1 6 
PGD use 
Medication clinically indicated and 
safe, but out with PGD restrictions   63   63 
INP= independent nurse prescribing, PGD= patient group directions, med= medication given, no med= no 
medication given; PEPSE = post exposure prophylaxis for sexual exposure; UKMEC= UK medical eligibility 
criteria [3=risks outweigh the benefits of specific contraception method]; TOP= termination of pregnancy, 












Documented PMH/ medications/ 
allergy 
Interactions with PMH & Allergies or medications 




Metronidazole 400mg BD for 7/7 
(PO assumed) 
PMH: Asthma, Acne, Pregnant 
(requesting termination of pregnancy) 
Meds: Tetracycline 
Allergy: Penicillin 
Pregnancy: manufacturer advises avoidance of high-
dose regimens; use only if potential benefit 
outweighs risk. Risk of using tetracycline while 
pregnant (concurrent medication) 
1) Taking into account the social picture of this patient's case (TOP), 
the decision of the choice of medication should lie with the clinician 
and patient to prescribe and take the medication that would 
otherwise be avoided in pregnancy. 2) For information, according to 
the [local] antibiotic app (Antibiotics in pregnancy and breastfeeding 
section) - ideally Penicillin or cephalosporin should be used first line 
but in the case of this patient due to her allergy status this would not 
be possible. Metronidazole is compatible in the first, second, third 
trimester and while breastfeeding. Tetracycline should be avoided in 
pregnancy (especially contraindicated in the second and third 
trimester - use with caution in the first - it should only be used if there 
are no other treatment options and administration cannot be 
delayed due to risk of infection to the mother 
Random Aciclovir 400mg PO TDS for 5/7 
PMH: Nil  
Meds: Azithroymcin (4/7 earlier) & 
Warticon  
Allergy: Penicillin 
No contraindications or cautions noted Agreed  
Random 
Nexplanon 68mg SC implant stat& 
Lidocaine 1% as directed 
PMH: Eating disorder & low bmi (13.1) 
Meds: Diazepam, Melatonin, 
Lansoprazole 
Allergy: Nil 
No contraindications or cautions noted Agreed  
Random Aciclovir 400mg PO BD for 4/12 
PMH: Type 2 Diabetes, Lichen schlerosis 
Meds: Statins 
Allergy: Nil 
No contraindications or cautions noted Agreed  
Random Alprostadil (Caverjet 20mcg x4) 
PMH: HIV 
Meds: Truvada, Darunavir, Ritonavir 
Allergy: Nil 
No contraindications or cautions noted No information found regarding interaction with ARVs stated  
Random 
Ceftriaxone 500mg IM stat, 
lidocaine 1% (as dilutent) & 




No contraindications or cautions noted No ARVs stated - unable to check for interactions  










Procedure/ diagnosis Medication delivered 
Face-to-face 
time (mins*) 
INP 1 New Maintain contraception (OCP) [asymptomatic screen] Microgynon 25 
INP 2 New Change contraception (IUD to oral pill) Microgynon 24 
INP 3 New Maintain contraception & genital warts Depo Provera; Warticon Cream 25 
INP 4 Follow-up Hepatitis B vaccination Twinrix (hepatitis A&B vaccine) 15 
INP 5 Follow-up Chlamydia (urethral & rectal); vaccine Doxycycline; Hepatitis B vaccine 30 
INP 6 New New contraception (OCP) to avoid bleeding on implant Microgynon 18 
INP 7 Follow-up Syphilis (primary) Benzathine 22 
INP 8 New Maintain contraception (implant) Nexplanon & lidocaine  44** 
INP 9 New Change contraception (patch to implant) Nexplanon & lidocaine 24 
INP 10 New Syphilis contact Benzathine 17 
INP 11 Follow-up Gonorrhoea (rectal) & chlamydia (rectal) Ceftriaxone, lidocaine & azithromycin; doxycycline 20 
INP 12 New Human papilloma virus vaccine Gardasil 13 
INP 13 Follow-up Chlamydia Azithromycin 5** 
INP 14 Follow-up Chlamydia (rectal) & Equivical gonorrhoea (throat) Doxycycline; spectinomycin & azithromycin 15 
INP 15 Follow-up Chlamydia & vulval-vaginal candidosis (prophalaxsis) Azithromycin; clotrimazole cream & pessary 11 
PGD 1 New Change contraception (IUD to diaphram) Diaphram 11 
PGD 2 New Change contraception (IUD to oral pill) Cerelle 35 
PGD 3 Follow-up Chlamydia Doxycycline 18 
PGD 4 New Maintain contraception (implant) Nexplanon & lidocaine  23 
PGD 5 New New contraception (OCP) Microgynon (everyday) 27 
PGD 6 New Maintain contraception (OCP) Microgynon 12 
PGD 7 Follow-up Chlamydia Azithromycin 13 
PGD 8 Follow-up Bacterial vaginosis & vulvo-vaginal candidosis Metronidazole; clotrimazole cream & pessary 8** 









Procedure/ diagnosis Medication delivered 
Face-to-face 
time (mins*) 
PGD 10 New Gonorrhoea Ceftriaxone, lidocaine & azithromycin 15 
PGD 11 Follow-up Chlamydia (rectal) Doxycycline 10 
PGD 12 New Change contraception (OCP to OCP) Cilest 25 
PGD 13 Follow-up Chlamydia/ epipidymitis  Doxycycline (INP prescription) 27 
PGD 14 New Maintain contraception (POP) Zelleta 8 
PGD 15 New Chlamydia contact Azithromycin 15 
* time is rounded up to nearest minute. Time refers to time nurses were known to spend face-to-face with patients, not duration of audio-recordings 
**additional support provided from a professional colleagues (time stated does not include the colleagues’ time) 








Appendix KK. Observational study: Detailed Prescribing Framework scoring of observations 
Prescribing Framework (RPS, 2016): 
Competency 1: ASSESS THE PATIENT 
INP PGD 
Observed Not observed Not applicable Observed Not observed Not applicable 
n % n % n % n % n % n % 
1.1 Takes an appropriate medical, social and medication history, 
including allergies and intolerances. 
15 100 0 0.0 0 0.0 15 100 0 0.0 0 0.0 
1.2 Undertakes an appropriate clinical assessment. 15 100 0 0.0 0 0.0 15 100 0 0.0 0 0.0 
1.3 Accesses and interprets all available and relevant patient 
records to ensure knowledge of the patient’s management to 
date. 
15 100 0 0.0 0 0.0 15 100 0 0.0 0 0.0 
1.4 Requests and interprets relevant investigations necessary to 
inform treatment options. 
12 80 0 0.0 3 20.0 13 86.7 0 0.0 2 13.3 
1.5 Makes, confirms or understands, the working or final 
diagnosis by systematically considering the various possibilities 
15 100 0 0.0 0 0.0 15 100 0 0.0 0 0.0 
1.6 Understands the condition(s) being treated, their natural 
progression and how to assess their severity, deterioration and 
anticipated response to treatment. 
15 100 0 0.0 0 0.0 15 100 0 0.0 0 0.0 
1.7 Reviews adherence to and effectiveness of current 
medicines. 
7 46.7 1 6.7 7 46.7 6 40.0 0 0.0 9 60 
1.8 Refers to or seeks guidance from another member of the 
team, a specialist or a prescribing information source when 
necessary. 
2 13.3 0 0.0 13 86.7 5 33.3 0 0.0 10 66.7 








Prescribing Framework (RPS, 2016): 
















n % n % n % n % n % n % n % n % 
2.1 Considers both non-pharmacological (including no 
treatment) and pharmacological approaches to modifying 
disease and promoting health. 
0 0.0 0 0.0 0 0.0 15 100 0 0.0 0 0.0 0 0.0 15 100 
2.2 Considers all pharmacological treatment options 
including optimising doses as well as stopping treatment 
(appropriate polypharmacy, de-prescribing). 
14 93.3 0 0.0 0 0.0 1 6.7 14 93.3 1 6.7 0 0.0 0 0.0 
2.3 Assesses the risks and benefits to the patient of taking 
or not taking a medicine or treatment. 
15 100 0 0.0 0 0.0 0 0.0 15 100 0 0.0 0 0.0 0 0.0 
2.4 Applies understanding of the mode of action and 
pharmacokinetics of medicines and how these may be 
altered (e.g. by genetics, age, renal impairment, pregnancy). 
4 26.7 11 73.3 0 0.0 0 0.0 7 46.7 8 53.3 0 0.0 0 0.0 
2.5 Assesses how co-morbidities, existing medication, 
allergies, contraindications and quality of life impact on 
management options. 
15 100 0 0.0 0 0.0 0 0.0 14 93.3 0 0.0 0 0.0 1 6.7 
2.6 Takes into account any relevant patient factors (e.g. 
ability to swallow, religion) and the potential impact on route 
of administration and formulation of medicines. 
8 53.3 6 40.0 1 6.7 0 0.0 5 33.3 10 66.7 0 0.0 0 0.0 
2.7 Identifies, accesses, and uses reliable and validated 
sources of information and critically evaluates other 
information. 
0 0.0 15 100 0 0.0 0 0.0 1 6.7 14 93.3 0 0.0 0 0.0 
2.8 Stays up-to-date in own area of practice and applies the 
principles of evidence-based practice, including clinical and 
cost-effectiveness. 





Prescribing Framework (RPS, 2016): 
















n % n % n % n % n % n % n % n % 
2.9 Takes into account the wider perspective including the 
public health issues related to medicines and their use and 
promoting health. 
12 80.0 3 20.0 0 0.0 0 0.0 14 93.3 1 6.7 0 0.0 0 0.0 
2.10 Understands antimicrobial resistance and the roles of 
infection prevention, control and antimicrobial stewardship 
measures. 
0 0.0 7 46.7 0 0.0 8 53.3 2 13.3 6 40.0 0 0.0 7 46.7 






Prescribing Framework (RPS, 2016): 
Competency 3: REACH A SHARDED DECISION 
INP PGD 
Observed Not observed Not applicable Observed Not observed Not applicable 
n % n % n % n % n % n % 
3.1 Works with the patient/carer in partnership to make informed 
choices, agreeing a plan that respects patient preferences 
including their right to refuse or limit treatment. 
15 100 0 0.0 0 0.0 15 100 0 0.0 0 0.0 
3.2 Identifies and respects the patient in relation to diversity, 
values, beliefs and expectations about their health and treatment 
with medicines. 
15 100 0 0.0 0 0.0 15 100 0 0.0 0 0.0 
3.3 Explains the rationale behind and the potential risks and 
benefits of management options in a way the patient/carer 
understands. 
15 100 0 0.0 0 0.0 15 100 0 0.0 0 0.0 
3.4 Routinely assesses adherence in a non-judgemental way 
and understands the different reasons non-adherence can occur 
(intentional or non-intentional) and how best to support 
patients/carers. 
12 80.0 0 0.0 3 20.0 15 100 0 0.0 0 0.0 
3.5 Builds a relationship which encourages appropriate 
prescribing and not the expectation that a prescription will be 
supplied. 
15 100 0 0.0 0 0.0 15 100 0 0.0 0 0.0 
3.6 Explores the patient/carers understanding of a consultation 
and aims for a satisfactory outcome for the patient/carer and 
prescriber. 
15 100 0 0.0 0 0.0 15 100 0 0.0 0 0.0 







Prescribing Framework (RPS, 2016): 
















n % n % n % n % n % n % n % n % 
4.1 Prescribes a medicine only with adequate, up-to-
date awareness of its actions, indications, dose, 
contraindications, interactions, cautions, and side 
effects. 
6 40.0 9 60.0 0 0.0 0 0.0 7 46.7 8 53.3 0 0.0 0 0.0 
4.2 Understands the potential for adverse effects and 
takes steps to avoid/minimise, recognise and 
manage them. 
14 93.3 0 0.0 1 6.7 0 0.0 15 100 0 0.0 0 0.0 0 0.0 
4.3 Prescribes within relevant frameworks for 
medicines use as appropriate (e.g. local formularies, 
care pathways, protocols and guidelines). 
15 100 0 0.0 0 0.0 0 0.0 14 93.3 1 6.7 0 0.0 0 0.0 
4.4 Prescribes generic medicines where practical 
and safe for the patient and knows when medicines 
should be prescribed by branded product. 
15 100 0 0.0 0 0.0 0 0.0 15 100 0 0.0 0 0.0 0 0.0 
4.5 Understands and applies relevant national 
frameworks for medicines use (e.g. NICE, SMC, 
AWMSG and medicines management/optimisation) 
to own prescribing practice. 
0 0.0 15 100 0 0.0 0 0.0 1 6.7 14 93.3 0 0.0 0 0.0 
4.6 Accurately completes and routinely checks 
calculations relevant to prescribing and practical 
dosing. 
2 13.3 2 13.3 0 0.0 11 73.3 1 6.7 0 0.0 0 0.0 14 93.3 
4.7 Considers the potential for misuse of medicines. 0 0.0 0 0.0 0 0.0 15 100 0 0.0 0 0.0 0 0.0 15 100 
4.8 Uses up-to-date information about prescribed 
medicines (e.g. availability, pack sizes, storage 
conditions, excipients, costs). 
0 0.0 15 100 0 0.0 0 0.0 2 13.3 13 86.7 0 0.0 0 0.0 
4.9 Electronically generates or writes legible 
unambiguous and complete prescriptions which 
meet legal requirements. 





Prescribing Framework (RPS, 2016): 
















n % n % n % n % n % n % n % n % 
4.10 Effectively uses the systems necessary to 
prescribe medicines (e.g. medicine charts, electronic 
prescribing, decision support). 
14 93.3 0 0.0 1 6.7 0 0.0 15 100 0 0.0 0 0.0 0 0.0 
4.11 Only prescribes medicines that are unlicensed, 
‘off-label’, or outside standard practice if satisfied that 
an alternative licensed medicine would not meet the 
patient’s clinical needs. 
4 26.7 0 0.0 0 0.0 11 73.3 1 6.7 0 0.0 0 0.0 14 93.3 
4.12 Makes accurate legible and contemporaneous 
records and clinical notes of prescribing decisions. 
13 86.7 0 0.0 2 13.3 0 0.0 15 100 0 0.0 0 0.0 0 0.0 
4.13 Communicates information about medicines 
and what they are being used for when sharing or 
transferring prescribing responsibilities/ information. 
13 86.7 0 0.0 1 6.7 1 6.7 15 100 0 0.0 0 0.0 0 0.0 






Prescribing Framework (RPS, 2016): 
Competency 5: PROVIDE INFORMATION 
INP PGD 
Observed Not observed Not applicable Observed Not observed Not applicable 
n % n % n % n % n % n % 
5.1 Checks the patient/carer’s understanding of and commitment 
to the patient’s management, monitoring and follow-up. 
15 100 0 0.0 0 0.0 14 93.3 0 0.0 1 6.7 
5.2 Gives the patient/carer clear, understandable and accessible 
information about their medicines (e.g. what it is for, how to use 
it, possible unwanted effects and how to report them, expected 
duration of treatment). 
15 100 0 0.0 0 0.0 15 100 0 0.0 0 0.0 
5.3 Guides patients/carers on how to identify reliable sources of 
information about their medicines and treatments. 
10 66.7 5 33.3 0 0.0 13 86.7 2 13.3 0 0.0 
5.4 Ensures that the patient/carer knows what to do if there are 
any concerns about the management of their condition, if the 
condition deteriorates or if there is no improvement in a specific 
time frame. 
12 80.0 3 20.0 0 0.0 13 86.7 2 13.3 0 0.0 
5.5 When possible, encourages and supports patients/carers to 
take responsibility for their medicines and self-manage their 
conditions. 
10 66.7 0 0.0 5 33.3 15 100 0 0.0 0 0.0 







Prescribing Framework (RPS, 2016): 
Competency 6: MONITOR AND REVIEW 
INP PGD 
Observed Not observed Not applicable Observed Not observed Not applicable 
n % n % n % n % n % n % 
6.1 Establishes and maintains a plan for reviewing the patient’s 
treatment. 
12 80.0 0 0.0 3 20.0 14 93.3 0 0.0 1 6.7 
6.2 Ensures that the effectiveness of treatment and potential 
unwanted effects are monitored. 
15 100 0 0.0 0 0.0 15 100 0 0.0 0 0.0 
6.3 Detects and reports suspected adverse drug reactions using 
appropriate reporting systems. 
0 0.0 0 0.0 15 100 0 0.0 0 0.0 15 100 
6.4 Adapts the management plan in response to on-going 
monitoring and review of the patient’s condition and preferences. 
12 80.0 0 0.0 3 20.0 12 80.0 0 0.0 3 20.0 







Appendix LL. Patient questionnaire: Satisfaction with 
Information about Medicines Scale (SIMS) scores 
 
Satisfaction with Information 
about Medicines Scale (SIMS) 




n % n % n % n % 
1. The name of 
the medicine 
Too much 10 5.7 8 4.7 0 0.0 18 5.2 
About right 152 87.4 151 89.3 5 100.0 308 88.5 
Too little 2 1.1 1 0.6 0 0.0 3 0.9 
None received 5 2.9 2 1.2 0 0.0 7 2.0 
Not applicable 5 2.9 7 4.1 0 0.0 12 3.4 
Missed 0 0.0 0 0.0 0 0.0 0 0.0 
2.What your 
medicine is for 
Too much 15 8.6 12 7.1 0 0.0 27 7.8 
About right 153 87.9 153 90.5 5 100.0 311 89.4 
Too little 0 0.0 0 0.0 0 0.0 0 0.0 
None received 0 0.0 0 0.0 0 0.0 0 0.0 
Not applicable 4 2.3 3 1.8 0 0.0 7 2.0 
Missed 2 1.1 1 0.6 0 0.0 3 0.9 
3. What it does 
Too much 17 9.8 14 8.3 0 0.0 31 8.9 
About right 149 85.6 149 88.2 4 80.0 302 86.8 
Too little 2 1.1 2 1.2 1 20.0 5 1.4 
None received 2 1.1 2 1.2 0 0.0 4 1.1 
Not applicable 3 1.7 2 1.2 0 0.0 5 1.4 
Missed 1 0.6 0 0.0 0 0.0 1 0.3 
4. How it works 
Too much 18 10.3 11 6.5 0 0.0 29 8.3 
About right 138 79.3 142 84.0 3 60.0 283 81.3 
Too little 7 4.0 3 1.8 2 40.0 12 3.4 
None received 7 4.0 8 4.7 0 0.0 15 4.3 
Not applicable 3 1.7 3 1.8 0 0.0 6 1.7 
Missed 1 0.6 2 1.2 0 0.0 3 0.9 
5. How long it 
will take to act 
Too much 19 10.9 12 7.1 0 0.0 31 8.9 
About right 146 83.9 143 84.6 4 80.0 293 84.2 
Too little 5 2.9 5 3.0 1 20.0 11 3.2 
None received 0 0.0 4 2.4 0 0.0 4 1.1 
Not applicable 3 1.7 5 3.0 0 0.0 8 2.3 
Missed 1 0.6 0 0.0 0 0.0 1 0.3 
6. How can you 
tell if it's working 
Too much 13 7.5 10 5.9 0 0.0 23 6.6 
About right 131 75.3 121 71.6 4 80.0 256 73.6 
Too little 6 3.4 8 4.7 1 20.0 15 4.3 
None received 10 5.7 13 7.7 0 0.0 23 6.6 
Not applicable 13 7.5 17 10.1 0 0.0 30 8.6 
Missed 1 0.6 0 0.0 0 0.0 1 0.3 
7. How long you 
will need to be 
on your 
medicine 
Too much 16 9.2 15 8.9 0 0.0 31 8.9 
About right 144 82.8 136 80.5 5 100.0 285 81.9 
Too little 0 0.0 0 0.0 0 0.0 0 0.0 





Satisfaction with Information 
about Medicines Scale (SIMS) 




n % n % n % n % 
Not applicable 12 6.9 14 8.3 0 0.0 26 7.5 
Missed 3 1.7 2 1.2 0 0.0 5 1.4 
8. How to get a 
further supply 
Too much 15 8.6 11 6.5 0 0.0 26 7.5 
About right 112 64.4 117 69.2 3 60.0 232 66.7 
Too little 5 2.9 2 1.2 0 0.0 7 2.0 
None received 10 5.7 4 2.4 2 40.0 16 4.6 
Not applicable 28 16.1 33 19.5 0 0.0 61 17.5 
Missed 4 2.3 2 1.2 0 0.0 6 1.7 




Too much 15 8.6 12 7.1 0 0.0 27 7.8 
About right 136 78.2 131 77.5 3 60.0 270 77.6 
Too little 1 0.6 5 3.0 0 0.0 6 1.7 
None received 13 7.5 10 5.9 2 40.0 25 7.2 
Not applicable 8 4.6 10 5.9 0 0.0 18 5.2 
Missed 1 0.6 1 0.6 0 0.0 2 0.6 
10. What are 
the risks of 
getting side 
effects 
Too much 14 8.0 13 7.7 0 0.0 27 7.8 
About right 137 78.7 124 73.4 3 60.0 264 75.9 
Too little 1 0.6 6 3.6 0 0.0 7 2.0 
None received 17 9.8 9 5.3 2 40.0 28 8.0 
Not applicable 4 2.3 14 8.3 0 0.0 18 5.2 
Missed 1 0.6 3 1.8 0 0.0 4 1.1 
11. What you 




Too much 13 7.5 12 7.1 0 0.0 25 7.2 
About right 127 73.0 121 71.6 3 60.0 251 72.1 
Too little 4 2.3 4 2.4 0 0.0 8 2.3 
None received 17 9.8 18 10.7 2 40.0 37 10.6 
Not applicable 12 6.9 13 7.7 0 0.0 25 7.2 
Missed 1 0.6 1 0.6 0 0.0 2 0.6 





Too much 11 6.3 13 7.7 0 0.0 24 6.9 
About right 94 54.0 89 52.7 3 60.0 186 53.4 
Too little 7 4.0 3 1.8 0 0.0 10 2.9 
None received 27 15.5 29 17.2 2 40.0 58 16.7 
Not applicable 32 18.4 33 19.5 0 0.0 65 18.7 
Missed 2 1.1 2 1.2 0 0.0 4 1.1 






Too much 10 5.7 9 5.3 0 0.0 19 5.5 
About right 117 67.2 109 64.5 4 80.0 230 66.1 
Too little 6 3.4 4 2.4 0 0.0 10 2.9 
None received 14 8.0 13 7.7 1 20.0 28 8.0 
Not applicable 23 13.2 32 18.9 0 0.0 55 15.8 
Missed 4 2.3 2 1.2 0 0.0 6 1.7 
14. Whether the 
medication will 
make you feel 
drowsy 
Too much 11 6.3 9 5.3 0 0.0 20 5.7 
About right 97 55.7 89 52.7 3 60.0 189 54.3 
Too little 5 2.9 6 3.6 0 0.0 11 3.2 
None received 25 14.4 27 16.0 2 40.0 54 15.5 
Not applicable 29 16.7 36 21.3 0 0.0 65 18.7 





Satisfaction with Information 
about Medicines Scale (SIMS) 




n % n % n % n % 
15. Whether you 
were able to 
have sex while 
taking the 
medicine 
Too much 16 9.2 16 9.5 0 0.0 32 9.2 
About right 133 76.4 126 74.6 4 80.0 263 75.6 
Too little 3 1.7 1 0.6 0 0.0 4 1.1 
None received 8 4.6 6 3.6 1 20.0 15 4.3 
Not applicable 14 8.0 18 10.7 0 0.0 32 9.2 
Missed 0 0.0 2 1.2 0 0.0 2 0.6 
16. What to do if 
you forget to 
take a dose 
Too much 10 5.7 10 5.9 0 0.0 20 5.7 
About right 96 55.2 86 50.9 3 60.0 185 53.2 
Too little 3 1.7 6 3.6 0 0.0 9 2.6 
None received 13 7.5 17 10.1 2 40.0 32 9.2 
Not applicable 48 27.6 45 26.6 0 0.0 93 26.7 
Missed 4 2.3 5 3.0 0 0.0 9 2.6 
INP = independent nurse prescribing, PGD = patient group directions 
 
 
